# Pompoli_2016_Psychological therapies for panic disorder with or without agoraphobia in adults a network meta-analysis.

Cochrane
Library

Cochrane Database of Systematic Reviews

Psychological therapies for panic disorder with or without
agoraphobia in adults: a network meta-analysis (Review)

Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G

Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G. 
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. 
Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD011004. 
DOI: 10.1002/14651858.CD011004.pub2.

www.cochranelibrary.com

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis
(Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
Figure 5..................................................................................................................................................................................................
Figure 6..................................................................................................................................................................................................
Figure 7..................................................................................................................................................................................................
Figure 8..................................................................................................................................................................................................
Figure 9..................................................................................................................................................................................................
Figure 10................................................................................................................................................................................................
Figure 11................................................................................................................................................................................................
Figure 12................................................................................................................................................................................................
Figure 13................................................................................................................................................................................................
Figure 14................................................................................................................................................................................................
Figure 15................................................................................................................................................................................................
Figure 16................................................................................................................................................................................................
Figure 17................................................................................................................................................................................................
Figure 18................................................................................................................................................................................................
Figure 19................................................................................................................................................................................................
Figure 20................................................................................................................................................................................................
Figure 21................................................................................................................................................................................................
Figure 22................................................................................................................................................................................................
Figure 23................................................................................................................................................................................................
Figure 24................................................................................................................................................................................................
Figure 25................................................................................................................................................................................................
Figure 26................................................................................................................................................................................................
Figure 27................................................................................................................................................................................................
Figure 28................................................................................................................................................................................................
Figure 29................................................................................................................................................................................................
Figure 30................................................................................................................................................................................................
Figure 31................................................................................................................................................................................................
Figure 32................................................................................................................................................................................................
Figure 33................................................................................................................................................................................................
Figure 34................................................................................................................................................................................................
Figure 35................................................................................................................................................................................................
Figure 36................................................................................................................................................................................................
Figure 37................................................................................................................................................................................................
Figure 38................................................................................................................................................................................................
Figure 39................................................................................................................................................................................................
Figure 40................................................................................................................................................................................................
Figure 41................................................................................................................................................................................................
Figure 42................................................................................................................................................................................................
Figure 43................................................................................................................................................................................................
Figure 44................................................................................................................................................................................................

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
4
10
13
13
19
21
22
24
25
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 45................................................................................................................................................................................................
Figure 46................................................................................................................................................................................................
Figure 47................................................................................................................................................................................................
Figure 48................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
ADDITIONAL TABLES....................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

69
70
71
72
73
75
76
88
195
221
221
222
222
222

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Psychological therapies for panic disorder with or without agoraphobia
in adults: a network meta-analysis

Alessandro Pompoli1, Toshi A Furukawa2, Hissei Imai2, Aran Tajika2, Orestis Efthimiou3, Georgia Salanti4

1Private practice, no academic affiliations, Malcesine, Italy. 2Department of Health Promotion and Human Behavior, Kyoto University
Graduate School of Medicine/School of Public Health, Kyoto, Japan. 3Department of Hygiene and Epidemiology, University of Ioannina
School of Medicine, Ioannina, Greece. 4Institute of Social and Preventive Medicine (ISPM) & Bern Institute of Primary Care (BIHAM),
University of Bern, Bern, Switzerland

Contact: Alessandro Pompoli, Private practice, no academic affiliations, Le grotte 12, Malcesine, Verona, 37018, Italy.
alepompoli@msn.com.

Editorial group: Cochrane Common Mental Disorders Group.
Publication status and date: New, published in Issue 4, 2016.

Citation:  Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G. Psychological therapies for panic disorder with or without
agoraphobia in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD011004. DOI:
10.1002/14651858.CD011004.pub2.

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Panic disorder is characterised by the presence of recurrent unexpected panic attacks, discrete periods of fear or anxiety that have a rapid
onset and include symptoms such as racing heart, chest pain, sweating and shaking. Panic disorder is common in the general population,
with a lifetime prevalence of 1% to 4%. A previous Cochrane meta-analysis suggested that psychological therapy (either alone or combined
with  pharmacotherapy)  can  be  chosen  as  a  first-line  treatment  for  panic  disorder  with  or  without  agoraphobia.  However,  it  is  not  yet
clear whether certain psychological therapies can be considered superior to others. In order to answer this question, in this review we
performed a network meta-analysis (NMA), in which we compared eight different forms of psychological therapy and three forms of a
control condition.

Objectives

To assess the comparative efficacy and acceptability of different psychological therapies and different control conditions for panic disorder,
with or without agoraphobia, in adults.

Search methods

We conducted the main searches in the CCDANCTR electronic databases (studies and references registers), all years to 16 March 2015. We
conducted complementary searches in PubMed and trials registries. Supplementary searches included reference lists of included studies,
citation indexes, personal communication to the authors of all included studies and grey literature searches in OpenSIGLE. We applied no
restrictions on date, language or publication status.

Selection criteria

We  included  all  relevant  randomised  controlled  trials  (RCTs)  focusing  on  adults  with  a  formal  diagnosis  of  panic  disorder  with  or
without  agoraphobia.  We  considered  the  following  psychological  therapies:  psychoeducation  (PE),  supportive  psychotherapy  (SP),
physiological  therapies  (PT),  behaviour  therapy  (BT),  cognitive  therapy  (CT),  cognitive  behaviour  therapy  (CBT),  third-wave  CBT  (3W)
and psychodynamic therapies (PD). We included both individual and group formats. Therapies had to be administered face-to-face. The
comparator interventions considered for this review were: no treatment (NT), wait list (WL) and attention/psychological placebo (APP).
For this review we considered four short-term (ST) outcomes (ST-remission, ST-response, ST-dropouts, ST-improvement on a continuous
scale) and one long-term (LT) outcome (LT-remission/response).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Data collection and analysis

Cochrane Database of Systematic Reviews

As a first step, we conducted a systematic search of all relevant papers according to the inclusion criteria. For each outcome, we then
constructed a treatment network in order to clarify the extent to which each type of therapy and each comparison had been investigated in
the available literature. Then, for each available comparison, we conducted a random-effects meta-analysis. Subsequently, we performed
a network meta-analysis in order to synthesise the available direct evidence with indirect evidence, and to obtain an overall effect size
estimate for each possible pair of therapies in the network. Finally, we calculated a probabilistic ranking of the different psychological
therapies and control conditions for each outcome.

Main results

We identified 1432 references; after screening, we included 60 studies in the final qualitative analyses. Among these, 54 (including 3021
patients) were also included in the quantitative analyses. With respect to the analyses for the first of our primary outcomes, (short-term
remission), the most studied of the included psychological therapies was CBT (32 studies), followed by BT (12 studies), PT (10 studies), CT
(three studies), SP (three studies) and PD (two studies).

The quality of the evidence for the entire network was found to be low for all outcomes. The quality of the evidence for CBT vs NT, CBT vs
SP and CBT vs PD was low to very low, depending on the outcome. The majority of the included studies were at unclear risk of bias with
regard to the randomisation process. We found almost half of the included studies to be at high risk of attrition bias and detection bias.
We also found selective outcome reporting bias to be present and we strongly suspected publication bias. Finally, we found almost half of
the included studies to be at high risk of researcher allegiance bias.

Overall the networks appeared to be well connected, but were generally underpowered to detect any important disagreement between
direct and indirect evidence. The results showed the superiority of psychological therapies over the WL condition, although this finding was
amplified by evident small study effects (SSE). The NMAs for ST-remission, ST-response and ST-improvement on a continuous scale showed
well-replicated evidence in favour of CBT, as well as some sparse but relevant evidence in favour of PD and SP, over other therapies. In
terms of ST-dropouts, PD and 3W showed better tolerability over other psychological therapies in the short term. In the long term, CBT and
PD showed the highest level of remission/response, suggesting that the effects of these two treatments may be more stable with respect
to other psychological therapies. However, all the mentioned differences among active treatments must be interpreted while taking into
account that in most cases the effect sizes were small and/or results were imprecise.

Authors' conclusions

There is no high-quality, unequivocal evidence to support one psychological therapy over the others for the treatment of panic disorder
with or without agoraphobia in adults. However, the results show that CBT - the most extensively studied among the included psychological
therapies - was often superior to other therapies, although the effect size was small and the level of precision was often insufficient or
clinically irrelevant. In the only two studies available that explored PD, this treatment showed promising results, although further research
is needed in order to better explore the relative efficacy of PD with respect to CBT. Furthermore, PD appeared to be the best tolerated
(in terms of ST-dropouts) among psychological treatments. Unexpectedly, we found some evidence in support of the possible viability
of non-specific supportive psychotherapy for the treatment of panic disorder; however, the results concerning SP should be interpreted
cautiously because of the sparsity of evidence regarding this treatment and, as in the case of PD, further research is needed to explore
this issue. Behaviour therapy did not appear to be a valid alternative to CBT as a first-line treatment for patients with panic disorder with
or without agoraphobia.

P L A I N   L A N G U A G E   S U M M A R Y

Psychological therapies for the treatment of panic disorder with or without agoraphobia

Why is this review important?

Many people suffer from panic disorder. Panic disorder can occur on its own or with agoraphobia. People with panic disorder experience
recurring panic attacks. During a panic attack people feel the sudden onset of intense fear alongside a series of bodily symptoms such as a
racing heart, chest pain, sweating, shaking, dizziness, flushing, stomach churning, faintness and breathlessness. People with agoraphobia
feel an intense fear of developing a panic attack in situations where escape might be difficult or embarrassing. This fear often leads to the
avoidance of such situations.

There are many different types of talking therapies that are used to treat panic disorder with or without agoraphobia. However it is not
clear whether certain talking therapies are more effective than others at treating panic disorder with or without agoraphobia. In this review
we compared the effectiveness of different types of talking therapy.

Who will be interested in this review?

People with panic disorder with or without agoraphobia.

Friends and family of people with panic disorder with or without agoraphobia.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

General practitioners, psychiatrists and psychologists.

Professionals working in adult mental health services.

What questions does this review aim to answer?

Cochrane Database of Systematic Reviews

Are any of the included psychological therapies more effective and better tolerated than others in the rapid reduction of panic/agoraphobia
symptoms?

Can any of the included psychological therapies guarantee better results one year after termination?

Which studies were included in the review?

We searched medical databases up to 16 March 2015 to find all studies (specifically randomised controlled trials) of talking therapies in the
treatment of panic disorder with or without agoraphobia. To be included in the review studies had to include people with a clear diagnosis
of panic disorder with or without agoraphobia.

We included 60 studies in the review. Fifty-four of the included studies (involving 3021 participants) were used in numerical analyses. The
review authors rated the overall quality of the studies as low to very low.

What does the evidence from the review tell us?

The results of the review show that in general talking therapies are more effective than no treatment. There was no strong evidence to
support one talking therapy over the others for the treatment of panic disorder with or without agoraphobia in adults. However, there was
some low-quality evidence in favour of cognitive behaviour therapy (CBT), psychodynamic therapy and supportive psychotherapy over
other talking therapies for short-term remission and short-term reduction in symptoms. The results concerning supportive psychotherapy
should, however, be treated with caution because of the small amount of evidence available about this treatment. On the other hand,
beyond the evidence regarding its efficacy, psychodynamic therapy also showed promising results in terms of tolerability: as a way of
assessing how well people tolerated the talking therapies, we assessed short-term dropout rates. We found that there were fewer dropouts
in psychodynamic therapy and third-wave CBT, suggesting that people tolerate these therapies better than other therapies.

What should happen next?

More  high-quality  research  is  needed  to  be  able  to  fully  compare  the  effectiveness  of  different  talking  therapies.  In  particular,  more
new studies are needed that compare the specific talking therapies CBT, psychodynamic therapy and supportive psychotherapy for the
treatment of panic disorder with or without agoraphobia.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
S U M M A R Y   O F   F I N D I N G S

Summary of findings for the main comparison.   Cognitive behaviour therapy compared to no treatment for panic disorder with or without
agoraphobia in adults

Cognitive behaviour therapy compared to no treatment for panic disorder with or without agoraphobia in adults

Patient or population: adult patients with panic disorder with or without agoraphobia

Setting: outpatients
Intervention: cognitive behaviour therapy (CBT)
Comparison: no treatment (NT)

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

No treatment (NT)

Cognitive-behavioral ther-
apy (CBT)

Short-term remission

Study population

(follow-up: mean 3
months)

36 per 100

Short-term response

Study population

(follow-up: mean 3
months)

36 per 100

Short-term dropouts

Study population

(follow-up: mean 3
months)

1 per 100 (no events were ob-
served in the available direct
evidence: this percentage was
assumed in order to calculate
the corresponding risk)

61 per 100
(24 to 89)

80 per 100
(42 to 97)

6 per 100
(0 to 50)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evi-
dence
(GRADE)

OR 2.78
(0.54 to 14.29)

OR 7.14
(1.25 to 50)

No direct evidence available:
indirect evidence based on 357
participants (2 studies via CT; 5
studies via PT)a

No direct evidence available:
indirect evidence based on 357
participants (2 studies via CT; 5
studies via PT)a

⊕⊝⊝⊝
VERY LOW 1,2,3

⊕⊝⊝⊝
VERY LOW 1,2,3

OR 6.25
(0.26 to 100)

No direct evidence available:
indirect evidence based on 278
participants (4 studies via PT)a

⊕⊝⊝⊝
VERY LOW 1,2,3

Long-term remission/re-
sponse

No data available for this com-
parison

-

-

-

-

(follow-up: mean 12
months)

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Short-term improve-
ment as measured on a
continuous scale

(follow-up: mean 3
months)

The mean short-term improve-
ment as measured on a contin-
uous scale in the control group
was 0

-

The mean short-term im-
provement, measured on
a continuous scale as SMD
(NMA results), was -0.83
(95% CI -1.5 to -0.16), indi-
cating a large effect size in
favour of CBT

27 participants
(1 RCT)

⊕⊕⊝⊝
LOW 4,5

Reported ORs are derived (as reciprocal values) from the results of network meta-analyses presented in Table 1, Table 4 and Table 7 (for ST-remission and ST-response we
used the results of NMA adjusted for SSE). Reported SMD is derived from the results of network meta-analysis presented in Table 10.

aIndirect comparison is performed using all possible intermediate comparisons in the network. For brevity we report the number of studies contributing indirect evidence
only via a single intermediate comparator.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NMA: network meta-analysis; OR: odds ratio; RCT: randomised controlled trial; SMD: standardised mean difference

GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

We downgraded the quality of the evidence one step at a time when one or more of the following criticisms was present:
1Only indirect evidence is available for this outcome.
2Wide 95% CI.
3The risk of bias of indirect evidence is often unclear.
4The risk of bias in the included study was unclear in almost every domain.
5Only one study, with a small sample size, available for direct comparison.

Summary of findings 2.   Cognitive behaviour therapy compared to supportive psychotherapy for panic disorder with or without agoraphobia in
adults

Cognitive behaviour therapy compared to supportive psychotherapy for panic disorder with or without agoraphobia in adults

Patient or population: adult patients with panic disorder with or without agoraphobia

Setting: outpatients
Intervention: cognitive behaviour therapy (CBT)
Comparison: supportive psychotherapy (SP)

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

5

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

6

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Supportive psy-
chotherapy (SP)

Cognitive behaviour therapy (CBT)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evi-
dence
(GRADE)

Short-term remission

Study population

(follow-up: mean 3 months)

38 per 100

Short-term response

Study population

(follow-up: mean 3 months)

32 per 100

Short-term dropouts

Study population

(follow-up: mean 3 months)

46 per 100

Long-term remission/re-
sponse

(follow-up: mean 12
months)

Study population

24 per 100

Short-term improvement as
measured on a continuous
scale

(follow-up: mean 3 months)

The mean short-term
improvement as mea-
sured on a continu-
ous scale in the control
group was 0

29 per 100
(13 to 52)

34 per 100
(16 to 60)

35 per 100
(19 to 55)

40 per 100
(19 to 65)

OR 0.67
(0.25 to 1.82)

176
(3 RCTs)

⊕⊕⊝⊝
LOW 1,2

OR 1.12
(0.4 to 3.26)

176
(3 RCTs)

⊕⊝⊝⊝
VERY LOW 1,2,3,4

OR 0.64
(0.28 to 1.43)

176
(3 RCTs)

⊕⊝⊝⊝
VERY LOW 1,2,3

OR 2.09
(0.73 to 5.98)

80
(1 RCT)

⊕⊕⊝⊝
LOW 1,5

-

The mean short-term improvement, mea-
sured on a continuous scale as SMD (NMA
results), was -0.05 (95% CI -0.56 to 0.47), in-
dicating almost no difference between CBT
and SP (the negative value of the point es-
timate indicates a slight trend in favour of
CBT)

152
(3 RCTs)

⊕⊕⊝⊝
LOW 1,2

Reported ORs and SMD are derived from the network meta-analyses.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NMA: network meta-analysis; OR: odds ratio; RCT: randomised controlled trial; SMD: standardised mean difference

GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

7

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

We downgraded the quality of the evidence one step at a time when one or more of the following criticisms was present:
1Risk of bias for the included studies was in many cases unclear.
2Only a few studies available for direct comparison. 95% CI still wide and non-significant even after combining direct and indirect evidence.
3Results were inconsistent across studies, although with wide confidence intervals.
4ST-response data were imputed from the continuous outcome for all the included studies.
5Only one study available for direct comparison. 95% CI still wide and non-significant even after combining direct and indirect evidence.

Summary of findings 3.   Cognitive behaviour therapy compared to psychodynamic psychotherapy for panic disorder with or without agoraphobia in
adults

Cognitive behaviour therapy compared to psychodynamic psychotherapy for panic disorder with or without agoraphobia in adults

Patient or population: adult patients with panic disorder with or without agoraphobia

Setting: outpatients
Intervention: cognitive behaviour therapy (CBT)
Comparison: psychodynamic psychotherapy (PD)

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Psychodynamic psy-
chotherapy (PD)

Cognitive behaviour therapy (CBT)

Short-term remission

Study population

(follow-up: mean 3 months)

44 per 100

Short-term response

Study population

(follow-up: mean 3 months)

47 per 100

43 per 100
(18 to 73)

48 per 100
(20 to 78)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evi-
dence
(GRADE)

OR 0.94
(0.27 to 3.45)a

54
(1 RCT)

⊕⊝⊝⊝
VERY LOW 1,2,3,4

OR 1.05
(0.28 to 4)a

54
(1 RCT)

⊕⊝⊝⊝
VERY LOW 1,2,3,4

Short-term dropouts

Study population

(follow-up: mean 3 months)

19 per 100

32 per 100

OR 1.92
(0.56 to 6.67)a

54
(1 RCT)

⊕⊝⊝⊝
VERY LOW 1,2,3,4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Long-term remission/re-
sponse

(follow-up: mean 12 months)

Study population

50 per 100

(12 to 62)

56 per 100
(27 to 81)

OR 1.25
(0.37 to 4.17)a

54
(1 RCT)

⊕⊕⊝⊝
LOW 1,4

Short-term improvement as
measured on a continuous
scale

(follow-up: mean 3 months)

The mean short-term
improvement as mea-
sured on a continu-
ous scale in the control
group was 0

The mean short-term improvement as
measured on a continuous scale in the in-
tervention group was 0.17 standard de-
viations higher (0.5 lower to 0.83 higher),
indicating a small effect size in favour of
PDb

-

54
(1 RCT)

⊕⊝⊝⊝
VERY LOW 1,3,4,5

a Reported ORs are derived (as reciprocal values) from the results of network meta-analyses presented in Table 1, Table 4, Table 7 and Table 13 (for ST-remission and ST-re-
sponse we used the results of NMA adjusted for SSE).

b Reported SMD is derived from the results of network meta-analysis presented in Table 10.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CBT: cognitive behaviour therapy; CI: confidence interval; NMA: network meta-analysis; OR: odds ratio; PD: psychodynamic psychotherapy; PT: physiological therapies;
RCT: randomised controlled trial; SMD: standardised mean difference

GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

We downgraded the quality of the evidence one step at a time when one or more of the following criticisms was present:
1The available direct evidence was affected by a high risk of bias in various important domains.
2Relevant (although non-significant) inconsistency was found in the loop PD-CBT-PT.
3Indirect evidence importantly influences the NMA results.
4Only one study available for direct comparison. 95% CI still wide and non-significant even after combining direct and indirect evidence.
5Statistically significant inconsistency was found in the loop PD-CBT-PT.

Summary of findings 4.   Network meta-analysis rankings of psychological therapies for panic disorder with or without agoraphobia in adults

NMA Rankings of psychological therapies for panic disorder with or without agoraphobia in adults

Patient or population: adult patients with panic disorder with or without agoraphobia

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Setting: outpatients
Intervention: psychoeducation (PE), supportive psychotherapy (SP), physiological therapies (PT), behaviour therapy (BT), cognitive therapy (CT), cognitive-behaviour ther-
apy (CBT), third-wave CBT (3W), psychodynamic psychotherapy (PD)
Comparison: no treatment (NT), waiting list (WL), attention/psychological placebo (APP)

Treatment hierarchy (in descending
order)

№ of participants
(studies)

Quality of the evidence
(GRADE)

Outcomes

Short-term remission
(follow up: mean 3 months)

Short-term response
(follow up: mean 3 months)

Short-term dropouts
(follow up: mean 3 months)

Long-term remission/response
(follow up: mean 12 months)

(SP)-CBT-PD-CT-BT-PT-NT-WL

CBT-PD-(SP)-BT-PT-WL-CT-NT

NT-PD-WL-3W-CBT-APP-PE-PT-CT-BT-SP

CBT-PD-PT-BT-SP-CT

2491
(40 RCTs)

2240
(37 RCTs)

2535
(47 RCTs)

464
(9 RCTs)

2318
(57 RCTs)

⊕⊕⊝⊝
LOW 1 2

⊕⊕⊝⊝
LOW 1 2

⊕⊕⊝⊝
LOW 1 3

⊕⊕⊝⊝
LOW 1 3

⊕⊕⊝⊝
LOW 1 3

Short-term improvement as measured on a continuous scale
(follow up: mean 3 months)

(PD)-CBT-SP-CT-3W-BT-PT-NT-WL

Reported rankings are based on absolute SUCRA values, which are derived from network meta-analyses (NMA).

The ranking of treatments reported in parenthesis must be interpreted with caution, because the evidence supporting those rankings is either too scarce or hampered by
relevant inconsistency.

The assessment of quality of evidence has been made by adapting the GRADE tool, designed for pairwise meta-analyses, to network meta-analyses, as suggested in Salanti
2014.

GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 Downgraded for study limitations because the risk of bias was unclear or high in more than one important domain for many of the included studies.
2 Downgraded for imprecision because too few comparisons remained clinically important after adjusting the results of NMA for SSE (See additional Table 1 and Table 4)
3 Downgraded for imprecision because too few comparisons showed clinically important results in NMA (See additional Table 7, Table 10 and Table 14)

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

9

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

A  panic  attack  is  a  discrete  period  of  fear  or  anxiety  that  has  a
rapid onset, reaches a peak within 10 minutes and in which at least
four of 13 characteristic symptoms are experienced. Many of these
symptoms involve bodily systems, such as racing heart, chest pain,
sweating, shaking, dizziness, flushing, stomach churning, faintness
and  breathlessness.  Further  recognised  panic  attack  symptoms
involve fearful cognitions, such as the fear of collapse, going mad
or dying, and derealisation (APA 2000).

According  to  the  Diagnostic  and  Statistical  Manual  of  Mental
Disorders (DSM-IV-TR) (APA 2000), panic disorder is characterised
by  the  presence  of  recurrent  unexpected  panic  attacks,  of  which
at  least  one  has  been  followed  by  one  month  (or  more)  of
persistent  concern  about  having  additional  attacks,  worry  about
the implications of the attack (or its consequences) or a significant
change in behaviour related to the attacks.

Panic  disorder  is  common  in  the  general  population,  with  a
lifetime prevalence of 1% to 4% (Bijl 1998; Eaton 1994). In primary
care  settings  panic  syndromes  have  been  reported  to  have  a
prevalence  of  around  10%  (King  2008).  The  aetiology  of  panic
disorder  is  not  fully  understood  and  is  probably  heterogeneous.
Biological  theories  incorporate  the  faulty  triggering  of  an  inbuilt
anxiety  response,  possibly  a  suffocation  alarm.  Evidence  for  this
comes from biological challenge tests (lactate and carbon dioxide
trigger  panic  in  those  with  the  disorder)  and  from  neuroimaging
studies that show activation of fear circuits, such as involving the
periaqueductal grey matter (Gorman 2000).

Agoraphobia  is  anxiety  about  being  in  places  or  situations  from
which  escape  might  be  difficult  or  embarrassing,  or  in  which
help  may  not  be  available  in  the  event  of  having  a  panic  attack
(APA  2000).  Agoraphobia  can  occur  with  panic  disorder  and  in
the  general  population  about  one  quarter  of  people  suffering
from panic disorder also have agoraphobia but this proportion is
much higher in the clinical samples (Kessler 2006). The presence
of  agoraphobia  is  associated  with  increased  severity  and  worse
outcomes (Kessler 2006). There are several risk factors that predict
the  development  of  agoraphobia  in  people  suffering  from  panic
disorder  including  female  gender,  more  severe  dizziness  during
panic attacks, cognitive factors, dependent personality traits and
social anxiety disorder (Starcevic 2009).

Panic disorder is more common among women, with a 2:1 ratio; in
the case of panic disorder with agoraphobia the ratio rises to 3:1.
Most typically, the disorder strikes between late adolescence and 35
years of age; early or late onset is possible, although less common
(APA 2000).

Panic  disorder,  with  or  without  agoraphobia,  is  highly  comorbid
with other psychiatric disorders such as drug dependence, major
depression,  bipolar  I  disorder,  social  phobia,  specific  phobia  and
generalised  anxiety  disorder  (Grant  2006).  It  is  estimated  that
generalised anxiety disorder co-occurs in 68% of people with panic
disorder, whilst major depression has a prevalence of 24% to 88%
among people with panic disorder (Starcevic 2009).

Cochrane Database of Systematic Reviews

Description of the intervention

Recent guidelines from the National Institute for Health and Clinical
Excellence  recommend  three  types  of  intervention  in  the  care  of
individuals  with  panic  disorder,  any  of  which  should  be  offered
promptly, taking into account the preference of the patient (NICE
2011). According to the NICE guidelines, the interventions that have
evidence for the longest duration of effect, in descending order, are
psychological  therapy,  pharmacological  therapy  (antidepressant
medication) and self help.

A psychological therapy can be defined as a therapeutic interaction
between  a  trained  professional  and  a  patient  (or  a  group  of
patients)  by  way  of  their  verbal  and  non-verbal  communication
for  the  purpose  of  ameliorating  the  sufferings  on  the  part  of  the
patient(s).

Although  NICE  guidelines  recommend  the  use  of  cognitive
behaviour  therapy  (CBT)  for  the  treatment  of  panic  disorder,
many other psychological therapies have been proposed as viable
therapeutic  options.  Each  therapy  is  characterised  by  a  certain
theoretical  framework,  according  to  which  a  set  of  therapeutic
ingredients (or 'components') and technical features can be defined
and briefly described as follows.

• Psychoeducation 

consists  of  providing  patients  with
information about their psychological disease. In this context,
it  can  be  explained  to  patients  that  their  symptoms  can
be  interpreted  in  the  light  of  a  certain  cause-effect  model,
according to a more general theoretical framework that can vary
across the different psychological approaches.

• Supportive  psychotherapy  is  a  dyadic  treatment  that  uses
direct  measures  to  ameliorate  symptoms  and  maintain,
restore  or  improve  self  esteem,  ego  function  and  adaptive
skills  (according  to  the  manual  of  Winston,  Rosenthal  and
Pinsker  (Winston  2004)).  Although  different  techniques  can
be  used  (e.g.  encouragement,  rationalising  and  reframing,
anticipatory  guidance,  etc.)  therapeutic  alliance  represents
the  most  important  element  of  the  therapy  (Winston  2004).
Rogerian  client-centred  psychotherapy  is  probably  the  most
representative  example  of  supportive  psychotherapy  (Rogers
1980).  In  this  approach,  within  the  context  of  a  warm,
empathic  and  non-directive  therapeutic  relationship  clients
are  led  to  become  aware  of  their  true  feelings  and  to  fully
accept  themselves  as  they  are,  including  imperfections  and
dysfunctions.

• Physiological  therapies  are  represented  by  a  set  of  different
possible  treatments  that  use  some  kind  of  physical  training
(e.g.  breathing  retraining,  relaxation  techniques,  biofeedback)
in  order  to  help  the  patient  to  control  the  physiological
manifestations  of  anxiety.  Among  the  physiological  therapies
proposed  for  the  treatment  of  panic  disorder,  breathing
retraining  and  relaxation  techniques  are  probably  the  most
studied.  Within  the  context  of  breathing  retraining,  different
strategies  have  been  proposed,  although  most  manuals  and
studies  describe  instructions  in  abdominal  breathing  as  their
central technique (Meuret 2012). Progressive muscle relaxation
(PMR),  as  formalised  by  Bernstein  and  Borkovec  (Bernstein
1973),  can  be  taught  to  panic  patients  in  order  to  reduce
general  tension  and  achieve  a  body  state  that  lowers  the  risk
for  stressors  to  elicit  panic.  The  so-called  applied  relaxation

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

is  a  slightly  different  form  of  physiological  therapy  in  which
relaxation training and exposure are combined (Ost 1987).
• The  behavioural  therapy  of  panic  disorder  consists  of
graded  exposure  to  the  body  sensations  that  accompany
panic  ('interoceptive  exposure')  or  to  situations  perceived  as
threatening  ('in  vivo  exposure',  'imagery  exposure',  'virtual
reality exposure'), or both, in order to progressively reduce the
patient's apprehensive reaction towards them.

• Cognitive  therapy  finds  its  roots  in  the  work  of  Albert  Ellis
and  Aaron  Beck.  Its  main  component  is  represented  by
cognitive restructuring, a psychotherapeutic process of learning
to identify and modify irrational or maladaptive thoughts using
strategies such as Socratic questioning, thought recording and
guided imagery.

• CBT for panic disorder is usually administered according to the
manuals of Clark 1986b and Barlow 2000b. Its main components
are represented by psychoeducation, breathing retraining, PMR,
cognitive restructuring, behavioural experiments, interoceptive
exposure and in vivo exposure.

• The  so-called  'third-wave'  therapies  are  represented  by  a
set  of  different  therapies  (e.g.  mindfulness-based  cognitive
therapy, acceptance and commitment therapy, compassionate
mind training, extended behavioural activation, metacognitive
therapy,  schema  therapy),  all  originating  from  the  cognitive
behavioural approach but compared to which more importance
is  given  to  the  form,  rather  than  the  content,  of  patients'
thoughts.  By  focusing  on  the  function  of  cognition,  third-
wave therapies aim to help patients to develop more adaptive
emotional  responses  to  situations.  When  mindfulness  and
acceptance are applied to anxiety disorders, the aim is for the
individual to be able to observe symptomatic processes without
overly identifying with them or without reacting to them in ways
that cause further distress (Roemer 2008). A systematic review
and meta-analysis of mindfulness-based and acceptance-based
interventions for anxiety disorders has been recently published
(Vøllestad 2012).

• Psychodynamic  therapies  consist  of  a  set  of  psychological
therapies,  different  in  length  and  depth,  represented  by
psychoanalysis  (as  conceptualised  by  S  Freud)  and  its  further
developments.  According  to  psychodynamic  psychotherapy,
psychological  symptoms  can  be  seen  as  manifestations  of
intrapsychic  or  unconscious  conflicts;  these  therapies  use
different  therapeutic  strategies  (e.g.  unconscious  contents
exploration,  dream  analysis,  analysis  of  past  experiences,
analysis  of  parental  relationships,  analysis  of  transference,
analysis  of  resistances)  in  order  to  reveal,  interpret  and
resolve  such  conflicts.  A  brief  panic-focused  psychodynamic
psychotherapy  is  described  in  Milrod  1997.  A  sightly  different
approach, derived from psychodynamic theories, is represented
by  so-called  emotion-focused  therapy  (EFT)  in  which  the
therapist  is  viewed  as  an  'emotion  coach'  who  works  to
enhance  emotion-focused  coping  by  helping  people  become
aware of, accept and make sense of their emotional experience
(Greenberg 2004).

A  further  level  of  distinction  among  psychological  therapies
concerns  the  form  of  delivery  of  the  intervention.  In  this  regard,
NICE  guidelines  suggest  that  the  intervention  (CBT)  should  be
optimally delivered in the form of one- to two-hour weekly sessions,
for a total of seven to 14 hours, within a maximum of four months
since  commencement.  However,  different  variables  have  been

Cochrane Database of Systematic Reviews

and  still  remain  the  subject  of  investigation  with  regard  to  cost-
effectiveness analyses. A number of variables including the number
of sessions, the duration of treatment and the therapeutic setting
(group  versus  individual;  face-to-face  versus  remote  versus  self
help) have been explored.

How the intervention might work

The  main  features  and  rationale  of  the  psychological  therapies
considered for this review can be summarised as follows.

The rationale of psychoeducation is that providing anxious patients
with  a  better  understanding  of  their  sufferings  may  in  itself
lead  to  symptom  relief  (Clark  1985;  Sorby  1991).  This  may  be
especially important in panic disorder, where the cognitive coping
mechanisms of the patients are disrupted and where anticipatory
anxiety may cause additional attacks (Dannon 2002). In this sense,
as the authors further suggest, a psychoeducational intervention
may increase the patients' sense of control leading to a reduction
of catastrophic thoughts and emotions.

Supportive  psychotherapy  is  non-specific  in  nature,  so  it  is  not
designed for the treatment of a psychiatric disorder in particular.
In  this  sense,  the  supportive  treatment  of  panic  disorder  and
agoraphobia  does  not  differ  from  the  treatment  of  any  other
disorder.  Although  scarce,  the  available  body  of  evidence  does
not  exclude  a  possible  role  of  supportive  psychotherapy  in  the
treatment  of  agoraphobia  (Klein  1983;  Zitrin  1978);  its  efficacy  in
the treatment of panic disorder without agoraphobia still remains
unclear.

regard 

particular 

abnormalities,  with 

Respiratory 
to
hyperventilation and hypocapnia, have been postulated as being
important  factors  in  the  development  or  maintenance  of  panic
disorder  (Klein  1993;  Ley  1985;  for  a  review  see  Meuret  2010b).
According  to  the  model  proposed  by  Ley  1985,  panic  attacks  are
caused by acute states of hypocapnia in a positive feedback loop
between hyperventilation and anxiety. Therefore, amelioration of
panic  symptoms  is  expected  when  patients  achieve  reductions
in transient and sustained hypocapnia. Results on the efficacy of
breathing  training  in  the  treatment  of  panic  disorder  are  mixed
(Meuret 2010b). The purpose of applied relaxation is to teach the
patient  to  observe  the  very  first  signs  of  a  panic  attack  and  to
apply a rapid and effective relaxation technique to cope with, and
eventually abort, these symptoms before they develop into a panic
attack. In a direct comparison with regard to remission from panic
disorder at the end of treatment, applied relaxation was not found
to be significantly better than PMR, although it performed better
than PMR on six out of 11 measures (Ost 1988).

Behaviour  therapy  (BT)  is  characterised  by  the  use  of  some  kind
of exposure in order to modify dysfunctional behaviours that may
contribute  to  the  development  and  persistence  of  psychological
symptoms.  The  principle  of  exposure  in  the  treatment  of  phobic
disorders  is  to  persuade  the  patient  to  enter  and  stay  in  his  or
her  phobic  situation  until  he  or  she  feels  better,  and  to  do  this
repeatedly  until  it  becomes  so  customary  that  the  situation  no
longer holds terror (Marks 1981). There is evidence that exposure
strategies  alone  are  effective  in  the  treatment  of  panic  disorder
(Gloster 2011; Ost 2004; Williams 1996).

In  the  case  of  cognitive  therapy  (CT)  for  panic  disorder,  it  has
been  proposed  that  panic  attacks  result  from  the  catastrophic

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

misinterpretation  of  certain  bodily  sensations  (Clark  1986a).
This  involves  the  sufferer  perceiving  sensations  involved  in
normal  anxiety  responses  as  much  more  dangerous  than  they
really  are,  for  example  perceiving  palpitations  as  evidence
impending  heart  attack.  The  cognitive  approach  would
of 
involve identifying patients' negative interpretations of the bodily
sensations  experienced  in  panic  attacks,  suggesting  alternative
non-catastrophic  interpretations  of  the  sensations,  and  then
helping  the  patient  to  test  the  validity  of  these  alternative
interpretations.  As  pointed  out  in  a  recent  review  (Meuret
2012),  CT  is  often  intermingled  with  behavioural  techniques
(for  example,  'behavioural  experiments',  'hypothesis  testing',
'instructions'  involving  exposure),  which  complicates  the  testing
of the efficacy of CT in its 'pure' form. Nonetheless, there is some
evidence that training in cognitive procedures in full isolation from
exposure  and  behavioural  procedures  is  efficacious  in  reducing
aspects  of  panic  (Beck  1994;  Meuret  2010a;  Salkovskis  1991;  Van
den Hout 1994).

Cognitive  behaviour  therapy  (CBT)  combines  elements  of  both
in  order  to  reduce  emotional  distress  and  psychological
symptoms, assuming that cognitions, behaviours and emotions are
interrelated. A fairly consistent body of evidence exists in support
of  the  efficacy  of  CBT  for  panic  disorder,  administered  either
in  individual  or  group  sessions  (among  others:  Clark  1999;  Dow
2000; Hendriks 2010; Telch 1993). Furthermore, a growing body of
evidence  supports  the  efficacy  of  self  administered  versions  (for
example, book-based, internet-based) of this psychological therapy
(Carlbring 2006; Nordin 2010; Wims 2010).

As  summarised  in  Ludwig  2008,  mindfulness  involves  attending
to  relevant  aspects  of  experience  in  a  non-judgemental  manner.
The  goal  of  mindfulness  is  to  maintain  awareness  moment  by
moment,  disengaging  oneself  from  strong  attachment  to  beliefs,
thoughts  or  emotions,  thereby  developing  a  greater  sense  of
emotional balance and well-being. An aim of mindfulness practice
is  to  take  greater  responsibility  for  one's  life  choices.  Although
scarce,  some  evidence  exists  in  support  of  the  efficacy  of  this
therapy for the treatment of generalised anxiety disorder and panic
disorder  (Kim  2009;  Lee  2007).  As  originally  developed  (Hayes
1999), acceptance and commitment therapy (ACT) was intended for
the treatment of psychopathology in general rather than a specific
disorder  in  particular.  ACT  conceptualises  psychological  events
as  a  set  of  ongoing  interactions  between  whole  organisms  and
historically and situationally defined contexts. Removal of a client's
problematic  behaviours  from  the  contexts  that  participate  in
that event (for example, merely analysing manifested behavioural
symptoms  themselves)  is  thought  to  miss  the  nature  of  the
problem and the avenues for its solution. ACT clients are therefore
encouraged to embrace a passionate and ongoing interest in how
to live according to their values. In ACT there is a conscious posture
of openness and acceptance toward all psychological events, even
if  they  are  formally  'negative',  'irrational'  or  even  'psychotic'.  For
example,  if  the  client  feels  trapped,  frustrated,  confused,  afraid,
angry  or  anxious,  the  ACT  stance  suggests  this  is  not  so  much  a
problem  as  it  is  an  opportunity  to  work  on  how  powerful  events
in the here and now can become barriers to growth (Hayes 2004).
Some evidence supports ACT possibly being as effective as CBT in
the treatment of anxiety disorders including panic disorder (Arch
2012).

Cochrane Database of Systematic Reviews

Following  a  psychodynamic  approach,  Busch  and  colleagues
proposed  that  during  childhood,  a  sense  of  fearful  dependency
on the parent may lead to the development of anger towards him
or  her  (Busch  1996).  As  a  consequence,  a  vicious  cycle  develops
in which the child's anger threatens the needed tie to the parent
and thereby increases fearful dependency, which promotes further
frustration  and  rage  at  the  parent.  This  cycle  may  then  recur  in
adulthood  when  threats  to  attachment  trigger  intense  feelings
of abandonment, anger and anxiety, leading to the development
of  the  disorder.  The  aim  of  psychodynamic  psychotherapy  is  to
address  such  underlying  psychological  factors  in  order  to  obtain
an improvement of panic symptoms. Although only a few studies
have  explored  the  effects  of  psychodynamic  psychotherapy  for
panic disorder, the available evidence suggests the viability of this
approach as a valid therapeutic option (Milrod 2007; Wiborg 1996).

Why it is important to do this review

A  previous  Cochrane  meta-analysis  comparing  combined
psychological  therapy  plus  antidepressants  versus  psychological
therapy  alone  or  pharmacotherapy  alone  showed  the  superiority
of  combined  therapy  over  either  monotherapies  in  the  short
term,  and  of  combined  therapy  and  psychological  therapy
alone  over  pharmacotherapy  alone  in  the  long  term,  thus
suggesting that either combined therapy or psychological therapy
alone  can  be  chosen  as  first-line  treatment  for  panic  disorder
with  or  without  agoraphobia  (Furukawa  2007).  In  particular,
behavioural  and  cognitive  behavioural  psychological  therapies
showed  the  strongest  evidence.  Another  meta-analysis,  aimed  at
analysing the efficacy of psychological interventions versus control
conditions  in  the  treatment  of  panic  disorder  with  or  without
agoraphobia  (Sánchez-Meca  2010),  showed  a  general  efficacy
of  psychological  therapies  over  different  clusters  of  symptoms,
with  the  most  consistent  results  in  favour  of  the  combination  of
exposure strategies with relaxation training or breathing retraining
techniques, or both. The study conducted by Sánchez-Meca et al
revealed the presence of substantial heterogeneity among included
studies  (I2  =  70.4%).  Exploratory  secondary  analyses  suggested
that  variables  such  as  type  of  therapy  and  type  of  control  group
may  explain  part  of  the  observed  heterogeneity.  The  observed
degree  of  heterogeneity  due  to  differences  in  the  psychological
therapies  suggests  that  some  psychological  therapies  may  be
more  effective  than  others  in  the  treatment  of  the  disorder.
However, both the existence and the eventual magnitude of such
differences  remain  unclear.  This  is  partly  due  to  the  presence  of
methodological diversity among available studies; as suggested by
Sánchez-Meca  et  al,  the  type  of  control  group  may  significantly
influence  the  measured  effect  size,  limiting  the  possibility  of
drawing conclusions. A further consideration is that only a few trials
compared different psychological approaches with each other and,
more generally, psychological therapies have not been all equally
investigated.

In an attempt to overcome these issues, in this review we performed
a network meta-analysis (NMA), also known as multiple treatment
meta-analysis,  in  which  eight  different  forms  of  psychological
therapy  and  three  forms  of  a  control  condition  (see  Types  of
interventions) have been independently compared with each other.
We expected this methodological strategy to reduce the amount of
heterogeneity that was observed in previous studies. Furthermore,
by synthesising the available direct and indirect evidence via NMA,
it  was  possible  to  obtain  an  overall  effect  size  estimate  for  each

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

possible  pair  of  therapies  in  the  network,  even  for  interventions
that had not been directly compared with each other in previous
trials. Finally, it was possible to calculate a probabilistic ranking in
order to help the identification of those interventions that are more
likely  to  be  more  effective  than  others  in  the  treatment  of  panic
disorder.

agoraphobia, rather than panic disorder, if operationally diagnosed
according  to  the  above-mentioned  criteria  and  when  it  could  be
safely assumed that at least 80% of the participants were suffering
from panic disorder. We explored the effect of the inclusion of trials
with different percentages of patients suffering from agoraphobia
in a meta-regression analysis.

This  review  along  with  several  others  in  progress,  contributes  to
the production of a comprehensive portfolio of Cochrane reviews in
the area of panic disorder (Furukawa 2007; Guaiana 2013; Guaiana
2013a; Guaiana 2013b; Watanabe 2009; Xiao 2011).

O B J E C T I V E S

To  assess  the  comparative  efficacy  and  acceptability  of  different
psychological therapies and different control conditions for panic
disorder, with or without agoraphobia, in adults.

M E T H O D S

Criteria for considering studies for this review

Types of studies

All relevant randomised controlled trials (RCTs).

We 
included  cluster-randomised  trials  when  the  effects  of
clustering  were  taken  account  of  (however,  we  found  no  such
cases).

We included cross-over randomised trials, but we only considered
results from the first randomisation period.

We  included  studies  in  which  the  replacement  of  dropouts  was
allowed as long as replacements were low in number (less than 15%
of the final sample) and evenly distributed among treatment arms.

We  excluded  quasi-randomised  controlled  trials 
(in  which
treatment  assignment  was  decided  through  methods  such  as
alternate days of the week).

Types of participants

Age range

Patients, aged 18 years or older, of both sexes. We included studies
that included some participants under the age of 18 as long as at
least 80% of patients were aged 18 years or above.

Diagnosis

We included studies that had enlisted participants with a primary
diagnosis of panic disorder with or without agoraphobia diagnosed
according  to  any  of  the  following  criteria:  Feighner  criteria
(Feighner 1972), Research Diagnostic Criteria (Spitzer 1978), DSM-
III (APA 1980), DSM-III-R (APA 1987), DSM-IV (APA 2000), DSM-5 (APA
2013) or ICD-10 (WHO 1992). When ICD-10 or DSM-5 were used, in
which panic disorder and agoraphobia are separately diagnosable,
this  review  focused  on  panic  disorder  comorbid  with  or  without
agoraphobia. We took the latter decision in order to be concordant
with the current body of literature, most of which used DSM-III-R or
DSM-IV and little, if any, used ICD-10 or DSM-5.

There is evidence that over 95% of patients with agoraphobia who
are  seen  clinically  suffer  from  panic  disorder  as  well  (Goisman
1995).  According  to  this  finding,  we  included  studies  focusing  on

Setting

Participants must have been outpatients at the time of enrolment.

Previous treatment

We included both treatment-naive patients and patients who had
already undergone some previous treatment (either psychological
long  as  they  satisfied  the  above-
or  pharmacological),  as 
mentioned inclusion criteria. However, we excluded studies where
all  participants  had  shown  resistance  to  previously  administered
psychological therapies.

Comorbidities

We included studies where participants had other anxiety disorders
(for example, generalised anxiety disorder, specific phobias) or with
subthreshold panic disorder if: 1) separate results for patients with
panic disorder were reported and 2) randomisation was stratified
by specific diagnoses. Stratification by diagnosis was not required
if  the  total  sample  included  at  least  40  participants  with  panic
disorder.

We  included  studies  in  which  the  participants  had  physical
comorbidities.  However,  we  excluded  studies  explicitly  focusing
on  panic  disorder  or  agoraphobia  among  patients  with  a  certain
physical comorbidity.

We  excluded  studies  in  which  all  participants  had  a  concurrent
primary diagnosis of Axis I or II disorders other than panic disorder
or agoraphobia.

Types of interventions

For  this  review,  we  chose  to  focus  on  most  representative
psychological  therapy  schools  (that  is  CBT  and  its  components
or  developments,  psychodynamic  psychotherapy  and  supportive
psychotherapy) and their control conditions.

Experimental interventions

We included the following psychological therapies.

1. PE:  psychoeducation,  intended  as  sessions  in  which  patients

were only provided information about their disease.

2. SP: 

supportive  psychotherapy,  with  or  without 

a
psychoeducational component, intended as sessions in which
patients  were  administered  an  active,  although  non-specific,
psychological treatment.

3. PT:  physiological 

therapies 

that  used  some  kind  of
physical training (e.g. breathing retraining, progressive muscle
relaxation,  applied  relaxation) 
in  order  to  reduce  the
physiological manifestations of anxiety.

4. BT:  behaviour 

therapy,  with  or  without  physiological
components,  aiming  at  patients'  habituation  to  anxiety-
provoking  situations  and  sensations  through  some  kind  of
exposure (e.g. interoceptive, in vivo).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

5. CT: cognitive therapy, with or without physiological components
and  behavioural  experiments,  aiming  at  the  modification
of  maladaptive  thoughts  through  some  kind  of  cognitive
restructuring.

6. CBT: cognitive behaviour therapy, with or without physiological
components,  containing  both  cognitive  and  behavioural
therapy elements.

7. 3W:  third-wave  CBT,  including  acceptance  and  commitment
therapy, mindfulness-based therapy, and other so-called 'third-
wave'  therapies  administered  with  or  without  other  CBT
components  (e.g.  exposure,  cognitive  restructuring,  breathing
retraining, muscle relaxation).

8. PD:  psychodynamic  therapies  focused  on  revealing  and

resolving intrapsychic or unconscious conflicts.

When  psychoeducation  or  psychological  support,  or  both,
were  accompanied  by  any  other  psychological  intervention,  we
classified the study arms according to the latter and we regarded
psychoeducation and psychological support as components of that
intervention.

Therapies could be of any length so that we accepted those given
in a single session.

We included both individual and group therapies.

We  included  the  so-called  component  studies  (for  example,
dismantling  studies)  as  long  as  each  arm  could  be  regarded  as
any  of  the  above-defined  experimental  interventions  compared
against another experimental or comparator treatment. Eventually,
study arms could be regarded as giving information about the same
experimental intervention and thus be combined.

Therapies  had  to  be  administered  face-to-face.  We  excluded
therapies  administered  in  their  self  help  (for  example,  book,
computer,  Internet)  or  remote  (for  example,  telephone,  video-
conference)  versions.  In  the  case  of  psychoeducation,  the  simple
provision  of  informational  material  without  any  face-to-face
session  was  not  considered  an  active  intervention  but  rather  a
comparator  intervention,  such  as  no  psychological  treatment  or
wait list (however, we found no similar cases).

We excluded combination therapies. However, we included studies
in which a pharmacological co-administration was allowed as long
as  there  were  no  systematic  differences  in  drug  administration
between  the  study  arms.  The  percentage  of  studies  in  which  a
drug co-administration was allowed, the percentage of studies that
required a stabilisation of therapy and, in this latter case, the time
required for stabilisation, is reported.

We  excluded  any  other  psychological  approach 
(such  as
interpersonal  therapy  (IPT),  eye  movement  desensitisation  and
reprocessing  (EMDR)  and  Morita  therapy)  on  the  grounds  that
they  do  not  meet  the  criteria  for  a  CBT  (and  its  components
and developments), psychodynamic psychotherapy or supportive
psychotherapy.

We excluded family therapy, couple therapy and other psychosocial
interventions  whose  focus  was  not  the  individual  but  rather  the
family system or couple as a whole.

Cochrane Database of Systematic Reviews

Comparator interventions

1. NT:  no  psychological 

received
treatment 
assessment  only,  with  or  without  simple  provision  of
informational  material  or  minimal  therapist  contact,  or  both,
and  they  knew  that  they  would  have  not  received  the  active
treatment in question after the trial).

(participants 

2. WL: wait list (participants received assessment, with or without
simple provision of informational material or minimal therapist
contact, or both, and they knew that they would have received
the active treatment in question after the waiting phase).

3. APP: attention or psychological placebo (participants received a

face-to-face inactive intervention*).

Given  the  general  inconsistency  of  the  definitions  of  comparator
interventions among different studies, the attribution of a control
group to one of these prespecified categories relied on its detailed
description rather than on the name given by the authors. However,
where  a  sufficiently  detailed  description  was  unavailable,  either
from the paper or by contacting the original authors, the attribution
relied solely on the given definition. Particular inconsistency exists
in the definition of what is intended for treatment as usual (TAU).
When  TAU  was  intended  as  no  treatment,  wait  list  or  supportive
psychotherapy, we classified groups accordingly.

*Attention placebo is defined as any form of inactive intervention
designed  by  the  original  authors  to  be  perceived  as  ineffective
by  patients;  psychological  placebo  is  defined  as  any  form  of
inactive  intervention  designed  by  the  original  authors  to  be
perceived as effective by patients. The inclusion of an intervention
among  attention  or  psychological  placebo  groups  required  the
intervention  to  be  inactive.  Any  form  of  active  intervention  was
therefore  included  among  experimental  interventions  even  if
defined as a control condition by the original authors.

We excluded studies in which a pharmacological placebo was either
co-administered or used as the control condition.

In  total  we  expected  the  network  to  have  11  nodes,  each  one
representing an intervention or control (see Data synthesis).

Types of outcome measures

Primary outcomes

1. Short-terma  remissionb  of  panic  disorder  with  or  without

agoraphobia

2. Short-term  responsec  of  panic  disorder  with  or  without

agoraphobia

3. Dropouts  for  any  reason  in  the  short  term  (as  a  proxy  for

treatment acceptability)

i.e.  within 

(a)  Short-term, 
treatment
commencement.  When  multiple  time  point  measures  in  the
short  term  were  available,  we  gave  preference  to  measures  at
approximately three months after treatment commencement.

six  months 

from 

(b) 'Remission' was intended as a dichotomous outcome expressing
the  number  of  patients  who  reached  a  satisfactory  end  state
as  defined  by  global  judgement  by  the  original  investigators.
Examples are 'panic-free' and 'no or minimal symptom' according
to the Clinical Global Impression Severity Scale (Guy 1976).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

(c) 'Response' was intended as a dichotomous outcome expressing
the  number  of  patients  who  had  a  substantial  improvement
from  baseline  as  defined  by  the  original  investigators.  Examples
are  'very  much  or  much  improved'  according  to  the  Clinical
Global  Impression  (CGI)  Change  Scale  (Guy  1976),  more  than
40%  reduction  in  the  score  of  the  Panic  Disorder  Severity  Scale
(PDSS)  (Shear  1997),  and  more  than  50%  reduction  in  the  Fear
Questionnaire Agoraphobia Subscale (FQ-ag) (Marks 1979).

When more than one index of remission or response was reported,
we  gave  preference  to  the  most  global  measure  (e.g.  in  the  case
of  remission,  'high  end-state  functioning'  status  was  usually  a
more  global  index  than  'panic-free'  status);  when  more  than  one
index  was  available  but  measures  were  equally  'global',  we  gave
preference according to the same criteria used for the continuous
scale  outcome  (see  below).  The  actual  measure  entered  into  the
meta-analysis is indicated in the table of included studies.

Secondary outcomes

4.  Short-term  improvement  of  panic  disorder  with  or  without
agoraphobia as measured on a continuous scaled

5.  Long-terme  remission  or  responsef  of  panic  disorder  with  or
without agoraphobia

(d)  Examples  are  Panic  Disorder  Severity  Scale  (total  score  0  to
28),  Panic  and  Agoraphobia  Scale  (total  score  0  to  45),  Clinical
Global Impression Severity Scale (1 to 7), Clinical Global Impression
Change Scale (1 to 7), etc. When more than one scale was available
in the paper, we gave preference in the following order:

• PDSS > Panic and Agoraphobia Scale (PAS) > ASI-R > ASI > ACQ >

BSQ > other scales specific for panic disorder;
• CGI-S > CGI-I > GAS > GAF > other global scales;
• FQ-ag  >  FQ-global  >  Mobile 

Inventory  for  Agoraphobia-
Avoidance-Alone  (MI-AAL)  >  MI-Avoidance-Accompanied  (MI-
AAC) > other scales specific for agoraphobia only;

• panic frequency > panic severity > other scales specific for panic

attacks only.

Once  the  scale  was  chosen,  if  both  self  and  observer-rated
assessments were available, we gave preference to the latter. The
actual measure entered into the meta-analysis is indicated in the
table of Characteristics of included studies.

i.e.  six  months  or 

(e)  Long-term, 
longer  after  treatment
commencement,  either  on  treatment  discontinuation  or  on
continued  treatment  (in  the  case  of  long-term  therapies).  When
multiple time point measures in the long term were available, we
gave preference to measures at approximately 12 to 15 months after
treatment commencement. In the case of missing data at the long-
term assessment, we considered studies for the analyses as long as
dropouts were low in number (< 30% of the original sample) and
evenly distributed across treatment arms.

(f) 'Response' and 'Remission' were intended as above. When both
remission  and  response  rates  were  reported,  we  considered  the
former. However, if remission rates were not reported but response
rates were available, we used these for the analyses.

Cochrane Database of Systematic Reviews

Search methods for identification of studies

CCDAN Specialised Register (CCDANCTR)

The  Cochrane  Depression,  Anxiety  and  Neurosis  Group  (CCDAN)
maintain  two  clinical  trials  registers  at  their  editorial  base  in
Bristol,  UK:  a  references  register  and  a  studies-based  register.
The  CCDANCTR-References  Register  contains  over  40,000  reports
of  trials  in  depression,  anxiety  and  neurosis.  Approximately  50%
of  these  references  have  been  tagged  to  individual,  coded  trials.
The  coded  trials  are  held  in  the  CCDANCTR-Studies  Register  and
records  are  linked  between  the  two  registers  through  the  use  of
unique Study ID tags. Coding of trials is based on the EU-Psi coding
manual. Please contact the CCDAN Trials Search Co-ordinator for
further details. Reports of trials for inclusion in the Group's registers
are  collated  from  routine  (weekly),  generic  searches  of  MEDLINE
(1950-), EMBASE (1974-) and PsycINFO (1967-); quarterly searches
of  the  Cochrane  Central  Register  of  Controlled  Trials  (CENTRAL)
and  review-specific  searches  of  additional  databases.  Reports  of
trials are also sought from international trials registers c/o World
Health Organization (WHO) trials portal (ICTRP), drug companies,
handsearching of key journals, conference proceedings and other
(non-Cochrane) systematic reviews and meta-analyses.

Details of CCDAN's generic search strategies can be found on the
Group's website.

Electronic searches

We conducted the following searches (all years) to 16 March 2015.

We  searched  the  CCDANCTR-Studies  Register  using  the  following
terms:

Condition/Comorbidity = panic
AND
Intervention = (attention* or behav* or biblio* or biofeedback or
cognitive  or  collaborative  or  contact  or  counsel*  or  desensiti*  or
educat* or expos* or feedback or ”group” or imag* or interpersonal
or intervention or management or panic or prevention or psycho*
or relaxation or self* or stress* or support* or *therap* or *train* or
treatment or unclear or ”not stated”)

We  searched  the  CCDANCTR-References  Register  using  a  more
sensitive set of terms to identify additional untagged or uncoded
reports of RCTs (Appendix 1).

We conducted a further search of the CCDANCTR to identify reports
of studies for ‘Anxiety Disorders Not Otherwise Specified’ (ADNOS):

The  CCDANCTR-Studies  Register  was  searched  for  CONDITION  =
"Anxiety Disorder*"

We manually screened out pharma studies and studies in children
and adolescents.

We  searched  the  CCDANCTR-References  Register  using  the
following terms to identify additional untagged or uncoded reports
of RCTs for ADNOS:

(“anxiety disorder*” and not (agoraphobi* or panic or (social and
(anxi*  or  phobi*))  or  generalised  or  generalized  or  obsessive  or
compulsive or OCD or PTSD or post-trauma* or “post trauma*” or
posttrauma* )) +(terms for psychotherapies as listed in Appendix 1).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

We manually screened out pharma studies and studies in children
and  adolescents  retrieved  from  this  sensitive  search  of  the
references register.

Supplementary searches

We  conducted  complementary  searches  in  PubMed  (Appendix
2)  as  well  as  in  trials  registries  such  as  the  WHO  International
Clinical  Trials  Registry  Platform  (http://apps.who.int/trialsearch/)
and ClinicalTrials.gov (http://clinicaltrials.gov/).

There were no restrictions on date, language or publication status
applied to the searches.

Searching other resources

Reference lists

training, 

and  timing  of  psychological  therapy  and  control  condition,
therapist 
intervention  components),  participants'
characteristics  (diagnostic  criteria,  percentage  of  agoraphobic
patients),  outcomes,  risk  of  bias  and  publication.  Again,  we
resolved any disagreement either by discussion or by consultation
of  a  fourth  member  of  the  review  team  (TAF).  If  necessary,
we  contacted  authors  of  studies  to  obtain  further  clarification.
Agreement  between  the  data  extractors  with  regard  to  primary
outcomes is reported.

Assessment of risk of bias in included studies

At least two out of three review authors (AP, AT, HI) independently
assessed  the  risk  of  bias  of  the  included  studies  using  the  tool
described  in  the  Cochrane  Handbook  for  Systematic  Reviews  of
Interventions (Higgins 2011). We assessed the following domains.

We checked the reference lists of all included studies and relevant
systematic reviews to identify additional studies missed from the
original electronic searches.

1. Random  sequence  generation  and  allocation  concealment

(selection bias).
2. Therapist  and 

researcher  allegiance, 

treatment 

fidelity

Citation indexes

We conducted a citation search on the Web of Science to identify
articles citing any of the included studies.

Personal communication

We  contacted  trialists  and  subject  experts  for  information  on
unpublished or ongoing studies or to request additional trial data.

(performance bias).

3. Blinding of outcome assessor (detection bias).
4. Incomplete outcome data reporting (attrition bias).
5. Selective outcome reporting (reporting bias).

We assessed and categorised the risk of bias, in each domain and
overall, into:

• low  risk  of  bias,  plausible  bias  unlikely  to  seriously  alter  the

Grey literature

results;

We searched the database OpenSIGLE (http://www.opengrey.eu/)
to  identify  reports  of  trials  not  formally  published  in  books  or
journals.

• high  risk  of  bias,  plausible  bias  that  seriously  weakens

confidence in the results;

• unclear risk of bias, plausible bias that raises some doubt about

Data collection and analysis

Selection of studies

At  least  two  out  of  three  review  authors  (AP,  AT,  HI)  examined
the  titles  and  abstracts  of  references  identified  by  the  electronic
search strategies described above to check whether the study was
likely  to  be  relevant.  We  then  obtained  each  potentially  relevant
study  located  in  the  search  as  a  full  article  and  the  same  two
review authors independently assessed each for inclusion. In the
case  of  discordance,  we  sought  resolution  by  discussion.  When
disagreement  could  not  be  solved  by  discussion,  arbitration  was
provided  by  a  fourth  author  (TAF).  Agreement  between  review
authors  in  the  study  selection  is  reported.  We  evaluated  the
discordance  in  the  selection  of  studies  by  quantifying  both  the
percentage  of  agreement  and  Cohen's  Kappa  (k)  (Cohen  1960).
Where  it  was  not  possible  to  evaluate  the  study  because  of
missing information, we classified the study as a 'Study awaiting
assessment'.  The  reasons  for  the  exclusion  of  trials  are  reported
in the Characteristics of excluded studies table. Decisions made in
the study selection process (along with number of references and
studies,  and  reasons  for  exclusion  of  studies)  are  presented  in  a
PRISMA flow diagram.

Data extraction and management

least  two  out  of  three  review  authors 

At 
(AP,  AT,  HI)
used  a  structured,  pilot-tested,  Excel  data  collection  form  to
independently extract the data from the included studies. Extracted
data concerned: study design, administered interventions (format

the results.

inadequate  details  of 

Where 
randomisation  and  other
characteristics  of  trials  were  provided,  we  classified  the  risk  of
bias  as  unclear,  unless  further  information  could  be  obtained  by
contacting  the  authors.  If  the  assessors  disagreed,  we  made  the
final  rating  by  discussion  or  with  the  involvement  of  another
member  of  the  review  group  (TAF),  if  necessary.  Agreement
between  the  two  independent  raters  in  the  'Risk  of  bias'
assessment is reported (see Risk of bias in included studies).

We  assessed  therapist  and  researcher  allegiance,  as  well  as
treatment  fidelity,  as  possible  sources  of  performance  bias.
Blinding  of  therapists,  the  common  way  to  minimise  the  risk  of
performance bias, is not feasible in these kinds of studies.

We evaluated the risk of detection bias for the first of the primary
outcomes  only.  We  classified  studies  as  having  a  low  risk  of
detection bias when the identification of a patient as a 'remitter'
required at least one observer rating and the observer was blind to
the treatment allocation.

We  separately  calculated  risk  of  attrition  bias  for  short-term  and
long-term outcomes, whenever such outcomes had been extracted.
We classified a study as being at low risk of attrition bias when data
for all randomised patients were available at short and long-term
assessment. In the case of dropouts, a study may still be assessed
as being at low risk of attrition bias when:

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

• missing outcome data were few and balanced in numbers across
intervention groups, with similar reasons for missing data across
groups;

• reasons for missing outcome data were unlikely to be related to

second phase of the study, especially if the condition of interest is
unstable  (Elbourne  2002).  As  this  is  the  case  with  panic  disorder,
randomised cross-over studies were eligible but we only used data
up to the point of the first cross-over.

true outcome;

• missing  data  had  been  imputed  using  appropriate  methods
(last observation carried forward (LOCF) was not considered an
appropriate method in itself. It was considered appropriate only
when the LOCF cases were few and balanced between arms).

Whenever possible, we retrieved study protocols in order to assess
the risk of reporting bias. We considered a study to be at low risk
of reporting bias when the study protocol was available and all of
the  study's  prespecified  (primary  and  secondary)  outcomes  that
are of interest in the review had been reported in the prespecified
way. When the study protocol was not available, we classified the
study as being at unclear risk of reporting bias unless the reported
information was enough to make a judgement (text of this nature
was uncommon).

Measures of treatment effect

Dichotomous data

As the measure of treatment effect for binary outcomes we used the
odds ratio (OR) and its 95% confidence interval (CI).

Continuous data

Since  different  studies  have  used  different  panic  rating  scales,
we  used  the  standardised  mean  difference  (SMD)  and  its  95%
confidence interval (CI).

Endpoint versus change data

We  first  planned  to  use  scale  endpoint  data,  which  typically
cannot  have  negative  values  and  are  easier  to  interpret  from
a  clinical  point  of  view.  However,  as  a  post  hoc  decision,  we
decided  to  use  change  data  in  an  attempt  to  reduce  the  amount
of  heterogeneity  due  to  the  baseline  imbalance  found  across
studies. This decision, which is in line with the Cochrane Handbook
for  Systematic  Reviews  of  Interventions  (Higgins  2011,  section
9.4.5.2: "In some circumstances an analysis based on changes from
baseline will be more efficient and powerful than comparison of final
values”) actually led to a great reduction of heterogeneity, for the
continuous outcome, as compared to the analysis of final scores.
In order to compute the change-from-baseline standard deviations
we followed the method described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011, section 16.1.3.2),
assuming a correlation coefficient of 0.5.

Unit of analysis issues

Cluster-randomised trials

In  cluster-randomised  trials,  groups  of  individuals  rather  than
individuals  are  randomised  to  different  interventions  (Higgins
2011). We planned to include cluster-randomised trials only when
the effects of clustering were taken account of. However, we found
no such cases.

Cross-over trials

Cross-over trials are trials where all participants receive both the
control  and  intervention  treatment  but  in  a  different  order.  The
major  problem  is  a  carry-over  effect  from  the  first  phase  to  the

Studies with multiple treatment groups

For  both  pair-wise  and  network  meta-analyses,  where  a  study
involved  more  than  two  treatment  arms,  especially  in  the  case
of  dismantling  studies,  we  combined  arms  as  long  as  they  could
be regarded as subtypes of the same psychological therapy under
review. When arms could not be regarded as if in each of them a
different subtype of the same intervention was administered, we
compared each arm with the common comparator separately.

When  such  a  situation  occurred,  we  subdivided  the  common
comparator  arm  for  pairwise  meta-analyses  (for  example,  we
halved the sample size and the number of responders of that arm
for  dichotomous  outcomes;  for  continuous  outcomes,  the  mean
and SD will remain the same but we halved the number of patients
included. The common comparator was not subdivided for NMA.

Dealing with missing data

We tried to contact the study authors for all relevant missing data.

Dichotomous outcomes

We  calculated  the  proportion  of  remissions  and  responses  using
an  intention-to-treat  analysis  (ITT)  following  the  principle  'once
randomised  always  analysed'.  To  this  end,  we  assumed  all
randomised  patients  for  which  outcome  data  were  not  available
to  be  non-responders.  This  assumption  has  been  used  in  two
previous NMAs (comparing antidepressants and antimanic drugs)
and  has  proven  to  be  a  sensible  assumption  (Spineli  2013).  We
applied  the  same  principle  to  short  and  long-term  outcomes.
When  dichotomous  outcomes  were  not  reported  but  the  means
and standard deviations on a panic disorder scale were reported,
we calculated the number of responding or remitted participants
according  to  a  validated  imputation  method  (Furukawa  2005).
In  order  to  check  the  reliability  of  imputed  data,  we  used
the  ANOVA  intraclass  correlation  coefficient  (ICC)  to  calculate
agreement between reported and imputed data (absolute numbers
of remitters and responders) whenever they were calculated on the
same scale. The ANOVA ICC was 0.81 (0.58 to 0.93) for short-term
remission and 0.99 (0.94 to 1.000) for short-term response, showing
an excellent correlation between reported and imputed data.

Continuous outcomes

We performed an 'available cases analysis' in which outcomes were
analysed on the basis of a pre-post change. Where change scores
were not reported but baseline and endpoint data were available
(including patients with either a final assessment or a LOCF to the
final assessment as reported in the original report), we calculated
change scores and entered them in the analyses.

Missing statistics

When  only  P  or  standard  error  (SE)  values  were  reported,  we
calculated standard deviations (SDs) (Altman 1996). If none of these
values were available, and in the absence of supplementary data
after requests to the authors, we calculated the SDs according to a
validated imputation method (Furukawa 2006).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Assessment of heterogeneity

Pairwise meta-analyses

For  each  direct  comparison,  we  calculated  the  Chi2  test  and
I2  statistic  in  order  to  detect  the  presence  of  heterogeneity
and,  respectively,  assess  its  degree.  I2  provides  an  estimate
of  the  percentage  of  variability  in  effect  estimates  that  is  due
to  heterogeneity  rather  than  chance  alone  (Higgins  2003).  We
interpreted  I2  values  according  to  the  Cochrane  Handbook  for
Systematic  Reviews  of  Interventions  (Higgins  2011),  section  9.5.2.
We  also  report  τ2,  the  between  study  variance  in  random-effects
model meta-analysis. We also used visual inspection of the forest
plots in order to investigate the presence and nature of statistical
heterogeneity.

Network meta-analysis (NMA)

An assumption underlying NMA is that effect modifiers are similarly
distributed  across  comparisons  in  the  network.  That  means  that
an  effect  modifier  should  be  similar  in  AB  and  BC  trials  in  order
to  obtain  a  valid  AC  estimate.  Equivalent  formulations  of  the
transitivity assumption are presented in Salanti 2012. In order to
verify this assumption, for each comparison we compiled a table
of important trial and patient characteristics and visually inspected
the similarity of factors we considered likely to modify treatment
effect. We also assessed the inclusion and exclusion criteria of every
trial in the network to ensure that patients, trial protocols, etc. were
similar in those aspects which might modify the treatment effect.

Lack of transitivity can be manifested in the data as disagreement
between  direct  and  indirect  evidence  (Caldwell  2005;  Lu  2004;
Lumley  2002).  This  can  be  evaluated  statistically  by  contrasting
the direct and the indirect estimates and calculating a test within
each  closed  loop  (Bucher  1997;  Salanti  2009).  The  percentage  of

inconsistent loops in the network is reported. We examined further
the  data  of  loops  that  appeared  particularly  inconsistent.  As  this
approach  does  not  provide  an  omnibus  test  and  is  associated
with multiple testing we also employed other approaches to make
inferences  about  the  statistical  inconsistency.  More  precisely,  we
performed  a  design-by-treatment  interaction  test  (Higgins  2012).
When a small amount of inconsistency was found, we incorporated
this in the estimation by fitting inconsistency models (Higgins 2012;
Lu 2004).

Assessment of reporting biases

We  examined  the  funnel  plots  for  those  pairwise  comparisons
for  which  at  least  10  studies  were  available.  We  investigated  the
presence  of  small  study  effects  for  the  primary  outcomes  only;
along  with  visual  inspection  of  the  plots,  we  formally  examined
whether  the  association  between  estimated  intervention  effects
and the study size was greater than it might have been expected to
occur by chance.

Data synthesis

Main planned comparisons

The present study is a network meta-analysis and therefore aims to
compare all the listed interventions and control conditions against
one another in terms of the listed primary and secondary outcomes.
In the network, each node represents an experimental or control
condition; comparisons explored in included trials are represented
by lines connecting the nodes. Ideally, the network should consist
of 11 nodes, each connected with all the others, meaning that all
the listed interventions and each possible comparison among them
has been directly explored in at least one included trial (see Figure
1). Please refer to Appendix 3 for details about the software used for
the analyses described below.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 1.   Ideal network of included treatment and control conditions.

Pairwise meta-analyses

For each available comparison explored by at least two trials, we
performed  a  pairwise  meta-analysis  in  order  to  provide  overall
estimates  of  treatment  effect.  Since  we  expected  some  clinical
heterogeneity  between  studies,  we  planned  to  use  a  random-
effects  model  to  incorporate  the  assumption  that  the  different
studies  are  estimating  different,  yet  related,  treatment  effects
(Higgins  2011).  We  therefore  calculated  an  'average'  treatment
effect  across  the  studies  for  each  available  comparison.  For
dichotomous outcomes, we calculated the average odds ratio with
the  95%  CI;  for  continuous  outcomes  we  calculated  the  average
SMD  (or  the  MD  if  all  trials  use  the  same  scale)  with  the  95%  CI.
Studies with zero events in all arms (as in the case of short-term
dropouts) were not included in the analyses.

In  order  to  have  comparable  results  with  the  NMA  (see  below),
beside  performing  standard  pairwise  meta-analyses,  we  also
performed  the  analyses  assuming  a  common  heterogeneity

standard deviation across all comparisons. This way, all pairwise
meta-analyses  were  essentially  analysed  as  random-effects  (they
include  uncertainty  due  to  heterogeneity),  even  for  those
comparisons only being reported by one study.

For this review, the results of pairwise comparisons are part of the
more complex network meta-analyses. However, in order to better
show the available 'direct' evidence, forest plots are presented for
pairwise comparisons when at least 10 studies are available.

Network meta-analysis (NMA)

An indirect comparison allows an estimate of the effect of treatment
B relative to treatment A via a common comparator C by statistically
combining the summary effects from 'A versus C' and 'B versus C'
studies (Caldwell 2005; Glenny 2005). A NMA combines direct and
indirect evidence across a network of studies to make inferences
regarding the relative effectiveness of multiple interventions.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

A NMA is only possible for a connected set of treatments. A network
diagram is constructed for our primary and secondary outcomes in
order to evaluate the extent to which treatments are connected.

We  conducted  a  random-effects  model  NMA,  taking  into  account
the correlations induced by multi-arm trials (Lu 2004; Salanti 2008;
White 2012). For each comparison, an average effect estimate along
with its 95% confidence interval (CI) is reported.

Besides  yielding  relative  treatment  effects  for  each  comparison,
a  NMA  allows  an  estimate  of  the  relative  ranking  of  treatments.
To  rank  the  treatments  according  to  each  outcome  accounting
for  the  uncertainty  in  the  treatment  effects,  we  used  the  surface
under  the  cumulative  ranking  curve  (SUCRA)  (Salanti  2011).  The
absolute  ranks  of  the  treatments  per  outcome  is  presented
using 'Rankograms' that visually show the distribution of ranking
probabilities (Salanti 2011). NMA models typically employ a single
heterogeneity  parameter.  We  reported  it  and,  for  dichotomous
outcomes,  we  judged  its  magnitude  against  the  distribution  of
values typically found in Cochrane reviews, as presented in Turner
2012.

Subgroup analysis and investigation of heterogeneity

Subgroup  and  meta-regression  analyses  are  often  exploratory  in
nature and should be interpreted cautiously. Firstly, because these
analyses  often  involve  multiple  analyses,  they  may  yield  false
positive results; secondly, because these analyses lack power and
are more likely to result in false negative results. Keeping in mind
the  above  reservations,  we  performed  meta-regression  analyses
to  investigate,  for  the  first  of  the  primary  outcomes  only  (short-
term remission of panic disorder with or without agoraphobia), the
following candidate explanatory variables.

• Year  of  publication  (measured  as  a  continuous  variable)  as  a
general proxy for various aspects (e.g. trial quality, definition of
diagnosis and outcomes).

• Mean number of treatment sessions: fewer than four sessions,
from four to 12 sessions, more than 12 sessions. Considerable
differences exist in the number of treatment sessions between
studies.  It  seems  reasonable  to  expect  this  variability  to  yield
some degree of heterogeneity.

• Therapist training: therapist with or without formally recognised
in  the  type  of  psychological  therapy

specific  training 
administered.

• Percentage  of  patients  with  agoraphobia:  measured  as  a

continuous variable.

• Percentage  of  patients  with  depression:  measured  as  a
continuous  variable.  We  explored  this  variable  in  order  to
investigate if a psychological intervention specifically designed
for  panic  disorder  is  less  effective  in  patients  with  depressive
comorbidity.

• Percentage  of  patients  on  drug  treatment:  measured  as  a
continuous  variable.  Since  we  were  not  including  studies
exploring  combined  therapies,  drug-treated  patients,  when
included,  were  often  those  who  meet  the  diagnosis  of  panic
disorder despite being on psychopharmacologic treatment. By
considering  such  patients  as  being  'drug-resistant',  we  may
have expected them to have a poorer outcome; however, since
there  is  evidence  that  combined  therapies  are  more  effective
than psychological therapies alone in the short term (Furukawa
2007),  we  could  also  have  expected  that  such  patients  had  a

Cochrane Database of Systematic Reviews

better outcome compared with patients who were not on drug
treatment.

Sensitivity analysis

The process of undertaking a systematic review and meta-analysis
involves  a  sequence  of  decisions,  some  of  which  are  somewhat
arbitrary or unclear (Higgins 2011). A sensitivity analysis is a repeat
of the primary analysis, substituting alternative decisions or range
of values for decisions that were arbitrary or unclear. We planned
to  perform  the  following  sensitivity  analyses  for  the  first  of  the
primary  outcomes  only  (short-term  remission  of  panic  disorder
with or without agoraphobia).

• Restrict the inclusion in the analyses only to studies considered
to  be  at  low  risk  of  selection  and  detection  bias  (i.e.
adequate allocation sequence generation, adequate allocation
concealment, blinding of assessor).

• Exclude from the analyses group therapy trials.
• Exclude  from  the  analyses  trials  in  which  a  concomitant

pharmacotherapy is allowed.

• Exclude  from  the  analyses  trials  in  which  drug  therapy  is  not

stabilised*.

• For pairwise meta-analyses, use a fixed-effect model instead of

a random-effects model.

(*)  Drug  therapy  was  considered  stabilised  when:  1)  drug
administration remained stable before randomisation (for at least
four  weeks  in  the  case  of  antidepressants  and  for  at  least  two
weeks  in  the  case  of  benzodiazepine  and  other  drugs),  and  2)
patients were asked to avoid any drug therapy change for the whole
duration of the study.

'Summary of findings' tables

Aiming to summarise the results in a way that could be as 'clinically
informative' as possible, we originally planned to present the main
results  of  pairwise  meta-analyses  in  three  'Summary  of  findings'
tables.

In  a  first  table  we  planned  to  present  the  NMA  results  of  the
comparison  between  the  psychological  therapy  that  would  have
ranked  first  versus  the  no  treatment  condition  (NT)  in  order  to
show the effects of the supposedly most effective treatment when
compared to no intervention at all.

In  a  second  table  we  planned  to  present  the  NMA  results  of  the
comparison  between  the  psychological  therapy  that  would  have
ranked  first  versus  supportive  psychotherapy  (SP)  in  order  to
show the effects of the supposedly most effective treatment when
compared to a non-specific psychological intervention.

In  a  third  table  we  planned  to  present  the  NMA  results  of  the
comparison  between  the  psychological  therapy  that  would  have
ranked first versus the one that would have ranked second, in order
to  show  the  magnitude  of  the  effect  sizes  across  the  two  active
interventions representing the supposedly most viable therapeutic
options.

Since  the  'wait  list'  and  'attention  or  psychological  placebo'
conditions  are  useful  comparators  for  clinical  trials,  but  do
not  represent  treatment  options  in  a  'real'  clinical  setting,  we
considered  the  choice  of  using  the  NT  and  SP  conditions  as
comparators to be more clinically informative.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

As  a  post-hoc  decision,  we  decided  to  add  an  extra  SoF  table
to  summarize  the  overall  results  of  network  meta-analyses  by
presenting  the  ranking  of  treatments  yielded  by  these  analyses
for  each  outcome.  We  came  to  this  decision  because  we  found
the simple presentation of pairwise comparisons, singularly taken,
insufficient  to  adequately  depict  the  overall  complexity  of  this
type  of  analyses.  SoF  table  formats  for  NMAs  are  currently
under  development  by  the  Cochrane  GRADEing  Group  (http://
methods.cochrane.org/gradeing/research),  so  we  adapted  the
standard  SoF  for  pairwise  comparisons  in  order  to  present
treatment hierarchy.

All the presented Sof tables include an assessment of the quality
of  evidence  obtained  by  following  the  approach  proposed  by
the Grading of Recommendations, Assessment, Development and
Evaluation  (GRADE)  Working  Group.  This  approach  consists  in
rating  the  quality  of  evidence  according  to  study  design  (RCT  or
observational  studies)  and  other  five  factors:  risk  of  bias  of  the
included  studies,  consistency  of  results,  directness  of  evidence,
precision  of  results  and  presence  of  publication  bias.  It  must
be  noted  that  at  the  time  of  writing,  standard  GRADE  tools
(usually  employed  to  assess  the  quality  of  evidence  in  pairwise
meta-analyses)  were  not  yet  developed  for  NMA,  where  many

Cochrane Database of Systematic Reviews

comparisons,  each  with  its  own  quality  of  evidence,  contribute
to  the  overall  quality  with  different  weights.  Therefore,  our
assessments of the quality of evidence for the results of network
meta-analyses  were  implemented  by  adapting  the  GRADE  tools
to  this  type  of  analysis,  in  line  with  the  methodology  suggested
in  Salanti  2014  and  with  interim  guidance  from  the  Cochrane
Comparing  Multiple  Interventions  Group  (Cochrane  Comparing
Multiple Interventions Group).

R E S U L T S

Description of studies

Results of the search

The number of references identified by the searches, run to March
2015,  was  2468.  Of  these,  1482  remained  after  de-duplication.
We  excluded  885  references  after  assessment  of  the  titles  and
abstracts. We retrieved a total of 597 full-text papers (345 studies)
for  full  inspection.  Of  these  345  studies,  we  excluded  269  with
reasons,  five  were  ongoing  trials  and  11  presented  too  little
information to be classified. We included the remaining 60 studies
in the final qualitative analyses; among these, we also included 54
in the final quantitative analyses. See Figure 2 for a PRISMA flow
diagram depicting the study selection process.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 2.   Study selection process: PRISMA flow diagram

Cohen's weighted kappa among assessors for the selection of 338
studies was 0.66 (percentage of agreement = 79.6%).

We contacted authors of 67 studies for additional information: in
25 cases we received a complete reply, in eight cases we received
an incomplete reply and in the remaining 34 cases we received no
reply. For six studies we have been unable to contact the author.

Included studies

We  included  60  studies  in  this  review,  among  which  we  included
54  in  quantitative  analyses.  Five  studies  were  published  only  as
doctoral dissertations (Creager Berger 2001; Griegel 1995; Karekla
2004;  Muncy  1991),  or  briefly  described  in  a  book  chapter  (Beck
1987; Karekla 2004).

The characteristics of the included studies can be summarised as
follows (see also Characteristics of included studies).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Design

All included studies were randomised controlled trials. In only one
case the study had a cross-over design (Beck 1992), although only
patients firstly assigned to the control group did actually cross over
in  the  second  phase  of  the  treatment.  Only  three  studies  had  a
multicentre design.

Sample sizes

In four cases the total number of randomised patients was unclear;
for  the  remaining  56  studies,  the  total  sample  size  went  from  17
(Malbos 2011) to 369 patients (Gloster 2010), with a mean sample
size of 60 patients (standard deviation (SD) 52). The total number of
patients included in the analyses is 3021.

Setting

Apart from one single case (Hoffart 1995), which was conducted in
an  inpatient  setting,  all  studies  were  conducted  in  an  outpatient
setting.

Participants

The  presence  of  agoraphobia  was  never  an  exclusion  criteria.
Participants were therefore diagnosed with panic disorder with or
without agoraphobia, and diagnosis was mostly based on DSM-III,
DSM-III-R or DSM-IV; in only one case it was based on ICD-10.

Age  usually  ranged  between  30  and  40  years.  The  percentage  of
agoraphobic patients, when specified, ranged from 18% to 100%,
being  above  65%  in  the  majority  of  cases.  In  about  half  of  the
included studies participants were required to be off medication for
the duration of the trial; in the remaining cases, the percentage of
patients on drug treatment, when reported for the full intention-to-
treat (ITT) sample, varied from 19% to 67%. In only a few studies
comorbid depression was an exclusion criteria; the percentage of
depressed patients in the remaining cases, when reported for the
full ITT sample, varied from 7% to 52%.

Interventions

Among  experimental  interventions,  cognitive  behaviour  therapy
(CBT) was by far the most studied (42 of the 54 studies included in
quantitative analyses), followed by behaviour therapy (13 studies)
and  physiological  therapies  (12  studies).  Other  psychological
therapies  were  studied  to  a  lesser  degree:  CT  in  six  studies,  SP
in  three  studies,  3W  in  two  studies,  PD  in  two  studies  and  PE  in
one  study.  In  the  majority  of  studies,  the  control  condition  was
represented by a wait list (30 studies); APP was used in only three
studies and NT in two.

Psychological therapy was individually administered in 18 studies,
whereas  a  group  therapy  was  used  in  13  studies.  In  one  case
patients could receive both types of therapy even within the same
study arm. In 22 studies the therapy format was not specified. The
number of sessions went from 1 to 24 (the average was 10 sessions):
sessions were weekly in almost every study. Each session could last
from 30 to 150 minutes (average 73 minutes).

Therapists  were  specifically 
the  administered
intervention  in  most  of  the  studies  (n  =  37).  No  specific  training
was required in six studies. No detail about therapist training was
reported in the remaining 11 studies.

trained 

in 

Cochrane Database of Systematic Reviews

Only  25  of  the  54  studies  included  in  quantitative  analyses
specified  the  percentage  of  patients  receiving  a  drug  therapy
during  the  trial.  Among  these,  12  studies  reported  that  patients
were  not  receiving  any  drug  therapy;  the  remaining  13  studies
reported  percentages  from  19%  to  67%  (average  value  45%).
Drug  stabilisation  before  study  commencement  was  required  in
27  studies,  and  the  stabilisation  period  ranged  from  1  to  24
weeks. Furthermore, 30 studies required patients not to change the
dosages of taken medications for the entire duration of the study
whereas four studies left the patients free to change dosages; in the
remaining 20 studies no information on this issue were reported.

Outcomes

In  terms  of  outcomes,  we  observed  great  variability.  The  most
common  measures  were:  panic  frequency,  Anxiety  Sensitivity
Index  (ASI),  Body  Sensations  Questionnaire  (BSQ),  Agoraphobic
Cognitions  Questionnaire  (ACQ),  Panic  Disorder  Severity  Scale
(PDSS), Mobility Inventory for Agoraphobia (MI), Fear Questionnaire
(FQ),  State–Trait  Anxiety  Inventory  (STAI)  and  Beck  Anxiety
Inventory (BAI). Remission was often defined as being panic-free,
although many other measures were used, such as scoring below
a certain cut-off for any of the above mentioned scales, or meeting
a composite index of high end-state functioning (where the set of
criteria varied among different studies).

Excluded studies

We  excluded  a  total  of  269  studies  because  they  did  not  meet
our inclusion criteria regarding the type of study (n=60), the type
of participants (n=102) or the type of interventions (experimental
intervention, n=57; comparator intervention, n=50).

Among  the  excluded  studies,  12  initially  seemed  to  meet  our
inclusion criteria, but were subsequently excluded for the reasons
reported in Characteristics of excluded studies.

Ongoing studies

We  identified  five  ongoing  studies.  Two  of  these  are  two-arm
trials exploring respectively CBT versus BT and CBT versus NT. The
remaining four studies are multi-arm trials exploring, respectively:
two  different  types  of  CBT  versus  WL;  CBT  versus  two  different
types of BT; CBT versus PD versus PT; randomised CBT/PD versus
chosen CBT/PD versus WL. For further details, see Characteristics of
ongoing studies.

Studies awaiting classification

We identified 11 potentially eligible studies that have not yet been
incorporated into the review. Details of these studies are presented
in  the  table  of  Characteristics  of  studies  awaiting  classification.
Apart from the case of Franklin 1990 (for which we were unable to
contact  the  authors),  all  other  authors  have  been  contacted.  We
received  a  reply  for  two  studies:  Irgens  2009  (author  unwilling  to
release  full  report  before  publication)  and  Richards  1997  (author
himself was unable to retrieve the full paper).

Risk of bias in included studies

For  details  of  the  risk  of  bias  judgements  for  each  study,  see
Characteristics  of  included  studies.  A  graphical  representation  of
the  overall  risk  of  bias  in  included  studies  is  presented  in  Figure
3  and  Figure  4.  The  reporting  and  methodological  quality  of
included studies was overall not good. This type of reporting has

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

been  associated  with  an  overestimate  of  the  estimate  of  effect
(Schulz  1995),  and  this  should  be  considered  when  interpreting
the results. Agreement between the two independent raters in the
'Risk of bias' assessment was overall low, ranging from 47% to 88%
(weighted Kappa showed an even lower agreement, although this

estimate  may  be  negatively  influenced  by  skewed  distribution  of
assessments): this may be due to the relatively poor expertise of
raters together with the generally low quality of reporting and to
the high degree of methodological variability between studies.

Figure 3.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   'Risk of bias' summary. Note that we left the boxes empty when the RoB assessment was not applicable
(e.g. in the case of incomplete outcome data in the long term when the study did not report any long term measure
that could be included in the analyses).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   (Continued)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   (Continued)

Allocation

Short-term

The majority of studies did not report the methods of generating
the random sequence, nor details about allocation concealment.
We assessed only four studies as being at low risk of bias for both
sequence  generation  and  allocation  concealment  (Botella  2004;
Malbos 2011; Meulenbeek 2008; Milrod 2006a). Agreement between
the two independent raters in the risk of allocation bias assessment
was 88% (weighted Kappa 0.47 for sequence generation and 0.29
for allocation concealment).

Blinding

We have rated the risk of bias for blinding of outcome assessment
in  relation  to  the  first  of  our  primary  outcomes  only  (short-term
remission),  whenever  available  (either  reported  or  imputed  from
continuous scale), in relation to the measure actually entered in the
analyses (in this sense, our aim was not to rate study quality but
rather the quality of available data). We considered eight studies
to be at low risk of bias (Al Kubaisy 1992; Beutel 2013; Clark 1994;
Clark 1999; Griegel 1995; Hoffart 1995; Klosko 1988; Milrod 2006a);
we considered 22 studies to be at high risk of bias; 10 studies did not
report enough information to make a judgement. In the remaining
cases,  we  did  not  rate  blinding  of  outcome  assessment  because
data regarding short-term remission were not available. Agreement
between the two independent raters in the risk of detection bias
assessment was 47% (weighted Kappa 0.16).

Incomplete outcome data

We have rated the risk of incomplete outcome reporting when at
least one relevant outcome was available (as for blinding, our aim
was  not  to  rate  study  quality  but  rather  the  quality  of  available
data). Agreement between the two independent raters in the risk
of  attrition  bias  assessment  was  59%  (weighted  Kappa  0.36)  for
short-term outcomes and 50% (weighted Kappa 0.12) for long-term
outcomes.

We  have  rated  the  risk  of  bias  for  incomplete  outcome  data
assessment in relation to short-term outcomes whenever at least
one of such outcomes was reported (ST-remission, ST-response, ST-
dropouts, ST-improvement as measured on a continuous scale). We
have rated 22 studies as being at low risk of attrition bias and 27
studies  as  being  at  high  risk;  five  studies  did  not  report  enough
information to make a judgement.

Long-term

We  have  rated  the  risk  of  bias  for  incomplete  outcome  data
assessment  in  relation  to  long-term  remission  or  response,
whenever reported. Long-term outcome data were available in 13
studies, among which we rated five as being at low risk of attrition
bias  and  six  as  being  at  high  risk;  three  studies  did  not  report
enough information to make a judgement. In two cases (Cottraux
2009; Shear 1994), we did not enter long-term outcome data in the
analyses because of excessive loss of data at follow-up assessments
(see also Secondary outcomes).

Selective reporting

A  study  protocol  was  available  for  seven  of  the  included  studies
(Beutel  2013;  Cottraux  2009;  Hendriks  2010;  Meulenbeek  2008;
Meyerbroker  2011;  Milrod  2006a;  Wollburg  2011).  We  rated  only
three  studies  as  being  at  low  risk  of  selective  outcome  reporting
(Cottraux 2009; Hendriks 2010; Milrod 2006a). We rated 12 studies
as  being  at  high  risk  (assessment  was  sometimes  possible  in  the
absence of a study protocol, when the results of measures planned
in  the  methods  section  were  omitted  from  the  study  report).  In
all  the  remaining  cases  reporting  bias  could  not  be  assessed.
Agreement  between  the  two  independent  raters  in  the  risk  of
reporting bias assessment was 85% (weighted Kappa 0.56).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Other potential sources of bias

Researcher allegiance

In almost 50% of cases we rated studies as being at high risk of bias
due  to  researcher  allegiance,  which  can  be  considered  a  general
proxy of various forms of bias that could affect results in favour of
one or more study arms towards which authors may have a vested
interest  (i.e.  authors  may  be  involved  in  the  conceptualisation
of  the  treatment  or  in  the  developing  of  a  treatment  manual).
In  this  sense,  this  source  of  bias  can  be  considered  analogue  to
sponsorship bias in studies involving pharmacological treatments.
Agreement  between  the  two  independent  raters  in  the  risk  of
researcher allegiance bias assessment was 50% (weighted Kappa
0.34).

Therapist allegiance

We first hypothesised that therapist allegiance may constitute a risk
of bias (as backed up by our own clinical sense and some literature).
When we rated this item, however, the agreement was low. We went
back  to  the  original  studies  and  found  that  they  rarely  provided
enough  information  to  make  solid  judgements.  We  therefore  re-
rated the risk of bias for therapist allegiance as 'unclear' when there
was  not  enough  information,  which  was  the  case  for  all  studies
except  two,  that  is  Addis  2004  and  Telch  1993,  rated  as  being
respectively at low and high risk of bias. Agreement between the
two  independent  raters  in  assessing  the  risk  of  this  performance
bias was 55% (weighted Kappa -0.02).

Treatment fidelity

We  rated  26  of  the  included  studies  as  being  at  low  risk  of  bias
with regard to treatment fidelity and three studies as being at high
risk.  In  the  remaining  31  studies,  the  available  information  was
not  enough  to  make  a  judgement.  Agreement  between  the  two

Cochrane Database of Systematic Reviews

independent raters in the risk of this performance bias assessment
was 79% (weighted Kappa 0.63).

Effects of interventions

to  no 

treatment 

therapy  compared 

See:  Summary  of  findings  for  the  main  comparison  Cognitive
behaviour 
for  panic
disorder  with  or  without  agoraphobia  in  adults;  Summary  of
findings  2  Cognitive  behaviour  therapy  compared  to  supportive
psychotherapy  for  panic  disorder  with  or  without  agoraphobia
in  adults;  Summary  of  findings  3  Cognitive  behaviour  therapy
compared  to  psychodynamic  psychotherapy  for  panic  disorder
with  or  without  agoraphobia  in  adults;  Summary  of  findings
4  Network  meta-analysis  rankings  of  psychological  therapies  for
panic disorder with or without agoraphobia in adults

1. Short-term remission of panic disorder with or without
agoraphobia

1.1 Network plot

Figure  5  shows  a  graphical  representation  of  the  network.
Nodes  and  edges  were  weighted  according  to  the  number  of
studies  including  the  respective  treatments  and  comparisons.
As  shown  in  the  figure,  short-term  (ST)-remission  data  were
available for six active and two comparison interventions. No study
explored  ST-remission  for  third-wave  CBT  (3W),  psychoeducation
(PE)  and  attention-psychological  placebo  (APP).  CBT  was  the
most  studied  intervention,  followed  by  behaviour  therapy  (BT),
physiological therapies (PT), cognitive therapy (CT) and supportive
psychotherapy (SP). Waiting list (WL) was the most studied among
comparator interventions. The most studied comparison was CBT
versus  WL,  followed  by  CBT  versus  BT.  The  network  appeared
to  be  well  connected,  with  the  only  exception  being  supportive
psychotherapy  (SP),  studied  only  in  the  comparison  versus  CBT.
Forty studies including 2491 participants contributed data to this
outcome.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 5.   Short-term remission: network plot

Cochrane Database of Systematic Reviews

1.2 Pairwise meta-analyses and their heterogeneity and small
study effects

Pairwise meta-analyses

As explained in the methods section, in order to have comparable
results with the NMA, beside standard pairwise meta-analyses, we
have performed the analyses assuming a common heterogeneity
standard  deviation  across  all  comparisons.  The  (common)
heterogeneity standard deviation was estimated to be τ = 0.69.

As  summarised  in  the  left  part  of  Table  1,  direct  evidence  was
available for 15 comparisons. For seven of these comparisons there
was only one study available; for the remaining eight comparisons

we  performed  a  random-effects  meta-analysis.  As  shown  in  the
table, only two comparisons were informed by 10 or more studies,
that is CBT versus WL (18 studies) and CBT versus BT (10 studies):
their forest plots are respectively presented in Figure 6 and Figure 7.
Among psychological therapies, four were shown to be significantly
better than WL in terms of short-term remission: PT (four studies;
odds  ratio  (OR)  4.8,  95%  confidence  interval  (CI)  1.4  to  17),  BT
(three studies; OR 8.3, 95% CI 2.3 to 25), CT (two studies; OR 8.3,
95% CI 1.6 to 50) and CBT (18 studies; OR 7.7, 95% CI 4.5 to 14.3).
The comparison CBT versus BT is the only comparison among two
active treatments that showed a statistically significant difference
in  terms  of  short-term  remission,  which  was  in  favour  of  CBT  (10
studies; OR 2.09, 95% CI 1.10 to 3.97).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 6.   Short-term remission: forest plot for the comparison WL vs CBT

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 7.   Short-term remission: forest plot for the comparison CBT vs BT

Heterogeneity

Small study effects

The  I2  values  and  their  95%  CIs,  for  the  comparisons  reported  in
three  studies  or  more,  are  presented  in  Table  2.  As  shown  in  the
table,  we  observed  the  highest  I2  values  in  the  comparisons  CBT
versus  WL  (I2  =  58,1%)  and  PT  versus  WL  (I2  =  56%).  According
to the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011, section 9.5.2) these values suggest that, in these two
comparisons, a moderate percentage of the observed variability in
the effect estimates was due to heterogeneity rather than sampling
error  (chance).  In  the  comparison  CBT  versus  WL,  heterogeneity
appeared to be related to small study effect (see below); in the case
of PT versus WL (four studies), heterogeneity was due to the study
Griegel 1995, a three-arm trial (PT versus PT versus WL) in which
no remission (i.e. panic-free status) was observed in the two active
treatment arms whereas one case of remission was observed in the
wait list. In this study, therefore, the unexpected OR was due to the
low number of events across all arms.

Following  the  protocol,  we  produced  funnel  plots  for  all
comparisons  appearing  in  more  than  10  studies.  There  were  two
comparisons appearing in 10 studies or more, that is WL versus CBT
(Figure 8) and CBT versus BT (Figure 9). From the first funnel plot
there was evidence of asymmetry. More specifically, small studies
were missing in the lower right part of the funnel plot. This means
that small studies comparing WL to CBT that (relatively) favour WL
seemed to be missing: in other words, small studies showed CBT
to be more efficacious. We performed a meta-regression for the WL
versus CBT comparison, which formally confirmed the presence of a
statistically significant correlation between the effect size (log odds
ratio) and the variance. The contour-enhanced funnel plot for the
comparison  WL  versus  CBT  (Figure  10)  showed  that  studies  were
missing in the area of non-significance, thus suggesting the role of
publication bias behind the small study effect (SSE). We found no
evidence of asymmetry in the funnel plot for the comparison CBT
versus BT.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 8.   Short-term remission: funnel plot for the comparison CBT vs WL

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 9.   Short-term remission: funnel plot for the comparison CBT vs BT

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 10.   Short-term remission: contour-enhanced funnel plot for the comparison CBT vs WL

1.3 Network meta-analysis and its inconsistency

Network meta-analysis

As  explained  in  the  previous  paragraph,  it  was  evident  from  the
funnel plots that there were small study effects (SSE) present in the
network for the comparison CBT versus WL. We found it reasonable
to  assume  that  there  were  SSE  in  all  other  comparisons  versus
WL,  even  though  we  might  not  have  had  enough  studies  to  see
this  effect.  The  presence  of  SSE  implies  that  a  simple  NMA  may
produce  biased  results.  For  this  reason  we  performed  a  network
meta-analysis  adjusting  for  SSE  in  studies  comparing  all  other
treatments to WL, by regressing on the variance of the study (see
Discussion).  We  performed  the  network  meta-analysis  adjusted
for  SSE  in  WinBUGS.  Thus  the  results  are  expressed  in  terms  of
credible intervals (CrI) and we use the median (instead of the mean)
because the posterior distribution of the estimated odds ratios is
asymmetrical.

Results  of  the  network  meta-analysis  (NMA)  for  short-term
remission, unadjusted and adjusted for SSE, are presented in Table
1.  Indirect  evidence  could  be  calculated  for  13  comparisons  for
which direct evidence was unavailable. The comparison between
CBT  and  WL  remained  statistically  significant  also  within  the

context  of  NMA,  showing  an  OR  of  3.0  in  favour  of  CBT  (95%  CrI
1.5  to  6.3)  in  the  analyses  adjusted  for  SSE  (note  that  the  point
estimate in standard NMA was higher, with an OR of 8.3). Although
unadjusted NMA basically confirmed the results of pairwise meta-
analyses  for  PT,  CT  and  BT  in  the  comparison  versus  WL,  results
ceased to be statistically significant in the NMA adjusted for SSE.
We found supportive psychotherapy (SP) to be significantly better
than  WL  (OR  4.5,  CrI  1.3  to  16.7);  however,  this  finding  must  be
interpreted  with  caution  since  SP  is  included  in  the  network  as
a  node  with  a  single  connection  (see  Discussion).  Finally,  two
comparisons among active treatments, that is CBT versus BT and
CBT versus PT, showed a statistically significant difference in terms
of short-term remission, in both cases in favour of CBT, with an OR
respectively of 1.77 (CrI 1.02 to 3.11) and 1.95 (CrI 1.02 to 3.97).

Network heterogeneity and inconsistency

For both adjusted and unadjusted NMAs, the estimated values of
heterogeneity lay well within the range of values usually found in
Cochrane reviews, as presented by Turner 2012.

We compiled a table of important trial and patient characteristics
including  therapy  duration  and  percentage  of  agoraphobic,
depressed and drug treated patients. Its visual inspection showed

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

that  those  effect  modifiers  were  similarly  distributed  across
comparisons  in  the  network:  we  therefore  concluded  that  there
wasn't important evidence against the transitivity assumption.

We  compared  the  inconsistency  factors  using  the  loop-specific
approach  (where  we  allow  the  same  τ  for  all  comparisons  in  a
loop) before and after the adjustment for small study effects. We
observed  no  important  differences  and  all  inconsistency  factors

were  statistically  non-significant  in  both  cases.  One,  however,
should  note  that  this  does  not  constitute  a  proof  for  consistency
in  the  network:  some  of  the  loops  include  few  studies  and  the
corresponding  factors  are  estimated  with  much  uncertainty.  In
Figure  11  we  give  all  inconsistency  factors  for  the  network.  As
shown in the figure, we observed the highest inconsistency factor
in the loop PT-CBT-PD.

Figure 11.   Short-term remission: inconsistency factors for the network

The  design-by-treatment  interaction  model  provided  no  proof  of
global  inconsistency  in  the  network  (Chi2  =  4.32  with  13  degrees
of  freedom;  P  value  for  the  null  hypothesis  of  consistency  in  the
network  0.98).  Also,  using  the  design-by-treatment  inconsistency
model we got an estimate of τ = 0.85, a value higher than the one
we obtained from the consistency model. Thus, we conclude that
there was no proof of inconsistency in the network. Again, this does
not constitute a proof of the absence of consistency because the
network was underpowered to detect any important disagreement
between direct and indirect evidence.

1.4 Ranking of treatments

The  ranking  of  treatments  with  respect  to  short-term  remission,
according  to  the  surface  under  the  cumulative  ranking  curve
(SUCRA) value derived from NMA adjusted for small study effects, is
presented in Table 3. We observed the highest rankings respectively
for  supportive  psychotherapy,  cognitive  behaviour  therapy  and
psychodynamic  therapy.  However,  results  regarding  supportive
psychotherapy  must  be  interpreted  with  caution  because,  as
specified  earlier,  SP  is  included  in  the  network  as  a  node  with  a

single connection to the network, being compared only with CBT
(three studies, OR 1.5 in favour of SP, 95% CrI 0.6 to 4).

2. Short-term response of panic disorder with or without
agoraphobia

2.1 Network plot

Figure 12 shows a graphical representation of the network. Nodes
and  edges  were  weighted  according  to  the  number  of  studies
including the respective treatments and comparisons. The network
is  similar  to  the  one  for  ST-remission:  as  shown  in  the  figure,  ST-
response  data  were  available  for  six  psychological  therapies  and
two control interventions. No study explored ST-response for third-
wave CBT (3W), psychoeducation (PE) and attention-psychological
placebo (APP). CBT appeared to be the most studied intervention,
followed  by  behaviour  therapy  (BT),  physiological  therapies  (PT),
cognitive  therapy  (CT)  and  supportive  psychotherapy  (SP).  Wait
list  (WL)  was  the  most  studied  among  comparator  interventions.
The most studied comparison was CBT versus WL, followed by CBT
versus  BT.  The  network  appeared  to  be  well  connected,  with  the
only exception being supportive psychotherapy (SP), studied only

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

in the comparison versus CBT. Thirty-seven studies including 2240
participants contributed data to this outcome.

Figure 12.   Short-term response: network plot

2.2 Pairwise meta-analyses and their heterogeneity and small
study effects

Pairwise meta-analyses

As  for  short-term  remission, 
in  order  to  have  comparable
results  with  the  NMA  we  have  performed  the  pairwise  meta-
analyses  assuming  a  common  heterogeneity  variance  across  all
comparisons. The (common) heterogeneity standard deviation was
estimated to be τ = 0.55.

As  summarised  in  the  left  part  of  Table  4,  direct  evidence  was
available for 15 comparisons. For eight of these comparisons there
was only one study available; for the remaining seven comparisons

we  performed  a  random-effects  meta-analysis.  As  shown  in  the
table, only two comparisons were informed by 10 or more studies,
that is CBT versus WL (17 studies) and CBT versus BT (10 studies):
their  forest  plots  are  respectively  presented  in  Figure  13  and
Figure 14. Among psychological therapies, three were shown to be
significantly  better  than  WL  in  terms  of  short-term  response:  PT
(four studies; OR 6.67, 95% CI 2.27 to 20), BT (four studies; OR 3.13,
95% CI 1.37 to 7.14) and CBT (17 studies; OR 5.26, 95% CI 3.23 to 20).
The comparison CBT versus BT is the only comparison among two
active treatments that showed a statistically significant difference
in  terms  of  short-term  remission,  which  was  in  favour  of  CBT  (10
studies; OR 1.78, 95% CI 1.0 to 3.18).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 13.   Short-term response: forest plot for the comparison WL vs CBT

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 14.   Short-term response: forest plot for the comparison CBT vs BT

Heterogeneity

Small study effects

I2 values and their 95% CIs, for the comparisons reported in three
studies or more, are presented in Table 5. As shown in the table, we
observed the highest I2 values in the comparisons CBT versus PT
(I2 = 45%) and WL versus CBT (I2 = 39%). According to the Cochrane
Handbook  for  Systematic  Reviews  of  Interventions  (Higgins  2011,
section 9.5.2) these values suggest that, in these two comparisons,
a  moderate  percentage  of  the  observed  variability  in  the  effect
estimates  was  due  to  heterogeneity  rather  than  sampling  error
(chance).  In  the  case  of  CBT  versus  PT  (four  studies)  we  could
not find a clear explanation for the observed heterogeneity; in the
comparison CBT versus WL heterogeneity appeared to be related
to small study effects (see below), as was the case for short-term
remission.

Following  the  protocol,  we  produced  funnel  plots  for  all
comparisons  appearing  in  more  than  10  studies.  There  were  two
comparisons  appearing  in  10  studies  or  more,  that  is  WL  versus
CBT (Figure 15) and CBT versus BT (Figure 16). From the first funnel
plot  there  was  evidence  of  asymmetry.  More  specifically,  small
studies were missing in the lower right part of the funnel plot. This
means  that  small  studies  comparing  WL  to  CBT  that  (relatively)
favour  WL  seemed  to  be  missing:  in  other  words,  small  studies
showed  CBT  to  be  more  efficacious.  Similar  to  ST-remission,  the
contour-enhanced funnel plot for the comparison WL versus CBT
(not  presented)  showed  that  studies  were  missing  mainly  in  the
area  of  non-significance,  thus  suggesting  the  role  of  publication
bias  behind  the  SSE.  We  found  no  evidence  of  asymmetry  in  the
funnel plot for the comparison CBT versus BT.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 15.   Short-term response: funnel plot for the comparison WL vs CBT

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 16.   Short-term response: funnel plot for the comparison CBT vs BT

2.3 Network meta-analysis and its inconsistency

Network meta-analysis

As  was  the  case  for  short-term  remission,  it  was  evident  from
the funnel plots that there were small study effects (SSE) present
in  the  network  for  the  comparison  CBT  versus  WL.  We  found  it
reasonable to assume that there were SSE in all other comparisons
versus  WL,  even  though  we  might  not  have  had  enough  studies
to  see  this  effect.  For  this  reason  we  performed  a  network  meta-
analysis adjusting for SSE in studies comparing all other treatments
to  WL,  by  regressing  on  the  variance  of  the  study.  We  performed
the network meta-analysis adjusted for SSE in WinBUGS. Thus the
results are expressed in terms of credible intervals and we use the
median (instead of the mean) because the posterior distribution of
the estimated odds ratios is asymmetrical.

Results  of  the  network  meta-analysis  (NMA)  for  short-term
response, unadjusted and adjusted for SSE, are presented in Table
4.  Indirect  evidence  could  be  calculated  for  13  comparisons  for
which  direct  evidence  was  unavailable.  The  three  comparisons
CBT  versus  WL,  BT  versus  WL  and  PT  versus  WL  lost  statistical
significance within the context of NMA adjusted for SSE. The same
happened for the comparison CBT versus BT. Interestingly, all cited

comparisons  showed  a  statistically  significant  difference  in  the
standard NMA (central part of Table 4), but lost significance when
adjusting the analyses for SSE. The only comparison that showed a
statistically significant difference in the NMA adjusted for SSE was
CBT versus NT (indirect evidence only), with an OR of 7.14 (95% CrI
1.25 to 50).

Network heterogeneity and inconsistency

For both adjusted and unadjusted NMAs, the estimated values of
heterogeneity lay well within the range of values usually found in
Cochrane reviews, as presented by Turner 2012.

We compiled a table of important trial and patient characteristics
including  therapy  duration  and  percentage  of  agoraphobic,
depressed and drug treated patients. Its visual inspection showed
that  those  effect  modifiers  were  similarly  distributed  across
comparisons  in  the  network:  we  therefore  concluded  that  there
wasn't important evidence against the transitivity assumption.

We  compared  the  inconsistency  factors  using  the  loop-specific
approach  (where  we  allow  the  same  τ  for  all  comparisons  in  a
loop)  before  and  after  the  adjustment  for  small  study  effects.
We  observed  no  important  differences  and  all  inconsistency

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

factors  were  statistically  non-significant  in  both  cases.  However,
as  explained  in  section  1.3,  this  does  not  constitute  a  proof
of  consistency  in  the  network:  some  of  the  loops  include  few
studies  and  the  corresponding  factors  are  estimated  with  much

uncertainty.  In  Figure  17  we  give  all  inconsistency  factors  for  the
network.  Again,  as  in  the  network  for  short-term  remission,  we
observed the highest inconsistency factor in the loop PT-CBT-PD.

Figure 17.   Short-term response: inconsistency factors for the network

We  found  no  proof  of  global  inconsistency  using  the  design-by-
treatment  inconsistency  model  (Chi2  =  7.74  with  12  degrees  of
freedom;  P  value  for  the  null  hypothesis  of  consistency  in  the
network 0.80).

2.4 Ranking of treatments

The  ranking  of  treatments  with  respect  to  short-term  response,
according  to  the  SUCRA  value  derived  from  NMA  adjusted  for
small  study  effects,  is  presented  in  Table  6.  We  observed  the
highest  rankings  respectively  for  cognitive  behaviour  therapy
(CBT), psychodynamic therapy (PD) and supportive psychotherapy
(SP).  Again,  results  regarding  supportive  psychotherapy  must  be
interpreted with caution because SP is included in the network as a
node with a single connection to the network, being compared only
with CBT (three studies, OR 1.02, 95% CrI 0.38 to 2.73).

3. Dropouts for any reason in the short term

3.1 Network plot

Figure 18 shows a graphical representation of the network. Nodes
and  edges  were  weighted  according  to  the  number  of  studies
including the respective treatments and comparisons. As shown in
the figure, ST-dropout data were available for all the psychological
therapies  and  the  control  conditions  considered  for  this  review.
CBT  appeared  to  be  the  most  studied  intervention,  followed  by
behaviour therapy (BT), physiological therapies (PT) and cognitive
therapy (CT). Wait list (WL) was the most studied among comparator
interventions.  The  most  studied  comparison  was  CBT  versus  WL.
The  network  appeared  to  be  moderately  connected,  with  three
interventions  represented  as  nodes  with  a  single  connection  to
the  network  (SP,  PE  and  3W).  Forty-seven  studies  including  2535
participants contributed data to this outcome.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 18.   Short-term dropouts: network plot

Cochrane Database of Systematic Reviews

3.2 Pairwise meta-analyses and their heterogeneity and small
study effects

Pairwise meta-analyses

We excluded all studies with zero events in all arms (n=10) in the
analyses. The study Ost 1993 is a three-arm study with zero events
in two of the arms (CBT, PT) and one event in the third (BT). For the
pairwise meta-analysis, we excluded the CBT versus PT comparison
for this study and only kept the other two comparisons (CBT versus
BT, PT versus BT).

As  summarised  in  the  left  part  of  Table  7,  direct  evidence  was
available for 14 comparisons. For seven of these comparisons there

was only one study available; for the remaining seven comparisons
we  performed  a  random-effects  meta-analysis.  As  shown  in  the
table, only two comparisons were informed by 10 or more studies,
that is CBT versus WL (14 studies) and CBT versus BT (10 studies):
their forest plots are respectively presented in Figure 19 and Figure
20. Only two comparisons showed statistically significant results:
we found that WL was associated with significantly fewer dropouts
than BT (four studies, OR 0.34, 95% CI 0.16 to 0.69), and that PD was
associated with significantly fewer dropouts than PT (one study, OR
0.16, 95% CI 0.03 to 0.84).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 19.   Short-term dropouts: forest plot for the comparison WL vs CBT

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 20.   Short-term dropouts: forest plot for the comparison CBT vs BT

Heterogeneity

Small study effects

I2 values and their 95% CIs, for the comparisons reported in three
studies or more, are presented in Table 8. We observed the highest
I2  value  in  the  comparisons  CBT  versus  SP  (I2  =  49%).  According
to the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011, section 9.5.2) these values suggest that, in these two
comparisons, a moderate percentage of the observed variability in
the effect estimates was due to heterogeneity rather than sampling
error (chance).

Following  the  protocol,  we  produced  funnel  plots  for  all
comparisons  appearing  in  more  than  10  studies.  There  were  two
comparisons appearing in 10 studies or more, that is WL versus CBT
(Figure 21) and CBT versus BT (Figure 22). We found no evidence of
asymmetry in either of the funnel plots.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 21.   Short-term dropouts: funnel plot for the comparison WL vs CBT

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 22.   Short-term dropouts: funnel plot for the comparison CBT vs BT

3.3 Network meta-analysis and its inconsistency

Network meta-analysis

Results  of  the  network  meta-analysis  (NMA)  for  short-term
dropouts are presented in the right part of Table 7. Indirect evidence
could be calculated for 41 comparisons for which direct evidence
was unavailable. Results for comparisons WL versus BT remained
statistically significant also within the context of NMA, with an OR
of 0.52 (95% CI 0.30 to 0.93).

Network heterogeneity and inconsistency

The estimated value of heterogeneity lay well within the range of
values usually found in Cochrane reviews, as presented by Turner
2012.

We compiled a table of important trial and patient characteristics
including  therapy  duration  and  percentage  of  agoraphobic,
depressed and drug treated patients. Its visual inspection showed
that  those  effect  modifiers  were  similarly  distributed  across
comparisons  in  the  network:  we  therefore  concluded  that  there
wasn't important evidence against the transitivity assumption.

Using  a 
loop-specific  approach,  we  found  no  evidence  of
inconsistency in the network. In Figure 23 we give all inconsistency
factors for the network. The study Ost 1993 was a three-arm study
with zero events in two of the arms (CBT, PT) and one event in the
third  (BT).  For  estimating  inconsistency  we  excluded  the  CBT-PT
comparison from this study. As a sensitivity analysis we excluded
the  study  Ost  1993  but  there  were  no  qualitative  changes  in  the
inconsistency factors.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 23.   Short-term dropouts: inconsistency factors for the network

for 

test 

The 
(design-by-treatment
inconsistency) provided no proof of inconsistency in the network
(Chi2 = 11.67 with 14 degrees of freedom; P value = 0.63).

inconsistency 

global 

3.4 Ranking of treatments

The  ranking  of  treatments  with  respect  to  short-term  dropouts,
according  to  the  SUCRA  value  derived  from  NMA,  is  presented
in  Table  9.  We  observed  the  highest  rankings  (that  correspond
with  a  lower  dropout  rate)  respectively  for  no  treatment  (NT),
psychodynamic therapy (PD) and third-wave CBT (3W).

4. Short-term improvement of panic disorder with or without
agoraphobia as measured on a continuous scale

4.1 Network plot

Figure  24  shows  a  graphical  representation  of  the  network.
Nodes  and  edges  were  weighted  according  to  the  number  of

studies  including  the  respective  treatments  and  comparisons.
As  shown  in  the  figure,  ST-improvement  data  were  available
for  all  the  psychological  therapies  and  the  control  conditions
considered  for  this  review.  CBT  appeared  to  be  the  most  studied
intervention,  followed  by  behaviour  therapy  (BT),  physiological
therapies  (PT)  and  cognitive  therapy  (CT).  Wait  list  (WL)  was  the
most studied among comparator interventions. The most studied
comparison was CBT versus WL. The network appeared to be poorly
connected,  with  two  interventions  represented  as  nodes  with  a
single connection (SP and 3W); two interventions were connected
only with each other but not with the rest of the network (PE and
APP),  so  they  could  not  be  included  in  the  analyses.  Excluding
those  four  interventions,  the  rest  of  the  network  appeared  to
be moderately well connected. Fifty-seven studies including 2318
participants contributed data to this outcome.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 24.   Short-term improvement: network plot

Cochrane Database of Systematic Reviews

4.2 Pairwise meta-analyses and their heterogeneity and small
study effects

Pairwise meta-analyses

As  summarised  in  the  left  part  of  Table  10,  direct  evidence  was
available  for  18  comparisons.  For  11  of  these  comparisons  there
was only one study available; for the remaining seven comparisons
we  performed  a  random-effects  meta-analysis.  As  shown  in  the
table, only two comparisons were informed by 10 or more studies,
that is CBT versus WL (17 studies) and CBT versus BT (10 studies):
their  forest  plots  are  respectively  presented  in  Figure  25  and

Figure 26. Among psychological therapies, three were shown to be
significantly better than WL in terms of short-term improvement:
PT (four studies: standardised mean difference (SMD) 0.87, 95% CI
0.09 to 1.65), BT (three studies: SMD 0.92, 95% CI 0.59 to 1.26) and
CBT  (seventeen  studies:  SMD  1.14,  95%  CI  0.87  to  1.41).  CBT  was
also found to be significantly better than NT (one study: SMD 1.30,
95%  CI  0.46  to  2.14).  Finally,  two  comparisons  among  two  active
treatments showed a statistically significant difference in terms of
short-term improvement: CBT versus BT (10 studies: SMD -0.24 in
favour of CBT, 95% CI -0.45 to -0.03) and PD versus PT (one study:
SMD -1.18 in favour of PD, 95% CI -1.59 to -0.57).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 25.   Short-term improvement: forest plot for the comparison WL vs CBT

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 26.   Short-term improvement: forest plot for the comparison CBT vs BT

Heterogeneity

I2 values and their 95% CIs, for the comparisons reported in three
studies  or  more,  are  presented  in  Table  11.  As  shown  in  the
table,  we  observed  the  highest  I2  values  in  the  comparisons  WL
versus  PT  (I2  =  79%)  and  WL  versus  CBT  (I2  =  61%).  According
to the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011, section 9.5.2) these values suggest that, in these two
comparisons, a substantial percentage of the observed variability in
the effect estimates was due to heterogeneity rather than sampling
error  (chance).  In  the  comparison  WL  versus  PT  (four  studies),
heterogeneity  appeared  to  be  related  to  the  study  Meuret  2008,
which  shows  an  unexpectedly  high  SMD  in  favour  of  PT,  possibly
related to a strong researcher allegiance bias (see Characteristics

of  included  studies);  in  the  case  of  WL  versus  CBT  (17  studies),
heterogeneity seems to be mainly due to two outlier studies, one
showing  a  very  high  SMD  in  favour  of  CBT  (Schmidt  1997a,  SMD
-2.36, 95% CI -3.19 to -1.54) and the other showing no effect in either
direction (Gould 1993, SMD 0.00, 95% CI -0.88 to 0.88).

Small study effects

Following  the  protocol,  we  produced  funnel  plots  for  all
comparisons  appearing  in  more  than  10  studies.  There  were  two
comparisons appearing in 10 studies or more, that is CBT versus WL
(Figure 27) and CBT versus BT (Figure 28). We found no evidence of
asymmetry in either of the funnel plots.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 27.   Short-term improvement: funnel plot for the comparison WL vs CBT

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 28.   Short-term improvement: funnel plot for the comparison CBT vs BT

4.3 Network meta-analysis and its inconsistency

Network meta-analysis

Results  of  the  network  meta-analysis  (NMA),  for  short-term
improvement  on  a  continuous  scale,  are  presented  in  the  right
part  of  Table  10.  Indirect  evidence  could  be  calculated  for  19
comparisons  for  which  direct  evidence  was  unavailable.  The
comparison PE versus APP, for which direct evidence was available,
is  not  included  in  the  NMA  because  it  is  disconnected  from  the
rest  of  the  network  (see  Figure  24).  Four  comparisons  remained
statistically  significant  also  within  the  context  of  NMA:  WL  versus
PT (SMD 0.80, 95% CI 0.47 to 1.13), WL versus BT (SMD 0.89, 95% CI
0.57 to 1.20), WL versus CBT (SMD 1.09, 95% CI 0.88 to 1.31) and NT
versus CBT (SMD 0.83, 95% CI 0.16 to 1.50). The comparisons CBT
versus BT and PD versus PT lost significance in the NMA. We also
found supportive psychotherapy (SP) and cognitive therapy (CT) to
be significantly better than WL, showing a SMD of respectively 1.05
(95% CI 0.49 to 1.60) and 0.88 (95% CI 0.34 to 1.42).

Inconsistency

We compiled a table of important trial and patient characteristics
including  therapy  duration  and  percentage  of  agoraphobic,
depressed and drug treated patients. Its visual inspection showed

that  those  effect  modifiers  were  similarly  distributed  across
comparisons  in  the  network:  we  therefore  concluded  that  there
wasn't important evidence against the transitivity assumption.

Using a loop-specific heterogeneity (where we allowed the same τ
for all comparisons in a loop), we identified one inconsistent loop
out  of  a  total  of  14  loops.  The  inconsistent  loop  was  PT-CBT-PD
(IF 1.79, 95% CI 0.78 to 2.60; see Figure 29 for other inconsistency
factors for the network). This loop was found to be inconsistent also
when allowing for a comparison-specific heterogeneity. Although
in  NMA  5%  of  the  loops  are  expected  to  be  inconsistent  by
chance, it must be noted that this same loop showed the highest
inconsistency  factor  (although  non-significant)  also  in  the  NMA
for  ST-remission  and  ST-response.  Furthermore,  two  of  the  three
edges  of  the  loop  were  only  informed  by  one  study  each,  both
considered  to  be  at  high  risk  of  researcher  allegiance  bias.  We
can  summarise  the  inconsistency  in  available  direct  evidence  as
follows: CBT appeared to perform better than PD (one study: SMD
0.57,  95%  CI  -0.07  to  1.20)  and  PD  appeared  to  perform  better
than PT (one study: SMD -1.18, 95% CI -1.79 to -0.57); however, the
comparison CBT versus PT showed almost no difference between
the two treatments (five studies: SMD -0.05, 95% CI -0.3 to 0.19).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 29.   Short-term improvement: inconsistency factors for the network

The  global  test  for  inconsistency  did  not  reveal  any  definite  proof
about inconsistency in the network (Chi2  =  9.13 with 14 degrees of
freedom, P value 0.82).

4.4 Ranking of treatments

The ranking of treatments with respect to short-term improvement,
according  to  the  SUCRA  value  derived  from  NMA,  is  presented
in  Table  12.  We  observed  the  highest  rankings  respectively  for
psychodynamic psychotherapy (PD), cognitive behaviour therapy
(CBT)  and  supportive  psychotherapy  (SP).  However,  results
regarding PD must be interpreted with caution because they relied
on only two studies (Beutel 2013; Milrod 2006a), both included in
the inconsistent loop PT-CBT-PD mentioned above.

5. Long-term remission or response of panic disorder with or
without agoraphobia

5.1 Network plot

Figure  30  shows  a  graphical  representation  of  the  network.
Nodes  and  edges  were  weighted  according  to  the  number  of
studies  including  the  respective  treatments  and  comparisons.  As
shown  in  the  figure,  long-term  data  were  available  for  only  six
active interventions. No study explored long-term (LT)-remission/
response for third-wave CBT (3W) and psychoeducation (PE), nor
for any control condition (WL, NT, APP). CBT was the most studied
intervention,  followed  by  behaviour  therapy  (BT),  physiological
therapies  (PT)  and  cognitive  therapy  (CT).  The  most  studied
comparison  was  CBT  versus  BT.  With  the  exception  of  SP  and
PD,  both  represented  as  nodes  compared  only  with  CBT,  the
network appeared to be well connected. Nine studies including 464
participants contributed data to this outcome.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 30.   Long-term remission/response: network plot

5.2 Pairwise meta-analyses and their heterogeneity and small
study effects

Pairwise meta-analyses

2011, section 9.5.2) this value suggests that the percentage of the
observed  variability  in  the  effect  estimates  due  to  heterogeneity
rather than sampling error may not have been important.

As  summarised  in  the  left  part  of  Table  13,  direct  evidence  was
available for eight comparisons. For six of these comparisons there
was only one study available; for the remaining two comparisons
we  performed  a  random-effects  meta-analysis.  As  shown  in  the
table,  no  comparison  was  informed  by  10  or  more  studies.
None of the available comparisons showed statistically significant
differences,  in  terms  of  long-term  remission/response,  between
active treatments. However, this finding must be interpreted while
taking into account the exiguity of available long-term data.

Heterogeneity

Only  the  comparison  CBT  versus  BT  was  informed  by  more  than
two studies and it showed an I2 value of 37%, with a 95% CI going
from 0% to 77% (standard pairwise meta-analysis). According to the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins

Small study effects

For this outcome, no comparison was informed by enough studies
to produce a funnel plot in order to explore the presence of small
study effects.

5.3 Network meta-analysis and its inconsistency

Network meta-analysis

long-term
Results  of  the  network  meta-analysis  (NMA)  for 
remission/response  are  presented  in  the  right  part  of  Table  13.
Indirect  evidence  could  be  calculated  for  seven  comparisons  for
which  direct  evidence  was  unavailable.  None  of  the  available
comparisons  showed  statistically  significant  differences  between
active  treatments.  Again,  this  finding  must  be  interpreted  while
taking into account the exiguity of available long-term data.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Network heterogeneity and inconsistency

The estimated value of heterogeneity lay well within the range of
values usually found in Cochrane reviews, as presented by Turner
2012.

We compiled a table of important trial and patient characteristics
including  therapy  duration  and  percentage  of  agoraphobic,
depressed and drug treated patients. Its visual inspection showed

that  those  effect  modifiers  were  similarly  distributed  across
comparisons  in  the  network:  we  therefore  concluded  that  there
wasn't important evidence against the transitivity assumption.

Using a loop-specific heterogeneity (where we allow the same τ for
all comparisons in a loop), we found no evidence of inconsistency
in the network. In Figure 31 we give all inconsistency factors for the
network.

Figure 31.   Long-term remission/response: inconsistency factors for the network

The global test for inconsistency showed no signs of inconsistency
in  the  network  (Chi2  =  1.80  with  4  degrees  of  freedom,  P  value  =
0.77).

5.4 Ranking of treatments

The  ranking  of  treatments  with  respect  to  long-term  remission/
response,  according  to  the  SUCRA  value  derived  from  NMA,  is
presented  in  Table  14.  The  highest  ranking  was  observed  for
cognitive behaviour therapy, followed by psychodynamic therapy.

6. Subgroup analyses

The following analyses were aimed at exploring possible sources of
heterogeneity for the first of the primary outcomes, that is short-
term remission of panic disorder with or without agoraphobia.

6.1 Year of publication

For  the  two  pairwise  comparisons  for  which  there  were  enough
studies  available  (CBT  versus  BT  and  CBT  versus  WL)  we
performed a meta-regression to investigate the effect of the year of
publication. In both pairwise comparisons older studies seemed to
favour CBT (compared to BT and WL) but the effect was not found
to be statistically significant in either of the cases. It must be noted

that older studies tended to be smaller than newer ones. Thus, the
small trend found was probably due to SSE. The meta-regression
parameters were, respectively, -0.02 (95% CI -0.10 to 0.05) for the
comparison CBT versus BT, and 0.04 (95% CI -0.06 to 0.15) for the
comparison WL versus CBT.

6.2 Mean number of treatment sessions

Following  the  protocol,  we  divided  the  included  studies  that
reported the mean number of treatment sessions into three groups.
The  first  group  was  for  studies  with  fewer  than  four  sessions,
the  second  was  for  studies  with  four  to  12  sessions  and  the  last
group was for studies with more than 12 sessions. We performed
a subgroup analysis for comparisons reported by enough studies
(CBT versus BT and CBT versus WL).

Figure  32  shows  the  forest  plot  for  the  comparison  WL  versus
CBT,  subgrouping  the  studies  that  reported  the  mean  number  of
treatment sessions, along with their meta-analysis (note that Clark
1999 had two CBT arms, one with 15 sessions and one with eight: for
the purposes of this analysis we broke this study in two). It is evident
from the plot that the number of sessions was not associated with
the treatment effect (test for subgroup differences: P value = 0.937;
I2 = 0.0%). A meta-regression also showed no difference between

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

the groups and no reduction in heterogeneity. A meta-regression

on the exact number of treatment sessions also showed no effect
(Figure 33).

Figure 32.   Subgroup analysis: number of treatment sessions, forest plot for the comparison WL vs CBT

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 33.   Subgroup analysis: number of treatment sessions, regression line for the comparison WL vs CBT

Figure  34  shows  the  forest  plot  for  the  comparison  CBT  versus
BT,  subgrouping  the  studies  that  reported  the  mean  number  of
treatment sessions, along with their meta-analysis. Again, the plot
showed no important differences among the two available groups
(test for subgroup differences: P value = 0.269; I2 = 18.2%). Results

of  the  meta-regression  on  the  (standardised)  number  of  sessions
showed  that  the  increase  in  the  number  of  sessions  tended  to
increase the relative efficacy of CBT versus BT (Figure 35), but the
increase was not statistically significant.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 34.   Subgroup analysis: number of treatment sessions, forest plot for the comparison CBT vs BT

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 35.   Subgroup analysis: number of treatment sessions, regression line for the comparison CBT vs BT

6.3 Therapist training

Following the protocol, we divided the included studies into groups
depending on the assessment of therapist training in the delivered
treatments.  We  performed  a  subgroup  analysis  for  comparisons
reported by enough studies (WL versus CBT and CBT versus BT).

For the comparison WL versus CBT we divided the studies into two
groups depending on the assessment of therapist training on CBT:

therapist trained (group 1) and therapist untrained (group 2). We
did  not  include  in  the  analysis  studies  that  were  unclear  about
therapist training. The forest plots (Figure 36) showed an overlap
of the confidence intervals among the groups. We thus concluded
that  our  data  showed  no  proof  that  therapist  training  affects  the
comparison between CBT and WL (test for subgroup differences: P
value = 0.175; I2 = 45.6%).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 36.   Subgroup analysis: therapist training, forest plots for the comparison WL vs CBT

For the comparison CBT versus BT we found three groups of studies:
therapists trained in both treatments (group 1), therapists trained
in  BT  with  unclear  training  in  CBT  (group  2,  one  study  only)  and

therapists with unclear training in both arms (group 3, one study
only). We could only analyse the first group (Figure 37).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 37.   Subgroup analysis: therapist training, forest plot for the comparison CBT vs BT

6.4 Percentage of patients with agoraphobia

We  performed  a  subgroup  analysis  for  comparisons  reported  by
enough studies (WL versus CBT and CBT versus BT).

For the comparison WL versus CBT there were 10 studies reporting
on  agoraphobia:  we  found  no  statistically  significant  linear
dependency between the percentage of patients with agoraphobia
and the effect size for this comparison (Figure 38).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 38.   Subgroup analysis: percentage of agoraphobic patients, regression line for the comparison WL vs CBT

For  the  comparison  CBT  versus  BT  there  were  nine  studies
reporting  on  agoraphobia:  all  studies  had  100%  of  patients  with
agoraphobia except one, so we could not perform an informative
meta-regression for this comparison.

For  the  comparison  WL  versus  CBT  there  were  10  studies
reporting on depression: we found no statistically significant linear
dependency between the percentage of patients with depression
and the effect size for this comparison (Figure 39).

6.5 Percentage of patients with depression

We  performed  a  subgroup  analysis  for  comparisons  reported  by
enough studies (WL versus CBT and CBT versus BT).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 39.   Subgroup analysis: percentage of depressed patients, regression line for the comparison WL vs CBT

For  the  comparison  CBT  versus  BT  there  were  only  four  studies
reporting  on  depression  so  we  could  not  perform  an  informative
meta-regression for this comparison.

6.6 Percentage of patients on drug treatment

We  performed  a  subgroup  analysis  for  comparisons  reported  by
enough studies (WL versus CBT and CBT versus BT).

For the comparison WL versus CBT there were 11 studies reporting
on  drug  treatment:  we  found  no  statistically  significant  linear
dependency between the percentage of patients on drug treatment
and the effect size for this comparison (Figure 40).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 40.   Subgroup analysis: percentage of drug-treated patients, regression line for the comparison WL vs CBT

For  the  comparison  CBT  versus  BT  there  were  only  four  studies
reporting  on  drug  treatment  so  we  could  not  perform  an
informative meta-regression for this comparison.

7. Sensitivity analyses

Following the protocol, we performed sensitivity analyses for the
first of the primary outcomes only (short-term remission of panic
disorder with or without agoraphobia).

7.1 Analyses restricted to studies considered to be at low risk
of selection and detection bias

Among the 54 studies included in quantitative analyses, only one
met the criteria (Milrod 2006a). Therefore, this sensitivity analyses
could not be performed.

7.2 Analyses restricted to individual therapy trials

We excluded from the analysis group therapy studies and redid the
analysis. We excluded 10 studies (Beck 1994; Carter 2003; Hoffart

1995;  Korrelboom  2013;  Lidren  1994;  Meulenbeek  2008;  Schmidt
1997a; Schmidt 1997b; Sharp 2004; Telch 1993).

7.2.1 Network plot

Figure 41 shows a graphical representation of the network. Nodes
and  edges  were  weighted  according  to  the  number  of  studies
including  the  respective  treatments  and  comparisons.  As  shown
in  the  figure,  ST-remission  data  were  available  for  six  active  and
one comparison interventions. Different from the primary analyses,
NT  was  no  longer  included  in  the  network.  CBT  remained  the
most  studied  intervention,  followed  by  behaviour  therapy  (BT),
physiological  therapies  (PT)  and  cognitive  therapy  (CT).  Wait  list
(WL)  was  the  only  comparator  intervention  available.  The  most
studied  comparison  remained  CBT  versus  WL,  followed  by  CBT
versus  BT.  The  network  remained  well  connected,  again  with
the  only  exception  of  supportive  psychotherapy  (SP),  studied
only  in  the  comparison  versus  CBT.  Thirty  studies  including  1821
participants contributed data to this outcome.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 41.   Sensitivity analyses: network plot for short-term remission excluding from the analyses group therapy
trials

7.2.2 Pairwise meta-analyses and their heterogeneity and small
study effects

Pairwise meta-analyses

As  for  the  primary  analyses,  in  order  to  have  comparable  results
with the NMA, we performed the pairwise meta-analyses assuming
a  common  heterogeneity  variance  across  all  comparisons.  This
way,  all  pairwise  meta-analyses  were  essentially  analysed  as
random-effects  (they  include  uncertainty  due  to  heterogeneity),
even for those comparisons only being reported by one study. The
(common) heterogeneity standard deviation was estimated to be τ
= 0.05.

As  summarised  in  the  left  part  of  Table  15,  direct  evidence  was
available for 12 comparisons. For four of these comparisons there

was only one study available; for the remaining eight comparisons
we  performed  a  random-effects  meta-analysis.  As  shown  in  the
table,  only  one  comparison  was  informed  by  10  or  more  studies,
that is CBT versus WL (11 studies, Figure 42); the comparison CBT
versus BT was informed by nine studies, however we will present its
forest plot in order to ease the comparison with primary analyses
results (Figure 43). Results appear to be similar to those observed in
primary analyses, with the exception of the comparison PD versus
PT, which became statistically significant in this sensitivity analysis
(OR 4.22, 95% CI 1.17 to 15.15), showing a superiority of PD in terms
of short-term remission. However, this comparison was informed
by only one study in both analyses, therefore this difference is only
due to the smaller common heterogeneity standard deviation (τ =
0.05 instead of 0.69) in this sensitivity analysis.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 42.   Sensitivity analyses: forest plot for the comparison WL vs CBT excluding group therapy trials

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 43.   Sensitivity analyses: forest plot for the comparison CBT vs BT excluding group therapy trials

Heterogeneity

Small study effects

I2 values and their 95% CIs, for the comparisons reported in three
studies  or  more,  are  presented  in  Table  16.  As  shown  in  the
table,  we  observed  the  highest  I2  values  in  the  comparisons  WL
versus  PT  (I2  =  56%).  According  to  the  Cochrane  Handbook  for
Systematic  Reviews  of  Interventions  (Higgins  2011,  section  9.5.2)
these values suggest that, in these two comparisons, a moderate
percentage of the observed variability in the effect estimates was
due  to  heterogeneity  rather  than  sampling  error  (chance).  In  the
comparison WL versus PT (four studies), heterogeneity was due to
the study Griegel 1995, a three-arm trial (PT versus PT versus WL) in
which no remission (i.e. panic-free status) was observed in the two
active treatment arms whereas one case of remission was observed
in the wait list. In this study, therefore, the unexpected OR was due
to the low number of events across all arms.

We  produced  funnel  plots  for  the  comparisons  WL  versus  CBT
(Figure 44) and CBT versus BT (Figure 45). From the first funnel plot
there was evidence of asymmetry. More specifically, small studies
were missing in the lower right part of the funnel plot. This means
that small studies comparing WL to CBT that (relatively) favour WL
seemed to be missing: in other words, small studies showed CBT
to be more efficacious. The contour-enhanced funnel plot for the
comparison  WL  versus  CBT  (not  presented)  showed  that  studies
were missing in the area of non-significance, thus suggesting the
role of publication bias behind the SSE. We found no evidence of
asymmetry  in  the  funnel  plot  for  the  comparison  CBT  versus  BT.
Taken  together,  these  findings  are  similar  to  those  found  in  the
primary analyses.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 44.   Sensitivity analyses: funnel plot for the comparison WL vs CBT excluding group therapy trials

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 45.   Sensitivity analyses: forest plot for the comparison CBT vs BT excluding group therapy trials

7.2.3 Network meta-analysis and its inconsistency

Network meta-analysis

As  explained  in  the  previous  paragraph,  it  was  evident  from  the
funnel  plots  that  there  were  small  study  effects  (SSE)  present  in
the network for the comparison CBT versus WL. As for the primary
analyses, we found it reasonable to assume that there were SSE in
all other comparisons versus WL, even though we might not have
had enough studies to see this effect. The presence of SSE implies
that a simple NMA may produce biased results. For this reason we
performed  a  network  meta-analysis  adjusting  for  SSE  in  studies
comparing all other treatments to WL, by regressing on the variance
of the study. We performed the network meta-analysis adjusted for
SSE in WinBUGS. Thus the results are expressed in terms of credible
intervals and we use the median (instead of the mean) because the
posterior distribution of the estimated odds ratios is asymmetrical.

context of NMA, showing an OR of 3.0 in favour of CBT (95% CrI 1.4 to
6.3). PT, CT and BT lost significance in the comparison versus WL. We
found supportive psychotherapy (SP) to be significantly better than
WL (OR 4.5, CrI 1.3 to 16.7); again, this finding must be interpreted
with caution since SP is included in the network as a node with a
single connection to the network. Two comparisons among active
treatments,  that  is  CBT  versus  BT  and  CBT  versus  PT,  showed  a
statistically significant difference in terms of short-term remission,
in  both  cases  in  favour  of  CBT,  with  an  OR  respectively  of  1.76
(CrI 1.02 to 3.13) and 1.94 (CrI 1.02 to 3.97). Taken together, these
sensitivity analyses confirmed the findings of primary analyses.

Network heterogeneity and inconsistency

The estimated value of heterogeneity lay well within the range of
values usually found in Cochrane reviews, as presented by Turner
2012.

Results of the network meta-analysis (NMA), adjusted for SSE, for
short-term  remission  are  presented  in  the  right  part  of  Table  15.
Indirect  evidence  could  be  calculated  for  nine  comparisons  for
which direct evidence was unavailable. The comparison between
CBT  and  WL  remained  statistically  significant  also  within  the

Using a loop-specific heterogeneity (where we allow the same τ for
all comparisons in a loop), we found no evidence of inconsistency
in the network. In Figure 46 we give all inconsistency factors for the
network. As shown in the figure, the highest inconsistency factor
was observed in the loop PT-CBT-PD.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 46.   Sensitivity analyses: inconsistency factors for the network of short-term remission excluding from the
analyses group therapy trials

The global test for inconsistency showed no proof of inconsistency
(Chi2 = 3.21 with 5 degrees of freedom, P value = 0.67).

7.3 Analyses restricted to trials in which a concomitant
pharmacotherapy is not allowed

7.2.4 Ranking of treatments

The  ranking  of  treatments  with  respect  to  short-term  remission,
according  to  the  SUCRA  value  derived  from  NMA  adjusted  for
small  study  effects,  is  presented  in  Table  17.  Results  confirmed
the  primary  analyses,  showing  the  highest  rankings  respectively
for  supportive  psychotherapy,  cognitive  behaviour  therapy  and
psychodynamic  therapy.  Again,  results  regarding  supportive
psychotherapy  must  be  interpreted  with  caution  because,  as
specified  earlier,  SP  is  included  in  the  network  as  a  node  with  a
single connection to the network, being compared only with CBT.

We  excluded  from  the  analysis  studies  in  which  a  concomitant
pharmacotherapy  was  allowed  and  redid  the  analysis.  Only  nine
studies  remained  and  could  be  included  in  these  analyses  (Beck
1994;  Carter  2003;  Cottraux  2009;  Craske  1995;  Craske  2005a;
Gloster 2010; Hoffart 1995; Reinecke 2013; Shear 1994).

7.3.1 Network plot

Figure 47 shows a graphical representation of the network. Nodes
and  edges  were  weighted  according  to  the  number  of  studies
including the respective treatments and comparisons. As shown in
the figure, ST-remission data were available for five active and two
comparison interventions. Different from the primary analyses, the
network was no longer connected, but consisted in two separated
sub-networks.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 47.   Sensitivity analyses: network plot for short-term remission excluding from the analyses trials in which a
concomitant pharmacotherapy is allowed

7.3.2 Pairwise meta-analyses and their heterogeneity and small
study effects

heterogeneity  in  the  small  sub-samples  of  studies  available  for
these sensitivity analyses.

Pairwise meta-analyses

Small study effects

As summarised in Table 18, direct evidence was available for seven
comparisons.  For  four  of  these  comparisons  there  was  only  one
study available; for the remaining three comparisons we performed
a  random-effects  meta-analysis.  As  shown  in  the  table,  the  most
represented comparison was CBT versus WL (three studies). Results
appear  to  be  similar  to  those  observed  in  primary  analyses.  The
main difference was represented by the comparison WL versus CBT,
which showed a larger effect (but also a larger CI) in favour of CBT
compared with the primary analyses (OR 14.3, 95% CI 3.3 to 100).

Heterogeneity

Since three or fewer studies were available for each comparison, we
could not explore the presence of small study effects.

7.3.3 Network meta-analysis and its inconsistency

Network meta-analysis

A  network  meta-analysis  could  not  be  performed  because  the
network was disconnected.

7.4 Analyses restricted to trials requiring stabilisation of drug
therapy

I2  values,  for  the  comparisons  reported  in  two  studies  or  more,
are  presented  in  Table  18.  As  shown  in  the  table,  we  found  no

We  excluded  from  the  analysis  studies  in  which  stabilisation  of
drug  therapy  was  not  explicitly  required  and  redid  the  analysis.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Only 11 studies remained and could be included in these analyses
(Barlow  1989;  Clark  1994;  Craske  2005a;  Dow  2000;  Griegel  1995;
Korrelboom 2013; Lidren 1994; Meuret 2008; Ost 1995; Ost 2004).

7.4.1 Network plot

Figure 48 shows a graphical representation of the network. Nodes
and  edges  were  weighted  according  to  the  number  of  studies

Cochrane Database of Systematic Reviews

including the respective treatments and comparisons. As shown in
the  figure,  ST-remission  data  were  available  for  three  active  and
one comparison interventions. Although with only a few treatments
were included, the network appeared to be well connected, with
direct evidence missing only for the comparison BT versus PT.

Figure 48.   Sensitivity analyses: network plot for short-term remission excluding from the analyses trials in which
pharmacotherapy stabilisation was not required

7.4.2 Pairwise meta-analyses and their heterogeneity and small
study effects

statistically significant, showing larger effects in favour of the active
treatment with respect to primary analyses.

Pairwise meta-analyses

Heterogeneity

As summarised in Table 19, direct evidence was available for five
comparisons.  For  one  of  these  comparisons  there  was  only  one
study available; for the remaining four comparisons we performed
a  random-effects  meta-analysis.  As  shown  in  the  table,  the  most
represented comparison was CBT versus WL (six studies). Different
from the primary analyses, the comparison CBT versus BT was no
longer  significant,  although  a  trend  in  favour  of  CBT  remained.
The  comparisons  CBT  versus  WL  and  BT  versus  WL  remained

I2  values,  for  the  comparisons  reported  in  two  studies  or  more,
are presented in Table 19. As shown in the table, we observed the
highest I2 values in the comparisons CBT versus BT (I2 = 72%) and
PT versus WL (I2 = 69%). According to the Cochrane Handbook for
Systematic  Reviews  of  Interventions  (Higgins  2011,  section  9.5.2)
these values suggest that, in these two comparisons, a substantial
percentage of the observed variability in the effect estimates was
due  to  heterogeneity  rather  than  sampling  error  (chance).  The
low  number  of  studies  available  for  these  comparisons  does  not

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

allow  us  to  make  inferences  about  the  nature  of  the  observed
heterogeneity.

D I S C U S S I O N

Small study effects

Since six or fewer studies were available for each comparison, we
could not explore the presence of small study effects.

7.4.3 Network meta-analysis and its inconsistency

Results  of  the  network  meta-analysis  (NMA)  for  short-term
remission  are  presented  in  the  right  part  of  Table  19.  Indirect
evidence  could  be  calculated  for  the  only  comparison  for  which
direct evidence was unavailable. The comparisons CBT versus WL
(OR 16.7, 95% CI 6.3 to 50) and BT versus WL (OR 5.3, 95% CI 1.1 to
25) remained statistically significant also within the context of NMA.
Furthermore,  the  comparison  WL  versus  PT  became  statistically
significant, showing an OR of 9.09 (95% CI 2.7 to 33.3).

Compared with the primary analyses, these results tended to show
larger  (and  statistically  significant)  effects  of  active  treatments
when compared with WL. Comparisons between active treatments
seemed to be less affected by the exclusion of studies in which the
stabilisation of drug therapy was not required.

Network heterogeneity and inconsistency

The estimated value of heterogeneity lay well within the range of
values usually found in Cochrane reviews, as presented by Turner
2012.

We found no evidence of inconsistency in the network using a loop-
specific approach.

The  global  test  for  inconsistency  also  showed  no  proof  of
inconsistency (Chi2 = 3.21 with 5 degrees of freedom, P value = 0.67).

7.4.4 Ranking of treatments

The  ranking  of  treatments  with  respect  to  short-term  remission,
according to the SUCRA value derived from NMA adjusted for small
study effects, was CBT (SUCRA 95), PT (SUCRA 62), BT (SUCRA 42)
and WL (SUCRA 0). With regard to the treatments included in this
sensitivity analysis, the results were similar to those observed in the
primary analyses.

7.5 Pairwise meta-analyses performed using a fixed-effect
model instead of a random-effects model

For these analyses we considered the same 40 studies included in
the primary analyses. As summarised in Table 20, direct evidence
was available for 15 comparisons, for which we performed a fixed-
effect meta-analysis and compared with the random-effects meta-
analyses results. With respect to primary analyses, we observed the
main difference in the comparison CBT versus WL. As we pointed
out in results section 1.2, this comparison is biased in favour of CBT
by the presence of small study effects; as expected, the magnitude
of  the  effect  size  for  this  comparison  was  reduced  using  the
fixed-effect model, which gives a relatively lower weight to small
studies compared to the random-effects model, thus reducing their
influence on meta-analysis results. A similar explanation can also
account for the effect size reduction observed in the comparison BT
versus WL.

Summary of main results

Overall results in terms of short-term (ST)-remission, ST-response
and  ST-improvement  on  a  continuous  scale  were  similar,
suggesting  a  superiority  of  cognitive  behaviour  therapy  (CBT),
psychodynamic therapies (PD) and supportive psychotherapy (SP)
over other treatments for the management of the acute phase of
panic disorder.

However,  results  concerning  SP  should  be  interpreted  cautiously
because  the  efficacy  of  this  treatment  was  explored  only  in  the
comparison  with  CBT  and  thus  was  not  included  in  any  closed
loop of the network (in which SP appeared as a node with a single
connection). As a result, the ranking of this treatment was strongly
influenced by this unique available comparison, which was directly
explored in three studies (Addis 2004; Craske 2005a; Shear 1994),
none of which found a statistically significant difference between
the two treatments in terms of ST-remission and ST-response. We
suspect  that  this  situation  may  have  produced  a  spuriously  high
ranking  of  SP,  because  the  estimation  of  the  relative  treatment
effects of CBT versus SP was only informed by these three trials (and
no additional indirect evidence from the rest of the network) while
the comparison of SP versus all other treatments was only informed
by indirect evidence (via the three CBT versus SP trials).

The  two  remaining  treatments,  that  is  PD  and  CBT,  were  directly
compared  in  only  one  study  (Beutel  2013),  which  suggested
a  superiority  of  CBT  over  PD,  although  the  results  were  not
statistically significant either in terms of ST-remission or in terms of
ST-response (it must be noted that the lack of significance may be
due to the relatively small sample size).

In terms of ST-dropouts, PD ranked higher than CBT (odds ratio (OR)
0.52, 95% confidence interval (CI) 0.15 to 1.8); a high ranking was
also achieved by third-wave CBT (3W), suggesting a possible better
tolerability of PD and 3W over other psychological treatments in the
short term.

In  the  long  term,  CBT  showed  the  highest  ranking,  followed  by
PD,  suggesting  that  the  effects  of  these  two  treatments  may  be
more  stable  with  respect  to  other  psychological  interventions.
As  for  the  short-term  outcomes,  only  one  study  explored  the
direct  comparison  between  PD  and  CBT  in  the  long  term  with
regard to remission, showing comparable rates of remission at six
months follow-up for the two treatments (Beutel 2013); however,
these  results  should  be  interpreted  while  taking  into  account
the  relatively  high  number  of  dropouts  (almost  30%  of  the
original sample). The superiority of CBT in the long term may be
due  to  the  administration  of  the  so-called  "relapse  prevention"
psychological component; however, we did not explore this specific
issue  and  a  separate  review  should  be  run  in  order  to  precisely
evaluate  the  effects  of  this  therapeutic  component  for  the  long-
term  management  of  the  disorder.  It  must  also  be  noted  that
in  this  review  we  did  not  explore  the  effects  of  drug  therapy
co-administration  (and  its  adherence)  on  long-term  remission/
response,  as  this  type  of  secondary  analysis  was  limited  to  the
first  of  our  primary  outcomes  only  (for  the  reasons  explained
in  Subgroup  analysis  and  investigation  of  heterogeneity).  Taken
together, the relative scarcity of long-term evidence (with respect
to  short-term  data),  the  high  number  of  dropouts  at  long-term
assessments and the above-mentioned lack of analyses regarding

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

concomitant  drug  treatment,  limit  the  reliability  of  our  findings
regarding  long-term  remission/response,  which  therefore  should
be interpreted with caution.

overall  results  of  network  meta-analyses  in  terms  of  treatment
hierarchy, together with the corresponding assessment of quality
of the evidence (Summary of findings 4).

More  generally,  the  results  showed  a  statistically  significant
superiority of psychological therapies over the wait list condition.
In particular: SP, PT, behaviour therapy (BT) and CBT were superior
to  wait  list  (WL)  both  in  terms  of  ST-remission  and  in  terms  of
ST-response. It must be noted, however, that the relative efficacy
of  psychological  therapies  over  WL  was  found  to  be  consistently
affected by small study effects (SSE), as shown in the two funnel
plots  comparing  CBT  versus  WL  (the  only  available  comparison
versus  WL  for  which  there  was  a  sufficient  number  of  studies  to
build  a  funnel  plot)  in  relation  to  ST-remission  and  ST-response.
In  the  presence  of  SSE,  studies  with  a  lower  standard  error  (i.e.
larger  sample  size  and  higher  number  of  events)  tend  to  show
smaller  effects  (in  the  case  of  'positive'  outcomes)  than  studies
with  a  higher  standard  error  (Sterne  2000),  which  implies  that
the  latter  may  lead  to  an  overestimation  of  the  effect  (in  this
case,  an  overestimation  of  ST-remission  and  ST-response  of  CBT
when  compared  to  WL).  Since  the  presence  of  SSE  is  difficult  to
detect  when  only  a  few  studies  are  available  for  a  comparison,
we found it reasonable to assume that what we clearly observed
in the comparison CBT versus WL could probably be extended to
other  comparisons  versus  WL.  In  other  words,  we  assumed  that
there  were  SSE  in  all  other  comparisons  versus  WL,  even  though
we  might  not  have  had  enough  studies  to  see  this  effect.  Since
the presence of SSE implies that a simple network meta-analysis
(NMA) may produce biased results, we decided to repeat the NMA
analyses  adjusting  for  small  study  effects  in  studies  comparing
all  other  treatments  to  WL,  by  regressing  on  the  variance  of  the
study. As suspected, in adjusted analyses, many of the comparisons
mentioned  above  lost  statistical  significance  (only  CBT  and  SP
remained  superior  to  WL  in  terms  of  ST-remission;  no  treatment
remained superior in terms of ST-response).

The  results  showed  a  statistically  significant  difference  between
two  active  treatments  only  for  the  comparisons  CBT  versus  BT
and  CBT  versus  PT,  where  CBT  appeared  to  be  superior  in  terms
of  ST-remission.  However,  the  confidence  interval  was  large  and
its  lower  end  was  very  close  to  1  (i.e.  no  difference)  for  both
comparisons, which limits the relevance of these findings in clinical
terms. A similar trend in favour of CBT over BT and PT was found in
terms of ST-response, ST-improvement and LT-remission/response,
although this was not statistically significant.

As  planned  in  the  protocol,  we  produced  three  'Summary  of
findings'  tables  presenting  the  NMA  results  for  the  comparison
between  the  psychological  therapy  that  ranked  first  versus,
respectively:  no  treatment  (NT),  supportive  psychotherapy  (SP)
and  the  psychological  therapy  that  ranked  second.  The  ranking
we  referred  to  was  the  one  related  to  the  first  of  our  primary
outcomes (short-term remission), presented in Table 3. According
to  these  results,  the  treatment  that  ranked  first  was  supportive
psychotherapy; however, for the reasons explained above, results
concerning SP were not reliable, which left CBT as the treatment
with the highest ranking. Therefore, in the 'Summary of findings'
tables we present the NMA results for the following comparisons:
CBT versus NT (Summary of findings for the main comparison), CBT
versus SP (Summary of findings 2) and CBT versus PD (Summary
of  findings  3).  We  also  produced  an  extra  summary  of  findings
table,  not  planned  in  the  protocol,  in  order  to  summarize  the

Overall completeness and applicability of evidence

Sufficient  evidence  supports  our  findings  in  relation  to  the
comparison  between  CBT  and  waiting  list:  despite  the  evidence
of  small  study  effects  affecting  results  for  ST-remission  and  ST-
response  in  favour  of  CBT,  the  stability  of  results  when  adjusting
NMA  for  SSE  suggests  a  good  reliability  of  this  finding.  We  found
evidence in relation to the comparison BT versus CBT, supporting
the superiority of the latter. Some evidence exists in support of the
possible viability of psychodynamic and supportive psychological
therapies  as  valid  alternatives  to  CBT  for  the  treatment  of  panic
disorder  with  or  without  agoraphobia;  scarce  evidence  exists  in
support  of  other  psychological  therapies  as  valid  alternatives  to
CBT.

Quality of the evidence

For the three comparisons presented in the SoF tables (CBT vs NT,
CBT vs SP, CBT vs PD), the quality of evidence was rated as low to
very  low  for  ST-remission,  very  low  for  ST-response,  very  low  for
ST-dropouts, low for LT-remission/response and low to very low for
ST-improvement as measured on a continuous scale (Summary of
findings for the main comparison; Summary of findings 2; Summary
of findings 3).

We found low quality evidence, for each of the included outcomes,
in  support  of  NMA  analyses  regarding  treatment  hierarchy
(Summary of findings 4).

The main factor affecting the quality of evidence was the presence
of an unclear or high risk of bias, for many included studies, in more
than one important domain. As shown in Figure 3 and Figure 4, the
majority of included studies were at unclear risk of bias with regard
to the randomisation process; we found almost half of the included
studies to be at high risk of attrition bias (both in the short and in the
long term) and detection bias (with regard to ST-remission); we also
found selective outcome reporting to be present. Finally, we found
almost half of the included studies to be at high risk of researcher
allegiance bias: however, we found no clear evidence of this bias
affecting our findings (extra analyses, not reported).

We strongly suspected the presence of publication bias based on
evidence of SSE and analysis of contour-enhanced funnel plots for
both ST-remission and ST-response, for the comparisons between
psychological  therapies  and  WL.  As  a  post-hoc  analysis  we  also
performed the Harbord and Peters tests, which showed no proof of
small study effects. However, given that the funnel plots provided
strong  evidence  for  publication  bias,  we  employed  a  hierarchical
network  meta-regression  model  to  adjust  the  NMA  results  (for
this reason we decided not to downgrade the quality of evidence
because of publication bias).

Another  factor  affecting  the  quality  of  evidence  was  the  lack  of
precision of results for many comparisons, which in many cases did
not show statistically significant differences: this was probably due
to the lack of enough (and adequately powered) studies exploring
such comparisons.

Despite the above mentioned limitations of available evidence, we
found substantial heterogeneity to be present in very few pairwise

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

comparisons, limited to one of the secondary outcomes, that is ST-
improvement  as  measured  on  a  continuous  scale.  For  this  same
outcome, the network analyses revealed the presence of relevant
inconsistency in one loop (PT-CBT-PD). This was the only clear case
of  inconsistency  identified  in  our  analyses,  although  it  must  be
said that the networks were generally underpowered to detect any
important disagreement between direct and indirect evidence.

Finally,  with  regard  to  the  directness  of  evidence,  we  found  the
networks  to  be  moderately  connected,  which  means  that  direct
evidence was available for about half of the possible comparisons
among included psychological therapies/control conditions. Only
in  the  case  of  ST-dropouts  results  were  informed  by  a  higher
proportion of indirect evidence; on the other hand, however, this
outcome was informed by the highest number of studies (47 RCTs,
2535 participants).

In Mitte 2005, the author hypothesised that the difference in effect
sizes  found  between  the  comparisons  (C)BT  versus  wait  list  and
(C)BT versus placebo suggested a relatively large common factor,
explaining more than half of the efficacy. In another meta-analysis
CBT  was  compared  with  placebo  (both  psychological  and  pill
placebo) for various anxiety disorders, among which the smallest
effect size was observed for panic disorder (Hedges' g = 0.35, 95%
CI 0.04 to 0.65), suggesting again that non-specific factors may play
an important role in the treatment of this disorder (Hofmann 2008).
Although psychological placebo and supportive psychotherapy are
deeply  different  concepts,  it  is  often  difficult  to  draw  a  clear  line
between them in psychotherapy trials. The evidence we found in
favour of supportive psychotherapy could therefore be considered
in  line  with  the  findings  of  above  mentioned  reviews,  suggesting
that non-specific factors may actually play an important role in the
treatment of panic disorder.

Potential biases in the review process

A U T H O R S '   C O N C L U S I O N S

Although  this  is  the  largest  and  most  comprehensive  systematic
review  and  network  meta-analysis  of  psychological  therapies  for
panic  disorder,  there  is  reason  to  suspect  that  the  available
literature may be affected by publication bias. Even when a study
was published, lack of unified outcome measures across studies,
especially  in  the  older  trials,  left  suspicion  of  outcome  reporting
bias. Many of the included studies were not ideal in terms of risk
of bias as individual studies. Our comprehensive literature search,
unified  and  reliable  data  extraction  and  study  assessment,  and
methodological  rigour  in  the  analyses  have  been  able  to  guard
against some but not all of these limitations.

Agreements and disagreements with other studies or
reviews

To our knowledge, this is the most extensive and methodologically
rigorous systematic review ever run on psychological therapies for
the treatment of panic disorder. Furthermore, this is the first time in
which such therapies have been compared with each other through
a network meta-analysis.

Our  results  confirm  the  findings  of  a  previous  pairwise  meta-
analysis  (Mitte  2005),  in  which  CBT  was  found  to  be  superior  to
waiting list in the reduction of anxiety and depressive symptoms
and  in  the  improvement  of  quality  of  life.  However,  in  Mitte
2005  no  difference  was  found  between  CBT  and  BT  in  terms  of
anxiety  reduction.  The  results  of  a  more  recent  meta-analysis
suggested that the combination of exposure, relaxation/breathing
techniques and cognitive therapy may represent the most effective
treatment  for  panic  disorder,  with  smaller  effect  sizes  for  any  of
these components if administered alone (Sánchez-Meca 2010). This
finding  is  more  in  line  with  our  results,  where  CBT  appeared  to
perform better than CT, BT and PT.

Different  from  Sánchez-Meca  2010  and  Mitte  2005,  where
publication bias was discarded as a possible threat to the validity of
results, we found clear evidence of small study effects (which may
be due, at least partly, to publication bias) affecting the comparison
of CBT versus waiting list.

Implications for practice

There  was  no  high-quality,  unequivocal  evidence  to  support
one  psychological  therapy  over  the  others  for  the  treatment
of  panic  disorder  with  or  without  agoraphobia  in  adults.  The
ranking of treatments according to the SUCRA value, derived from
NMAs,  showed  that  cognitive  behaviour  therapy  (CBT),  the  most
extensively  studied  among  the  included  psychological  therapies,
was often superior to other therapies, although the effect size was
small and the level of precision was often insufficient or clinically
irrelevant.

In  the  only  two  available  studies  exploring  psychodynamic
psychotherapies,  this  treatment  showed  promising  results,
although  further  research  is  needed  in  order  to  better  explore
the relative efficacy of psychodynamic therapies (PD) with respect
to  CBT.  Unexpectedly,  we  found  some  evidence  in  support  of
the possible viability of non-specific supportive psychotherapy for
the  treatment  of  panic  disorder;  however,  the  results  concerning
supportive  psychotherapy  (SP)  should  be  interpreted  cautiously
because of the sparsity of evidence regarding this treatment and,
as was the case for PD, further research is needed to explore this
issue. Behaviour therapy did not appear to be a valid alternative to
CBT as a first-line treatment for patients with panic disorder with or
without agoraphobia.

Implications for research

An important finding of this review regards the quality level of trials.
It is desirable that future trials present more detailed descriptions
of  the  randomisation  process,  ensure  the  blinding  of  outcome
assessors  and  provide  an  a  priori  specification  of  primary  and
secondary outcomes.

There  seems  to  be  no  further  need  to  explore  the  comparison
between CBT and wait list (WL), nor between CBT and behaviour
therapy  (BT);  rather,  there  is  a  need  for  studies  exploring  the
comparison  between  active  treatments,  with  particular  regard  to
CBT,  PD  and  supportive  psychotherapy,  possibly  in  the  context
of  multi-arm  trials,  with  large  sample  sizes,  including  long-term
assessments.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Addis 2004 {published data only}

Addis ME, Hatgis C, Cardemil E, Jacob K, Krasnow AD,
Mansfield A. Effectiveness of cognitive-behavioral treatment
for panic disorder versus treatment as usual in a managed care
setting: 2-year follow-up. Journal of Consulting and Clinical
Psychology 2006;74(2):377-85.

*  Addis ME, Hatgis C, Krasnow AD, Jacob K, Bourne L,
Mansfield A. Effectiveness of cognitive-behavioral treatment
for panic disorder versus treatment as usual in a managed
care setting. Journal of Consulting and Clinical Psychology
2004;72(4):625-35.

Al Kubaisy 1992 {published and unpublished data}

*  Al Kubaisy T, Marks I, Logsdail S, Marks MP, Lovell K, Sungur M,
et al. Role of exposure homework in phobia reduction: a
controlled study. Behavior Therapy 1992;23:599-621.

Park JM, Mataix-Cols D, Marks IM, Ngamthipwatthana T,
Marks M, Araya R, et al. Two-year follow-up after a randomised
controlled trial of self- and clinician-accompanied exposure
for phobia/panic disorders. British Journal of Psychiatry
2001;178:543-8.

Arch 2012 {published data only}

*  Arch JJ, Eifert GH, Davies C, Plumb VJC, Rose RD, Craske MG.
Randomized clinical trial of cognitive behavioral therapy (CBT)
versus acceptance and commitment therapy (ACT) for mixed
anxiety disorders. Journal of Consulting and Clinical Psychology
2012;80(5):750-65.

Arch JJ, Wolitzky-Taylor KB, Eifert GH, Craske MG. Longitudinal
treatment mediation of traditional cognitive behavioral therapy
and acceptance and commitment therapy for anxiety disorders.
Behaviour Research and Therapy 2012;50:469-78.

Arntz 2002 {published data only (unpublished sought but not
used)}

Arntz A. Cognitive therapy versus interoceptive exposure as
treatment of panic disorder without agoraphobia. Behaviour
Research and Therapy 2002;40(3):325-41.

Barlow 1989 {published data only (unpublished sought but not
used)}

Barlow DH, Brown TA, Craske MG, Rapee RM, Antony MM.
Treatment of panic disorder: follow-up and mechanisms
of action. 25th Annual Meeting of the Association for the
Advancement of Behavior Therapy. New York, 1991.

*  Barlow DH, Craske MG, Cerny JA, Klosko JS. Behavioral
treatment of panic disorder. Behavior Therapy
1989;20(2):261-82.

Brown TA, Barlow DH. Long-term outcome in cognitive-
behavioral treatment of panic disorder: clinical predictors and
alternative strategies for assessment. Journal of Consulting and
Clinical Psychology 1995;63(5):754-65.

Craske MG, Brown TA, Barlow DH. Behavioral treatment
of panic disorder: a two-year follow-up. Behavior Therapy
1991;22(3):289-304.

Margraf J, Barlow DH, Clark DM, Telch MJ. Psychological
treatment of panic: work in progress on outcome, active
ingredients, and follow-up. Behavior Research and Therapy
1993;31(1):1-8.

Beck 1987 {published data only (unpublished sought but not used)}

*  Beck AT. Cognitive approaches to panic disorder: theory and
therapy. In: Rachman S, Maseck J editor(s). Panic: Psychological
Perspectives. Hillsdale, NJ: L. Erlbaum Associates, 1988:91-109.

Sokol-Kessler L, Beck AT. Cognitive treatment of panic
disorders. 140th Annual Meeting of the American Psychiatric
Association. Chicago, May 1987.

Beck 1992 {published data only (unpublished sought but not used)}

Beck AT, Sokol L, Clark DA, Berchick R, Wright F. A crossover
study of focused cognitive therapy for panic disorder. American
Journal of Psychiatry 1992;149(6):778-83.

Beck 1994 {published data only}

*  Beck JG, Stanley MA, Baldwin LE, Deagle EA, Averill PM.
Comparison of cognitive therapy and relaxation training for
panic disorder. Journal of Consulting and Clinical Psychology
1994;62(4):818-26.

Stanley MA, Beck JG, Averill PM, Baldwin LE, Deagle EA,
Stadler JG. Patterns of change during cognitive behavioral
treatment for panic disorder. Journal of Nervous and Mental
Disease 1996;184(9):567-72.

Beutel 2013 {published and unpublished data}

Beutel M. Short-term psychotherapy for patients with
panic disorder with or without agoraphobia - a randomised
comparative study between the panic-focused psychodynamic
and cognitive behavioural psychotherapy [Kurzzeittherapie
der Panikstörung mit oder ohne Agoraphobie mittels
panikfokussierender Psychodynamischer Psychotherapie
(PfPP) und kognitiver Verhaltenstherapie (KVT) - eine
randomisierte und kontrollierte Therapievergleichsstudie].
https://drks-neu.uniklinik-freiburg.de/ 2009 (accessed 16 March
2015):S00000245. [DRKS00000245]

*  Beutel ME, Scheurich V, Knebel A, Michal M, Wiltink J,
Graf-Morgenstern M, et al. Implementing panic-focused
psychodynamic psychotherapy into clinical practice. Canadian
Journal of Psychiatry 2013;58(6):326-34.

Brown TA, Antony MM, Barlow DH. Diagnostic comorbidity in
panic disorder: effect on treatment outcome and course of
comorbid diagnoses following treatment. Journal of Consulting
and Clinical Psychology 1995;63(3):408-18.

Botella 2004 {published and unpublished data}

Botella C, Garcia-Palacios A, Villa H, Banos RM, Quero S,
Alcaniz M, et al. Virtual reality exposure in the treatment of

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

panic disorder and agoraphobia: a controlled study. Clinical
Psychology and Psychotherapy 2007;14(3):164-75.

*  Botella C, Villa H, Garcia Palacios A, Quero S, Banos RM,
Alcaniz M. The use of VR in the treatment of panic disorders
and agoraphobia. Studies in Health Technology & Informatics
2004;99:73-90.

Brown 1997 {published data only (unpublished sought but not
used)}

Brown GK, Beck AT, Newman CF, Beck JS, Tran GQ. A
comparison of focused and standard cognitive therapy for panic
disorder. Journal of Anxiety Disorders 1997;11(3):329-45.

Burke 1997 {published data only}

Burke M, Drummond LM, Johnston DW. Treatment choice
for agoraphobic women: exposure or cognitive-behaviour
therapy?. British Journal of Clinical Psychology 1997;36(Pt
3):409-20.

Carter 2003 {published data only}

Carter MM, Sbrocco T, Gore KL, Marin NW, Lewis EL. Cognitive-
behavioral group therapy versus a wait-list control in the
treatment of African American women with panic disorder.
Cognitive Therapy and Research 2003;27(5):505-18.

Craske 1995 {published data only}

Craske MG, Maidenberg E, Bystritsky A. Brief cognitive-
behavioral versus nondirective therapy for panic disorder.
Journal of Behavior Therapy and Experimental Psychiatry
1995;26(2):113-20.

Craske 2005a {published data only}

*  Craske MG, Lang AJ, Aikins D, Mystkowski JL. Cognitive
behavioral therapy for nocturnal panic. Behavior Therapy
2005;36(1):43-54.

Tsao JC, Mystkowski JL, Zucker BG, Craske MG. Impact of
cognitive-behavioral therapy for panic disorder on comorbidity:
a controlled investigation. Behaviour Research and Therapy
2005;43(7):959-70.

Creager Berger 2001 {published data only}

*  Creager Berger B. The treatment of panic disorder: a
comparative study between breathing retraining and cognitive
behavioral therapy. Dissertation Abstracts International 2001;
Vol. 61, issue 8b.

Creager Berger B, Gevirtz R. The treatment of panic disorder:
a comparison between breathing retraining and cognitive
behavioral therapy. Biological Psychology 2001;56(1):78-9.

Clark 1994 {published data only}

De Ruiter 1989 {published data only}

Clark DM, Salkovskis PM, Hackmann A, Middleton H,
Anastasiades P, Gelder M. A comparison of cognitive therapy,
applied relaxation and imipramine in the treatment of panic
disorder. British Journal of Psychiatry 1994;164(6):759-69.

Clark 1999 {published data only}

Clark DM, Salkovskis PM, Hackmann A, Wells A, Ludgate J,
Gelder M. Brief cognitive therapy for panic disorder: a
randomized controlled trial. Journal of Consulting and Clinical
Psychology 1999;67(4):583-9.

Cottraux 2009 {published data only (unpublished sought but not
used)}

Cottraux J. A comparative controlled study of virtual reality
therapy and cognitive behavior therapy in panic disorder with
agoraphobia. https://clinicaltrials.gov/ct2/show/NCT00129610
2005 (accessed 16 March 2015).

Lambrey S, Jouvent R, Allilaire JF, Pelissolo A. Virtual reality
therapies in the treatment of phobic disorders [French]. Annales
Medico-Psychologiques 2010;168(1):44-6.

*  Pelissolo A, Zaoui M, Aguayo G, Yao SN, Roche S, Ecochard R,
et al. Virtual reality exposure therapy versus cognitive behavior
therapy for panic disorder with agoraphobia: a randomized
comparison study. Journal of CyberTherapy and Rehabilitation
2012;5(1):35-43.

Pull C, Pelissolo A, Zaoui M, et al. A randomized controlled
study of virtual reality exposure therapy and cognitive-behavior
therapy in panic disorder with agoraphobia. Cyberpsychology &
Behavior (Abstracts from CyberTherapy 14 Designing the Future
of Healthcare, June 21–23, 2009, Lago Maggiore, Verbania, Italy)
2009;12(5):647.

Rijken H, Kraaimaat F, de Ruiter C, Garssen B. A follow-up study
on short-term treatment of agoraphobia. Behaviour Research
and Therapy 1992;30(1):63-6.

*  de Ruiter C, Ryken H, Garssen B, Kraaimaat F. Breathing
retraining, exposure and a combination of both, in the
treatment of panic disorder with agoraphobia. Behaviour
Research and Therapy 1989;27(6):647-55.

Dow 2000 {published data only (unpublished sought but not used)}

Casey LM, Newcombe PA, Oei TP. Cognitive mediation of panic
severity: the role of catastrophic misinterpretation of bodily
sensations and panic self-efficacy. Cognitive Therapy and
Research 2005;29(2):187-200.

Dow MG, Kenardy JA, Johnston DW, Newman MG, Taylor CB,
Thomson A. Prognostic indices with brief and standard CBT for
panic disorder: I. Predictors of outcome. Psychological Medicine
2007;37(10):1493-502.

Kenardy J, Robinson S, Dob R. Cognitive behaviour therapy
for panic disorder: long-term follow up. Cognitive Behaviour
Therapy 2005;34(2):75-8.

*  Kenardy JA, Dow MG, Johnston DW, Newman MG, Thomson A,
Taylor CB. A comparison of delivery methods of cognitive-
behavioral therapy for panic disorder: an international
multicenter trial. Journal of Consulting and Clinical Psychology
2003;71(6):1068-75.

Dreessen 1994 {published data only (unpublished sought but not
used)}

Arntz A, van den Hout M. Psychological treatments of panic
disorder without agoraphobia: cognitive therapy versus applied
relaxation. Behaviour Research and Therapy 1996;34(2):113-21.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Emmelkamp 1986 {published data only (unpublished sought but
not used)}

the role of therapist-guided exposure in situ in CBT. Journal of
Consulting and Clinical Psychology 2011;79(3):406-20.

Emmelkamp PM, Brilman E, Kuiper H, Mersch PP. The treatment
of agoraphobia. A comparison of self-instructional training,
rational emotive therapy, and exposure in vivo. Behavior
Modification 1986;10:37-53.

Erickson 2003 {published data only (unpublished sought but not
used)}

Erickson DH, Janeck AS, Tallman K. A cognitive-behavioral
group for patients with various anxiety disorders. Psychiatric
Services 2007;58(9):1205-11.

Erickson DH, Janeck AS, Tallman K. Group CBT for
heterogeneous anxiety disorders. 34th Annual Conference
of the British Association for Behavioural and Cognitive
Psychotherapies. Warwick, 19-21 July 2006.

Erickson DH, Janeck AS, Tallman K. Group CBT for
heterogeneous anxiety disorders: preliminary evidence for
effectiveness. 31st Annual Conference of the British Association
for Behavioural and Cognitive Psychotherapies. York, 16-19 July
2003.

Gloster 2010 {published data only}

Arolt V, Zwanziger P, Strohle A, Hamm A, Gerlach A, Kircher T, et
al. The research network PANIC-NET: improving the treatment
of panic disorder - From a better understanding of fear circuit
mechanisms to more effective psychological treatment and
routine care. Psychotherapie Psychosomatik Medizinische
Psychologie 2009;59:124-31.

Emmrich A, Beesdo-Baum K, Gloster AT, Knappe S, Hfler M,
Arolt V, et al. Depression does not affect the treatment outcome
of CBT for panic and agoraphobia: results from a multicenter
randomized trial. Psychotherapy and Psychosomatics
2012;81(3):161-72.

Kircher T, Arolt V, Jansen A, Pyka M, Reinhardt I, Kellermann T,
et al. Effect of cognitive-behavioral therapy on neural correlates
of fear conditioning in panic disorder. Biological Psychiatry
2013;73(1):93-101.

Lang T, Helbig-Lang S, Gloster AT, et al. Effects of therapist-
guided exposure in CBT for panic disorder and agoraphobia
[Effekte therapeutenbegleiteter versus patientengeleiteter
Exposition bei Panikstörung mit Agoraphobie]. Zeitschrift für
klinische Psychologie und Psychotherapie 2012;41(2):114-24.

Wittchen HU, Lang T. Improving cognitive behavioural
therapy for panic by identifying the active ingredients and
understanding the mechanisms of action: a multicentre study.
http://www.isrctn.com/ISRCTN80046034 2007 (accessed 16
March 2015).

Goldstein 2000 {published data only (unpublished sought but not
used)}

Goldstein AJ, De Beurs E, Chambless DL, Wilson KA. EMDR for
panic disorder with agoraphobia: comparison with waiting list
and credible attention-placebo control conditions. Journal of
Consulting and Clinical Psychology 2000;68(6):947-56.

Gould 1993 {published data only}

Gould R, Clum GA, Shapiro D, Weaver T, Blalock J. Evidence for
a self-help coping approach for treating panic disorder. Annual
Meeting of the Southeastern Psychological Association. New
Orleans, LA, 1991.

*  Gould RA, Clum GA, Shapiro D. The use of bibliotherapy in
the treatment of panic: a preliminary investigation. Behavior
Therapy 1993;24:241-52.

Griegel 1995 {published data only}

Gloster AT, Hauke C, Hofler M, Einsle F, Fydrich T, Hamm A, et al.
Long-term stability of cognitive behavioral therapy effects for
panic disorder with agoraphobia: a two-year follow-up study.
Behaviour Research and Therapy 2013;51(12):830-9.

Griegel LE. Breathing retraining in panic disorder: physiological
mechanisms or perceived controllability. Dissertation Abstracts
International: Section B: The Sciences and Engineering
1995;55(9):4120.

Gloster AT, Klotsche J, Gerlach AL, Hamm A, Strohle A,
Gauggel S, et al. Timing matters: change depends on the stage
of treatment in cognitive behavioral therapy for panic disorder
with agoraphobia. Journal of Consulting and Clinical Psychology
2014;82(1):141-53.

Gloster AT, Wittchen HU, Einsle F, Hofler M, Lang T, Helbig-
Lang S, et al. Mechanism of action in CBT (MAC): methods of
a multi-center randomized controlled trial in 369 patients
with panic disorder and agoraphobia. European Archives of
Psychiatry & Clinical Neuroscience 2009;259(Suppl 2):S155-66.

Gloster AT, Wittchen HU, Einsle F, Lang T, Helbig-Lang S,
Fydrich T, et al. Correction to Gloster et al. (2011). Journal of
Consulting and Clinical Psychology 2011;79(5):652.

*  Gloster AT, Wittchen HU, Einsle F, Lang T, Helbig-Lang S,
Fydrich T, et al. Psychological treatment for panic disorder
with agoraphobia: a randomized controlled trial to examine

Hazen 1996 {published data only (unpublished sought but not
used)}

Hazen AL, Walker JR, Eldridge GD. Anxiety sensitivity and
treatment outcome in panic disorder. Anxiety 1996;2(1):34-9.

Walker JG, Eldridge A, Hazen, Rallo J, O'Riordan J, Frankel S.
Evaluation of a self-help book and workbook for treatment of
panic disorder used independently, in a self-help group, or a
professional group [Thesis]. University of Manitoba 1996.

Hendriks 2010 {published data only}

Hendriks GJ. The efficacy of paroxetine and cognitive-
behavioural therapy in the treatment of late-life panic disorder:
a randomized controlled trial. http://www.trialregister.nl/ 2007
(accessed 16 March 2015). [NTR1144]

Hendriks GJ, Keijsers GPJ, Kampman M, Hoogduin CAL, Oude
Voshaar RC. Predictors of outcome of pharmacological and
psychological treatment of late-life panic disorder with

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

agoraphobia. International Journal of Geriatric Psychiatry
2012;27(2):146-50.

Treatment and Variables Affecting Course and Outcome.
Springer-Verlag, 1988.

Hendriks GJ, Keijsers GPJ, Kampman M, Oude Voshaar RC,
Verbraak M, Broekman TG, et al. A randomized controlled study
of paroxetine and cognitive-behavioural therapy for late-life
panic disorder. Acta Psychiatrica Scandinavica 2010;122(1):11-9.

Hoffart 1995 {published data only}

*  Hoffart A. A comparison of cognitive and guided mastery
therapy of agoraphobia. Behaviour Research and Therapy
1995;33(4):423-34.

Hoffart A. Cognitive and guided mastery therapy of
agoraphobia: long-term outcome and mechanisms of change.
Cognitive Therapy and Research 1998;22(3):195-207.

Hoffart A. Cognitive mediators of situational fear in
agoraphobia. Journal of Behavior Therapy and Experimental
Psychiatry 1995;26(4):313-20.

Hoffart A. Interpersonal problems among patients
suffering from panic disorder with agoraphobia before
and after treatment. British Journal of Medical Psychology
1997;70(2):149-57.

Hoffart A, Hedley LM. Personality traits among panic disorder
with agoraphobia patients before and after symptom-focused
treatment. Journal of Anxiety Disorders 1997;11(1):77-87.

Hoffart A, Hedley LM, Thornes K, Larsen SM, Friis S. Therapists'
emotional reactions to patients as a mediator in cognitive
behavioural treatment of panic disorder with agoraphobia.
Cognitive Behaviour Therapy 2006;35(3):174-82.

Karekla 2004 {published data only (unpublished sought but not
used)}

Karekla M. A Comparison Between Acceptance Enhanced
Cognitive Behavioral and Panic Control Treatment for Panic
Disorder [Doctoral dissertation]. University at Albany, State
University of New York, 2004.

Karekla M. A comparison between acceptance-enhanced
panic control treatment and panic control treatment for panic
disorder. Dissertation Abstracts International 2005;65(9b):4835.

Levitt Jill T, Karekla M. Integrating acceptance and mindfulness
with cognitive behavioral treatment for panic disorder.
Acceptance and mindfulness-based approaches to anxiety:
conceptualization and treatment. Springer US, 2005:165-88.

Klosko 1988 {published data only}

Klosko JS. Comparison of alprazolam and cognitive-behavior
therapy in treatment of panic disorder. Dissertation Abstracts
International 1988;49(5-b):1945.

Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison
of alprazolam and behavior therapy in treatment of panic
disorder. Journal of Consulting and Clinical Psychology
1990;58(1):77-84.

Klosko JS, Barlow DH, Tassinari RB, Cerny JA. Comparison of
alprazolam and cognitive-behavior therapy in the treatment
of panic disorder. A preliminary report. Panic and Phobias:

Korrelboom 2013 {published data only}

Korrelboom K, Peeters S, Blom S, Huijbrechts I. Competitive
memory training (COMET) for panic and applied relaxation
(AR) are equally effective in the treatment of panic in panic-
disordered patients. Journal of Contemporary Psychotherapy
2014;44(3):183-90. [DOI: 10.1007/s10879-013-9259-3]

Lidren 1994 {published data only}

Lidren DM. The differential efficacy of self-help and group
therapy in the treatment of panic disorder and agoraphobia:
a treatment comparison study. Dissertation Abstracts
International 1994;54(12-b):6465.

*  Lidren DM, Watkins PL, Gould RA, Clum GA, Asterino M,
Tulloch HL. A comparison of bibliotherapy and group therapy
in the treatment of panic disorder. Journal of Consulting and
Clinical Psychology 1994;62(4):865-9.

Malbos 2011 {published and unpublished data}

*  Malbos E, Rapee RM, Kavakli M. A controlled study of
agoraphobia and the independent effect of virtual reality
exposure therapy. Australian and New Zealand Journal of
Psychiatry 2013;47(2):160-8.

Malbos E, Rapee RM, Kavakli M. Isolating the effect of
virtual reality based exposure therapy for agoraphobia: a
comparative trial. Studies in Health Technology and Informatics
2011;167:45-50.

Marchione 1987 {published data only}

Marchione KE, Michelson L, Greenwald M, Dancu C. Cognitive
behavioral treatment of agoraphobia. Behaviour Research and
Therapy 1987;25(5):319-28.

Meulenbeek 2008 {published and unpublished data}

Meulenbeek P, Spinhoven P, Smit F, van Balkom A, Cuijpers P.
Cognitive mediation of panic reduction during an early
intervention for panic. Acta Psychiatrica Scandinavica
2010;122(1):20-9.

*  Meulenbeek P, Willemse G, Smit F, van Balkom A, Spinhoven P,
Cuijpers P. Early intervention in panic: pragmatic randomised
controlled trial. British Journal of Psychiatry 2010;196:326-31.

Meulenbeek P, Willemse G, Smit F, van Balkom A, Spinhoven P,
Cuijpers P. Early intervention in panic: pragmatic randomised
controlled trial: Erratum. British Journal of Psychiatry
2010;196(6):497.

Meulenbeek P, Willemse G, Smit F, van Balkom A, Spinhoven P,
Cuijpers P. Early intervention in panic: randomized controlled
trial and cost-effectiveness analysis. Trials 2008;9:67.

Willemse G. Prevention of panic disorder: a randomised clinical
trial adjoining cost-effectiveness study. http://www.isrctn.com/
ISRCTN33407455 2005 (accessed 16 March 2015).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Meuret 2008 {published data only (unpublished sought but not
used)}

Meuret AE, Wilhelm FH, Ritz T, Roth WT. Feedback of end-tidal
pCO2 as a therapeutic approach for panic disorder. Journal of
Psychiatric Research 2008;42(7):560-8.

Meuret 2010 {published data only (unpublished sought but not
used)}

Meuret AE, Hofmann SG, Rosenfield D. Catastrophic appraisal
and perceived control as moderators of treatment response
in panic disorder. International Journal of Cognitive Therapy
2010;3(3):262-77.

*  Meuret AE, Rosenfield D, Seidel A, Bhaskara L, Hofmann SG.
Respiratory and cognitive mediators of treatment change in
panic disorder: evidence for intervention specificity. Journal of
Consulting and Clinical Psychology 2010;78(5):691-704.

Meuret AE, Seidel A, Rosenfield B, Hofmann SG, Rosenfield D.
Does fear reactivity during exposure predict panic symptom
reduction?. Journal of Consulting and Clinical Psychology
2012;80(5):777-85.

Meyerbroker 2011 {published and unpublished data}

Emmelkamp PMG. Virtual reality exposure therapy in
agoraphobic participants. https://clinicaltrials.gov/ct2/show/
NCT00734370 2008 (accessed 16 March 2015).

Meyerbroker K, Morina N, Kerkhof G, Emmelkamp PM. Virtual
reality exposure treatment of agoraphobia: a comparison
of computer automatic virtual environment and head-
mounted display. Studies in Health Technology & Informatics
2011;167:51-6.

*  Meyerbroker K, Morina N, Kerkhof G, Emmelkamp PMG.
Virtual reality exposure therapy does not provide any additional
value in agoraphobic patients: a randomized controlled trial.
Psychotherapy and Psychosomatics 2013;82(3):170-6.

Meyerbroker K, Morina N, Kerkhof G, Emmelkamp PMG. Virtual
reality exposure treatment of agoraphobia: a comparison of
computer automatic virtual environment and head-mounted
display. Annual Review of CyberTherapy and Telemedicine
2011;9(1):41-5.

Milrod 2006a {published and unpublished data}

Klass ET, Milrod BL, Leon AC, Kay SJ, Schwalberg M, Li C, et
al. Does interpersonal loss preceding panic disorder onset
moderate response to psychotherapy? An exploratory study.
Journal of Clinical Psychiatry Diseases of the Nervous System
2009;70(3):406-11.

Milrod B. Outcome studies in psychodynamic psychotherapy
for panic disorder. 37th International Meeting of the Society
for Psychotherapy Research; 2006 21-24 June. Edinburgh,
2006:103-4.

Milrod B. Randomized controlled trial of psychodynamic
psychotherapy vs. applied relaxation for panic disorder. https://
clinicaltrials.gov/ct2/show/NCT00128388 2005 (accessed 16
March 2015). [NCT00128388]

*  Milrod B, Leon AC, Busch F, Rudden M, Schwalberg M,
Clarkin J, et al. A randomized controlled clinical trial
of psychoanalytic psychotherapy for panic disorder
[published erratum appears in The American Journal of
Psychiatry 2009;164(7):1123]. American Journal of Psychiatry
2007;164(2):265-72.

Milrod B, Leon AC, Busch F, Rudden M, Schwalberg M, Clarkin J,
et al. A randomized controlled clinical trial of psychoanalytic
psychotherapy for panic disorder: Erratum. The American
Journal of Psychiatry 2007;164(3):529.

Muncy 1991 {published data only}

Muncy SM. Panic: a comparison of four treatment methods.
Dissertation Abstracts International 1991;51(12b, pt 1):6115.

Ost 1993 {published data only (unpublished sought but not used)}

Ost LG, Westling BE, Hellstrom K. Applied relaxation, exposure
in vivo and cognitive methods in the treatment of panic
disorder with agoraphobia. Behaviour Research and Therapy
1993;31(4):383-94.

Ost 1995 {published data only}

Ost LG, Westling BE. Applied relaxation vs cognitive behavior
therapy in the treatment of panic disorder. Behaviour Research
and Therapy 1995;33(2):145-58.

Ost 2004 {published data only (unpublished sought but not used)}

Ost LG, Thulin U, Ramnero J. Cognitive behavior therapy
vs exposure in vivo in the treatment of panic disorder
with agoraphobia. Behaviour Research and Therapy
2004;42(10):1105-27.

Ramnero J, Ost LG. Panic and avoidance in panic disorder with
agoraphobia: clinical relevance of change in different aspects
of the disorder. Journal of Behavior Therapy and Experimental
Psychiatry 2007;38(1):29-39.

Petterson 1996 {published data only}

Petterson K, Cesare S. Panic disorder: a cognitive-behavioural
approach to treatment. Counselling Psychology Quarterly
1996;9(2):191-201.

Rees 1999 {published data only}

Rees CS, Richards JC, Smith LM. The efficacy of information-
giving in cognitive-behavioural treatment for panic disorder.
Behaviour Change 1999;16(3):175-81.

Reinecke 2013 {published data only}

Reinecke A, Waldenmaier L, Cooper MJ, Harmer CJ. Changes
in automatic threat processing precede and predict clinical
changes with exposure-based cognitive-behavior therapy for
panic disorder. Biological Psychiatry 2013;73(11):1064-70.

Salkovskis 1999 {published data only}

Salkovskis PM, Clark DM, Hackmann A, Wells A, Gelder MG.
An experimental investigation of the role of safety-
seeking behaviours in the maintenance of panic disorder
with agoraphobia. Behaviour Research and Therapy
1999;37(6):559-74.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Salkovskis PM, Hackmann A, Wells A, Gelder MG, Clark DM.
Belief disconfirmation versus habituation approaches to
situational exposure in panic disorder with agoraphobia: a pilot
study. Behaviour Research and Therapy 2007;45(5):877-85.

Schmidt 1997a {published data only}

Schmidt NB, Trakowski JH, Staab JP. Extinction of panicogenic
effects of a 35% CO2 challenge in patients with panic disorder.
Journal of Abnormal Psychology 1997;106(4):630-8.

Schmidt 1997b {published data only (unpublished sought but not
used)}

*  Schmidt NB, Staab JP, Trakowski JH Jr, Sammons M. Efficacy
of a brief psychosocial treatment for panic disorder in an
active duty sample: implications for military readiness. Military
Medicine 1997;162(2):123-9.

Schmidt NB, Woolaway-Bickel K, Trakowski J, Santiago H,
Storey J, Koselka M, et al. Dismantling cognitive-behavioral
treatment for panic disorder: questioning the utility of
breathing retraining. Journal of Consulting and Clinical
Psychology 2000;68(3):417-24.

Scott 1995 {published data only (unpublished sought but not
used)}

Scott MJ, Stradling SG, Greenfield TA. The efficacy of brief group
cognitive therapy programmes for anxiety and depression,
and the relevance of a personality disorder diagnosis. World
Congress of Behavioural and Cognitive Therapies; 1995 July
11-15. Copenhagen, 1995.

Sharp 2004 {published data only}

Sharp DM, Power KG, Swanson V. A comparison of the efficacy
and acceptability of group versus individual cognitive behaviour
therapy in the treatment of panic disorder and agoraphobia
in primary care. Clinical Psychology and Psychotherapy
2004;11(2):73-82.

Shear 1994 {published data only}

Shear MK, Leon AC, Portera L, Klosko J, Cloitre M.
Psychoeducation /reflective listening compared to cognitive-
behavioural treatment in panic disorder. New Research
Program and Abstracts - 144th Annual Meeting of the American
Psychiatric Association; 1991 May 11-16. New Orleans,
Louisiana, US, 1991.

*  Shear MK, Pilkonis PA, Cloitre M, Leon AC. Cognitive
behavioral treatment compared with nonprescriptive
treatment of panic disorder. Archives of General Psychiatry
1994;51(5):395-401.

Taylor 1982 {published data only (unpublished sought but not
used)}

Taylor CB, Kenigsberg ML, Robinson JM. A controlled
comparison of relaxation and diazepam in panic disorder.
Journal of Clinical Psychiatry 1982;43(10):423-5.

Telch 1993 {published data only}

Telch MJ, Lucas JA, Schmidt NB, Hanna HH, LaNae Jaimez T,
Lucas RA. Group cognitive-behavioral treatment of panic
disorder. Behaviour Research and Therapy 1993;31(3):279-87.

Cochrane Database of Systematic Reviews

Tyrer 1988 {published data only (unpublished sought but not
used)}

Kingdon D, Tyrer P, Seivewright N, Ferguson B, Murphy S.
The Nottingham Study of Neurotic Disorder: influence of
cognitive therapists on outcome. British Journal of Psychiatry
1996;169:93-7.

Klein DF. Nottingham study of neurotic disorder. Lancet
1988;2:1015.

Knerer G, Byford S, Johnson T, Seivewright H, Tyrer P. The
Nottingham study of neurotic disorder: predictors of 12 year
costs. Acta Psychiatrica Scandinavica 2005;112(3):224-32.

Seivewright H, Tyrer P, Johnson T. Change in personality status
in neurotic disorders. Lancet 2002;359:2253-4.

Seivewright H, Tyrer P, Johnson T. Prediction of outcome in
neurotic disorder: a 5-year prospective study. Psychological
Medicine 1998;28(5):1149-57.

Seivewright N, Tyrer P, Ferguson B, Murphy S, Johnson T.
Longitudinal study of the influence of life events and
personality status on diagnostic change in three neurotic
disorders. Depression & Anxiety 2000;11(3):105-13.

Tyrer P, Seivewright H, Ferguson B, Johnson T. Cold calling in
psychiatric follow up studies: is it justified?. Journal of Medical
Ethics 2003;29(4):238-42.

Tyrer P, Seivewright H, Johnson T. The Nottingham Study of
Neurotic Disorder: Predictors of 12-year outcome of dysthymic,
panic and generalized anxiety disorder. Psychological Medicine
2004;34(8):1385-94.

Tyrer P, Seivewright H, Simmonds S, Johnson T. Prospective
studies of cothymia (mixed anxiety-depression): How do they
inform clinical practice?. European Archives of Psychiatry &
Clinical Neuroscience 2001;251(Suppl 2):1153-6.

Tyrer P, Seivewright N, Ferguson B, Murphy S, Darling C,
Brothwell J, et al. The Nottingham Study of Neurotic Disorder:
relationship between personality status and symptoms.
Psychological Medicine 1990;20(2):423-31.

Tyrer P, Seivewright N, Ferguson B, Murphy S, Johnson AL. The
Nottingham Study of Neurotic Disorder: effect of personality
status on response to drug treatment, cognitive therapy
and self-help over two years. British Journal of Psychiatry
1993;162:219-26.

Tyrer P, Seivewright N, Ferguson B, Tyrer J. The general
neurotic syndrome: a coaxial diagnosis of anxiety, depression
and personality disorder. Acta Psychiatrica Scandinavica
1992;85(3):201-6.

*  Tyrer P, Seivewright N, Murphy S, Ferguson B, Kingdon D,
Barczak P, et al. The Nottingham Study of Neurotic Disorder:
comparison of drug and psychological treatments. Lancet
1988;2:235-40.

Tyrer P, Seivewright N, Seivewright H. Long-term outcome of
hypochondriacal personality disorder. Journal of Psychosomatic
Research 1999;46(2):177-85.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Williams 1996 {published data only (unpublished sought but not
used)}

Williams SL, Falbo J. Cognitive and performance-based
treatments for panic attacks in people with varying degrees
of agoraphobic disability. Behaviour Research and Therapy
1996;34(3):253-64.

Wollburg 2011 {published data only}

*  Kim S, Wollburg E, Roth WT. Opposing breathing therapies
for panic disorder: a randomized controlled trial of lowering
vs raising end-tidal PCO2. Journal of Clinical Psychiatry
2012;73(7):931-9.

Roth WT. Breathing regulation training for individuals with panic
disorder. https://clinicaltrials.gov/ct2/show/NCT00183521 2005
(accessed 16 March 2015).

Wollburg E, Roth WT, Kim S. Effects of breathing training on
voluntary hypo- and hyperventilation in patients with panic
disorder and episodic anxiety. Applied Psychophysiology &
Biofeedback 2011;36:81-91.

References to studies excluded from this review

Andersson 2011 {published and unpublished data}

Andersson G. Internet-administrated treatment of anxiety
symptoms for young adults. https://clinicaltrials.gov/ct2/show/
NCT01402258 2011 (accessed 16 March 2015).

Barlow 2000a {published data only}

*  Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-
behavioral therapy, imipramine, or their combination
for panic disorder. a randomized controlled trial. JAMA
2000;283(19):2529-36.

Barlow DH, Gorman JM, Shear MK, Woods SW. ERRATUM:
Cognitive-behavioral therapy, imipramine, or their combination
for panic disorder. a randomized controlled trial. JAMA
2000;284(19):2450.

Barlow DH, Gorman JM, Shear MK, Woods SW. ERRATUM:
Cognitive-behavioral therapy, imipramine, or their combination
for panic disorder. a randomized controlled trial. JAMA
2001;284(20):2597.

Shear MK, Houck P, Greeno C, Masters S. Emotion-focused
psychotherapy for patients with panic disorder. American
Journal of Psychiatry 2001;158(12):1993-8.

Bélanger 2006 {published and unpublished data}

Bélanger C, Vaillancourt L, Dulude D, Archambault M,
Rochfort J, Pecknold J, et al. The differential effect of two
behavioral therapies on attentional processes of subjects
presenting panic disorder [L'effet différentiel de deux thérapies
comportementales sur les processus attentionnels de sujets
présentant un trouble panique]. Revue Francophone de Clinique
Comportamentale et Cognitive 2008;13(2):11-23.

Benecke 2014 {published data only}

Benecke C. Psychoanalytic therapy (PT) and cognitive-
behavioral therapy (CBT) in outpatients with anxiety (panic
disorder/agoraphobia) and comorbid personality disorders: a

Cochrane Database of Systematic Reviews

multicenter prospective randomized superiority trial. http://
www.isrctn.com/ISRCTN12449681 2014 (accessed 16 March
2015).

Borden 1986 {published data only}

Clum GA, Watkins PL, Borden JW, Broyles S, Hayes J. A
comparison of guided imaginal coping and imaginal exposure
in the treatment of panic disorder. Journal of Rational-Emotive &
Cognitive-Behavior Therapy 1993;11(4):179.

Elsesser 2002 {published and unpublished data}

Elsesser K, Mosch A, Sartory G. Brief psychological treatment
for the relief of panic disorder. Behavioural and Cognitive
Psychotherapy 2002;30(4):423-30.

Fava 1997 {published data only (unpublished sought but not used)}

Fava GA, Savron G, Zielezny M, Grandi S, Rafanelli C, Conti S.
Overcoming resistance to exposure in panic disorder with
agoraphobia. Acta Psychiatrica Scandinavica 1997;95(4):306-12.

Gloster 2010a {published data only (unpublished sought but not
used)}

Gloster AT. Acceptance and commitment therapy (ACT) for
treatment-resistant panic disorder with agoraphobia. http://
www.isrctn.com/ISRCTN12042066 2010 (accessed 16 March
2015).

Ito 2001 {published data only}

Ito LM, De Araujo LA, Tess VLC, De Barros-Neto TP, Asbahr FR,
Marks I. Self-exposure therapy for panic disorder with
agoraphobia. British Journal of Psychiatry 2001;178(4):331-6.

Michelson 1996 {published data only}

Michelson LK, Marchione KE, Greenwald MT, Testa S,
Marchione NJ. A comparative outcome and follow-up
investigation of panic disorder with agoraphobia: the relative
and combined efficacy of cognitive therapy, relaxation training,
and therapist-assisted exposure. Journal of Anxiety Disorders
1996;10(5):297-330.

Murphy MT, Michelson LK, Marchione K, Marchione N, Testa S.
The role of self-directed in vivo exposure in combination with
cognitive therapy, relaxation training, or therapist-assisted
exposure in the treatment of panic disorder with agoraphobia.
Journal of Anxiety Disorders 1998;12(2):117-38.

Teusch 1996 {published data only (unpublished sought but not
used)}

Teusch L, Bohme H, Gastpar M. The benefit of an insight-
oriented and experiential approach on panic and agoraphobia
symptoms. Results of a controlled comparison of client-
centered therapy alone and in combination with behavioral
exposure. Psychotherapy & Psychosomatics 1997;66:293-301.

Zane 1993 {published data only (unpublished sought but not used)}

Zane G, Williams SL. Performance-related anxiety in
agoraphobia: treatment procedures and cognitive mechanisms
of change. Behavior Therapy 1993;196:625-43.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

References to studies awaiting assessment

Bressi 2010a {published data only (unpublished sought but not
used)}

Bressi C, Ciabatti M, Nocito EP, Catenacci E, Porcellana, M,
Invernizzi G, et al. A preliminary longitudinal study on the
importance of early intervention in panic disorder [conference
abstract]. Journal of Psychosomatic Research [abstracts from
the 19th European Congress of Psychiatry, EPA 2011 Vienna
Austria, 12-15 Mar]. 2011:610.

Foley 2006 {published data only (unpublished sought but not
used)}

Foley D, Baille A, Renner P. 29th Australian Association for
Cognitive and Behaviour Therapy Annual Conference. Manly,
18-23 October 2006:43.

Franklin 1990 {published data only}

Franklin JA. Behavioural therapy for panic disorder.
International Journal of Neuroscience 1990;51:138.

Irgens 2009 {published data only (unpublished sought but not
used)}

Irgens AC. Thought field therapy and cognitive therapy for
agoraphobia. https://clinicaltrials.gov/ct2/show/NCT00932919
2009 (accessed 16 March 2015).

Margraf 1991 {published data only (unpublished sought but not
used)}

Margraf J, Schneider S. Outcome and active ingredients of
cognitive-behavioural treatments for panic disorder. 25th
Conference of the Association for Advancement of Behavior
Therapy. New York, 1991.

Milrod 2006b {published data only (unpublished sought but not
used)}

Milrod B, Leon AC, Fishman B, Barber JP, Chambless D. Dynamic
treatment vs. CBT for panic disorder. https://clinicaltrials.gov/
ct2/show/NCT00353470 2006 (accessed 16 March 2015).

Richards 1997 {published data only (unpublished sought but not
used)}

Richards JB, Bickley N, Rees C, Beros P. An investigation of the
mechanisms of change in the cognitive behavioural treatment
of panic disorder. Health Perspectives: Research Policy and
Practice 1997;1(1):35-44.

Roache 1998 {published data only (unpublished sought but not
used)}

Roache JD, Oswald LM, Stanley MA, Creason DR, Shah NN.
Effects of psychotherapy-induced anxiety reduction on
alprazolam self-medication behavior. CPDD 1998 Annual
Meeting. Scottsdale, 1998:121.

Strauss 1997 {published data only (unpublished sought but not
used)}

Strauss WH, Klieser E. Combination of pharmaco- and
psychotherapy in the treatment of panic disorder. European
Neuropsychopharmachology 1996;6(Suppl 3):206 (O-24-6).

Cochrane Database of Systematic Reviews

Vincelli 2003 {published data only (unpublished sought but not
used)}

Vincelli F, Anolli L, Bouchard S, Wiederhold BK, Zurloni V,
Riva G. Experiential cognitive therapy in the treatment
of panic disorders with agoraphobia: a controlled study.
Cyberpsychology and Behavior 2003;6(3):321-8.

Vincelli 2004 {published data only (unpublished sought but not
used)}

Vincelli F, Molinari E, Riva G. CBT Virtual Reality Assisted
for the Treatment of Panic Disorders with Agoraphobia: A
Controlled Study. 35th International Meeting of the Society for
Psychotherapy Research. Rome, 16-19 June 2004:35.

References to ongoing studies

Barlow 2010 {published data only (unpublished sought but not
used)}

Barlow DH. Efficacy evaluation of a unified transdiagnostic
treatment for anxiety disorders. https://clinicaltrials.gov/ct2/
show/NCT01243606 2010 (accessed 16 March 2015).

Caspi 2012 {published data only (unpublished sought but not
used)}

Caspi A. The assessment and treatment of balance impairment
using virtual reality (VR) in panic disorder patients. https://
clinicaltrials.gov/ct2/show/NCT01677429 2012 (accessed 16
March 2015).

Gensichen 2012 {published data only (unpublished sought but not
used)}

Gensichen J. Evaluation of a practice team-supported, self-
managed exposure training for patients with panic disorder
and agoraphobia in primary care [Jena-PARADISE (Patient
Activation foR Anxiety DISordErs)]. http://www.isrctn.com/
ISRCTN64669297 2012 (accessed 16 March 2015).

Gensichen J, Hiller TS, Breitbart J, Teismann T, Brettschneider C,
Schumacher U, Piwtorak A, König HH, Hoyer H, Schneider N,
Schelle M, Blank W, Thiel P, Wensing M, Margraf J. Evaluation of
a practice team-supported exposure training for patients with
panic disorder with or without agoraphobia in primary care -
study protocol of a cluster randomised controlled superiority
trial [2014]. Trials 2014;15:112.

Sandell 2012 {published data only}

Sandell R. Psychotherapy outcome and self-selection effects in
panic disorder. https://clinicaltrials.gov/ct2/show/NCT01606592
2012 (accessed 16 March 2015).

Teismann 2012 {published data only}

Teismann T. Cognitive behavior therapy vs exposure in vivo
in the treatment of panic disorder with agoraphobia. https://
clinicaltrials.gov/ct2/show/NCT01680237 2012 (accessed 16
March 2015).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Additional references

Altman 1996

Altman DG, Bland MJ. Detecting skewness for summary
information. BMJ 1996;313:1200.

APA 1980

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 3rd Edition. American Psychiatric
Association, 1980.

APA 1987

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 3rd Edition. American Psychiatric
Association, 1987.

APA 2000

Carlbring 2006

Carlbring P,  Bohman S,  Brunt S,  Buhrman M,  Westling BE,
 Ekselius L, et al. Remote treatment of panic disorder: a
randomized trial of internet-based cognitive behavior therapy
supplemented with telephone calls. American Journal of
Psychiatry 2006;163(12):2119-25.

Chaimani 2013

Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G.
Graphical tools for network meta-analysis in STATA. PLoS ONE
2013;8(10):e76654. [DOI: 10.1371/journal.pone.0076654]

Clark 1985

Clark DM, Salkovskis PM, Chakley J. Respiratory control as a
treatment for panic attacks. Journal of Behavior Therapy and
Experimental Psychiatry 1985;16:23-30.

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 4th Edition. Washington DC: APA,
2000.

Clark 1986a

Clark DM. A cognitive approach to panic. Behaviour Research
and Therapy 1986;24(4):461-70.

APA 2013

Clark 1986b

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 5th Edition. Arlington, VA: American
Psychiatric Publishing, 2013.

Clark DA, Salkovskis PM. Cognitive Treatment of Panic:
Therapist's Manual. Oxford, UK: Department of Psychiatry,
University of Oxford, 1986.

Barlow 2000b

Barlow DH, Craske MG. Mastery of Your Anxiety and Panic:
MAP-3. New York: Graywind Publications, 2000.

Bernstein 1973

Bernstein DA, Borkovec TD. Progressive Relaxation Training: A
Manual for the Helping Professions. Champaign, IL: Research
Press, 1973.

Bijl 1998

Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric
disorder in the general population: results of The Netherlands
Mental Health Survey and Incidence Study (NEMESIS). Social
Psychiatry and Psychiatric Epidemiology 1998;33:587-95.

Brooks 1998

Brooks SP, Gelman A. General methods for monitoring
convergence of iterative simulations. Journal of Computational
and Graphical Statistics 1998;7:434–55.

Bucher 1997

Bucher HC,  Guyatt GH,  Griffith LE,  Walter SD. The results of
direct and indirect treatment comparisons in meta-analysis of
randomized controlled trials. Journal of Clinical Epidemiology
1997;50(6):683-91.

Busch 1996

Busch F, Milrod B, Cooper A, Shapiro T. Psychodynamic
approaches to panic disorder. Journal of Psychotherapy Practice
and Research 1996;5(1):72-83.

Caldwell 2005

Caldwell DM,  Ades AE,  Higgins JP. Simultaneous comparison
of multiple treatments: combining direct and indirect evidence.
BMJ 2005;331(7521):897-900.

Cochrane Comparing Multiple Interventions Group

Cochrane Comparing Multiple Interventions Group. [Stream
3: summary of findings tables and GRADE assessments for
network meta-analysis]. http://methods.cochrane.org/cmi/
sites/methods.cochrane.org.cmi/files/uploads/SoFTs%20and
%20GRADE%20for%20NMA.pdf (accessed 11 April 2016).

Cohen 1960

Cohen J. A coefficient of agreement for nominal scales.
Educational and Psychological Measurement 1960;20:37-46.
[DOI: 10.1177/001316446002000104]

Dannon 2002

Dannon PN, Iancu I, Grunhaus L. Psychoeducation in panic
disorder patients: effect of a self-information booklet in a
randomized, masked-rater study. Depression and Anxiety
2002;16(2):71-6.

Eaton 1994

Eaton WW, Kessler RC, Wittchen H-U, Magee WJ. Panic and panic
disorder in the United States. American Journal of Psychiatry
1994;151:413-20.

Elbourne 2002

Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV,
Vail A. Meta-analyses involving cross-over trials: methodological
issues. International Journal of Epidemiology 2002;31:140-9.
[DOI: 10.1093/ije/31.1.140]

Feighner 1972

Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G,
Munoz R. Diagnostic criteria for use in psychiatric research.
Archives of General Psychiatry 1972;26:57-63.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Furukawa 2005

Guaiana 2013a

Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N.
Imputing response rates from means and standard deviations
in meta-analysis. International Clinical Psychopharmacology
2005;20:49-52.

Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC,
Koesters M. Antidepressants versus placebo for panic disorder
in adults. Cochrane Database of Systematic Reviews 2013, Issue
7. [DOI: 10.1002/14651858.CD010676]

Furukawa 2006

Guaiana 2013b

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N.
Imputing missing standard deviations in meta-analyses can
provide accurate results. Journal of Clinical Epidemiology
2000;59:7-10.

Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC,
Koesters M. Benzodiazepines versus placebo for panic disorder
in adults. Cochrane Database of Systematic Reviews 2013, Issue
7. [DOI: 10.1002/14651858.CD010677]

Furukawa 2007

Guy 1976

Furukawa TA, Watanabe N, Churchill R. Combined
psychotherapy plus antidepressants for panic disorder with or
without agoraphobia. Cochrane Database of Systematic Reviews
2007, Issue 1. [DOI: 10.1002/14651858.CD004364.pub2]

Glenny 2005

Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ,
D’Amico R, et al. Indirect comparisons of competing
interventions. Health Technology Assessment 2005;9(26):1-134.

Gloster 2011

Gloster AT,  Wittchen HU,  Einsle F,
 Lang T,  Helbig-Lang S,  Fydrich T, et al.
Psychological treatment for panic disorder with agoraphobia:
a randomized controlled trial to examine the role of therapist-
guided exposure in situ in CBT. Journal of Consulting and Clinical
Psychology 2011;79(3):406-20.

Guy W. Clinical Global Impressions. In: ECDEU Assessment
Manual for Psychopharmacology, revised (DHEW Publ No ADM
76-338). National Institute of Mental Health, 1976:218–222.

Hayes 1999

Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment
Therapy: An Experiential Approach to Behavior Change. New
York, NY: Guilford Press, 1999.

Hayes 2004

Hayes SC. Acceptance and commitment therapy, relational
frame theory, and the third wave of behavioral and cognitive
therapies. Behavior Therapy 2004;35:639-65.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.

Goisman 1995

Higgins 2011

Goisman RM, Warshaw MG, Steketee GS, Fierman EJ,
Rogers MP, Goldenberg I, et al. DSM-IV and the disappearance
of agoraphobia without a history of panic disorder: new data
on a controversial diagnosis. American Journal of Psychiatry
1995;152:1438-43.

Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.

Higgins 2012

Gorman 2000

Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical
hypothesis of panic disorder, revised. American Journal of
Psychiatry 2000;157:493-505.

Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR.
Consistency and inconsistency in network meta-analysis:
concepts and models for multi-arm studies. Research Synthesis
Methods 2012;3(2):98-110.

Grant 2006

Hofmann 2008

Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB,
Smith S, et al. The epidemiology of DSM-IV panic disorder and
agoraphobia in the United States: results from the National
Epidemiologic Survey on Alcohol and Related Conditions.
Journal of Clinical Psychiatry 2006;67:363-74.

Greenberg 2004

Greenberg LS. Emotion–focused therapy. Clinical Psychology
and Psychotherapy 2004;11:3-16.

Guaiana 2013

Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC, Imai H,
et al. Azapirones versus placebo for panic disorder in adults.
Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI:
10.1002/14651858.CD010828]

Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for
adult anxiety disorders: a meta-analysis of randomized
placebo-controlled trials. Journal of Clinical Psychiatry
2008;69(4):621-32.

Kessler 2006

Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The
epidemiology of panic attacks, panic disorder, and agoraphobia
in the National Comorbidity Survey Replication. Archives of
General Psychiatry 2006;63:415-24.

Kim 2009

Kim YW,  Lee SH,  Choi TK,  Suh SY,  Kim B,  Kim CM, et al.
Effectiveness of mindfulness-based cognitive therapy as an
adjuvant to pharmacotherapy in patients with panic disorder
or generalized anxiety disorder. Depression and Anxiety
2009;26(7):601-6.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

King 2008

Meuret 2012

King M, Nazareth I, Levy G, Walker C, Morris R, Weich S,
et al. Prevalence of common mental disorders in general
practice attendees across Europe. British Journal of Psychiatry
2008;192:362-7.

Klein 1983

Klein DF,  Zitrin CM,  Woerner MG,  Ross DC.
Treatment of phobias. II. Behavior therapy and supportive
psychotherapy: are there any specific ingredients?. Archives of
General Psychiatry 1983;40(2):139-45.

Klein 1993

Klein DF. False suffocation alarms, spontaneous panics, and
related conditions. An integrative hypothesis. Archives of
General Psychiatry 1993;50:306–17.

Lee 2007

Lee SH,  Ahn SC,  Lee YJ,  Choi TK,  Yook KH,  Suh SY.
Effectiveness of a meditation-based stress management
program as an adjunct to pharmacotherapy in patients
with anxiety disorder. Journal of Psychosomatic Research
2007;62:189–95.

Ley 1985

Ley RA. Blood, breath and fears: a hyperventilation theory of
panic attacks and agoraphobia. Clinical Psychology Review
1985;5:271–85.

Lu 2004

Lu G, Ades AE. Combination of direct and indirect evidence
in mixed treatment comparisons. Statistics in Medicine
2004;30(20):3105-24.

Ludwig 2008

Ludwig DS,  Kabat-Zinn J. Mindfulness in medicine. JAMA
2008;300(11):1350-2.

Meuret AE,  Wolitzky-Taylor KB,  Twohig MP,  Craske MG.
Coping skills and exposure therapy in panic disorder and agoraphobia: latest advances and future directions.
Behavior Therapy 2012;43(2):271-84.

Milrod 1997

Milrod B, Busch F, Cooper A, Shapiro T. Manual of Panic-Focused
Psychodynamic Psychotherapy. Arlington: American Psychiatric
Publishing, 1997.

Milrod 2007

Milrod B,  Leon AC,  Busch F,  Rudden M,  Schwalberg M,
 Clarkin J, et al. A randomized controlled clinical trial of
psychoanalytic psychotherapy for panic disorder. American
Journal of Psychiatry 2007;164(2):265-72.

Mitte 2005

Mitte K. A meta-analysis of the efficacy of psycho- and
pharmacotherapy in panic disorder with and without
agoraphobia. Journal of Affective Disorders 2005;88(1):27-45.

NICE 2011

[CG113] Generalised anxiety disorder and panic disorder (with
or without agoraphobia) in adults: management in primary,
secondary and community care. NICE clinical guidelines 2011.

Nordin 2010

Nordin S,  Carlbring P,  Cuijpers P,  Andersson G. Expanding the
limits of bibliotherapy for panic disorder: randomized trial of
self-help without support but with a clear deadline. Behavior
Therapy 2010;41(3):267-76.

Ost 1987

Ost LG. Applied relaxation: description of a coping technique
and review of controlled studies. Behaviour Research and
Therapy 1987;25(5):397-409.

Ost 1988

Lumley 2002

Lumley T. Network meta-analysis for indirect treatment
comparisons. Statistics in Medicine 2002;21(16):2313-24.

Ost LG. Applied relaxation vs progressive relaxation in the
treatment of panic disorder. Behaviour Research and Therapy
1988;26(1):13-22.

Marks 1979

Roemer 2008

Marks IM, Mathews AM. Brief standard self-rating for phobic
patients. Behavior Research and Therapy 1979;17:263-7.

Marks 1981

Roemer L, Erisman SM, Orsillo SM. Mindfulness and acceptance-
based treatments for anxiety disorders. In: Antony MM, Stein MB
editor(s). Oxford Handbook of Anxiety and Related Disorders.
Oxford: Oxford University Press, 2008:476-87.

Marks IM. Cure and Care of Neuroses: Theory and Practice of
Behavioural Psychotherapy. New York: Wiley, 1981.

Rogers 1980

Meuret 2010a

Rogers CR. A Way of Being. Boston: Houghton Mifflin, 1980.

Meuret AE, Rosenfield D, Seidel A, Bhaskara L, Hofmann SG.
Respiratory and cognitive mediators of treatment change in
panic disorder: evidence for intervention specificity. Journal of
Consulting and Clinical Psychology 2010;78:691-704.

Salanti 2008

Salanti G, Higgins JPT, Ades AE, Ioannidis JPA. Evaluation of
networks of randomized trials. Statistical Methods in Medical
Research 2008;17:279. [DOI: 10.1177/0962280207080643]

Meuret 2010b

Salanti 2009

Meuret AE,  Ritz T. Hyperventilation in panic disorder and
asthma: empirical evidence and clinical strategies. International
Journal of Psychophysiology 2010;78(1):68-79.

Salanti G,  Marinho V,  Higgins JP. A case study of multiple-
treatments meta-analysis demonstrates that covariates
should be considered. Journal of Clinical Epidemiology
2009;62(8):857-64.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Salanti 2011

Sterne 2000

Salanti G, Ades AE, Ioannidis JPA. Graphical methods and
numerical summaries for presenting results from multiple-
treatment meta-analysis: an overview and tutorial. Journal of
Clinical Epidemiology 2011;64:163-71.

Salanti 2012

Salanti G. Indirect and mixed-treatment comparison, network,
or multiple-treatments meta-analysis: many names, many
benefits, many concerns for the next generation evidence
synthesis tool. Research Synthesis Methods 2012;3(2):80-97.

Salanti 2014

Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP.
Evaluating the quality of evidence from a network meta-
analysis. PLoS One 2014;9(7):e99682.

Salkovskis 1991

Salkovskis PM, Clark DM, Hackmann A. Treatment of panic
attacks using cognitive therapy without exposure or breathing
retraining. Behaviour Research and Therapy 1991;29:161-6.

Schmidt 1994

Schmidt NB. Elimination of Safety Maneuvers: Cognitive
Behavioral Treatment for Panic Disorder with Agoraphobia.
Bethesda: USUHS, 1994.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence
of bias. Dimensions of methodological quality associated
with estimates of treatment effects in controlled trials. JAMA
1995;273(5):408–12.

Shear 1997

Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE,
Woods SW, et al. Multicenter collaborative panic
disorder severity scale. American Journal of Psychiatry
1997;154(11):1571-5.

Sorby 1991

Sorby NG,  Reavley W, Huber JW. Self help programme for
anxiety in general practice: controlled trial of an anxiety
management booklet. British Journal of General Practice
1991;41(351):417-20.

Sterne JA, Gavaghan D, Egger M. Publication and related bias in
meta-analysis: power of statistical tests and prevalence in the
literature. Journal of Clinical Epidemiology 2000;53(11):1119-29.

Sánchez-Meca 2010

Sánchez-Meca J,  Rosa-Alcázar AI,  Marín-Martínez F,  Gómez-
Conesa A. Psychological treatment of panic disorder with or
without agoraphobia: a meta-analysis. Clinical Psychology
Review 2010;30(1):37-50.

Telch 1990

Telch MJ, Schmidt NB. Cognitive–behavioral Treatment for
Panic Disorder and Agoraphobia: Panic Inoculation Treatment
Manual. Unpublished manuscript, 1990.

Turner 2012

Turner RM,  Davey J,  Clarke MJ,  Thompson SG,  Higgins JP.
Predicting the extent of heterogeneity in meta-analysis,
using empirical data from the Cochrane Database of
Systematic Reviews. International Journal of Epidemiology
2012;41(3):818-27.

Van den Hout 1994

Van den Hout M, Arntz A, Hoekstra R. Exposure reduced
agoraphobia but not panic, and cognitive therapy reduced
panic but not agoraphobia. Behaviour Research and Therapy
1994;32:447-51.

Vøllestad 2012

Vøllestad J,  Nielsen MB,  Nielsen GH. Mindfulness- and
acceptance-based interventions for anxiety disorders: a
systematic review and meta-analysis. British Journal of Clinical
Psychology 2012;51:239–60.

Watanabe 2009

Watanabe N, Churchill R, Furukawa TA. Combined
psychotherapy plus benzodiazepines for panic disorder.
Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI:
10.1002/14651858.CD005335.pub2]

White 2011

White IR. Multivariate random-effects meta-regression: updates
to mvmeta. The STATA Journal 2011;11:255–70.

Spineli 2013

White 2012

Spineli LM,  Higgins JPT,  Cipriani A,  Leucht S, Salanti G.
Evaluating the impact of imputations for missing participant
outcome data in a network meta-analysis. Clinical Trials
2013;10(3):378-88. [DOI: 10.1177/1740774512470317]

White IR, Barrett JK, Jacksona D, Higgins JPT. Consistency and
inconsistency in network meta-analysis: model estimation
using multivariate meta-regression. Research Synthesis Methods
2012;3:111-25.

Spitzer 1978

WHO 1992

Spitzer RL, Robins E. Research diagnostic criteria: rationale and
reliability. Archives of General Psychiatry 1978;35(6):773-82.

Starcevic 2009

Starcevic V. Anxiety Disorders in Adults: a Clinical Guide. Oxford
University Press, 2009.

World Health Organization. The ICD-10 Classification of Mental
and Behavioural Disorders: Diagnostic Criteria for Research.
Geneva: World Health Organization, 1992.

Wiborg 1996

Wiborg IM, Dahl AA. Does brief dynamic psychotherapy
reduce the relapse rate of panic disorder?. Archives of General
Psychiatry 1996;53:689-94.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Williams 1990

Williams SL. Guided mastery treatment of agoraphobia:
beyond stimulus exposure. Progress in Behavior Modification
1990;26:89-121.

Wims 2010

Wims E,  Titov N,  Andrews G,  Choi I. Clinician-assisted Internet-
based treatment is effective for panic: a randomized controlled
trial. Australian and New Zealand Journal of Psychiatry
2010;44(7):599-607.

Winston 2004

Winston A, Rosenthal RN, Pinsker H. Introduction to Supportive
Psychotherapy. American Psychiatric Publishing, 2004.

Xiao 2011

Xiao Z, Li C, Wang J. Repetitive transcranial magnetic
stimulation (rTMS) for panic disorder. Cochrane

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Cochrane Database of Systematic Reviews

Database of Systematic Reviews 2011, Issue 4. [DOI:
10.1002/14651858.CD009083]

Zitrin 1978

Zitrin CM,  Klein DF,  Woerner MG.
Behavior therapy, supportive psychotherapy, imipramine, and
phobias. Archives of General Psychiatry 1978;35(3):307-16.

References to other published versions of this review

Pompoli 2014

Pompoli A, Furukawa T A, Imai H, Tajika A, Efthimiou O,
Salanti G. Psychological therapies for panic disorder with
or without agoraphobia in adults. Cochrane Database of
Systematic Reviews 2014, Issue 2.

* Indicates the major publication for the study

Addis 2004 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: participants were eligible for the study if they met DSM-IV diagnostic criteria for
panic disorder with or without agoraphobia or were subthreshold for a strict diagnosis of panic disor-
der but identified panic symptoms as their primary reason for seeking treatment (no subthreshold pa-
tient actually entered the study: "seventy-three percent of participants met criteria for panic disorder
with agoraphobia, and 27% met criteria for panic disorder without agoraphobia")

Exclusion criteria: participants were excluded if they were seeking treatment for a problem other than
panic or anxiety, had an untreated substance-use problem in the last 6 months, had a diagnosis of psy-
chosis in the past 5 years, were currently judged to be at risk for suicide, or were concurrently involved
in other individual psychotherapy. No exclusions were made on the basis of medication use for anxiety
or other comorbid psychological or medical problems.

Characteristics of the sample:

• Age: mean age 39.9 years (SD 12.9, range 18 to 70)
• Percentage of agoraphobic patients: 73%
• Percentage of patients on drug therapy: 65%
• Percentage of patients with major depression: 39%

Interventions

Participants (n = 80) were randomly assigned to either:

1) Panic control therapy (classified as CBT, n = 38)

• Therapy format: not stated
• Duration of each session: not stated
• Mean number of sessions: 12 to 15
• Duration of intervention: 12 to 15 weeks

2) Treatment as usual (classified as SP, n = 42)

• Therapy format: not stated
• Duration of each session: not stated
• Mean number of sessions: not stated

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Addis 2004  (Continued)

• Duration of intervention: not stated

Outcomes

Time points for assessment: baseline, 5.5 months, 8.5 months, 1 year, 2 years

Measures: Panic Disorder Severity Scale (PDSS), Fear Questionnaire (FQ), Beck Depression Inventory
(BDI–1), Outcome Questionnaire (OQ–45)

The following outcomes were used for quantitative analyses:

ST-Remission: PDSS below a cut-off score* at 5.5-month follow-up

ST-Response: not measured (imputed from continuous scale)

ST-Dropouts: patients who completed fewer than 6 sessions

Continuous scale: PDSS at baseline and at 5.5 months

LT-Remission/Response: PDSS below a cut-off score* at 1 year follow-up

* "Cut scores from published norms were obtained for the PDSS (Shear et al., 2001), the OQ–45 (Lambert et
al., 1996), the FQ (Gillis, Haaga, & Ford, 1995), and the BDI–1 (Seggar, Lambert, & Hansen, 2002)"

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Unclear risk

No information provided

Low risk

All randomised patients (n = 80) were assessed at 5.5-month follow-up

Low risk

All randomised patients (n = 80) were assessed at 1-year follow-up

Unclear risk

Study protocol unavailable

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Incomplete outcome data
(attrition bias) 
Short-term

Incomplete outcome data
(attrition bias) 
Long-term

Selective reporting (re-
porting bias)

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Low risk

Treatment fidelity

Low risk

"Ten therapists agreed to participate. None of them identified their primary the-
oretical orientation as cognitive–behavioral; as a group they were approximate-
ly equally distributed between eclectic, family systems, psychodynamic, and hu-
manistic in their self-described orientation."

"We rated therapist adherence for 67 of the 80 cases in the study. Data were
missing for 11 cases in which the clients did not attend any treatment sessions
and 2 cases in which the therapists had audiotaping difficulties. Cases with miss-
ing adherence data did not differ from the rest of the sample on any of the pri-
mary outcome measures at pre- or posttreatment.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Addis 2004  (Continued)

Cochrane Database of Systematic Reviews

PCT therapists scored higher than TAU therapists on all of the PCT interventions
except for agoraphobic exposure, in which the frequency of use was low with no
differences between the treatments."

Al Kubaisy 1992 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: age between 18 and 60 years, agora-, social or specific phobic disorder on ICD-10
criteria for at least a year, mean 4-phobic-targets score of greater than 20 on a 0 to 32 scale, written in-
formed consent (patients were told they would be in a research study about the best way to treat their
kind of problem)

Exclusion criteria: severe organic disease; failed exposure treatment in the last year; more than 2 units
of alcohol a day from at least 3 weeks before entering the trial; on medication or on a stable dose of
more than the daily equivalent of 5 mg of diazepam, 100 mg imipramine or 10 mg propranolol, taken
only at night, for at least 4 months (by when it was unlikely to have any further effect, so this minority
was retained to boost cell size)

Characteristic of the sample (agoraphobia sub-sample):

• Age: not specified
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 34) were randomly assigned to either:

1) Daily live self exposure homework + clinician accompanied live exposure (classified as BT, n = 13)

• Therapy format: not stated
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks

2) Daily live self exposure homework with six negotiation and monitoring sessions (classified as
BT, n = 11)

• Therapy format: not stated
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks

3) Daily self relaxation homework with six negotiation and monitoring sessions (classified as PT, n
= 10)

• Therapy format: not stated
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks

Outcomes

Time points for assessment: baseline, 8 weeks, 14 weeks, 26 weeks

Measures: Fear Questionnaire (FQ), panic frequency, Beck Depression Inventory (BDI), Hamilton De-
pression (HAM-D), Global Improvement (CGI-I), Global Severity (CGI-S)

The following outcomes were used for quantitative analyses:

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Al Kubaisy 1992  (Continued)

ST-Remission: not measured (imputed from continuous scale)

ST- Response: not measured for agoraphobia sub-sample (imputed from continuous scale)

ST-Dropouts: refusers and dropouts before week 8

Continuous scale: although measured (CGI) detailed data are not reported

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Low risk

ST-Remission not measured: imputed from CGI-S, which was rated by "an as-
sessor (psychiatrists, psychologists and nurse therapists) kept blind to the treat-
ment condition."

Incomplete outcome data
(attrition bias) 
Short-term

High risk

29% of randomised patients (agoraphobia sub-sample) did not receive/com-
plete the assigned intervention. Dropouts imbalanced in number across the 3
arms. Refusers and dropouts data not reported.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"Both Ee and e patients had the rationale of exposure explained at the 1st ses-
sion, and were asked to read the self-help chapter from Living With Fear (Marks
IM, 1980) and to follow its guidelines". Marks IM is among the study authors.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Other bias

Unclear risk

Modification of the original sample with replacements. Number and randomi-
sation of replacements not specified.

Arch 2012 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM–IV diagnosis of one or more anxiety disorders, including panic disorder with or
without agoraphobia (PD/A), social anxiety disorder (SAD), specific phobia (SP), obsessive-compulsive
disorder (OCD), or generalised anxiety disorder (GAD)

Exclusion criteria: none

Characteristic of the sample (agoraphobia sub-sample):

• Age: not specified
• Percentage of agoraphobic patients: not specified

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arch 2012  (Continued)

Cochrane Database of Systematic Reviews

• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified

Interventions

Participants (n = unclear) were randomly assigned to either:

1) Acceptance and commitment therapy (classified as 3W, n = unclear)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

2) Cognitive behaviour therapy (classified as CBT, n = unclear)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

Outcomes

Time points for assessment: pre-treatment, post-treatment, 6 months follow-up, 12 months follow-up

Measures: Anxiety Disorders Interview Schedule–IV (ADIS–IV), Anxiety Sensitivity Index (ASI), Penn
State Worry Questionnaire (PSWQ), Fear Questionnaire (FQ), Main Target Phobia Scale (a single-item
avoidance rating for each participant's "main phobia"), Quality of Life Inventory (QOLI), Acceptance
and Action Questionnaire–16 (AAQ)

The following outcomes were used for quantitative analyses:

ST-Remission: although reported (Clinical Severity Rating on ADIS-IV lower than 4), ST-Remission
could not be calculated following an ITT principle (number of PD/A patients randomised to each arm
not specified)

ST- Response: not measured

ST-Dropouts: not measured

Continuous scale: ASI at pre- and post-treatment

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Low risk

"Randomization sequences were produced by http://www.randomizer.org"

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"One hundred and forty-three participants [...] were randomized to ACT (n=65) or
CBT (n=78). All participants who began treatment (n=128) were included in the
intent-to-treat (ITT) sample (n 57=ACT, n=71 CBT)".

Data for randomised patients who did not begin treatment unavailable.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arch 2012  (Continued)

Researcher allegiance

Unclear risk

Cochrane Database of Systematic Reviews

"CBT for anxiety disorders followed a protocol authored by Craske"; "ACT for anx-
iety disorders followed a manual authored by Eifert and Forsyth".

Both Craske MG and Eifert GH are among the study authors: although possible,
the direction of a researcher allegiance bias would be unclear.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"All sessions were videotaped for supervision purposes with a hidden video cam-
era; sessions were also audiotaped for therapy adherence purposes with a dis-
crete digital recorder. Videos were generally played in supervision sessions or
watched beforehand by supervisors."

Arntz 2002 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age between 17 and 70 years, primary DSM-III-R diagnosis of panic disorder with
no or mild agoraphobic avoidance, panic disorder for at least 3 months, at least one panic attack dur-
ing the previous 4 weeks, asking for treatment of panic disorder. No use of serotonergic antidepres-
sants or benzodiazepines (for at least 4 weeks; patients using this medication were, if they agreed, tak-
en off medication), or if unwilling to stop medication, keeping this medication at a constant level dur-
ing treatment or stopping it during treatment.

Exclusion criteria: depressive disorder preceding the current episode of panic disorder or requiring
immediate treatment; behaviour therapy received for panic disorder; evidence of organic mental dis-
orders, mental retardation, psychotic disorders, alcohol or drug dependence, cardiovascular disease,
asthma, epilepsy; medical contraindication for exposure, behavioural experiments or hyperventilation.

Characteristic of the sample:

• Age: 34.8 years (range 20 to 65)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 27.5%
• Percentage of patients with major depression: not specified (mood disorder 33.3%)

Interventions

Participants (n = 69) were randomly assigned to either:

1) Cognitive therapy (classified as CT, n = unclear)

• Therapy format: individual/group
• Duration of each session: 60 minutes (individual sessions)/105 minutes (group sessions)
• Mean number of sessions: 16
• Duration of intervention: 14 weeks (plus 2 sessions after 1 and 6 months)

2) Interoceptive exposure (classified as BT, n = unclear)

• Therapy format: individual/group
• Duration of each session: 60 minutes (individual sessions)/105 minutes (group sessions)
• Mean number of sessions: 16
• Duration of intervention: 14 weeks (plus 2 sessions after 1 and 6 months)

Outcomes

Time points for assessment: baseline, post-treatment (16 weeks), 1-month follow-up, 6 months fol-
low-up

Measures: panic diary, Fear of Fear Questionnaire, Fear Questionnaire (FQ), State–Trait Anxiety Inven-
tory (STAI), Symptom Check List (SCL-90)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Arntz 2002  (Continued)

The following outcomes were used for quantitative analyses:

ST-Remission: although measured (panic-free at post-treatment), data cannot be used to calculate re-
mission following an ITT principle (n randomised for each arm is unclear)

ST- Response: not measured

ST-Dropouts: detailed data are not reported

Continuous scale: although measured, detailed data are not reported

LT-Remission/Response: although measured (panic-free at 6 months follow-up) detailed data are not
reported

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Selective reporting (re-
porting bias)

High risk

Study protocol unavailable. Pre-planned measures are not reported with suffi-
cient details.

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"There were weekly supervisions, during which each case was presented in de-
tail and adherence to the protocol was checked. Care was taken to exclude cog-
nitive techniques from the IE treatment, and exposure techniques from the CT
treatment."

Barlow 1989 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM III-R diagnosis of panic disorder with mild or no agoraphobic avoidance. The
interviewers rated the severity of the disturbance on a 0 to 8-point scale (reflecting co-jointly distress
and disability from the disorder), and only clients whose severity rating was at least 4 were included in
the study. Finally, only subjects who reported the presence of at least 1 panic attack in a 2-week period
prior to assessment were included. Subjects on medications or receiving alternative psychotherapies
for the requisite time, and who met suitability criteria, were included under the agreement that med-
ication regime and psychotherapy contact were maintained at constant levels throughout.

Exclusion criteria: aged below 18 or above 65 years; current alcohol or drug dependency/abuse; pri-
mary diagnosis of major depression, and any signs of psychosis or organic brain syndrome. In addition,
clients concurrently involved in other psychotherapy programs were assessed for suitability only if the
alternative therapy was not focused on anxiety management, and they had been in therapy for at least
6 months. Finally, subjects were excluded if they had begun benzodiazepines within the past 3 months
or MAO inhibitors or tricyclic antidepressants within the past 6 months.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Barlow 1989  (Continued)

Characteristic of the sample:

Cochrane Database of Systematic Reviews

• Age: not specified for the ITT sample (completers sub-sample mean age 31.7 years, SD 8.3)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified for the ITT sample (25% in completers sub-

sample)

• Percentage of patients with major depression: not specified for the ITT sample (5% in completers

sub-sample)

Interventions

Participants (n = 71) were randomly assigned to either:

1) Wait list (classified as WL, n = 16)

• Mean number of sessions: 0
• Duration of intervention: 15 weeks

2) Applied progressive muscle relaxation (classified as PT, n = 15)

• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks

3) Exposure and cognitive restructuring (classified as CBT, n = 16)

• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks

4) Relaxation combined exposure and cognitive restructuring (classified as CBT, n = 24)

• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks

Outcomes

Time points for assessment: assessments were conducted at pre-treatment and post-treatment. Ac-
tive treatment group subjects were also assessed 3 months, 6 months, 12 months and 24 months after
treatment completion.

Measures: Anxiety Disorder Interview Schedule-Revised (ADIS-R), Trait Scale of the State-Trait Anxiety
Inventory (STAI-T), Cognitive-Somatic Anxiety Questionnaire, Fear Questionnaire (FQ), Beck Depression
Inventory (BDI), Psychosomatic Rating Scale, Subjective Symptom Scale, self monitoring records (re-
garding daily fluctuations in anxiety and depression and occurrence of panic attacks), composite crite-
ria for treatment responder (20% improvement in at least 3 of the following 4 measures: (1) clinical rat-
ing of severity (at least 2 points); (2) client's self rating from the Fear Questionnaire (at least 2 points);
(3) number of panic attacks per week, and (4) Subjective Symptom Scale total score (at least 8 points)
and End-State Functioning (applied only to treatment responders. At least three of the following five
criteria had to be obtained for high end-state status: (1) score of 2 or less on the clinician's rating of
severity; (2) score of 2 or less for the client's self rating; (3) 0 panic attack per week; (4) score of 2 or less
for the mean anxiety rating, and (5) score of 10 or less for the Subjective Symptom Scale total score).

The following outcomes were used for quantitative analyses:

ST-Remission: high end-state functioning* at post-treatment

ST- Response: treatment responder as defined by composite criteria

ST-Dropouts: subjects who did not complete assigned treatment

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Barlow 1989  (Continued)

Continuous scale: Fear Questionnaire (FQ)

LT-Remission/Response: reported data were not included in the analyses because of high level of
dropouts (see Secondary outcomes): "data were available for 23 subjects at the 6-month follow-up peri-
od (R n=9; E&C n=8; COMB n=6)"

* "At least three of the following five criteria had to be obtained for high end state status: (1) score of 2 or
less on the clinician's rating of severity; (2) score of 2 or less for the client's selfrating; (3) zero panic at-
tack per week; (4) score of 2 or less for the mean anxiety rating, and (5) score of 10 or less for the Subjective
Symptom Scale total score. End state functioning was determined if data from only three different mea-
sures were present but all three reflected positive or negative responding. End state status could not be
determined if more than two of the five measures were missing."

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Unclear risk

At least 3 out of 5 criteria had to be obtained for high end-state status. Al-
though assessor was a "blind, independent rater", only one of those 5 criteria
was assessor-rated, so it was possible for a patient to fall into the end-state
category on the basis of self rated measures only.

Incomplete outcome data
(attrition bias) 
Short-term

High risk

Incomplete outcome data
(attrition bias) 
Long-term

High risk

"The percentage of dropouts for each condition were 6%, 33%, 6%, and 17%. For
the study completers, data were missing at post-test for several variables due to
non-compliance. The number of missing data points ranged from 1 to 4 variables
within each group. Missing data were not replaced by averages."

"data were available for 23 subjects at the 6-month follow-up period (R n=9; E&C
n=8; COMB n=6)."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

Barlow DH and Craske MG are authors of a CBT manual (see Barlow 2000b)

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"Treatment delivery was examined by means of ratings of the content of thera-
py sessions from periodic spot checks of audiotapes (all therapy sessions were
audiotaped to avoid the possibility of response bias in the therapists verbal be-
havior during spot checking). Thirty-five tapes were randomly selected, with the
stipulation that each therapist and each treatment phase of each treatment
condition were represented in the sample. Two randomly selected five minute
segments (excluding the first and last five minutes of the session and including
at least three minutes of therapist talk) were rated from each tape. In all cases,
raters identified correctly the treatment condition represented by the sample.
Judgments of the treatment phase from which the sample came were correct
in 31 of the 35 cases; two misjudgements were from the E & C condition and two
from the R condition. There were only two instances of inappropriate material;
both of which referred to nontargeted problem areas and not to inappropriate
treatment technique."

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Beck 1987 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: not specified, probably DSM-III diagnosis of panic disorder (as in another previous
study by Ottaviani and Beck described in the book)

Exclusion criteria: not specified

Characteristic of the sample:

• Age: not specified
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 29) were randomly assigned to either:

1) Cognitive therapy (classified as CBT, n = 13)

• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

2) Brief supportive therapy (classified as APP, n = 16)

• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 8
• Duration of intervention: 8 weeks

Outcomes

Time points for assessment: baseline, 4 weeks, 8 weeks, 12 weeks (only for cognitive therapy group)

Measures: panic frequency

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (not imputed because of skewed distribution of available continuous
scale)

ST- Response: not measured (not imputed because of skewed distribution of available continuous
scale)

ST-Dropouts: non-completers

Continuous scale: although measured (panic frequency), detailed data are not reported

Notes

Risk of bias

Bias

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information provided

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Beck 1987  (Continued)

Allocation concealment
(selection bias)

Incomplete outcome data
(attrition bias) 
Short-term

Selective reporting (re-
porting bias)

Unclear risk

No information provided

Low risk

"There were no dropouts in either group".

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

Beck AT is involved in conceptualisation of cognitive therapy (see Description
of the intervention)

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Beck 1992 

Methods

Participants

Study design: randomised controlled trial, cross-over design

Inclusion criteria: age between 18 and 65 years, DSM-III diagnosis of panic disorder or agoraphobia
with panic disorder

Exclusion criteria: none

Characteristic of the sample:

• Age: not specified
• Percentage of agoraphobic patients: 18%
• Percentage of patients on drug therapy: 52%
• Percentage of patients with major depression: not specified (35% according to imputation from

BDI)

Interventions

Participants (n = 33) were randomly assigned to either:

1) Focused cognitive therapy (classified as CT, n = 17)

• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

2) Brief supportive psychotherapy (classified as WL*, n = 16)

• Therapy format: not specified
• Duration of each session: 30 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks

Outcomes

Time points for assessment: baseline, 4 weeks, 8 weeks, 12 weeks (only for focused cognitive therapy
group)

Measures: panic frequency, Mobility Inventory for Agoraphobia (MI), Beck Depression Inventory (BDI),
Beck Anxiety Inventory (BAI), Specific Fear Inventory, end-state functioning (only for focused cognitive
therapy group)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Beck 1992  (Continued)

Cochrane Database of Systematic Reviews

The following outcomes were used for quantitative analyses:

ST-Remission: absence of panic attacks (clinician rating, before cross-over)

ST- Response: not measured (not imputed)

ST-Dropouts: non-completers (before cross-over)

Continuous scale: not extracted (number of assessed patients unclear: "Ns varied across analyses from
14 to 17 patients in the cognitive therapy group and 15 to 16 patients in the brief supportive psychothera-
py group")

LT-Remission/Response: not measured

*Brief supportive psychotherapy arm was classified as WL (wait list) because: 1) patients received "8
weeks of supportive contact", apparently different from a proper supportive therapy (which therefore
cannot be classified as an active treatment, but rather as a comparator intervention); 2) although this
study is presented as having a cross-over design, only patients in supportive psychotherapy group (all
of them) actually did cross-over.

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Unclear risk

"At each assessment interval, independent clinical raters reviewed patients’ dai-
ly logs of panic frequency to determine whether the recorded panic attacks actu-
ally met the DSM-III criteria for panic".

It is unclear whether raters were blind to patients' allocation.

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Because of missing values for some variables, Ns varied across analyses from
14 to 17 patients in the cognitive therapy group and 15 to 16 patients in the brief
supportive psychotherapy group"

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

Beck AT is involved in conceptualisation of cognitive therapy (see Description
of the intervention)

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Beck 1994 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age 18 to 65 years, DSM-III primary diagnosis of panic disorder. Patients who report-
ed use of psychotropic medication were withdrawn from these regimes, with at least a 2-week drug
clearance before taking the ADIS-R.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Beck 1994  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria: severe agoraphobia, primary diagnosis of an alternate Axis I diagnosis, current
involvement in psychotherapy, alcohol or substance abuse within the previous 6 months, psychotic
symptoms, evidence of organic impairment.

Characteristic of the sample:

• Age: not specified for the randomised sample (n = 64) but only for the initially selected sample (n =

70, mean age 37.5 years, SD 9.7)

• Percentage of agoraphobic patients: not specified for the randomised sample (n = 64) but only for

the initially selected sample (n = 70, 87% being moderately or mildly agoraphobic)

• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified for the randomised sample (n = 64)
but only for the initially selected sample. Depression percentage among randomised sample was 23%
according to imputation based on HAM-D-17 score)

Interventions

Participants (n = 64) were randomly assigned to either:

1) Cognitive therapy (classified as CT, n = 22)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks

2) Relaxation training (classified as PT, n = 20)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks

3) Minimal contact control (classified as NT, n = 22)

• Therapy format: weekly telephone contact
• Duration of each session: not specified
• Mean number of sessions: 0
• Duration of intervention: 10 weeks

Outcomes

Time points for assessment: baseline, 5 weeks, 10 weeks. Subjects in the 2 intervention groups were
asked to return for 1-, 3- and 6-months follow-up visits.

Measures: panic frequency, Anxiety Disorders Interview Schedule-Revised (ADIS-R), Anxiety Sensitivity
Index (ASI), Body Sensations Questionnaire (BSQ), Agoraphobic Cognitions Questionnaire (ACQ), State-
Trait Anxiety Inventory (STAI), Fear Questionnaire (FQ), Hamilton Anxiety and Depression Scales (HAM-
A, HAM-D), composite index of treatment response (based on 4 variables: global PD severity, number of
panic attacks in the previous month, average ACQ and BSQ score, FQ-Ag score).

The following outcomes were used for quantitative analyses:

ST-Remission: panic-free at post-test (10 weeks)

ST- Response: at least mild improvement on composite index of treatment response*

ST-Dropouts: non-completers

Continuous scale: Anxiety Sensitivity Index (ASI)

LT-Remission/Response: panic-free at 6 months follow-up

Notes

* "A composite index of treatment response was derived, using guidelines established by Himadi, Boice,
and Barlow (1986) and Barlow et al. (1989). This measure quantified treatment response based on four

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Beck 1994  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

variables: global PD severity, number of panic attacks in the previous month, an average of ACQ and BSQ
scores, and FQ-Ag score".

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Unclear risk

No information provided

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Six subjects dropped out, with 5 (23%) from the CT condition, 1 (5%) from the RT
condition, and none (0%) from the MCC condition".

Incomplete outcome data
(attrition bias) 
Long-term

High risk

"Of the 17 subjects who completed CT, 16 (94%) were assessed at all three fol-
low-up points, with 1 subject not assessed at 3 and 6 months. All 19 RT subjects
were evaluated at each follow-up assessment".

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapies under study (note that first author is
Beck JG, not Beck AT).

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"We provided weekly clinical supervision for each session to ensure treatment
competence. All sessions were videotaped, with 24% (n=34) selected randomly
for treatment integrity monitoring"

Beutel 2013 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age 18 to 60 years, primary panic disorder with or without agoraphobia according to
DSM-IV criteria, fluency in the German language, living in the proximity of Mainz. Psychotropic medica-
tion, if present, had to be held constant.

Exclusion criteria: psychosis, bipolar disorder, borderline or antisocial personality disorder, active
substance abuse, severe medical or neurological disease precluding exposure therapy and ongoing
psychotherapy.

Characteristic of the sample:

• Age: 36.22 years (SD 10.8)
• Percentage of agoraphobic patients: 74.1%
• Percentage of patients on drug therapy: 22.2%
• Percentage of patients with major depression: 22.2%

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Beutel 2013  (Continued)

Interventions

Participants (n = 54) were randomly assigned to either:

1) Panic focused psychodynamic therapy (classified as PD, n = 36)

• Therapy format: not specified
• Duration of each session: 50 minutes
• Mean number of sessions: 24
• Duration of intervention: 12 weeks

2) Cognitive behaviour therapy (classified as CBT, n = 18)

• Therapy format: not specified
• Duration of each session: 50 minutes
• Mean number of sessions: 24
• Duration of intervention: 12 weeks

Outcomes

Time points for assessment: baseline, treatment termination, 6 months follow-up

Measures: Structured Clinical Interview for DSM-IV (SCID-I and II), Panic Disorder Severity Scale (PDSS),
Clinical Global Impression scale (CGI), Hamilton Depression Rating Scale (HAM-D), Symptom Checklist
(SCL-90R), Beck Depression Inventory (BDI), Levels of Emotional Awareness Scale (LEAS)

The following outcomes were used for quantitative analyses:

ST-Remission: PDSS score < 5 in PD or < 7 in PDA at termination

ST- Response: at least 40% reduction of PDSS

ST-Dropouts: non-completers

Continuous scale: Panic Disorder Severity Scale (PDSS)

LT-Remission/Response: PDSS score < 5 in PD or < 7 in PDA at 6 months follow-up

None

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

"subjects were allocated by an a priori computer-generated list in a 2: 1 random-
ization ratio either to Panic Focused Psychodynamic Psychotherapy or to manu-
alized cognitive behavioral therapy plus exposure."

Allocation concealment
(selection bias)

Unclear risk

No information provided

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Low risk

"Independent, experienced evaluators, blinded to subject condition and thera-
pist orientation, assessed subjects at baseline, at treatment termination and at 6
months follow-up."

Incomplete outcome data
(attrition bias) 
Short-term

Incomplete outcome data
(attrition bias) 
Long-term

High risk

Patients analysed at post-treatment:

PFPP n = 28

CBT n = 14

High risk

Patients analysed at follow-up:

PFPP n = 25

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Beutel 2013  (Continued)

CBT n = 13

Selective reporting (re-
porting bias)

High risk

Study protocol available (registered retrospectively). Reported primary out-
come is one among other primary outcomes cited in the protocol: "Principal
outcome criterion is the reduction of panic-related symptoms at the follow-up 6-
months after treatment. Panic-related symptoms are measured with standard-
ized questionnaires and interviews, e. g. the AKV-MI/BSQ/ACQ questionnaires, the
Hamilton Anxiety Scale, HAMA, and the Panic Disorder Severity scale, PDSS."

Researcher allegiance

High risk

Milrod B is co-author of PFPP manual (see Milrod 1997)

Therapist allegiance

Unclear risk

Insufficient information provided

Treatment fidelity

Low risk

"All treatments were videotaped as a basis for supervision and for later indepen-
dent assessment of treatment adherence"

Botella 2004 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: 18 years of age or older, met DSM-IV (American Psychiatric Association, 2000) crite-
ria for the diagnosis of PDA as principal diagnosis and, in the case of taking medication for PDA, did not
increase or modify the kind of medication during the study.

Exclusion criteria: psychosis, severe organic illness or substance abuse or dependence

Characteristic of the sample:

• Age: mean 34.7 years (SD 12.31)
• Percentage of agoraphobic patients: 82.9%
• Percentage of patients on drug therapy: 66.6%
• Percentage of patients with major depression: not reported (29.7% according to imputation from

BDI)

Interventions

Participants (n = 37) were randomly assigned to either:

1) In vivo exposure (classified as CBT, n = 12)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 9
• Duration of intervention: 9 weeks

2) Virtual reality exposure (classified as CBT, n = 12)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 9
• Duration of intervention: 9 weeks

3) Wait list (classified as WL, n = 13)

• Mean number of sessions: 0
• Duration of intervention: 9 weeks

Outcomes

Time points for assessment: pre-treatment, post treatment, 12 months follow-up

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Botella 2004  (Continued)

Cochrane Database of Systematic Reviews

Measures: Anxiety Diagnostic Interview Schedule IV (ADIS-IV), Fear and Avoidance Scales, panic attack
record, Panic Disorder Severity Scale (PDSS), Anxiety Sensitivity Index (ASI), Agoraphobia Subscale of
the Fear Questionnaire (FQ-Ag), Beck Depression Inventory (BDI), Maladjustment Scale (MS), Clinician
Global Impression (CGI)

The following outcomes were used for quantitative analyses:

ST-Remission: ASI score < 27

ST- Response: panic-free OR a 50% reduction in panic frequency

ST-Dropouts: non-completers

Continuous scale: Panic Disorder Severity Scale (PDSS)

LT-Remission/Response: not entered in the analyses (reported LT data refer to the 2 treatment arms,
both classified as CBT in this review: comparison not feasible)

Notes

Risk of bias

Bias

None

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Random numbers table was used (personal communication)

Allocation concealment
(selection bias)

Low risk

Randomisation was performed by an experimenter who did not participate in
the study (personal communication)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

Assessors were blind to the conditions (personal communication). However,
ASI (used to determine ST-Remission) is a self administered scale.

"All participants in the treatment conditions were assessed at post treatment 1
week after the treatment completion"

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

Authors involved in the developing of virtual reality exposure treatment for
panic disorder ("This finding has encouraged us to design a VRE treatment for
PDA. Our VR programme for PDA includes several VR scenarios")

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"The therapists were well trained in CBT programmes for PDA. Treatment adher-
ence across the therapists was ensured by a specific training in the treatment
programmes. Also, the complete team held weekly meetings to supervise the on-
going treatment of all patients"

Brown 1997 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age between 18 and 65 years, DSM-III-R diagnosis of panic disorder with or without
agoraphobia, at least 1 panic attack in the month preceding the intake evaluation

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Brown 1997  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria: actively psychotic, immediate suicidal or homicidal risk, current abuse of any sub-
stance, brain-damage, in the manic phase of a bipolar disorder without medication

Characteristic of the sample:

• Age: not specified for ITT sample (among the 40 completers, mean age was 33 years, SD 9.8, range

19 to 56)

• Percentage of agoraphobic patients: not specified for ITT sample (75% among the 40 completers)
• Percentage of patients on drug therapy: not specified for ITT sample (52.5% among the 40 com-

pleters)

• Percentage of patients with major depression: not specified

Interventions

Participants (n = 48) were randomly assigned to either:

1) Focused cognitive therapy (classified as CBT, n = unclear)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 14
• Duration of intervention: 14 weeks

2) Standard cognitive therapy (classified as CT, n = unclear)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 14
• Duration of intervention: 14 weeks

Outcomes

Time points for assessment: baseline, termination, 6 months follow-up, 12 months follow-up

Measures: panic frequency, Hamilton Anxiety Rating Scale-Revised (HARS-R), Hamilton Rating Scale
for Depression-Revised (HRSD-R), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), Agora-
phobic Cognition Questionnaire (ACQ), Panic Belief Questionnaire (PBQ)

The following outcomes were used for quantitative analyses:

ST-Remission: although reported (panic-free at termination), ST-Remission could not be calculated fol-
lowing an ITT principle (number of patients randomised to each arm not specified)

ST- Response: not measured (not imputed)

ST-Dropouts: not measured

Continuous scale: panic frequency

LT-Remission/Response: although reported (panic-free at 12 months follow-up), ST-Remission could
not be calculated following an ITT principle (number of patients randomised to each arm not specified)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Brown 1997  (Continued)

Incomplete outcome data
(attrition bias) 
Short-term

High risk

Cochrane Database of Systematic Reviews

"Forty-eight subjects initially agreed to participate in the study and 40 patients
successfully completed the study through the l-year follow-up period. Of eight
patients who dropped out of the study, one patient was hospitalized for medical
reasons after receiving five SCT sessions, one patient failed to complete a sig-
nificant portion of the outcome measures at several assessment points, one pa-
tient decided to pursue pharmacotherapy exclusively for panic disorder, three
patients decided to pursue alternative psychotherapy interventions, and two pa-
tients dropped out of the study for unknown reasons."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"Focused cognitive therapy for panic disorder was developed from a theoretical
model of panic disorder (Beck, Emery, & Greenberg, 1985; Clark, 1986)."

Therapist allegiance

Unclear risk

No information provided

Beck AT is among the study authors.

Treatment fidelity

High risk

"Results of tape ratings indicated that all therapists addressed catastrophic in-
terpretations according to protocol for the 21 patients in the FCT group. Howev-
er, protocol violations were noted for 8 of the 19 patients who received SCT."

Burke 1997 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: females, primary DSM-III diagnosis of agoraphobia. Patients were instructed not to
change their medication during the trial.

Exclusion criteria: none

Characteristic of the sample:

• Age: in exposure group, mean age was 40 years, SD 8.9; in CBT group, mean age was 40.1, SD 11.08
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified for ITT sample (53.8% among the 26 com-

pleters)

• Percentage of patients with major depression: not specified

Interventions

Participants (n = 39) were randomly assigned to either:

1) Exposure (classified as BT, n = 20)

• Therapy format: individual
• Duration of each session: 150 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks

2) Cognitive behaviour therapy (classified as CBT, n = 19)

• Therapy format: individual
• Duration of each session: 180 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks

Outcomes

Time points for assessment: baseline, post-treatment, 6 months follow-up

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Burke 1997  (Continued)

Cochrane Database of Systematic Reviews

Measures: Fear Questionnaire (FQ), Agoraphobia Questionnaire, Spielberger Trait Anxiety Inventory
(STAI), Beck Depression Inventory (BDI), behavioural test, Agoraphobic Cognitions Questionnaire (ACQ),
Anxiety Scale of the Cognitions Checklist (CCLAS), Probability Questionnaire (PQ), Evaluation Question-
naire (EQ)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (imputed from continuous scale)

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

High risk

ACQ (used to determine ST-Remission) is a self administered scale

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Thirteen participants dropped out of treatment." Reported data refer to treat-
ment completers.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapies under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"CBT session and a tape of an Exp session from each therapist to send to an in-
dependent assessor not involved in the trial. The assessor had been trained to
teach CT at the Center for Cognitive Therapy, Philadelphia and she teaches a
specialist training course in CT in the UK.' A table of random numbers was used
to select which of each therapist's CBT and Exp tapes were sent to the assessor.
The total sample of tapes came to 18 (10 CBT and eight Exp)."

Carter 2003 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: African American population, DSM-IV diagnosis of panic disorder with agoraphobia

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Carter 2003  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria: any psychotic disorder, current substance abuse or dependence, significant suici-
dal ideation/gestures, any comorbid condition receiving a clinical severity rating equal to or greater
than that assigned the panic disorder diagnosis

Characteristic of the sample:

• Age: not specified for ITT sample (among the 25 completers, mean age was 42.36 years, SD 6.7, for

treatment group; mean age was 4.55 years, SD 5.5, for wait list)

• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified for ITT sample (among the 25 com-

pleters, 84.5% had comorbid depression)

Interventions

Participants (n = 32) were randomly assigned to either:

1) Panic control treatment (classified as CBT, n = 17)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 11
• Duration of intervention: 11 weeks

2) Wait-list control(classified as WL, n = 15)

• Mean number of sessions: 0
• Duration of intervention: 11

Outcomes

Time points for assessment: baseline, post-treatment

Measures: Structured Clinical Interview for DSM-IV Axis I Disorders (ADIS-IV), Anxiety Sensitivity Index
(ASI), State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI), Beck Depression Invento-
ry (BDI), The Hyperventilation Questionnaire - Cognitive Subscale (HQC), The Mobility Inventory (MI),
African American Acculturation Scale - Short Form (AAAS), Attitude Toward Treatment Questionnaire
(ATQ)

The following outcomes were used for quantitative analyses:

ST-Remission: recovery (based on ASI)*

ST- Response: improvement + recovery (based on ASI)*

ST-Dropouts: non-completers

Continuous scale: Anxiety Sensitivity Index (ASI)

LT-Remission/Response: not measured

Notes

Risk of bias

Bias

* "To assess clinically significant change, the method described by Jacobson and Truax (1991) was em-
ployed. For each dependent variable (except the HQC) for which there were established cutoff scores and
test–retest reliability statistics, the level of functioning following therapy for each patient was examined
and judged whether it was closer to the mean of a functional population than it was to the dysfunctional
population. As suggested by Jacobson and Truax (1991), a reliable change (RC) index was computed for
each group to assess whether fluctuations were likely the result of imprecise measurement. Each patient
was categorized as recovered (score closer to the mean of the functional than dysfunctional group and RC
greater than 1.96), improved but not recovered (score closer to the mean of the functional group, but the
change noted did not exceed the RC cutoff of 1.96), or unimproved."

Authors' judgement

Support for judgement

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Carter 2003  (Continued)

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Unclear risk

No information provided

Unclear risk

No information provided

High risk

ASI (used to determine ST-Remission) is a self administered scale

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Three of the 17 treatment patients were classified as non-completers. Of the
15 assigned to the wait-list condition, 4 did not return for the second evaluation
(26.6% attrition). We report the data from the remaining 25 patients who com-
pleted either treatment or the wait-list assessment."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

"The lead therapist for all groups was a licensed clinical psychologist who is an
African American male with 15 years experience with cognitive behavioral thera-
py for anxiety disorders."

Treatment fidelity

Unclear risk

No information provided

Clark 1994 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age 18 to 60 years, DSM-III-R diagnosis of panic disorder with no, mild or moder-
ate agoraphobic avoidance, current episode duration at least 6 months (this criterion was intended to
minimise spontaneous remission, at least 3 panic attacks in the last 3 weeks, consider panic their main
problem, willing to accept random allocation.

Exclusion criteria: depressive disorder severe enough to require immediate psychiatric treatment;
cognitive therapy, applied relaxation or imipramine in the current episode; evidence of organic mental
disorder, schizophrenia, alcohol or drug dependence, cardiovascular disease, asthma, epilepsy; preg-
nancy or intention to become pregnant. Concurrent Axis II personality disorder was not a reason for ex-
cluding patients unless personality disorder was clearly the primary problem.

Characteristic of the sample:

• Age: not specified for ITT sample (among the 64 completers, mean age was 34.6 years, SD 9.2)
• Percentage of agoraphobic patients: not specified for ITT sample (among the 64 completers, 81%

had mild or moderate agoraphobic avoidance)
• Percentage of patients on drug therapy: unclear
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 72) were randomly assigned to either:

1) Cognitive therapy + in vivo exposure (classified as CBT, n = 17, n = 21 after re-randomisation of WL
patients)

• Therapy format: not specified
• Duration of each session: 60 minutes

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Clark 1994  (Continued)

• Mean number of sessions: 15
• Duration of intervention: 24 weeks

2) Applied relaxation + in vivo exposure (classified as BT, n = 17, n = 21 after re-randomisation of WL
patients)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 15
• Duration of intervention: 24 weeks

3) Imipramine + in vivo exposure (not included in this review, n = 22, n = 26 after re-randomisation of
WL patients)

• Therapy format: not specified
• Duration of each session: 25 minutes
• Mean number of sessions: 15
• Duration of intervention: 24 weeks

4) Wait list (classified as WL, n = 16; after waiting period, 12 patients were re-randomised to 1 of the 3
active treatments)

• Mean number of sessions: 0
• Duration of intervention: 12 weeks

Outcomes

Time points for assessment: baseline, 3 months follow-up, 6 months follow-up, 15 months follow-up

Measures: panic frequency, panic-related distress/disability, Beck Anxiety Inventory (BAI), Hamilton
Anxiety Rating Scale (HARS), Fear Questionnaire (FQ), Bodily Sensations Questionnaire (BSQ), Body
Sensations Interpretation Questionnaire (BSIQ), Agoraphobic Cognitions Questionnaire (ACQ), Beck De-
pression Inventory (BDI)

The following outcomes were used for quantitative analyses:

ST-Remission: high end-state functioning* at 3 months (original sample + re-randomised WL patients)

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers (< 3 sessions) at 3 months (original sample)

Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ), measured on original sample + re-
randomised WL patients

LT-Remission/Response: high end-state functioning* at 15 months (original sample + re-randomised
WL patients)

*High end-state function was defined as panic-free and an assessor panic-related distress/disability rat-
ing equal or below 2 ('slight').

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 

Low risk

"Assessments, which included ratings completed by an assessor who was blind
to treatment allocation, were at pre-treatment/waiting-list, 3, 6, and 15 months."

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Clark 1994  (Continued)

ST-Remission

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

Cochrane Database of Systematic Reviews

"Of 72 patients meeting acceptance criteria,3 dropped out (1per treatment). Five
who agreed initially to random allocation refused to take imipramine when al-
located to that condition. Drop-outs and refusers after randomisation were re-
placed and not included in the data analysis.To be classified as a drop-out, pa-
tients had to start treatment but attend no more than two sessions. Patients who
attended at least three sessions were considered completers and included in all
analyses."

For this review we are not considering the imipramine arm, therefore dropouts
(CBT n = 1; BT n = 1; WL n = 0) were low in number and evenly distributed.
Therefore, the proportion of missing outcomes is not enough to have a clini-
cally relevant impact on the intervention effect estimate.

Incomplete outcome data
(attrition bias) 
Long-term

Selective reporting (re-
porting bias)

Low risk

(See above)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"Cognitive therapy (CT) was based on the cognitive theory of panic. Several cog-
nitive and behavioural techniques (see Clark, 1989; Salkovskis & Clark, 1991)
were used to help patients identify and change misinterpretations of bodily sen-
sations." Both Clark DM and Salkovskis PM are among the study authors.

Therapist allegiance

Unclear risk

Insufficient information provided

Treatment fidelity

Low risk

"To check therapists' adherence to the treatment protocol ten audiotapes per
treatment (each from a different patient) were randomly selected and rated for
the presence/absence of features which should be unique to that treatment and
for time spent on procedures which should be common to all treatments. There
were no protocol violations and the treatments did not differ in times spent on
the common procedures."

Clark 1999 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age 18 to 60 years, DSM-III-R diagnosis of panic disorder with no, mild or moder-
ate agoraphobic avoidance, current episode duration at least 6 months (this criterion was intended to
minimise spontaneous remission, at least 3 panic attacks in the last 3 weeks, consider panic their main
problem, willing to accept random allocation, no use of medication (or, if taking psychotropic medica-
tion, on a stable dose for at least 3 months with an agreement not to change dosage), record of at least
one panic attack while keeping a daily panic diary during a post-interview 2-week baseline period.

Exclusion criteria: depressive disorder severe enough to require immediate psychiatric treatment;
previous treatment with cognitive therapy or exposure therapy for panic disorder; evidence of organic
mental disorder, schizophrenia, alcohol or drug dependence, cardiovascular disease, asthma, epilepsy;
pregnancy or intention to become pregnant.

Characteristic of the sample:

• Age: mean age 34 years (SD 11.1)
• Percentage of agoraphobic patients: 85%
• Percentage of patients on drug therapy: 12%

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Clark 1999  (Continued)

• Percentage of patients with major depression: not specified (30.2% imputed from BDI)

Interventions

Participants (n = 43) were randomly assigned to either:

1) Full cognitive therapy (classified as CBT, n = 15)

• Therapy format: not specified
• Duration of each session: 66 minutes (average)
• Mean number of sessions: 15
• Duration of intervention: 24 weeks

2) Brief cognitive therapy (classified as CBT, n = 14)

• Therapy format: not specified
• Duration of each session: 71.25 (average)
• Mean number of sessions: 8
• Duration of intervention: 24 weeks

3) Wait list (classified as WL, n = 14)

• Mean number of sessions: 0
• Duration of intervention: 12 weeks

Outcomes

Time points for assessment: baseline, post-treatment/wait list, 3 months post-treatment follow-up,
12 months post-treatment follow-up

Measures: panic-anxiety composite measure, panic frequency, panic-related distress/disability, Beck
Anxiety Inventory (BAI), Hamilton Anxiety Rating Scale (HARS), Fear Questionnaire (FQ), Body Sensa-
tions Interpretation Questionnaire (BSIQ), Agoraphobic Cognitions Questionnaire (ACQ), Beck Depres-
sion Inventory (BDI)

The following outcomes were used for quantitative analyses:

ST-Remission: high end-state functioning*

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)

LT-Remission/Response: although measured (high end-state functioning*), data could not be extract-
ed because the comparison was between the 2 active treatment arms, both classified as CBT (compari-
son not feasible).

* "We defined high end-state functioning as panic free and as an assessor-scored panic-related distress—
disability rating of 2 or less ('slight')"

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Low risk

"Assessments, which included ratings completed by an independent assessor
who was unaware of treatment allocation, were at pretreatment/wait list, post-

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Clark 1999  (Continued)

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

Cochrane Database of Systematic Reviews

treatment/wait list, 3-month post-treatment follow-up, and 12-month post-treat-
ment follow-up."

"43 patients were randomized. One patient (allocated to FCT) dropped out af-
ter one session, having indicated that she was much improved and could not
arrange time off work for further sessions. All other patients completed treat-
ment" (and assessments).

The proportion of missing outcomes is not enough to have a clinically relevant
impact on the intervention effect estimate.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"During the 1980s, several effective cognitive—behavioral treatments for pan-
ic disorder were developed. The two that have been most extensively evaluat-
ed are the panic control treatment (PCT) developed by Barlow, Craske, and col-
leagues and the cognitive therapy program developed by Clark, Salkovskis,
Beck, and colleagues."

"To maximize the amount of change achieved in each therapy session, we devel-
oped a set of self-study modules covering the main aspects of therapy and asked
patients to complete the modules prior to therapy sessions."

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

"Regular individual supervision was provided throughout the trial." Insufficient
information provided

Cottraux 2009 

Methods

Participants

Study design: Randomised controlled trial

Inclusion criteria: DSM-IV diagnosis of panic disorder with agoraphobia. Eligible patients were not al-
lowed to take any psychotropic medication, with the exception of low doses hypnotics, and could not
receive psychotherapy during the study.

Exclusion criteria: current major depression, or a score greater than 18 on the Hamilton rating scale
for depression; bipolar disorder, schizophrenia or other psychotic disorders; alcoholism, or street drugs
use; history of CBT for PDA, or a current psychotherapy; treatment with antidepressants, neuroleptics,
anxiolytics or mood stabilisers within the 2 weeks preceding the entry.

Characteristic of the sample:

• Age: VRET group mean age 37.7 years (SD 7.3); CBT mean age 36.6 years (SD 10.6); WL mean age 37

(SD 11.3)

• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: 0%

Interventions

Participants (n = 92) were randomly assigned to either:

1) Virtual reality exposure therapy (classified as BT, n = 29; n = 43 after re-randomisation of WL pa-
tients)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 12

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cottraux 2009  (Continued)

• Duration of intervention: 12 weeks

2) Cognitive behaviour treatment (classified as CBT, n = 31; n = 44 after re-randomisation of WL pa-
tients)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

3) Wait list (classified as WL, n = 32)

• Mean number of sessions: 0
• Duration of intervention: 12 weeks

Outcomes

Time points for assessment: baseline, post-treatment/WL (3 months), 6 months follow-up, 12 months
follow-up

Measures: Fear Questionnaire (FQ), Panic Disorder Severity Scale (PDSS), Chambless Agoraphobic Cog-
nitions scale (ACQ), Panic, Phobia and Generalized Anxiety Scale (PPGAS), State and Trait Anxiety ques-
tionnaire (STAI), Hamilton Anxiety Rating Scale (HARS), 21-item Beck Depression Inventory (BDI), Shee-
han Disability Scale (SDS), Global Assessment of Functioning scale (GAF), Dissociative Experience Scale
(DES), Work and Social Adjustment scale (WSA)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (imputed from continuous scale)

ST- Response: at least 50% reduction of FQ-Ag score (original sample) at post-treatment

ST-Dropouts: non-completers (original sample)

Continuous scale: Panic Disorder Severity Scale (PDSS; measured on original + re-randomised sample)

LT-Remission/Response: although measured (at least 50% reduction of FQ-Ag score at 12 months
follow-up) data were not entered in the analyses because dropouts exceeded 30% of originally ran-
domised sample (see Secondary outcomes).

Notes

Risk of bias

Bias

None

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information provided

Allocation concealment
(selection bias)

Low risk

"Randomization was kept secret and delivered by the biostatistics department
of the CHU of Lyon through a phone call to the secretary of each center"

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Unclear risk

No information provided

Incomplete outcome data
(attrition bias) 
Short-term

High risk

Incomplete outcome data
(attrition bias) 
Long-term

High risk

At post-treatment, 63 patients (on 92 originally randomised) were assessed
(see study flow chart).

At 12 months follow-up, 51 patients (on 87 randomised) were assessed (see
study flow chart).

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cottraux 2009  (Continued)

Selective reporting (re-
porting bias)

Low risk

Cochrane Database of Systematic Reviews

Study protocol available. All of the study's pre-specified (primary and sec-
ondary) outcomes that are of interest in the review have been reported in the
pre-specified way.

Researcher allegiance

Unclear risk

Insufficient information provided

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Craske 1995 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age between 18 and 65 years, principal diagnosis of panic disorder with or with-
out agoraphobia according to DSM-III-R criteria, willingness to random assignment to 17 weeks of ei-
ther placebo or varying dosage regimes of a psychoactive medication, successful withdrawal from psy-
chotropic medications for at least 7 days prior to initial diagnostic evaluation.

Exclusion criteria: hypersensitivity to benzodiazepines; diagnoses of organic disorders, obses-
sive-compulsive disorder, psychoses, bipolar disorder, adjustment disorder and current (within the last
6 months) substance abuse/dependence; suicidality; serious medical conditions.

Characteristic of the sample:

• Age: 36.1 years (SD 11, range 21 to 57)
• Percentage of agoraphobic patients: 67%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 30) were randomly assigned to either:

1) Cognitive behaviour therapy (classified as CBT, n = 16)

• Therapy format: individual
• Duration of each session: 75 minutes
• Mean number of sessions: 4
• Duration of intervention: 4 weeks

2) Nondirective supportive therapy (classified as SP, n = 14)

• Therapy format: individual
• Duration of each session: 75 minutes
• Mean number of sessions: 4
• Duration of intervention: 4 weeks

Outcomes

Time points for assessment: baseline, post-treatment

Measures: panic disorder and agoraphobia sections of the ADIS-R, Anxiety Sensitivity Index (ASI), Fear
Questionnaire (FQ), Four Dimensional Anxiety, Subjective Symptoms Scale

The following outcomes were used for quantitative analyses:

ST-Remission: ASI reduced from baseline and < 28 at post-treatment

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Craske 1995  (Continued)

Cochrane Database of Systematic Reviews

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Incomplete outcome data
(attrition bias) 
Short-term

Continuous scale: Anxiety Sensitivity Index (ASI)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

High risk

ASI is a self rated measure

Unclear risk

"Sixteen subjects were assigned randomly to CBT, and 14 to NST. One subject
dropped out from NST, none dropped out from CBT."

The proportion of missing outcomes is not enough to have a clinically relevant
impact on the intervention effect estimate.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

Craske MG is author of a CBT manual (see Barlow 2000b)

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

"Treatment integrity was addressed via manualized treatments, and ongoing
therapy supervision, with review and feedback of approximately 25% of audio-
tapes of treatment sessions by the principal author."

It is unclear whether all sessions were recorded and selection of audiotapes
was randomised.

Craske 2005a 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM-IV principal diagnosis of panic disorder with or without agoraphobia. Those
who were medicated at the time of the initial diagnostic evaluation were withdrawn from psychotropic
medications over a minimum of 4 weeks and washed out for at least 2 weeks prior to a repeat diagnos-
tic evaluation to re-determine study eligibility.

Exclusion criteria: history of bipolar disorder, psychosis, posttraumatic stress disorder or current sub-
stance abuse/dependence

Characteristic of the sample:

• Age: not specified for randomised sample
• Percentage of agoraphobic patients: 29.2%
• Percentage of patients on drug therapy: 0%

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Craske 2005a  (Continued)

• Percentage of patients with major depression: 30.3%

Interventions

Participants (n = 43) were randomly assigned to either:

1) Cognitive behaviour therapy (classified as CBT, n = 27)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 11
• Duration of intervention: 10 weeks

2) Wait list (classified as WL, n = 16)

• Mean number of sessions: 0
• Duration of intervention: 10 weeks

Outcomes

Time points for assessment: baseline, post-treatment, 12 months (after commencement) follow-up

Measures: panic disorder severity (ADIS-IV), Anxiety Sensitivity Index (ASI), Fear Questionnaire-Ago-
raphobia subscale (FQ-Ag), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Subjective
Symptoms Scale (SSS)

The following outcomes were used for quantitative analyses:

ST-Remission: high end-state functioning*

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Anxiety Sensitivity Index (ASI)

LT-Remission/Response: not measured

* "Defined as zero daytime and zero nocturnal panic attacks per week over last 2 weeks, panic disorder
severity of 3 or less, and no/mild agoraphobia"

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Unclear risk

No information provided

Unclear risk

"Of 43 participants, 27 were assigned to CBT; 3 (11.1%) withdrew during treat-
ment. Sixteen were assigned to WL; none withdrew during WL, but 3 (18.8%)
withdrew before (n = 2) or during (n = 1) delayed CBT. Reasons for withdrawal are
not known."

It is unclear whether non-completers were assessed at post-treatment (proba-
bly so)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Incomplete outcome data
(attrition bias) 
Short-term

Incomplete outcome data
(attrition bias) 

Unclear risk

Number of assessed patients at 12 months follow-up is not reported

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Craske 2005a  (Continued)

Long-term

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

Craske MG is author of a CBT manual (see Barlow 2000b)

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"Each treatment session was audiotaped and 25% (n = 112) were selected ran-
domly for independent adherence ratings of each content item of each session
(1 = none, 7 = complete adherence) 2 and percent of off-task discussion. [...] Aver-
age adherence ratings ranged from 4.95 (SD = 0.77) to 6.01 (SD = 1.00), with a to-
tal average of 5.64 (SD -- 0.96), indicating good adherence overall."

Creager Berger 2001 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: age 18 to 60 years, DSM-IV diagnosis of panic disorder

Exclusion criteria: exhibiting characteristics of, or currently diagnosed with schizophrenia or any
personality disorder; evidence of organic brain syndrome or mental retardation; any change in psy-
chotropic or other medications or currently taking a medication for less than 2 weeks; medical con-
ditions that would interfere with the diagnosis and/or treatment of panic disorder not due to a med-
ical condition; report or exhibition of characteristics of present substance abuse that would meet DSM-
IV criteria; unwillingness or inability to give informed consent; experiencing less than 3 panic attacks
within a 4-week period

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 35.3 years, SD 10.14)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified on ITT sample (90% among completers)
• Percentage of patients with major depression: not specified

Interventions

Participants (n = unclear) were randomly assigned to either:

1) Breathing retraining (classified as PT, n = unclear)

• Therapy format: group/individual
• Duration of each session: 45 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks

2) Cognitive therapy (classified as CBT, n = unclear)

• Therapy format: group/individual
• Duration of each session: 67.5 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks

Outcomes

Time points for assessment: pre-treatment, baseline (first session), termination (last session), 4 weeks
after termination

Measures: panic diary, Beck Depression Inventory (BDI), Panic Disorder Severity Scale (PDSS), end tidal
carbon dioxide level (ETCO2), respiratory rate

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Creager Berger 2001  (Continued)

The following outcomes were used for quantitative analyses:

ST-Remission: although reported (panic-free at termination), ST-Remission could not be calculated fol-
lowing an ITT principle (number of patients randomised to each arm not specified)

ST- Response: not measured (not imputed)

ST-Dropouts: not reported

Continuous scale: Panic Disorder Severity Scale (PDSS) at pre-treatment and at 4 weeks after termina-
tion

Notes

Risk of bias

Bias

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Random assignment occurred by using the random number table from a Sharp
scientific calculator"

Allocation concealment
(selection bias)

Unclear risk

No information provided

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Of those accepted into the study, one became ineligible after beginning an-
tidepressants after session 3 of the cognitive therapy group, one failed to at-
tend her 6th breathing retraining session and could not be reached by phone,
one dropped out of the cognitive behavioral therapy after session 6, five people
failed to show up for the first session and could not be reached by phone, three
people stated that they were too busy or not interested in beginning the study,
and four people did not return phone calls after the initial screening."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"The primary investigator of the study trained each of the therapists and met
with each therapist for 2 hours per week during the treatment phase to review
the previous session and preview the following session. Additionally, the CBT
therapists brought a script into each session with them in order to ensure thor-
ough deliverance of the treatment."

De Ruiter 1989 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: DSM-III-R diagnosis of Panic Disorder with Agoraphobia. Only patients who recog-
nised the symptoms induced by voluntary hyperventilation as similar to their panic attacks were in-
cluded in the study.

Exclusion criteria: psychotic symptoms; substance abuse

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

De Ruiter 1989  (Continued)

Characteristic of the sample:

Cochrane Database of Systematic Reviews

• Age: mean 34 years (SD 9.2, range 22 to 60). These data probably refer to the completers sub-sample.
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified for ITT sample (49% among completers)
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 49) were randomly assigned to either:

1) Breathing retraining/cognitive restructuring (classified as CBT, n = 17)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks

2) Exposure therapy (classified as BT, n = 17)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks

3) Breathing retraining/cognitive restructuring + exposure therapy (classified as CBT, n = 15)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks

Outcomes

Time points for assessment: baseline (4 weeks prior to treatment), pre-treatment, post-treatment

Measures: Fear Surrey Schedule-III (FSS-IZZ), phobic anxiety and avoidance scales, panic attack diary,
Bodily Sensations Questionnaire (BSQ), Symptom CheckIist-90 (SCL-90), respiratory rate (RR) and end
tidal carbon dioxide pressure (pC02).

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (imputed from continuous scale)

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Bodily Sensations Questionnaire (BSQ)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

De Ruiter 1989  (Continued)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

BSQ (used to impute ST-Remission) is a self rated measure

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Of the 49 patients who entered treatment, 40 completed the program. Attrition
rates were 4 (24%) for BRCR, 4 (24%) for EXP and 1 (6%) for BRCR + EXP"

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

"Supervision by a senior clinical psychologist (the second author) was provid-
ed on a weekly basis." Unclear whether all sessions for all patients were super-
vised.

Dow 2000 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: between 18 and 60 years of age; DSM-IV diagnosis of panic disorder, with or with-
out agoraphobia; current episode duration of at least 3 months; consider panic the main problem; will-
ing to accept random allocation, including the wait list condition. All patients taking medication at the
time of entry must have been on a stable dose for 3 months and must have been willing and able to re-
main on a stable regime for 3 months during the course of treatment.

Exclusion criteria: depressive disorder severe enough to require urgent treatment; undergoing CBT for
the current episode; evidence of organic mental disorder, schizophrenia, alcohol or drug dependence,
cardiovascular disease, asthma, epilepsy, or pregnancy or intention to become pregnant during the
course of the study. Concurrent Axis II personality disorder was not a reason for exclusion unless the
personality disorder was clearly the primary problem.

Characteristic of the sample:

• Age: mean age 36.8 years (SD 10)
• Percentage of agoraphobic patients: 76.1%
• Percentage of patients on drug therapy: not specified for ITT sample (among completers: 46.4% of

Australian patients and 14.1% of Scottish patients)

• Percentage of patients with major depression: not specified

Interventions

Participants (n = 186) were randomly assigned to either:

1) CBT - 12 sessions - therapist delivered (classified as CBT, n = 45)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

2) CBT - 6 sessions - therapist delivered (classified as CBT, n = 45)

• Therapy format: individual
• Duration of each session: 60 minutes

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Dow 2000  (Continued)

• Mean number of sessions: 6
• Duration of intervention: 6 weeks

3) CBT - 6 sessions - computer augmented (classified as CBT, n = 50)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks

4) Wait list (classified as WL, n = 46)

• Mean number of sessions: 0
• Duration of intervention: unclear

Outcomes

Time points for assessment: baseline, post-treatment, 6 months follow-up

Measures: panic frequency, panic-related distress/disability, Fear Questionnaire (FQ), Mobility Invento-
ry for Agoraphobia (MI), Body Sensations Questionnaire (BSQ), Agoraphobic Cognitions Questionnaire
(ACQ), State–Trait Anxiety Inventory, Trait subscale (STAI–T), Beck Depression Inventory (BDI), Medical
Outcomes Survey Short Form 36 (SF-36)

The following outcomes were used for quantitative analyses:

ST-Remission: panic-free at post-treatment

ST- Response: not measured (not imputed)

ST-Dropouts: not measured (the number of non-completers for each arm is not specified)

Continuous scale: although measured, data cannot be used because number of assessed patients is
not reported

LT-Remission/Response: although measured (panic-free at follow-up), data cannot be used because
re-randomisation of WL patients leaves only 3 arms, all classified as CBT (comparison not feasible)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Unclear risk

No information provided

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"In total, 186 patients met entry criteria and were offered and accepted a place
in the study. Of these, 163 patients (87.6%) commenced treatment (wait list,
n=41; CBT6, n=39; CBT6-CA, n=41; CBT12, n=42). Twenty-three patients (14.1%)
failed to receive at least three sessions of their respective course of treatment or
to provide adequate data and were classified as dropouts."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dow 2000  (Continued)

Researcher allegiance

Low risk

Cochrane Database of Systematic Reviews

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"All sessions for all treatment conditions were tape-recorded, and a random se-
lection (20%) of tapes were exchanged between sites and rated by Justin A. Ke-
nardy and Michael G. T. Dow to ensure adherence to treatment protocols and
therapeutic competence. There were no significant effects for site, treatment, or
Site Treatment on protocol adherence or therapeutic adequacy. Therapists al-
so completed a separate checklist for each therapy session to evaluate adher-
ence to the protocol. The correlation between therapist-rated and externally rat-
ed protocol adherence was 0.92 (p .001). No significant differences were found
on therapist-rated treatment protocol compliance across site or treatment or for
Site Treatment. Overall, there was 97.1% protocol adherence."

Other bias

Unclear risk

Modification of the original sample with replacements. Number and randomi-
sation of replacements not specified.

Dreessen 1994 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: age between 17 and 70 years, primary DSM-III-R diagnosis of panic disorder with no
or mild agoraphobic avoidance, panic disorder for at least 12 months, at least a mean of 1 panic attack
per week during the previous 4 weeks, asking for treatment of panic disorder, no use of serotonergic
antidepressants or benzodiazepines (for at least 4 weeks).

Exclusion criteria: depressive disorder preceding the current episode of panic disorder or requiring
immediate treatment; behaviour therapy received for panic disorder; evidence of organic mental disor-
ders, psychotic disorders, alcohol or drug dependence, cardiovascular disease, asthma, epilepsy; med-
ical contraindication for exposure, behavioural experiments or hyperventilation

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 34.1 years, range 21 to 52)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 0%
• Percentage  of  patients  with  major  depression:  not  specified  (mood  disorder  11%  among  com-

pleters)

Interventions

Participants (n = 37) were randomly assigned to either:

1) Cognitive therapy (classified as CT, n = unclear)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 15
• Duration of intervention: 13 weeks (plus 2 sessions after 1 and 6 months)

2) Applied relaxation (classified as PT, n = unclear)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 15
• Duration of intervention: 13 weeks (plus 2 sessions after 1 and 6 months)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

123

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dreessen 1994  (Continued)

Cochrane Database of Systematic Reviews

Note that "after the last patient entered the study, a waiting-list control group was formed. The first 11
men and 7 women meeting the same criteria as used for the treatment group were drawn from the wait-
ing-list to form a control group." This control group is not considered for this review because it is not
randomised.

Outcomes

Time points for assessment: baseline, post-treatment (13 weeks), 1-month follow-up, 6-month fol-
low-up

Measures: panic diary, Fear of Fear Questionnaire, Fear Questionnaire (FQ), State–Trait Anxiety Inven-
tory (STAI), Depressive Symptoms Inventory (DSI), Symptom Check List (SCL-90)

The following outcomes were used for quantitative analyses:

ST-Remission: although measured (panic-free at post-treatment) detailed data are not reported

ST- Response: not measured

ST-Dropouts: detailed data are not reported

Continuous scale: although measured, detailed data are not reported

LT-Remission/Response: although measured (panic-free at 6 months follow-up) detailed data are not
reported

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Selective reporting (re-
porting bias)

High risk

Study protocol unavailable. Pre-planned measures are not reported with suffi-
cient details.

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

"Weekly supervision was given by the first author during the whole treatment." It
is unclear whether all sessions for all patients were supervised.

Emmelkamp 1986 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: DSM-III diagnosis of agoraphobia

Exclusion criteria: none

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 36 years, SD 18 to 56)
• Percentage of agoraphobic patients: 100%

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Emmelkamp 1986  (Continued)

Cochrane Database of Systematic Reviews

• Percentage of patients on drug therapy: not specified for ITT sample (34.8% among completers)
• Percentage of patients with major depression: not specified

Interventions

In a first phase of the study, participants (n = 51) were randomly assigned to either:

1) Exposure in vivo (classified as BT, n = unclear)

• Therapy format: group
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 3 weeks (1st phase)

2) Rational emotive therapy (classified as CT, n = unclear)

• Therapy format: group
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 3 weeks (1st phase)

3) Self instructional training (classified as CT, n = unclear)

• Therapy format: group
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 3 weeks (1st phase)

In a second phase of the study, all patents received 6 group sessions (150 minutes each) of exposure in
vivo.

Outcomes

Time points for assessment: baseline, post-test

Measures: behavioural walk, phobic anxiety and avoidance scales, Fear Questionnaire (FQ), Irrational
Belief Test (IBT), Symptom Check List (SCL-90)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured

ST- Response: not measured

ST-Dropouts: not reported

Continuous scale: although measured, detailed data are not reported

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Selective reporting (re-
porting bias)

High risk

Study protocol unavailable. Pre-planned measures are not reported with suffi-
cient details.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Emmelkamp 1986  (Continued)

Researcher allegiance

Low risk

Cochrane Database of Systematic Reviews

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

"Therapists received a special training for the research project and extensive
manuals were used. Therapists were supervised by the senior author." It is un-
clear whether all sessions for all patients were supervised.

Erickson 2003 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM-IV diagnosis of either panic disorder with or without agoraphobia, OCD, so-
cial phobia, generalised anxiety disorder, specific phobia or PTSD. There were no limitations on past or
concurrent treatments.

Exclusion criteria: active substance abuse or dependence or psychosis

Characteristic of the sample (PDA sub-sample):

• Age: not specified for PDA sub-sample
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified for PDA sub-sample
• Percentage of patients with major depression: not specified for PDA sub-sample

Interventions

Participants (PDA sub-sample, n = 36) were randomly assigned to either:

1) Cognitive behaviour therapy (classified as CBT, n = unclear)

• Therapy format: group
• Duration of each session: 120 minutes
• Mean number of sessions: 11
• Duration of intervention: 11 weeks

2) Wait list (classified as WL, n = unclear)

• Mean number of sessions: 0
• Duration of intervention: 11 weeks

Outcomes

Time points for assessment: baseline, post-treatment

Measures: Beck Anxiety Inventory (BAI)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured

ST- Response: although measured (40% reduction in BAI score), data for the PDA sub-sample are not
reported

ST-Dropouts: not reported for PDA sub-sample

Continuous scale: the only available measure (BAI) is not considered among outcomes of interest for
this review (see Secondary outcomes)

LT-Remission/Response: not measured

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Erickson 2003  (Continued)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Selective reporting (re-
porting bias)

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"We assessed clinicians’ adherence to the protocol by asking independent raters
to listen to audiotapes of a random sample of sessions (33 tapes, or one of every
four sessions). Overall, the ratings indicated that group leaders adhered close-
ly to the intended protocol and that quality of implementation was midway be-
tween good and very good."

Gloster 2010 

Methods

Participants

Study design: multicentre randomised controlled trial

Inclusion criteria: 18 to 65 years old (see protocol), DSM–IV–TR diagnosis of panic disorder with ago-
raphobia, score of 18 or more on the Hamilton Anxiety Scale (HAM-A), score of 4 or more on the Clini-
cal Global Impression (CGI). Patients had to agree to discontinue all psychopharmacological medica-
tion and were not allowed to have any concomitant psychotherapy. Patients on psychopharmacologi-
cal medication underwent a washout period prior to baseline.

Exclusion criteria: unable to comply with the study schedule or requirements; clinically significant sui-
cidal intent; DSM-IV-TR diagnosis of any psychotic or bipolar disorder, borderline personality disorder,
or current alcohol dependence; medical condition that could explain symptoms. Other current comor-
bid diagnoses, including unipolar depression and other anxiety disorders, were allowed unless they
were of primary clinical concern.

Characteristic of the sample:

• Age: in the 3 groups age mean (SD) were respectively: 35.5 (SD 11); 35.5 (SD 10.4); 35.6 (SD 11.2)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: 43.2%

Interventions

Participants (n = 369) were randomly assigned to either:

1) CBT variant with therapist-guided exposure outside the therapy room (classified as BT, n = 163)

• Therapy format: individual
• Duration of each session: 100 minutes
• Mean number of sessions: 14

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gloster 2010  (Continued)

Cochrane Database of Systematic Reviews

• Duration of intervention: unclear (12 sessions over 6 weeks + 2 booster sessions at unspecified time)

2) CBT variant with non-therapist-guided exposure outside the therapy room (classified as BT, n =
138)

• Therapy format: individual
• Duration of each session: 100 minutes
• Mean number of sessions: 14
• Duration of intervention: unclear (12 sessions over 6 weeks + 2 booster sessions at unspecified time)

3) Wait list (classified as WL, n = 68)

• Mean number of sessions: 0
• Duration of intervention: not specified

Outcomes

Time points for assessment: baseline, intermediate (after the 4th session), post-treatment, 6 months
follow-up

Measures: Structured Interview Guide for the Hamilton Anxiety Scale (HAM-A/SIGH-A), Clinical Global
Impression (CGI), Panic Agoraphobia Scale (PAS), Mobility Inventory - Agoraphobia subscale (MI-Ag)

The following outcomes were used for quantitative analyses:

ST-Remission: PAS score ≤ 8 at post-treatment

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Panic Agoraphobia Scale (PAS)

LT-Remission/Response: although measured (PAS score ≤ 8 at 6 months follow-up), data cannot be
used because re-randomisation of WL patients leaves only 2 arms, both classified as BT (comparison
not feasible)

Notes

Risk of bias

Bias

None

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information provided

Allocation concealment
(selection bias)

Low risk

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"The randomization list was generated at the clinical coordination center (Dres-
den) by personnel not associated with patient care. The study centers were blind
to the assignment of subsequent cases and were informed of treatment status
only after a fax documenting the included patient was sent to the clinical coor-
dination center. More numbers for each center were drawn than necessary so
that treatment condition of final patients in each study center remained unpre-
dictable, thereby ensuring blinding of the randomization throughout the study."

The Panic Agoraphobia Scale (PAS, used to determine ST-Remission) is a self
report questionnaire

A total of 63 patients (34 + 25 + 4) were lost at post-treatment assessment (see
study flow chart)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gloster 2010  (Continued)

Selective reporting (re-
porting bias)

High risk

Cochrane Database of Systematic Reviews

Not all of the study's pre-specified primary outcomes have been reported (Ag-
gregated Panic Disorder Scale and Mobility Inventory: PDS-MI score). One re-
ported outcome was not pre-specified (PAS).

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"All treatment sessions were videotaped, and a randomly selected sample of al-
most 18% was evaluated. All raters were blind to treatment condition and eval-
uated each tape using the therapist adherence and competence rating scale for
PD and AG. Adherence and competence were assessed on the basis of a 9-point
scale from 0 (nonexistent) to 8 (optimal adherence/excellent competence).The
mean overall ratings of therapy adherence and competence across all sessions
were 5.53 (SD 1.29) and 5.73 (SD 1.26), respectively, indicating that therapists
demonstrated good levels of adherence to the manual and implemented it with
good levels of competence."

Goldstein 2000 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: age between 18 and 65 years, DSM-IV diagnosis of panic disorder with agorapho-
bia at least 1 year's duration, agoraphobic avoidance at least moderately severe for the prior 6 months.
Participants excluded on the basis of recent medication changes were eligible for reconsideration once
medications were stabilised in appropriate limits.

Exclusion criteria: being in therapy elsewhere if not willing to suspend that treatment until the end
of the study; on dosages of alprazolam in excess of 1.5 mg daily (or similar dosages for other benzodi-
azepines); taking antidepressant or antianxiety medication for less than 6 months or change of medica-
tion within the last 12 weeks; comorbid diagnoses of thought disorder, major depression, bipolar disor-
der, or substance dependence; presence of another anxiety disorder more severe than the PDA; DSM-IV
diagnosis of any of the following Axis II disorders: paranoid, schizoid, schizotypal, antisocial or border-
line

Characteristic of the sample:

• Age: mean 38.16 years (range 22 to 63)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 45.65%
• Percentage of patients with major depression: 0%

Interventions

Participants (n = 46) were randomly assigned to either:

1) EMDR (not included in this review, n = 18)

• Therapy format: not specified
• Duration of each session: 90 minutes
• Mean number of sessions: 6
• Duration of intervention: 4 weeks

2) Association and relaxation therapy (classified as PT, n = 13)

• Therapy format: not specified
• Duration of each session: 90 minutes
• Mean number of sessions: 6

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Goldstein 2000  (Continued)

• Duration of intervention: 4 weeks

3) Wait list (classified as WL, n = 15)

• Mean number of sessions: 0
• Duration of intervention: 4 weeks

Cochrane Database of Systematic Reviews

Outcomes

Time points for assessment: baseline, termination, 5 to 6 weeks after termination

Measures: Agoraphobic Cognitions Questionnaire (ACQ), Body Sensations Questionnaire (BSQ), Brief
Body Sensations Interpretation Questionnaire (BBSIQ), Panic Appraisal Inventory (PAl), Mobility Inven-
tory (MI), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Brief Symptom Inventory (BSI),
Social Adjustment Scale-Self-Report (SAS-SR), Distress Questionnaire, Panic Disorder Symptom
Severity interview (PDSS), panic/anxiety diary

The following outcomes were used for quantitative analyses:

ST-Remission: not measured

ST- Response: not measured

ST-Dropouts: non-completers

Continuous scale: although measured, data concerning ART group are not reported. EMDR is not an in-
cluded treatment, therefore only data on WL patients could be extracted (comparison not feasible)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Of the 46 participants who entered the study, 4 dropped out prior to the com-
pletion of treatment. One dropped out during the waiting list period before she
provided posttest data or received her treatment condition assignment. Three
participants (one of whom had previously been in the waiting list condition)
dropped out or were terminated during EMDR: one because of a marital crisis,
another because of deterioration, and a third for repeated cancellations of ap-
pointments."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable. Data concerning ART group are not reported.

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"To ensure that therapists adhered to the treatment protocol, all sessions were
audio- Or videotaped and reviewed by Alan J. Goldstein prior to supervision
meetings, which were held weekly to discuss clinical issues and proper provision
of treatment. Two of the authors, Dianne L. Chambless and Kimberly A. Wilson,
and their trained research assistants followed detailed integrity checklists that

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Goldstein 2000  (Continued)

Cochrane Database of Systematic Reviews

assessed adherence to treatment protocol, presence of therapist support and
reinforcement, and protocol violations, which included introducing other treat-
ments into the session. Adherence checks were conducted on 31% (n = 80) of all
sessions. Of these, 33 were independently rated by additional coders to assess
reliability. Average percent agreement was 95% for the integrity items identified
a priori to be most important. The adherence monitoring team was not other-
wise involved in participants' treatment and was unaware of participants' treat-
ment outcome."

Other bias

Unclear risk

Modification of the original sample with replacements. Number and randomi-
sation of replacements not specified.

Gould 1993 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM-III-R diagnosis of panic disorder with or without agoraphobia. Subjects were
dissuaded from participating in other therapy or self help procedures during the study. Subjects tak-
ing medication for anxiety or depression were allowed to participate if they had been stabilised on the
medication for at least 4 weeks and continued to have panic symptoms.

Exclusion criteria: seizure disorder, kidney disease, stroke, schizophrenia, organic brain syndrome,
emphysema, heart attack, chronic hypertension

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 35.7, SD 10.2, range 19 to 59 years)
• Percentage of agoraphobic patients: not specified for ITT sample (94% among completers)
• Percentage of patients on drug therapy: not specified for ITT sample (16% among completers)
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 33) were randomly assigned to either:

1) Bibliotherapy (not included in this review, n = 12)

• Therapy format: self help
• Duration of each session: 0 minutes
• Mean number of sessions: 0
• Duration of intervention: 4 weeks

2) Guided imaginal coping (classified as CBT, n = 9)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 4 weeks

3) Wait list (classified as WL, n = 12)

• Mean number of sessions: 0
• Duration of intervention: 7 weeks

Outcomes

Time points for assessment: baseline, post-treatment

Measures: Daily Panic Attack Records (DPAR), Panic Cognitions Questionnaire (PACQ), Panic Symptoms
Questionnaire (PASQ), Mobility Inventory for Agoraphobia (MI), Anxiety Sensitivity Index (ASI), Beck
Depression Inventory (BDI), Likelihood of Having a Panic Attack, Your Thoughts During a Panic Attack,
Coping with Panic Attacks, Panic Self-Efficacy Questionnaire.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Gould 1993  (Continued)

Cochrane Database of Systematic Reviews

The following outcomes were used for quantitative analyses:

ST-Remission: panic-free

ST- Response: panic-free OR 50% reduction in number of panic attacks, panic symptoms

ST-Dropouts: non-completers

Continuous scale: Anxiety Sensitivity Index (ASI). Note that reported SDs are uncommonly low, so we
considered them as being SEs.

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

High risk

Panic frequency (used to determine ST-Remission) was self rated

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

"Only 2 subjects dropped out: 1 from the WL group and 1 from the BT group. The
subject from the WL group reported that she had to move to a different state to
seek employment and could no longer continue in the study. The subject from
the BT condition completed all the dependent measures of the study, but was
not included in the analyses because she had failed to read the book."

For this review we are not considering the bibliotherapy arm, therefore data
are missing for only one subject (WL) and reasons for missing outcome data
are unlikely to be related to true outcome.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

In bibliotherapy arm, "subjects read the book Coping with Panic (Clum, 1990)."
In Guided Imaginal Coping arm, "the protocol for each of the eight treatment
sessions was outlined for therapists. These plans were derived primarily from
material in Coping with Panic."

Clum G is among the study authors.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"The second author supervised the four therapists weekly in order to ensure the
uniformity of treatment procedures, and the research team met regularly for dis-
cussion. In addition, some treatment sessions were observed directly, or video-
taped and later observed by the first and second authors. A random sample of 8
sessions was observed to ensure treatment integrity."

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Griegel 1995 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM-III-R diagnosis of panic disorder with or without agoraphobia. Subjects using
psychotropic medications were required to maintain a stable dosage for at least 1 month and through-
out treatment and evaluation.

Exclusion criteria: comorbid DSM-III-R diagnosis rated as severe as panic disorder; being in psy-
chotherapy for anxiety (subjects who were in psychotherapy for other psychological difficulties were
included if they had been in a stable therapeutic relationship for at least 3 months).

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 36.03 years, SD 8.02, range 21

to 52)

• Percentage  of  agoraphobic  patients:  unclear  (data  are  measured  on  36  patients,  not  37.  Among

these 36 patients, 86% are agoraphobic)

• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 37) were randomly assigned to either:

1) Breathing retraining - slow respiration rate (classified as PT, n = 11)

• Therapy format: not specified
• Duration of each session: 42.5 minutes
• Mean number of sessions: 3
• Duration of intervention: 2 weeks

2) Breathing retraining - increase respiration rate (classified as PT, n = 12)

• Therapy format: not specified
• Duration of each session: 42.5 minutes
• Mean number of sessions: 3
• Duration of intervention: 2 weeks

3) Wait list (classified as WL, n = 14)

• Mean number of sessions: 0
• Duration of intervention: 4

Outcomes

Time points for assessment: baseline, post-treatment.

Measures: Anxiety Disorders Interview Schedule–R (ADIS–R), Anxiety Sensitivity Index (ASI), Emotion-
al Control Questionnaire (ECQ), Self-Efficacy Questionnaire (SEQ), Diagnostic Symptom Questionnaire
(DSQ), Interoceptive Exposure Test (IET), respiratory rate

The following outcomes were used for quantitative analyses:

ST-Remission: panic-free

ST- Response: not measured

ST-Dropouts: non-completers

Continuous scale: Anxiety Sensitivity Index (ASI)

LT-Remission/Response: not measured

Notes

None

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Griegel 1995  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Low risk

Panic frequency was rated by assessors. "Assessors who conducted evaluations
at pre- and post-assessment were blind to the subjects' experimental condition."

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"The first 37 subjects agreeing to participate were randomly assigned to one of
three groups to enlist the requisite sample size of 10 subjects per cell (7 subjects
dropped out of the study before completion of the post-assessment)."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

"All sessions were audiotaped and 25% of these tapes were rated by an assessor
blind to the treatment conditions, who was then asked to identify the treatment
condition being conducted. Accurate identification of treatment protocol was
made 93% of the time (14/15). One tape was inaudible and could not be rated." It
is unclear whether the selection of tapes to assess was random.

Hazen 1996 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: 18 years of age or older, primary DSM-III-R diagnosis of panic disorder with or with-
out agoraphobia, minimum Grade 8 reading and writing ability, physician agreement regarding partici-
pation

Exclusion criteria: presence of organic disease which might be related to panic disorder or interfere
with participation in the study; presence of other serious psychiatric disorders, specifically psychotic
disorders, substance abuse and current major depressive disorder; presence of significant suicidal risk;
involvement in other psychological treatment; current pharmacological treatment for panic disorder,
with the exception of low doses of benzodiazepines (equivalent of 20 mg diazepam or less) or stable
doses of antidepressants (i.e. prescribed for at least 6 months and stable dose for at least 3 months)

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 37.12 years, SD 9.57, range 20

to 73 years)

• Percentage of agoraphobic patients: not specified for ITT sample (92.4% among completers)
• Percentage of patients on drug therapy: not specified for ITT sample (45% among completers)
• Percentage of patients with major depression: 0%

Interventions

Participants (n = 117) were randomly assigned to either:

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hazen 1996  (Continued)

1) Individual self administration of the self help manual (not included, n = unclear)

• Therapy format: individual
• Mean number of sessions: 0
• Duration of intervention: weeks

2) Use of the manual in a self help treatment group (not included, n = unclear)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 13
• Duration of intervention: 14 weeks

3) Use of the manual in a treatment group led by professional therapists (classified as CBT, n = un-
clear)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 13
• Duration of intervention: 14 weeks

4) Wait list (classified as WL, n = unclear)

• Mean number of sessions: 0
• Duration of intervention: 14 weeks

Outcomes

Time points for assessment: baseline, post-treatment

Measures: Anxiety Sensitivity Index (ASI), Fear Questionnaire-Agoraphobia Subscale (FQ-Ag), Sheehan
Patient-Rated Anxiety Scale (SPRAS), Clinical Global Improvement (CGI)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (not imputed: number of randomised patients for each arm not specified)

ST- Response: not measured (not imputed: number of randomised patients for each arm not specified)

ST-Dropouts: not reported by treatment group

Continuous scale: Anxiety Sensitivity Index (ASI)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Of the 117 subjects enrolled in the evaluation study, 106 completed the Anxiety
Sensitivity Index at pre- and posttreatment. These subjects comprised the sam-
ple for the present study." No further detail about these 11 dropouts is report-
ed.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hazen 1996  (Continued)

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Hendriks 2010 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: adults aged over 60 years, principal DSM-IV diagnosis of panic disorder with or with-
out agoraphobia. Co-morbidity with other anxiety disorders, depression or dysthymia was allowed as
long as PD(A) was the principal diagnosis. Participants using benzodiazepines were asked to adhere to
a fixed daily dose for the duration of the study.

Exclusion criteria: presence of severe psychiatric disorders (e.g. psychotic disorder, bipolar disorder),
severe somatic condition that would hinder appropriate application of CBT (e.g. severe cardiovascular
disease), contraindication for paroxetine, current use of an antidepressant in an adequate dose, cur-
rent and adequate psychological treatment, failure of paroxetine or CBT in the past, abuse of or depen-
dency on alcohol or psychoactive substances, dementia and a score of 23 or less on the Mini-Mental
State Examination

Characteristic of the sample:

• Age: mean age 68.6 years (SD 4.6)
• Percentage of agoraphobic patients: 48%
• Percentage of patients on drug therapy: 22%
• Percentage of patients with major depression: not specified (mood disorder 12.2%)

Interventions

Participants (n = 49) were randomly assigned to either:

1) Cognitive behaviour therapy (classified as CBT, n = 20)

• Therapy format: individual
• Duration of each session: 50 minutes
• Mean number of sessions: 14
• Duration of intervention: 14 weeks

2) Paroxetine (not included, n = 17)

• Therapy format: individual
• Duration of each session: 30 minutes
• Mean number of sessions: 9
• Duration of intervention: 14 weeks

3) Wait list (classified as WL, n = 12)

• Mean number of sessions: 0
• Duration of intervention: 14 weeks

Outcomes

Time points for assessment: baseline, 8 weeks, 14 weeks (termination), 26 weeks (3 months fol-
low-up)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hendriks 2010  (Continued)

Cochrane Database of Systematic Reviews

Measures: Agoraphobic Cognitions Questionnaire (ACQ), Mobility Inventory (MI), Symptom Checklist
(SCL-90)

The following outcomes were used for quantitative analyses:

ST-Remission: panic-free (zero panic attacks in the preceding week) at termination

ST- Response: improvement > 30% on one of the primary outcome scales

ST-Dropouts: non-completers

Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)

LT-Remission/Response: although measured (panic-free at 26 weeks), details are not reported and
anyway refer to the comparison paroxetine versus CBT

Notes

Risk of bias

Bias

None

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"A sealed envelope was randomly selected from an initial total of 75 envelopes
containing the treatment assignments, with 30 being labelled as CBT, 30 as
paroxetine and 15 as waiting list."

Allocation concealment
(selection bias)

Unclear risk

See above. It is unclear whether envelopes were opaque and sequentially
numbered

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

"All assessments were administered by trained, independent psychologists who
were blind to the study and treatments delivered." However, panic frequency
was rated through MI, which is a self rated measure.

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

"Five patients (10.2%) failed to complete the 14-week treatment protocol: three
dropped out in the paroxetine condition (side-effects, n = 1; protocol violation,
n = 1; broken hip, n = 1), one in the CBT condition (protocol violation) and one in
the WL condition (severe somatic illness." We are not considering the paroxetine
group for this review, therefore the proportion of missing outcomes compared
with the observed event risk is not enough to have a clinically relevant impact
on the intervention effect estimate.

Selective reporting (re-
porting bias)

Low risk

Study protocol available. All primary outcomes coincide (however, note that
BDI, a secondary outcome, is not reported).

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

Other bias

Unclear risk

"Throughout the study, they were weekly supervised by a registered supervi-
sor (a member of the Dutch Association of Behavioural and Cognitive Therapy).
Per session, the therapists recorded which specific CBT component they had ap-
plied and any deviations from the treatment manual were discussed." It is un-
clear whether all sessions for all patients were supervised; no detail is reported
about supervisor assessments.

This study has been funded by Glaxo Smith Kline, so a sponsorship bias is pos-
sible. However, because the Paroxetine arm is not considered for this review, it
is unclear whether the comparison CBT versus WL can be affected by this pos-
sible source of bias.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hoffart 1995 

Methods

Participants

Study design: randomised controlled trial, inpatient setting

Inclusion criteria: age from 20 to 65 years, DSM-III-R diagnosis of panic disorder with agoraphobia,
DSM-III-R agoraphobia severity rated as moderate or severe, patients considered the symptoms of ago-
raphobia (that is avoidance behaviour and situational panic or symptom attacks and not spontaneous
panics or other mental problems) as their main problem. A plan for the reduction or discontinuation
of medication before hospital admission was agreed upon and patients were informed that use of psy-
chotropic medication was prohibited during the 6-week inpatient treatment period.

Exclusion criteria: none

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 40.1 years, SD 9.3)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 0%
• Percentage  of  patients  with  major  depression:  not  specified  for  ITT  sample  (63%  among  com-

pleters)

Interventions

Participants (n = 52) were randomly assigned to either:

1) Cognitive therapy (classified as CBT, n = 26)

• Therapy format: group
• Duration of each session: unclear
• Mean number of sessions: unclear
• Duration of intervention: 6 weeks

2) Guided mastery therapy (classified as BT, n = 26)

• Therapy format: group
• Duration of each session: unclear
• Mean number of sessions: unclear
• Duration of intervention: 6 weeks

Outcomes

Time points for assessment: precare (before hospital admission), pre-treatment (1 week), post-inten-
sive period (4 weeks), post-treatment (6 weeks), 1 year follow-up

Measures: Behavioral Avoidance Tests (BATs), Structured Clinical Interview for the DSM-III-R (SCID-
I), Phobic Avoidance Rating Scale (PARS), Body Sensations Questionnaire (BSQ), Agoraphobic Cogni-
tions Questionnaire (ACQ), Mobility Inventory for Agoraphobia (M), Self-Efficacy Scales for Agoraphobia
(SESA), State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI), panic diary

The following outcomes were used for quantitative analyses:

ST-Remission: high end-state functioning* at post-treatment

ST- Response: improvement > 50% on PARS separation avoidance sub-scale

ST-Dropouts: non-completers

Continuous scale: Body Sensations Questionnaire (BSQ)

LT-Remission/Response: high end-state functioning* at 1 year follow-up

Notes

* "It was decided a priori to give a status of high endstate functioning to those who at posttreatment (l)
had a score of 1.5 or lower at the PARS separation avoidance subscale, implying that at least half of the six
situations of this subscale were approached regularly without use of safety signals (e.g. medication); (2)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

138

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hoffart 1995  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

had a score of 3--"symptoms interfere with work or social activity only in minor ways"--or less in interview-
er rated global severity; and (3) were free of spontaneous panic attacks in the two weeks after discharge."

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Low risk

"A symptom rating interview was performed by a psychiatrist who worked in an-
other institution and was blind to the treatment condition of the patients. The in-
terview included the 0 to 4 point Phobic Avoidance Rating Scale (PARS)."

Incomplete outcome data
(attrition bias) 
Short-term

Unclear risk

"Six of the 52 patients, 3 in each condition, dropped out from the study. Four pa-
tients dropped out before or within the first 24 hours after admission to the hos-
pital: 2 because of problematic family circumstances, 1 was not allowed finan-
cial coverage for the hospital stay from her home country, and 1 withdrew as she
experienced overwhelming fantasies of being locked in forever in a mental hos-
pital. Two patients, 1 in each condition, withdrew just after the discontinuation
of anxiolytics because they could not tolerate being without them." Missing out-
come data are balanced in numbers across intervention groups, with similar
reasons for missing data across groups. However, it is unclear whether the pro-
portion of missing outcomes is enough to have a clinically relevant impact on
the intervention effect estimate.

Incomplete outcome data
(attrition bias) 
Long-term

Selective reporting (re-
porting bias)

Unclear risk

All treatment completers (n = 46, see above) were assessed at 1-year follow-up

High risk

Study protocol unavailable. Results of ACQ measurements are not reported.

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

"The two psychologists alternated between being supervisor and being the pri-
mary therapist, responsible for the overall treatment and for conducting the
group sessions together with a co-therapist, in the 6 groups. In the intensive
three-week period, the supervising psychologist conducted two 45 min supervi-
sion sessions per week, addressing immediate treatment problems and ques-
tions about adherence to the manuals. In addition, the supervisor listened to au-
diotapes of therapy sessions and gave written feedback to the therapists." It is
unclear whether all therapy sessions were assessed.

Karekla 2004 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: primary DSM-IV diagnosis of panic disorder with or without agoraphobia

Exclusion criteria: psychosis, substance abuse, suicidal ideation or intent

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Karekla 2004  (Continued)

Characteristic of the sample:

Cochrane Database of Systematic Reviews

• Age: not specified for ITT sample (among those who attended at least the first treatment session,

mean age was 34.95, SD 11.07, range 20 to 67)

• Percentage of agoraphobic patients: not specified for ITT sample (78.3% among those who attended

at least the first treatment session)

• Percentage of patients on drug therapy: not specified for ITT sample (72.7% among those who at-

tended at least the first treatment session)

• Percentage of patients with major depression: not specified for ITT sample (34.8% among those

who attended at least the first treatment session)

Interventions

Participants (n = 28) were randomly assigned to either:

1) Panic control treatment (classified as CBT, n = 14)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks

2) Acceptance-enhanced panic control treatment (classified as 3W, n = 14)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks

Outcomes

Time points for assessment: pre-treatment, mid-treatment, post-treatment, 6 months follow-up

Measures: State-Trait Anxiety Inventory (STAI), Acceptance and Action Questionnaire (AAQ), Automat-
ic Thoughts Questionnaire (ATQ), Beck Depression Inventory (BDI), Anxiety Sensitivity Index (ASI), Ago-
raphobic Cognitions Questionnaire (ACQ), Panic and Agoraphobia Scale (PAS), Panic Disorder Severity
Scale (PDSS), quality of life (SF-36), Valued Living Questionnaire (VLQ), White Bear Suppression Inven-
tory (WBSI), Subjective Units of Distress Scale (SUDS), Diagnostic Symptoms Questionnaire (DSQ), Anxi-
ety and Willingness Scale (AWS)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured

ST- Response: not measured

ST-Dropouts: non-completers (including early dropouts)

Continuous scale: although measured, data cannot be used because number of assessed patients is
not reported

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Karekla 2004  (Continued)

Incomplete outcome data
(attrition bias) 
Short-term

High risk

Cochrane Database of Systematic Reviews

"Twenty-eight individuals met inclusion criteria and were scheduled for treat-
ment. Of those, 22 attended at least the first session. Fourteen participants com-
pleted the full 10 weeks of treatment. The cases of participants who prematurely
dropped out of treatment are dropped out from further analyses."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Klosko 1988 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age between 18 and 65 years, DSM-III-R primary diagnosis of panic disorder with a
clinician's severity rating of at least 4 on a 0 to 8 scale (moderate severity), at least 1 panic attack in the
week before starting treatment

Exclusion criteria: pharmacotherapy or psychotherapy begun in the past 6 months; either in drug or
psychotherapeutic treatment more than 6 months (unless subjects agreed to stop such treatment for
the duration of the study); on 4 mg or more of alprazolam for any 3-week period and were non-respon-
ders; evidence of benzodiazepine hypersensitivity; undergone cognitive behaviour therapy for anxiety
at any time; females who were pregnant or lactating or at risk to become pregnant; significant medical
problems, as determined by history, medical report and laboratory values; history of psychotic disor-
der or dementia; history of alcohol or other substance abuse within the last 6 months; current or past
bipolar disorder. Subjects with major depression were excluded only if depression predominated over
panic disorder at the time of presentation and if depression preceded panic disorder chronologically.
Subjects with acute suicidal ideation were excluded.

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 37, SD 11.04)
• Percentage of agoraphobic patients: not specified for ITT sample (79% among completers)
• Percentage of patients on drug therapy: not specified for ITT sample (59.6% among completers)
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 69) were randomly assigned to either:

1) Alprazolam (not included, n = 17)

• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks

2) Placebo (not included, n = 18)

• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Klosko 1988  (Continued)

3) Behaviour therapy (classified as CBT, n = 18)

• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks

4) Wait list (classified as WL, n = 16)

• Mean number of sessions: 0
• Duration of intervention: 15 weeks

Outcomes

Time points for assessment: baseline, post-treatment.

Measures: daily self monitoring, Anxiety Disorders Interview Schedule - R (ADIS-R), Hamilton Anxiety
Rating Scale (HAM-A), Hamilton Rating Scale for Depression (HAM-D)

The following outcomes were used for quantitative analyses:

ST-Remission: ADIS-IV severity < 4

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Anxiety Disorders Interview Schedule - R (ADIS-R)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Low risk

"Posttreatment clinical assessment measures were gathered through admin-
istration of a short form of the ADIS-R. The ADISR administrators were blind to
group assignment"

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Out of 69 initial subjects, 57 subjects completed the study, and 12 subjects
dropped out. A higher rate of dropout was observed in the placebo group com-
pared with the other three groups. One subject out of 17 (5.9%) dropped from
the alprazolam group, 7 out of 18 (38.9%) from the placebo group, 3 out of 18
(16.7%) from the PCT group, and 1 out of 16 (6.3%) from the waiting-list group."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

Barlow DH is author of a CBT manual (see Barlow 2000b)

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"All therapy sessions were tape-recorded and checked for treatment integrity."

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Klosko 1988  (Continued)

Other bias

High risk

Cochrane Database of Systematic Reviews

Performance bias: in contrast with patients in the CBT group, patients in the
WL were not asked to withdraw medications.

Korrelboom 2013 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: age 18 to 65 years, DSM-IV-TR clinical diagnosis of panic disorder with or without
agoraphobia, being able to read, speak and understand Dutch well enough to participate in the treat-
ment groups and to fill in all assessments. Use of psychotropic medication was permitted only if the
medication dose was stable during the study and had been stable for at least 2 months prior to study
inclusion. Patients who changed their medication during treatment were considered to be dropouts,
patients who started (a new) medication less than 2 months before inclusion had to wait for participa-
tion until they had fulfilled this 2-month criterion.

Exclusion criteria: severe co-morbid psychopathology, such as psychosis; addiction; being suicidal;
mental retardation; concurrent psychological treatments, or cognitive behavioural treatments in the
past 6 months

Characteristic of the sample:

• Age: mean age 36.1 years (SD 11.9)
• Percentage of agoraphobic patients: 79%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 143) were randomly assigned to either:

1) Competitive memory training for panic (classified as CBT, n = 70)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 7
• Duration of intervention: 7 weeks

2) Applied relaxation (classified as PT, n = 73)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 7
• Duration of intervention: 7 weeks

Outcomes

Time points for assessment: baseline, post-treatment, 6 months follow-up

Measures: Panic Appraisal Inventory (PAI), Mobility Inventory (MI)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (imputed from continuous scale)

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Mobility Inventory for agoraphobia when alone (MI-A)

LT-Remission/Response: not measured

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Korrelboom 2013  (Continued)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

High risk

MI is a self rated scale

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

"During treatment, a total of 24 patients (17%) dropped out (13 in AR and 11 in
COMET). Analyses were on an intention-to-treat basis. First, in a binary logistic
regression analysis, it was checked whether dropout was predicted by age, di-
agnosis, gender or any of the outcome measures at M-pre. Then missing values
were imputed with the SPSS 20 multiple imputation algorithm."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

It seems that authors are involved in conceptualisation of COMET-panic: "Since
this COMET-panic protocol appeared to be effective in two pilot studies in rou-
tine clinical settings (Korrelboom et al. 2008; Peeters et al. 2005), it was decided
to put the new protocol to the test in a randomized controlled trial versus an evi-
dence-based anti-panic procedure, in this case AR."

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"Both panic management techniques were available in written form (a manual)
for therapists and patients. In regular meetings therapists and researchers dis-
cussed adherence to the treatment protocols. As an additional check on treat-
ment integrity, patients filled in a checklist containing specific questions about
the nature of the treatments they had just received. This checklist contained
statements about specific differential identifying elements of both therapies. If
both treatments had been delivered properly, AR patients should identify more
AR ingredients in the treatment they had received and few/none of the COMET
elements, and vice versa for the COMET patients. In the AR condition the mean
score for ‘AR ingredients’ was 36.7 (SD = 3.1) whereas the highest possible score
was 40, while the mean score for ‘COMET ingredients’ in this condition was only
16.6 (SD = 9.5) whereas the lowest possible score was 4. On the other hand, in the
COMET condition these figures were 34.0 (SD = 5.7) for ‘COMET ingredients’ (pos-
sible maximum of 40) and 15.2 (SD = 7.6) for ‘AR ingredients’ (possible minimum
of 4)."

Lidren 1994 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM-III-R diagnosis of panic disorder with or without agoraphobia. Individuals tak-
ing medication for anxiety could participate if they were still suffering from panic symptoms after 6

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lidren 1994  (Continued)

Cochrane Database of Systematic Reviews

weeks of stabilisation on medication, if they maintained the same dosages throughout treatment, and
if they recorded both the type and amount of medication usage throughout the study.

Exclusion criteria: seizure disorder, kidney disorder, stroke, myocardial infarction, chronic hyperten-
sion, emphysema, organic brain syndrome, chronic use of alcohol, drug dependence, major depressive
disorder, psychotic disorders, involvement in any type of therapy focusing on anxiety management

Characteristic of the sample:

• Age: 33.7 years (SD 11.8)
• Percentage of agoraphobic patients: 83.3%
• Percentage of patients on drug therapy: 39%
• Percentage of patients with major depression: 0%

Interventions

Participants (n = 36) were randomly assigned to either:

1) Bibliotherapy (not included, n = 12)

• Therapy format: self help
• Mean number of sessions: 0
• Duration of intervention: 8 weeks

2) Group therapy (classified as CBT, n = 12)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks

3) Wait list (classified as WL, n = 12)

• Mean number of sessions: 0
• Duration of intervention: 8 weeks

Outcomes

Time points for assessment: baseline, post-treatment, 3 months follow-up, 6 months follow-up

Measures: panic frequency and severity, Panic Attack Symptom Questionnaire (PASQ), Panic Attack
Cognition Questionnaire (PACQ), Mobility Inventory (MI), Panic Self-Efficacy Questionnaire (PSEQ), Beck
Depression Inventory (BDI)

The following outcomes were used for quantitative analyses:

ST-Remission: Mobility Inventory (MI) score < 32 at post-treatment

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Mobility Inventory for agoraphobia when alone (MI-A)

LT-Remission/Response: Mobility Inventory (MI) score < 32 at 6 months follow-up

None

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Unclear risk

No information provided

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lidren 1994  (Continued)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Incomplete outcome data
(attrition bias) 
Short-term

Incomplete outcome data
(attrition bias) 
Long-term

Selective reporting (re-
porting bias)

Unclear risk

No information provided

High risk

Mobility Inventory (MI) is a self rated measure

Low risk

"Attrition rates were zero for all three conditions"

Low risk

(see above)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"The BT condition used Clum's (1990) Coping with panic book. Subjects in the GT
condition also used Clum's (1990) Coping with panic text." Glum GA is among the
study authors.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"We videotaped all sessions, with the faculty member on the research team
viewing these tapes for treatment integrity."

Malbos 2011 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: DSM-IV diagnosis of panic disorder with agoraphobia

Exclusion criteria: epilepsy, dissociative or non-dissociative chronic psychosis, recent discontinuation
of psychotropic drugs, substance dependence

Characteristic of the sample:

• Age: mean age 44.11 years (SD 13.79, range 24 to 72)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: 23.5%

Interventions

Participants (n = 17) were randomly assigned to either:

1) Virtual reality exposure only (classified as BT, n = 9)

• Therapy format: not specified
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks

2) Virtual reality exposure + cognitive therapy (classified as CBT, n = 8)

• Therapy format: not specified
• Duration of each session: 90 minutes
• Mean number of sessions: 10

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Malbos 2011  (Continued)

• Duration of intervention: 10 weeks

Outcomes

Time points for assessment: baseline, post-treatment, 3 months follow-up

Measures: Presence Questionnaire (PQ v3.0), Subjective Units of Discomfort (SUD), Depression Anxiety
Stress Scales (DASS 21), Anxiety Sensitivity Index (ASI), Agoraphobia Cognitions Questionnaire (ACQ),
Mobility Inventory for Agoraphobia (MI), Simulation Sickness Questionnaire (SSQ), Behavioural Avoid-
ance Test (BAT), heart rate (HR) and heart rate variability (HRV)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (imputed from continuous scale)

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Anxiety Sensitivity Index (ASI)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

"The allocation to each group was done using a randomisation table generated
by a computerised sequence generator."

Allocation concealment
(selection bias)

Low risk

"It was impossible to foresee the assignment of the next patient entering the
study" (personal communication)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

ASI is a self rated measure

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

"One participant (VRO)dropped out at an early stage due to a severe myopia."
The proportion of missing outcomes is not enough to have a clinically relevant
impact on the intervention effect estimate.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Unclear risk

"In the present study we designed all required VEs for the VRET of agoraphobia
within a game level editor." Although possible, the extent to which this source
of bias may affect the results is unclear, because both arms are administered
the same VEs.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Marchione 1987 

Methods

Study design: randomised controlled trial

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Marchione 1987  (Continued)

Participants

Inclusion criteria: DSM-III diagnosis of agoraphobia with panic attacks, other inclusion criteria are
mentioned but not reported.

Exclusion criteria: none reported

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 38.1 years, SD 11.8, range 25 to 65)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 19) were randomly assigned to either:

1) Cognitive therapy + graduated exposure (classified as CBT, n = unclear)

• Therapy format: group
• Duration of each session: 120 minutes (first 2 sessions), 60 minutes (following 14 sessions)
• Mean number of sessions: 16
• Duration of intervention: not specified

2) Progressive deep muscle relaxation + graduated exposure (classified as BT, n = unclear)

• Therapy format: group
• Duration of each session: 120 minutes (first 2 sessions), 60 minutes (following 14 sessions)
• Mean number of sessions: 16
• Duration of intervention: not specified

3) Graduated exposure alone (classified as BT, n = unclear)

• Therapy format: group
• Duration of each session: 120 minutes (first 2 sessions), 90 minutes (following 14 sessions)
• Mean number of sessions: 16
• Duration of intervention: not specified

Outcomes

Time points for assessment: baseline, mid-treatment, post-treatment

Measures: Global Assessment of Severity, Self-Rating of Severity, Phobic Anxiety and Avoidance Scale,
Fear Survey Schedule, Fear Questionnaire (FQ), Taylor Manifest Anxiety Scale, Panic Scale, Beck De-
pression Inventory (BDI), Hopkins Symptom Checklist, Subjective Symptom Checklist, Standardised
Behavioral Avoidance Course (S-BAC), heart rate

The following outcomes were used for quantitative analyses:

ST-Remission: although measured (high end-state functioning*) detailed data are not reported

ST- Response: not measured

ST-Dropouts: detailed data are not reported

Continuous scale: although measured, detailed data are not reported

LT-Remission/Response: not measured

Notes

* "Five criteria were used to classify subjects’ level of Endstate (low-medium-high) functioning. Subjects
were assigned 1 point for each of the following scores: (a) ≤2 on the Global Assessment of Severity; (b) ≤2
on the Self-Rating of Severity; (c) ≤3 on the Phobic Anxiety and Avoidance Scale; (d) Completing the Stan-
dardized-Behavioral Avoidance Course; and, (e) ≤3 SUDS (in vivo anxiety). Subjects with 0-1 points = low
Endstate functioning; 2-3 points = medium Endstate functioning, and those with 4-5 points were classified
as having high Endstate functioning."

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Marchione 1987  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Selective reporting (re-
porting bias)

High risk

Study protocol unavailable. Pre-planned measures are not reported with suffi-
cient detail.

Researcher allegiance

High risk

"The cognitive therapy was developed by Michelson (1984), adapted from Antaki
and Brewin (1982), Beck and Emery (1979), Bums (1980), Mckay, Davis and Fan-
ning (1981), and Sank and Shaffer (1984)." Michelson L is among the study au-
thors.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"To ensure the treatment procedures were administered consistently, weekly
meetings were held to discuss and review all treatment sessions. Treatment in-
tegrity probes were randomly conducted on 25% of the sessions and revealed
consistently high (100%) levels of fidelity."

Meulenbeek 2008 

Methods

Study design: multicentre randomised controlled trial

Participants

Inclusion criteria: over 18 years of age, subthreshold or mild panic disorder with or without agorapho-
bia (DSM-IV), defined as having symptoms of panic disorder falling below the cut-off of 13 on the Panic
Disorder Severity Scale–Self Report (PDSS–SR). If a participant used medication for anxiety or depres-
sion (e.g. benzodiazepines or antidepressants) it was agreed to keep medication use stable during the
study period.

Exclusion criteria: severe panic disorder (PDSS–SR > 12), current psychological treatment for panic
disorder-related complaints, presence of other severe mental or social problems, suicidal intention
warranting treatment or likely to interfere with participation in the group course as assessed by an ex-
perienced psychologist during intake.

Characteristic of the sample:

• Age: not specified for clinical sub-sample (among all participants, mean age was 42 years, SD 12.4,

range 20 to 75)

• Percentage of agoraphobic patients: not specified for clinical sub-sample (62% among all partici-

pants)

• Percentage of patients on drug therapy: not specified for clinical sub-sample (38.7% among all par-

ticipants)

• Percentage of patients with major depression: not specified

Interventions

Participants (clinical sub-sample, n = 100) were randomly assigned to either:

1) "Don't Panic" intervention (classified as CBT, n = 50)

• Therapy format: group
• Duration of each session: 120 minutes
• Mean number of sessions: 8

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Meulenbeek 2008  (Continued)

• Duration of intervention: 8 weeks

2) Wait list (classified as WL, n = 50)

• Mean number of sessions: 0
• Duration of intervention: 12

Cochrane Database of Systematic Reviews

Outcomes

Time points for assessment: baseline, post-intervention, 6 months follow-up

Measures: Panic Disorder Severity Scale–Self Report (PDSS–SR), Mini International Neuropsychiatric
Interview–Plus (MINI–Plus), Mobility Inventory (MI), sub-scale for anxiety of the Hospital Anxiety and
Depression Scale (HADS–Anxiety), Beck Depression Inventory (BDI–II)

The following outcomes were used for quantitative analyses:

ST-Remission: PDSS at post-treatment < 1 SD compared to baseline mean and below 4 (cut-off value)

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: not reported for clinical sub-sample

Continuous scale: Panic Disorder Severity Scale–Self Report (PDSS–SR, data for clinical sub-sample
available on personal communication)

Notes

Risk of bias

Bias

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"A blocked randomisation scheme was used, stratified by mental health centre,
subthreshold panic disorder v. mild panic disorder, and by presence v. absence
of co-occurring agoraphobia."

Allocation concealment
(selection bias)

Low risk

"The randomisation took place after administration of the Mini International
Neuropsychiatric Interview–Plus (MINI–Plus)8 and was carried out centrally by
an independent third party."

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

Selective reporting (re-
porting bias)

High risk

ST-Remission is calculated from the Self Report of Panic Disorder Severity
Scale

All randomised patients (clinical sub-sample) were assessed with PDSS-SR at
post-treatment (personal communication)

Study protocol available: declared primary outcome is "incidence of DSM-IV
panic disorder." In published report: "we used the PDSS–SR and the MINI–Plus
as the primary outcome measures."

Researcher allegiance

High risk

"We developed an early intervention for panic symptoms, called the ‘Don't Panic’
course"

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Other bias

High risk

Performance bias: WL patients are free to make use of other interventions

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Meuret 2008 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age between 18 and 60 years, principal DSM-IV diagnosis of panic disorder with or
without agoraphobia, no additional psychological treatment until after the 2-month follow-up. If on
psychotropic medications, on stable doses for at least 3 months prior to treatment with an agreement
not to change dosage at least until after the 2-month follow-up

Exclusion criteria: evidence of organic mental disorder, suicidality, schizophrenia, alcohol or drug de-
pendence, cardiovascular disease, pulmonary disease, epilepsy or pregnancy

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 41 years, SD 8.9)
• Percentage of agoraphobic patients: not specified for ITT sample (83.8% among completers)
• Percentage of patients on drug therapy: not specified for ITT sample (32.4% among completers)
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 43) were randomly assigned to either:

1) Breathing training therapy (classified as PT, n = 24)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 5
• Duration of intervention: 4 weeks

2) Wait list (classified as WL, n = 19)

• Mean number of sessions: 0
• Duration of intervention: 4 weeks

Outcomes

Time points for assessment: baseline, post-treatment (week 4), 2 months follow-up (week 12), 12
months follow-up

Measures: Panic Disorder Severity Scale (PDSS), Clinical Global Impression Scale (CGI), Anxiety Sensi-
tivity Index (ASI), Sheehan Disability Scale (SDS), Mobility Inventory for Agoraphobia (MI-AAL), Beck De-
pression Inventory (BDI), week-by-week changes in end-tidal pCO2 (mm Hg) and RR (breaths/minute)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (imputed from continuous scale)

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Panic Disorder Severity Scale (PDSS)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Unclear risk

No information provided

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Meuret 2008  (Continued)

Allocation concealment
(selection bias)

Unclear risk

No information provided

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Unclear risk

"An assessment battery was administered at baseline (week 0), post-treatment
(week 4), 2-month follow-up (week 12), and 12-month follow-up (week 53). It in-
cluded the PDSS (Shear et al., 1997), a clinician-rated scale of PD severity and the
Clinical Global Impression Scale (CGI; Guy, 1976) (both assessed by independent
raters)." It is unclear whether raters were blind to treatment allocation.

Incomplete outcome data
(attrition bias) 
Short-term

Selective reporting (re-
porting bias)

High risk

35 patients were analysed at post-treatment (see study flow chart)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"We devised a capnometry-assisted breathing training therapy (BRT) that uses
immediate feedback to teach patients how to raise their pCO2 over a series of
training and practice sessions."

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Meuret 2010 

Methods

Participants

Study design: 2-site, randomised controlled trial

Inclusion criteria: minimum age of 18 years, current principal DSM-IV diagnosis (i.e. the disorder
presently associated with the greatest life interference) of panic disorder with agoraphobia, being on a
stable dose of psychotropic medication for at least 3 months before study initiation (if applicable) and
agreement to continue this dose through the 2-month follow-up appointment, agreement not to initi-
ate additional therapy until after the final follow-up appointment.

Exclusion criteria: indication of a history of bipolar disorder, psychotic disorder or suicidal intention,
or current substance abuse or dependence, organic mental disorder, serious unstable medical disease,
respiratory illness or seizures

Characteristic of the sample:

• Age: not reported for ITT sample (among initiators, mean age was 33.2 years, SD 9.9, range 20 to 57)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not reported for ITT sample (62.2% among initiators)
• Percentage of patients with major depression: not reported for ITT sample (mood disorders 3.3%

among initiators)

Interventions

In a first phase of the study, participants (n = 47) were randomly assigned to 5 weekly sessions of either
capnometry-assisted breathing training (n = 24) or cognitive training (n = 23)

In a second phase of the study, participants of both groups underwent 3 weekly sessions of in vivo ex-
posure plus a 4th session at 2-month follow-up, therefore:

1) Capnometry-assisted breathing training + in vivo exposure (classified as BT, n = 24)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 9

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

152

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Meuret 2010  (Continued)

• Duration of intervention: 16 weeks

2) Cognitive training + in vivo exposure (classified as CBT, n = 23)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 9
• Duration of intervention: 16 weeks

Outcomes

Time points for assessment: baseline, pre-phase 1, post-phase 1/pre-exposure (beginning of phase 2),
post-exposure (after the 3 weekly sessions of in vivo exposure), 2 months follow-up (last exposure ses-
sion)

Measures: Panic Disorder Severity Scale (PDSS), Body Sensations Questionnaire (BSQ), Anxiety Sensi-
tivity Index (ASI), combined measure of symptom appraisal (ASI/BSQ), Mobility Inventory for Agorapho-
bia (MI), Anxiety Control Questionnaire (ACQ), end-tidal pCO2, respiration rate (RR)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured

ST- Response: not measured

ST-Dropouts: non-completers at termination (last exposure session)

Continuous scale: although measured, detailed data are not reported

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Low risk

"Randomization software was used to assign patients to condition."

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Incomplete outcome data
(attrition bias) 
Short-term

High risk

In the CT + exposure arm, a total of 12 patients (out of 23 randomised) com-
pleted all sessions; in the CART + exposure arm, a total of 16 patients (out of 24
randomised) completed all sessions.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"CART is based on the theory that sustained levels of hypocapnia contribute to
symptom development and maintenance of PD ( Meuret 2008 )."

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"All sessions were audio- or video-taped and discussed in the weekly supervi-
sion meetings by expert clinicians to ensure that therapists adhered to the treat-
ment protocol. A random sample of 10% of all recorded treatment sessions (10
CART and 10 CT sessions) was evaluated blindly for protocol adherence by two
independent, experienced master’s-level clinicians. In addition, 50% of the rat-
ed sessions (5 CART and 5 CT) were randomly selected and rated by another mas-
ter’s-level and one doctoral-level clinician to assess interrater reliability. Adher-
ence to the given model/protocol was rated high for both conditions (CART: M

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Meuret 2010  (Continued)

Cochrane Database of Systematic Reviews

6.25, SD 0.92; CT: M 5.50, SD 1.20), and ratings were not significantly different be-
tween conditions. Interrater agreement was calculated with intraclass correla-
tion coefficients. The results suggest that coders showed high agreement (intra-
class correlation [2, 1] 0.85; Shrout & Fleiss, 1979)."

Meyerbroker 2011 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: age between 18 and 65 years, DSM-IV-TR diagnosis of panic disorder with agorapho-
bia

Exclusion criteria: presence of a medical condition (pregnancy, seizure disorder, pacemaker), current
use of tranquillisers or not on a stable dose of antidepressants, current substance dependence, current
depression with suicidal ideation, bipolar disorder, borderline or antisocial personality disorder, histo-
ry of psychosis, severe cognitive impairment

Characteristic of the sample:

• Age: not specified
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 55) were randomly assigned to either:

1) CBT + virtual reality exposure (classified as CBT, n = 19)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 10
• Duration of intervention: not specified

2) CBT + in vivo exposure (classified as CBT, n = 18)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 10
• Duration of intervention: not specified

3) Wait list (classified as WL, n = 18)

• Mean number of sessions: 0
• Duration of intervention: 8 weeks

Outcomes

Time points for assessment: baseline, post-treatment.

Measures: Panic Disorder Severity Scale (PDSS), Mobility Inventory (MI), Bodily Sensation Question-
naire (BSQ), Agoraphobic Cognitions Questionnaire (ACQ), Panic Appraisal Inventory (PAI), Avoidance
Scale of Watson and Marks

The following outcomes were used for quantitative analyses:

ST-Remission: not measured

ST- Response: not measured

ST-Dropouts: non-completers

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Meyerbroker 2011  (Continued)

Cochrane Database of Systematic Reviews

Continuous scale: although measured, data cannot be used (n, mean and SD are reported only for the
comparison VRET versus IVExp, both classified as CBT: comparison not feasible)

Notes

Risk of bias

Bias

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"Patients were randomized with randomly permuted blocks" (personal commu-
nication)

Allocation concealment
(selection bias)

Unclear risk

No information provided

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"After randomization, 9 of the 55 patients declined to start the treatment. Dur-
ing treatment 15 patients dropped out for various reasons: medical issues (n
= 2), acute crisis 2), could not experience the virtual environment as real (n =
2), had no further complaints (n = 3) and personal circumstances (n = 1). Com-
pleter analyses included the remaining sample of 31 patients who completed
all treatment sessions (n = 29) or at least 80% of the sessions (n = 2). Intent-to-
treat analyses were done with multiple imputation on the full sample (n = 46)
who started at least 1 treatment session"

Selective reporting (re-
porting bias)

High risk

Study protocol available: declared primary outcomes are PDSS and MI (plus
Behavioural Avoidance Test, added subsequently). Primary outcomes are not
specified in published report.

Researcher allegiance

Low risk

"None of the authors has any conflict of interest"

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Milrod 2006a 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: diagnosis with primary DSM-IV panic disorder with or without agoraphobia, mini-
mum severity score of 5 on the 0- to 8-point Anxiety Disorders Interview Schedule for DSM-IV (ADIS-IV-
Lifetime Version), minimum of 1 weekly panic attack. Patients were included whether or not they were
taking anti-panic medication: subjects meeting study entrance criteria while taking stable doses of
medication agreed to keep medication type and dose constant throughout the study. Patients discon-
tinued ongoing psychotherapy to gain study entrance. Patients with comorbid major depression, per-
sonality disorders and severe agoraphobia were included.

Exclusion criteria: psychosis, bipolar disorder and active substance abuse (6 months remission neces-
sary for inclusion)

Characteristic of the sample:

• Age by treatment group: PFPP group mean age 33.4 (SD 9.6); ART group mean age 33.5 (SD 8.5)
• Percentage of agoraphobic patients: PFPP group 69%; ART group 86%
• Percentage of patients on drug therapy: PFPP group 19%; ART group 17%

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Milrod 2006a  (Continued)

• Percentage of patients with major depression: PFPP group 19%; ART group 26%

Interventions

Participants (n = 49) were randomly assigned to either:

1) Panic focused psychodynamic psychotherapy (classified as PD, n = 26)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 24
• Duration of intervention: 12 weeks

2) Applied relaxation training (classified as PT, n = 23)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 24
• Duration of intervention: 12 weeks

Outcomes

Time points for assessment: baseline, termination, 2 months follow-up, 4 months follow-up, 6
months follow-up, 12 months follow-up

Measures: Panic Disorder Severity Scale (PDSS), Sheehan Disability Scale (SDS), Hamilton Depression
Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (imputed from continuous scale)

ST- Response: 40% reduction in PDSS at termination

ST-Dropouts: non-completers

Continuous scale: Panic Disorder Severity Scale (PDSS)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

"Subjects were randomly assigned using a computer generated treatment as-
signment list that was stratified by presence or absence of 1) comorbid current
DSM-IV major depression and 2) stable doses of antipanic medication."

Allocation concealment
(selection bias)

Low risk

"All study staff was blinded" (personal communication)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Low risk

"Independent evaluators, blinded to subject condition and therapist orienta-
tion, assessed subjects at baseline, treatment termination, and at 2, 4, 6, and 12
months posttreatment termination"

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Rates of dropout from the 12-week randomized controlled clinical trial differed
significantly between the randomly assigned treatment groups: two out of 26
(7%) panic-focused psychodynamic psychotherapy subjects and eight out of 23
(34%) applied relaxation training subjects dropped out. The analyses described
above adhered to the intention-to-treat principle using last observation forward
to impute missing data for the primary outcome and three continuous secondary

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Milrod 2006a  (Continued)

Cochrane Database of Systematic Reviews

outcomes." Although a LOCF method was used, LOCF cases are many and un-
balanced between arms.

Selective reporting (re-
porting bias)

Low risk

Study protocol available. All of the study's pre-specified (primary and sec-
ondary) outcomes have been reported in the pre-specified way.

Researcher allegiance

High risk

Milrod B and Busch F are co-authors of PFPP manual (see Milrod 1997)

Therapist allegiance

Unclear risk

Insufficient information provided

Treatment fidelity

Unclear risk

"Therapists in both modalities met monthly for group supervision and received
individual supervision as needed. Therapists in both modalities were monitored
for adherence to treatment protocol by adherence raters in each modality with
equal frequency. Three videotapes were rated for adherence per individual
treatment. All therapists met predetermined adherence standards." It is unclear
whether all sessions for both therapies were recorded and if the 3 videotapes
monitored for adherence where chosen randomly.

Muncy 1991 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM-III-R diagnosis of panic disorder with or without agoraphobia, drug-free, in rea-
sonably good health, not currently in therapy (or, in this case, able to arrange with the therapist to work
within the structure of the project)

Exclusion criteria: none

Characteristic of the sample:

• Age: not specified
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified (68.4% imputed from BDI in the 3 arms

considered for this review)

Interventions

Participants (n = 26) were randomly assigned to either:

1) Rational emotive therapy (classified as CT, n = 7)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 6
• Duration of intervention: 6 weeks

2) Rational emotive therapy + biofeedback (classified as CT, n = 8)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 6
• Duration of intervention: 6 weeks

3) Imipramine (not included, n = 7)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: not specified

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Muncy 1991  (Continued)

• Duration of intervention: 6 weeks

4) Wait list (classified as WL, n = 4)

• Mean number of sessions: 0
• Duration of intervention: 6 weeks

Cochrane Database of Systematic Reviews

Outcomes

Time points for assessment: baseline, mid-treatment (3 weeks after commencement), termination (6
weeks after commencement).

Measures: Minnesota Multiphasic Personality Inventory (MMPI), Millon Clinical Multiaxial Inventory
(MCMI), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured

ST- Response: not measured

ST-Dropouts: non-completers

Continuous scale: not measured (none of the available measures meets our inclusion criteria, see Se-
condary outcomes)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

"Two subjects from G3 (Imipramine arm)abandoned the study in the first three
weeks of the treatment due to their inability to tolerate the side-effects of
imipramine. Thus, the number of observations was reduced to 24 [...]." Since
we are not considering the imipramine arm for this review, the number of
dropouts is 0

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Ost 1993 

Methods

Study design: randomised controlled trial

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ost 1993  (Continued)

Participants

Inclusion criteria: age between 20 and 60 years, DSM-III-R diagnosis of panic disorder with agorapho-
bia, express a willingness to participate in the study for a period of 3 months. If any medication was
used the intake was to be held constant during the study; participants had to agree not to receive any
other kind of psychiatric or psychological treatment except for any ongoing medication during the
treatment.

Exclusion criteria: any other psychiatric complaint in need of immediate treatment; psychotic or or-
ganic symptoms

Characteristic of the sample:

• Age: not reported for ITT sample (among completers, mean age was 37.42 years, SD 8.38, range 23

to 56)

• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not reported for ITT sample (51% among completers)
• Percentage  of  patients  with  major  depression:  not  reported  for  ITT  sample  (38%  among  com-

pleters)

Interventions

Participants (n = 46) were randomly assigned to either:

1) Applied relaxation (classified as PT, n = 15)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

2) Exposure in vivo (classified as BT, n = 16)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

3) Cognitive treatment (classified as CBT, n = 15)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

Outcomes

Time points for assessment: baseline, post-treatment, 1 year follow-up

Measures: Agoraphobia Scale, Fear Questionnaire (FQ), Mobility Inventory for Agoraphobia (MI), Agora-
phobic Cognitions Questionnaire (ACQ), Body Sensations Questionnaire (BSQ), Hamilton Anxiety Scale
(HAM-A), State-Trait Anxiety Inventory (STAI), Hamilton Depression Scale (HAM-D), Beck Depression In-
ventory (BDI), Behavior Test (BAT), Autonomic Perception Questionnaire (APQ)

The following outcomes were used for quantitative analyses:

ST-Remission: clinically significant improvement* (Agoraphobia Scale criteria) at post-treatment

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)

LT-Remission/Response: clinically significant improvement* (Agoraphobia Scale criteria) at 1 year fol-
low-up

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ost 1993  (Continued)

Notes

* "To assess the degree of clinically significant improvement achieved by the patients the method de-
scribed by Jacobson, Follette and Revenstorf (1984) was used. On any single measure a patient’s post-
treatment or follow-up score must be outside the range of the patient group’s pre-treatment scores, or
inside a normal group’s range, in the direction of functionality, defined as Mean ±1.96 x SD . Besides, the
change must be statistically reliable. For this study we chose to apply two criteria; percentage of situa-
tions completed in the BAT, and score on the avoidance part of Agoraphobic Scale. The respective cutoff
scores were:

BAT: Mean 23.23, SD 14.57, criterion: 22.23 + 1.96(14.57) = 51.79, i.e. 52.

Agoraphobia Scale-Avoidance: Mean 20.56, SD 6.76, criterion 20.56 - 1.96(6.76) = 7.31."

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

The Agoraphobia Scale (used to determine ST-Remission) is a self report mea-
sure

"One patient from the Exposure group dropped out after 2 sessions and was re-
placed. All the AR- and CT-patients completed the study. At follow-up I patient (in
the AR-group) had died, I refused participation in the assessment (E-group), and
1 (AR-group) had moved and was unreachable by mail or telephone. Thus, fol-
low-up assessment was done on 42 (93.3%) of the original patients."

Incomplete outcome data
(attrition bias) 
Long-term

Low risk

(See above). Missing outcome data balanced in numbers across intervention
groups; the proportion of missing outcomes compared with the observed
event risk is not enough to have a clinically relevant impact on the interven-
tion effect estimate.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

Ost LG is involved in conceptualisation of Applied Relaxation (see Ost 1987)

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Other bias

Unclear risk

Modification of the original sample with one replacement

Ost 1995 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age between 18 and 60 years, DSM-III-R diagnosis of panic disorder with mild or no
agoraphobic avoidance, duration of the panic disorder of at least 1 year, at least 3 panic attacks dur-
ing the 3 weeks baseline, panic disorder seen as the patient's primary problem, agreeing to take part
in the study for 18 weeks, including pre- and post-assessment, and 1 year follow-up, and be willing to

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ost 1995  (Continued)

Cochrane Database of Systematic Reviews

accept random allocation. If on prescribed drugs for panic disorder: (a) the dosage had to be constant
for 3 months before the start of the treatment; and (b) the patient had to agree to keep the dosage con-
stant throughout the study.

Exclusion criteria: primary depression (i.e. onset before the start of the panic disorder), any other psy-
chiatric disorder in immediate need of treatment

Characteristic of the sample:

• Age: not reported for ITT sample (among completers, mean age was 32.6 years, SD 7.1, range 23 to 45)
• Percentage of agoraphobic patients: 21.05%
• Percentage of patients on drug therapy: not reported for ITT sample (72% among completers)
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 38) were randomly assigned to either:

1) Applied relaxation (classified as PT, n = 19)

• Therapy format: individual
• Duration of each session: 55 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

2) Cognitive therapy (classified as CBT, n = 19)

• Therapy format: individual
• Duration of each session: 55 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

Outcomes

Time points for assessment: baseline, post-treatment, 1 year follow-up.

Measures: Anxiety Disorders Interview Schedule-Revised (ADIS-R), Hamilton Anxiety Scale (HAM-A),
Hamilton Depression Scale (HAM-D), panic diary, Panic Attack Scale (PAS), Beck Anxiety Inventory (BAI),
State-Trait Anxiety Inventory (STAI), Self-Rating of Anxiety Scale (SAS), Beck Depression Inventory (BDI),
Body Sensations Questionnaire (BSQ), Agoraphobic Cognitions Questionnaire (ACQ), Bodily Sensations
Interpretations Questionnaire

The following outcomes were used for quantitative analyses:

ST-Remission: high end-state functioning* at post-treatment

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Body Sensations Questionnaire (BSQ)

LT-Remission/Response: high end-state functioning* at 1 year follow-up

Notes

Risk of bias

Bias

* "High end-state functioning (HEF) was defined as being panic-free and having an independent assessor
rating of severity of the panic disorder of ≤2 (i.e. 'slight') on the (ADIS-R)0-8 scale."

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information reported

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ost 1995  (Continued)

Allocation concealment
(selection bias)

Unclear risk

No information reported

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Unclear risk

"High end-state functioning (HEF) was defined as being panic-free and having an
independent assessor rating of severity of the panic disorder of ≤2 (i.e. 'slight')
on the (ADIS-R)0-8 scale." It is unclear whether the assessor was blind to treat-
ment allocation.

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

2 patients, both in the AR group, dropped out at an early stage of treatment
due to scheduling difficulties. All 36 patients that completed the study were
followed up 1 year later. The proportion of missing outcomes compared with
the observed event risk is not enough to have a clinically relevant impact on
the intervention effect estimate.

Incomplete outcome data
(attrition bias) 
Long-term

Low risk

(see above)

Selective reporting (re-
porting bias)

High risk

Study protocol unavailable. Agoraphobic Cognitions Questionnaire (ACQ) re-
sults are not reported, although this should be an administered scale accord-
ing to the methods section.

Researcher allegiance

High risk

Ost LG is involved in conceptualisation of Applied Relaxation (see Ost 1987)

Therapist allegiance

Unclear risk

No information reported

Treatment fidelity

Unclear risk

No information reported

Ost 2004 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age between 18 and 60 years, primary DSM-IV diagnosis of panic disorder with ago-
raphobia, severity of at least 4 on the ADIS-IV 0 to 8 scale, minimum of 1 year duration of the phobia. If
on psychotropic medication: have been on a constant dose for at least 4 months and accept to keep the
dosage constant throughout therapy.

Exclusion criteria: primary major depression (i.e. onset before the PDA), current alcohol or substance
abuse, psychotic or organic symptoms, ongoing psychotherapy

Characteristic of the sample:

• Age: mean 36.1 years (SD 10.3, range 18 to 58)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 52%
• Percentage of patients with major depression: 12.3%

Interventions

Participants (n = 73) were randomly assigned to either:

1) Exposure in vivo (classified as BT, n = 25; after re-randomisation of WL n = 35)

• Therapy format: individual
• Duration of each session: 67.5 minutes
• Mean number of sessions: 14 (12 to 16)
• Duration of intervention: 14 (12 to 16) weeks

2) Cognitive behaviour therapy (classified as CBT, n = 26; after re-randomisation of WL n = 36)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ost 2004  (Continued)

Cochrane Database of Systematic Reviews

• Therapy format: individual
• Duration of each session: 67.5 minutes
• Mean number of sessions: 14 (12 to 16)
• Duration of intervention: 14 (12 to 16) weeks

3) Wait list (classified as WL, n = 22)

• Mean number of sessions: 0
• Duration of intervention: 16

Outcomes

Time points for assessment: baseline, post-treatment, 1 year follow-up.

Measures: Anxiety Disorders Interview Schedule-IV (ADIS-IV), Hamilton Anxiety Scale (HAM-A), Hamil-
ton Depression Scale (HAM-D), Agoraphobia Scale, Mobility Inventory (MI), Fear Questionnaire (FQ),
Panic Attack Scale (PAS), Anxiety Sensitivity Index (ASI), Body Sensations Questionnaire (BSQ), Ago-
raphobic Cognitions Questionnaire (ACQ), Beck Anxiety Inventory (BAI), State-Trait Anxiety Inventory
(STAI), Beck Depression Inventory (BDI), Quality of Life Inventory panic diary, behavioural approach
tests

The following outcomes were used for quantitative analyses:

ST-Remission: no longer meet DSM-IV criteria for PDA at post-treatment (original sample)

ST- Response: not measured (imputed from the continuous scale for the original sample)

ST-Dropouts: non-completers (original sample)

Continuous scale: Anxiety Sensitivity Index (ASI) measured on the original sample (SDs are not report-
ed but could be borrowed from other studies using ASI)

LT-Remission/Response: no longer meet DSM-IV criteria for PDA at 1 year follow-up (original + re-ran-
domised sample)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Unclear risk

"An independent research assistant not involved with the treatment performed
all the diagnostic interviews and ratings." It is unclear whether the assessor
was blind to treatment allocation.

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

"Seven patients dropped out of treatment before completion; 3 (13%) in the E-
group, 2 (8%) in the CBT-group, and 2 (9%) in the WLC-group, a non-significant
difference." Missing outcome data balanced in numbers across intervention
groups. The proportion of missing outcomes compared with the observed
event risk is not enough to have a clinically relevant impact on the interven-
tion effect estimate.

Incomplete outcome data
(attrition bias) 
Long-term

High risk

"After the post-assessment of the waiting list two patients dropped out and the
remaining were randomized to the two treatment conditions with 10 in each.
When the former WLC-patients were treated 3 of the 10 randomized to the E-
group, but none in the CBT-group, dropped out." Reason for missing outcome

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ost 2004  (Continued)

Cochrane Database of Systematic Reviews

data likely to be related to true outcome, with imbalance in numbers for miss-
ing data across intervention groups.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"The therapy sessions were audiotaped and upon completion, three sessions
were randomly selected for every patient, one from each third of the therapy, for
analysis. Three licensed psychotherapists with long experience of CBT and blind
to the allocation of the patients listened to the tapes and classified the sessions
as either an exposure or a CBT-session. They also rated the competency of the
therapists using a modified version of the Cognitive therapy scale (Young & Beck,
1980), consisting of nine specific items and a general item (rated on a 0–6 scale).
Which treatment the patient was receiving was correctly identified in 96.7% of
the sessions rated by the experts, indicating a satisfying degree of treatment in-
tegrity."

Petterson 1996 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: DSM-III-R diagnosis of panic disorder

Exclusion criteria: none

Characteristic of the sample:

• Age: range 20 to 63 years
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 27*) were randomly assigned to either:

1) Cognitive behaviour treatment (classified as CBT, n = 14?)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 6
• Duration of intervention: 6 weeks

2) No treatment (classified as NT, n = 13?)

• Mean number of sessions: 0
• Duration of intervention: 6 weeks

Outcomes

Time points for assessment: baseline, post-treatment

Measures: Anxiety Sensitivity Index (ASI), State-Trait Anxiety Inventory (STAI), Panic Attack Record,
physiologic measures (blood pressure, pulse rate, finger temperature)

The following outcomes were used for quantitative analyses:

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Petterson 1996  (Continued)

Cochrane Database of Systematic Reviews

ST-Remission: not measured (not imputed because number of randomised patients is unclear)

ST- Response: not measured (not imputed because number of randomised patients is unclear)

ST-Dropouts: unclear

Continuous scale: Anxiety Sensitivity Index (ASI). SDs are not reported but could be borrowed from
other studies using ASI

LT-Remission/Response: not measured

*It is unclear whether the reported number participants (n = 27) refers to the ITT sample or to treat-
ment completers ("Twenty-seven adults completed the study. [...] The subjects were randomly assigned
to either the Treatment (n = 14) or Control (n = 13) conditions").

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Unclear risk

No information provided

Unclear risk

Study protocol unavailable

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Incomplete outcome data
(attrition bias) 
Short-term

Selective reporting (re-
porting bias)

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Rees 1999 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: DSM-III diagnosis of panic disorder with little or no agoraphobic avoidance

Exclusion criteria: secondary diagnosis with an overall severity rating less than 2 points away from the
panic disorder severity rating on the clinician's 9-point rating scale in ADIS; any medical condition such
as asthma, angina, emphysema that might have complicated the panic disorder

Characteristic of the sample:

• Age: not specified
• Percentage of agoraphobic patients: 82.5%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: 11.1%

Interventions

Participants (n = 40) were randomly assigned to either:

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

165

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rees 1999  (Continued)

1) Information giving + self monitoring (classified as PE, n = 20)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 2
• Duration of intervention: 2 weeks

2) Self monitoring alone (classified as APP, n = 20)

• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 2
• Duration of intervention: 2 weeks

Outcomes

Time points for assessment: baseline, post-treatment.

Measures: daily records of panic, anxiety, depression and anticipatory fear of panic

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (not imputed because of skewed distribution of available continuous
scale)

ST- Response: not measured (not imputed because of skewed distribution of available continuous
scale)

ST-Dropouts: non-completers

Continuous scale: panic frequency

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Low risk

No dropouts

Unclear risk

Study protocol unavailable

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Incomplete outcome data
(attrition bias) 
Short-term

Selective reporting (re-
porting bias)

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Reinecke 2013 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: DSM-IV diagnosis of panic disorder with or without agoraphobia, naive to expo-
sure-based CBT; at least moderate agoraphobic avoidance, panic-related safety behaviours (e.g. med-
ication, or standing close to an escape exit to prevent panic attacks) and catastrophic panic cognitions
(e.g. "If I stay here my heart will beat even faster, and I will suffer a heart attack"), assessed with a struc-
tured panic assessment interview. Occasional medication with benzodiazepines
or β-blockers as needed was not an exclusion criterion; however, patients were required to be medica-
tion-free 48 hours before the test sessions to avoid any interference with experimental testing and CBT.

Exclusion criteria: lifetime history of epilepsy, psychotic disorders, bipolar disorder or substance
abuse, primary depressive disorder, insufficient English skills, psychopharmacological or psychothera-
peutic treatment during the last 6 months

Characteristic of the sample:

• Age by group: treatment group mean age 36 (SD 14.7); wait list group mean age 35.1 (SD 14.1)
• Percentage of agoraphobic patients: treatment group 100%; wait list group 85.7%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: 7.14%

Interventions

Participants (n = 28) were randomly assigned to either:

1) Single session exposure-based CBT (classified as CBT, n = 14)

• Therapy format: not specified
• Duration of each session: 30 minutes
• Mean number of sessions: 1
• Duration of intervention: not applicable (single session)

2) Wait list (classified as WL, n = 14)

• Mean number of sessions: 0
• Duration of intervention: 4 weeks

Outcomes

Time points for assessment: baseline (day 1), post-treatment (day 2), follow-up (4 weeks)

Measures: Hospital Anxiety and Depression Scale, Body Sensations Questionnaire (BSQ), Agoraphobic
Cognitions Questionnaire (ACQ), Mobility Inventory (MI), Faces Dot Probe Task, Stress Test

The following outcomes were used for quantitative analyses:

ST-Remission: MI-Ag score falling within the range reported for healthy control subjects

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

167

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Reinecke 2013  (Continued)

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Incomplete outcome data
(attrition bias) 
Short-term

Selective reporting (re-
porting bias)

Unclear risk

No information provided

Unclear risk

No information provided

High risk

Mobility Inventory (used to determine ST-Remission) is a self rated measure.

Low risk

All patients were assessed at 4 weeks follow-up.

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"Our single-session treatment was a very condensed version of psychological in-
tervention recommended for delivery in routine clinical care"

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Salkovskis 1999 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: DSM-III-R diagnosis of panic disorder with moderate or severe avoidance, at least 2
panic attacks occurring in the 4 weeks prior to assessment, a score of 9 or more on the modified Fear
Questionnaire, agoraphobic avoidance sub-scale (FQ-Ag), being unable to complete the penultimate
step of a pre-determined standardised behavioural avoidance test course conducted prior to the exper-
imental procedure, it was possible to identify both catastrophic thoughts which occurred during pan-
ic attacks, and safety-seeking behaviours which the patients said they carried out during the attacks to
prevent the feared catastrophes. In addition, it was required that the patient rated an increase of anxi-
ety from baseline of at least 20 points on a 100 point visual analogue scale when entering the 5-minute
individualised behaviour test.

Exclusion criteria: none

Characteristic of the sample:

• Age by group: decreased safety behaviours group mean age 42.11 (SD 13.5); exposure only group

mean age 33.6 (SD 11.7)

• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified (44% according to imputation from

BDI)

Interventions

Participants (n = 18) were randomly assigned to either:

1) Cognitive behaviour therapy (classified as CBT, n = 9)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 4

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

168

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Salkovskis 1999  (Continued)

• Duration of intervention: 8 days

2) Habituation-based exposure therapy (classified as BT, n = 9)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 4
• Duration of intervention: 8 days

Outcomes

Time points for assessment: baseline, post-treatment.

Measures: Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), panic frequency, Fear Ques-
tionnaire (FQ), Agoraphobic Cognitions Questionnaire (ACQ), standardised behavioural walk (BW), indi-
vidualised behavioural test (BT).

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (imputed from continuous scale)

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

"Randomisation was on the basis of sampling without replacement, using
sealed envelopes opened on completion of the initial assessments"

Allocation concealment
(selection bias)

Unclear risk

It is unclear whether envelopes were opaque and sequentially numbered.

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

Incomplete outcome data
(attrition bias) 
Short-term

Unclear risk

Agoraphobic Cognitions Questionnaire (ACQ), used to impute ST-remission, is
a self rated measure.

Missing outcome data balanced in numbers across intervention groups (1
dropout from each arm), it is unclear whether the proportion of missing out-
comes compared with the observed event risk is enough to have a clinically
relevant impact on the intervention effect estimate.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

Both Salkovskis PM and Clark DM are authors of a manual for CBT in panic dis-
order (see Clark 1986b)

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Schmidt 1997a 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: principal DSM-IV diagnosis of panic disorder

Exclusion criteria: change in medication type or dose during the 8 weeks preceding entry, evidence of
serious suicide intent, current substance abuse, current or past schizophrenia, bipolar disorder, organ-
ic mental disorder

Characteristic of the sample:

• Age: not specified
• Percentage of agoraphobic patients: 58%
• Percentage of patients on drug therapy: 59%
• Percentage of patients with major depression: not specified (16.6% according to imputation from

BDI)

Interventions

Participants (n = 54) were randomly assigned to either:

1) Cognitive behaviour therapy + respiratory training (classified as CBT, n = 18)

• Therapy format: group
• Duration of each session: not specified
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

2) Cognitive behaviour therapy (classified as CBT, n = 20)

• Therapy format: group
• Duration of each session: not specified
• Mean number of sessions: 12
• Duration of intervention: 12 weeks

3) Wait list (classified as WL, n = 16)

• Mean number of sessions: 0
• Duration of intervention: 12 weeks

Outcomes

Time points for assessment: baseline, post-treatment (12 weeks)

Measures: Clinical Global Impression - Severity (CGI-S), panic diary, Shehan Patient-Rated Scale
(SPRAS), Fear Questionnaire (FQ), Anxiety Sensitivity Inde (ASI), Panic Appraisal Inventory (PAI), Beck
Depression Inventory (BDI), Shehan Disability Scale (SDS), Acute Panic Inventory (API), physiological
measures (vital capacity, CO2 intake volume), psychophysiological measures (heart rate, systolic blood
pressure, diastolic blood pressure)

The following outcomes were used for quantitative analyses:

ST-Remission: high end-state functioning* at post-treatment

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Anxiety Sensitivity Inde (ASI)

LT-Remission/Response: not measured

Notes

* High end-state functioning: "A patient was classified as recovered when scores on each of three clinical
dimensions (i.e. panic frequency, anxiety and phobic avoidance) fell within the normal range. Recovery
criteria for the SPRAS and FQ are based on established cutoff scores reported in the literature. The recov-
ery criterion for panic attacks was zero."

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Schmidt 1997a  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

Incomplete outcome data
(attrition bias) 
Short-term

High risk

The 3 measures used to assess the high end-state functioning status (panic fre-
quency, SPRAS score, FQ score) are all self reported.

"Of those patients assigned to the treatment conditions (n=54), 34 were assessed
at post-treatment."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"Treatment integrity was maintained by using a structured and manualized
treatment protocol ( Schmidt 1994 ) that described specific goals and strategies
for each session." Schmidt NB is among the study authors.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

High risk

"Treatment integrity was maintained by using a structured and manualized
treatment protocol that described specific goals and strategies for each ses-
sion."

Schmidt 1997b 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: principal DSM-IV diagnosis of panic disorder with or without agoraphobia (active
duty military sample)

Exclusion criteria: change in medication type or dose during the 8 weeks preceding entry, evidence of
serious suicide intent, current substance abuse, current or past schizophrenia, bipolar disorder, organ-
ic mental disorder

Characteristic of the sample:

• Age: mean 31.8 years (SD 9.7)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified (20% according to imputation based

on BDI)

Interventions

Participants (n = 37) were randomly assigned to either:

1) Cognitive behaviour treatment (classified as CBT, n = 25)

• Therapy format: group
• Duration of each session: not specified

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schmidt 1997b  (Continued)

• Mean number of sessions: 12
• Duration of intervention: 12 weeks

2) Wait list (classified as WL, n = 12)

• Mean number of sessions: 0
• Duration of intervention: 12 weeks

Cochrane Database of Systematic Reviews

Outcomes

Time points for assessment: baseline (week 0), post-treatment (week 9), 3 months follow-up (week
21)

Measures: Texas Panic Attack Record Form, Shehan Patient-Rated Scale (SPRAS), Fear Questionnaire
(FQ), Shehan Disability Scale (SDS), Beck Depression Inventory (BDI)

The following outcomes were used for quantitative analyses:

ST-Remission: high end-state functioning* at post-treatment

ST- Response: not measured

ST-Dropouts: non-completers

Continuous scale: not measured

LT-Remission/Response: not measured

* High end-state functioning: "A patient was classified as recovered when scores on each of three clinical
dimensions (i.e. panic frequency, anxiety and phobic avoidance) fell within the normal range. Recovery
criteria for the SPRAS and FQ are based on established cutoff scores reported in the literature. The recov-
ery criterion for panic attacks was set at zero."

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

Incomplete outcome data
(attrition bias) 
Short-term

High risk

The 3 measures used to assess the high end-state functioning status (panic fre-
quency, SPRAS score, FQ score) are all self reported.

"Of those patients assigned to a treatment condition (n=37), 29 were assessed at
post-treatment. Dropouts were similar across conditions, with 20% of patients
in the immediate treatment condition (n=5) and 25% of patients in the delayed
treatment condition (n=3) discontinuing their participation."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"Treatment integrity was maintained by utilizing a structured and manualized
treatment protocol ( Schmidt 1994 ) that described specific goals and strategies
for each session." Schmidt NB is among the study authors.

Therapist allegiance

Unclear risk

No information provided

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

172

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schmidt 1997b  (Continued)

Treatment fidelity

High risk

Cochrane Database of Systematic Reviews

"Treatment integrity was maintained by utilizing a structured and manualized
treatment protocol that described specific goals and strategies for each ses-
sion."

Scott 1995 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM-III-R diagnosis of generalised anxiety disorder, panic disorder with or without
agoraphobia and major depression

Exclusion criteria: none

Characteristic of the sample (panic disorder sub-sample):

• Age: not specified
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified

Interventions

Participants (panic disorder sub-sample, n = 21) were randomly assigned to either:

1) Cognitive behaviour therapy (classified as CBT, n = 15)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 7
• Duration of intervention: 7 weeks

2) Wait list (classified as WL, n = 6)

• Mean number of sessions: 0
• Duration of intervention: 7 weeks

Outcomes

Time points for assessment: baseline, start of treatment, termination, 6 weeks follow-up, 3 months
follow-up, 6 months follow-up, 12 months follow-up

Measures: Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured

ST- Response: not measured

ST-Dropouts: non-completers

Continuous scale: not measured

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Scott 1995  (Continued)

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Incomplete outcome data
(attrition bias) 
Short-term

Selective reporting (re-
porting bias)

Unclear risk

No information provided

Unclear risk

No information provided

Low risk

No dropouts

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Sharp 2004 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age between 18 and 70 years, DSM-IV diagnosis of panic disorder with or without
agoraphobia, score a minimum of 15 on the Hamilton Anxiety Scale, score a maximum of 20 on the
Montgomery Asberg Depression Rating Scale, symptoms lasting at least 3 months. Patients taking con-
current psychotropic medications were not excluded from the study, but were required to continue
taking these medications as prescribed throughout the study period.

Exclusion criteria: having received a psychological treatment for panic disorder and agoraphobia in
the past 6 months

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age ranged from 34.6 to 41.7 depending

on group)

• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified for ITT sample (50% among completers)
• Percentage of patients with major depression: not specified

Interventions

Participants (n = 97) were randomly assigned to either:

1) Group CBT (classified as CBT, n = 38)

• Therapy format: group
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 12 weeks

2) Individual CBT (classified as CBT, n = 37)

• Therapy format: group
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 12 weeks

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Sharp 2004  (Continued)

3) Wait list (classified as WL, n = 22)

• Mean number of sessions: 0
• Duration of intervention: 12 weeks

Cochrane Database of Systematic Reviews

Outcomes

Time points for assessment: baseline, post-treatment, 3 months follow-up

Measures: Hamilton Anxiety Scale (HAM-A), Symptom Rating Test (SRT), Montgomery Asberg Depres-
sion Rating Scale (MADRS), Fear Questionnaire - agoraphobia sub-scale (FQ-Ag), panic diary

The following outcomes were used for quantitative analyses:

ST-Remission: FQ-Ag below 10 at post-treatment

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Fear Questionnaire - agoraphobia sub-scale (FQ-Ag)

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

Incomplete outcome data
(attrition bias) 
Short-term

High risk

Although assessor was blind to treatment allocation, FQ (used to extract ST-
Remission), is a self rated measure

"A total of n = 27 patients dropped out of treatment early failing to complete five
sessions of study treatment. Group treatment had a significantly higher drop-out
rate (n=18, 47%), than either individual treatment (n=6, 16%), or waiting list (n=3,
14%)."

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Unclear risk

"For the two treatment groups all patients received the same CBT and all re-
ceived identical treatment instructions with the same written treatment manu-
al being supplied to all patients." It is unclear whether authors were involved in
writing the administered manual.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Shear 1994 

Methods

Study design: randomised controlled trial

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Shear 1994  (Continued)

Participants

Inclusion criteria: DSM-III-R diagnosis of panic disorder with or without agoraphobia. All subjects were
required to discontinue psychotropic medication for at least 2 weeks before study entry and to refrain
from using medication or any other psychotherapeutic treatment during the study.

Exclusion criteria: none

Characteristic of the sample:

• Age: not specified for ITT sample (among completers, mean age was 34.7 years, SD 9.7)
• Percentage of agoraphobic patients: 92%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified (18.2% according to imputation from

BDI)

Interventions

Participants (n = 66) were randomly assigned to either:

1) Cognitive behaviour treatment (classified as CBT, n = 37)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks

2) Non-prescriptive treatment (classified as SP, n = 29)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks

Outcomes

Time points for assessment: baseline, post-treatment, 6 months follow-up

Measures: Anxiety Disorders Interview Schedule–R (ADIS-R), panic diary, Brief Fear Questionnaire, Mo-
bility Inventory (MI), Beck Depression Inventory (BDI), Hopkin's Symptom Checklist (SCL-90), Sheehan
Disability Scale (SDS), Hamilton Rating Scale for Anxiety (HAM-A), Hamilton Rating Scale for Depression
(HAM-D), State-Trait Anxiety Inventory (STAI), Anxiety Sensitivity Index (ASI), Body Sensations Question-
naire (BSQ), Agoraphobic Cognitions Questionnaire (ACQ)

The following outcomes were used for quantitative analyses:

ST-Remission: panic-free at post-treatment

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Anxiety Sensitivity Index (ASI)

LT-Remission/Response: although measured (panic-free at 6 months follow-up) data were not entered
in the analyses because dropouts exceeded 30% of the originally randomised sample (see Secondary
outcomes).

Notes

Risk of bias

Bias

None

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

No information provided

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Shear 1994  (Continued)

Allocation concealment
(selection bias)

Unclear risk

No information provided

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

Incomplete outcome data
(attrition bias) 
Short-term

High risk

"Most pretreatment and all posttreatment and follow-up interviews were con-
ducted by an independent evaluator who was "blind" to the treatment condi-
tion, study aims, and methods." However, ST-remission is defined as being pan-
ic-free, a self rated measure.

"Pretreatment data were obtained on 45 subjects (CBT=24, NPT=21). Forty-one
subjects completed posttreatment assessments (CBT=20, NPT=21)."

Incomplete outcome data
(attrition bias) 
Long-term

High risk

"43 subjects completed the follow-up assessments (CBT=23, NPT=20)."

Selective reporting (re-
porting bias)

High risk

Study protocol unavailable. The results of some measures planned in the
methods section are not reported (e.g. ACQ, BSQ).

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"All treatments were supervised by one of us (MKS) in weekly meetings. The CBT
sessions were rated for treatment adherence by Michelle Craske, PhD, and Kar-
la Moras, PhD, from the Albany Stress and Anxiety Clinic. The NPT sessions were
rated for absence of CBT material. The CBT intervention was rated separately for
protocol adherence, general skill, and specific skill on a scale of 0 through 8. The
NPT intervention was screened for absence of CBT. Thirty audiotapes were ran-
domly selected from each condition. The mean adherence ratings for CBT ses-
sions was 4.5 on a scale of 0 through 8. [...] There was no indication that NPT ses-
sions 3 through 16 included CBT techniques. The NPT intervention was not rated
for adherence or skill in this study."

Taylor 1982 

Methods

Participants

Study design: randomised controlled trial, cross-over design

Inclusion criteria: DSM-III diagnosis of panic disorder, at least 1 panic attack in the last 3 weeks, agree-
ment to discontinue all psychotropic medications except as prescribed in the study

Exclusion criteria: none

Characteristic of the sample:

• Age: mean 34.9 years (range 18 to 25)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified

Interventions

In the first phase of the treatment (before cross-over), participants (n = unclear) were randomly as-
signed to either:

1) Relaxation (classified as, n = unclear)

• Therapy format: not specified

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Taylor 1982  (Continued)

Cochrane Database of Systematic Reviews

• Duration of each session: 30 minutes
• Mean number of sessions: up to 5
• Duration of intervention: not specified

2) Diazepam (not included, n = unclear)

• Therapy format: not specified
• Duration of each session: 30 minutes
• Mean number of sessions: 4 to 5
• Duration of intervention: not specified

3) Placebo (not included, n = unclear)

• Therapy format: not specified
• Duration of each session: 30 minutes
• Mean number of sessions: 4 to 5
• Duration of intervention: not specified

4) No treatment (classified as WL, n = unclear)

• Mean number of sessions: 0
• Duration of intervention: not specified

Outcomes

Time points for assessment: baseline, post-treatment

Measures: self report diary (anxiety, mood), State-Trait Anxiety Inventory (STAI), Profile of Mood States,
physiological measures (heart rate, skin conductance)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured

ST- Response: not measured

ST-Dropouts: detailed data are not reported

Continuous scale: the only available measure (STAI) is not considered among the outcomes of interest
for this review (see Secondary outcomes). Furthermore, detailed data are not reported.

LT-Remission/Response: not measured

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Selective reporting (re-
porting bias)

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

Unclear risk

Study protocol unavailable

Researcher allegiance

Unclear risk

It is unclear whether the researchers involved have a vested interest for or
against the psychological therapy under study (ref. 1 of study report).

Therapist allegiance

Unclear risk

No information provided

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Taylor 1982  (Continued)

Treatment fidelity

Unclear risk

No information provided

Telch 1993 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: age between 18 and 65 years, principal DSM-III-R diagnosis of panic disorder with or
without agoraphobia, at least 1 panic attack during the past 30 days

Exclusion criteria: recent change in psychotropic medications; current psychosis, bipolar disorder or
substance abuse disorder

Characteristic of the sample:

• Age: mean 34.6 years (SD 10.3)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 61.2%
• Percentage of patients with major depression: not specified (34.3% according to imputation from

BDI)

Interventions

Participants (n = 67) were randomly assigned to either:

1) Panic inoculation training (classified as CBT, n = 34)

• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 12
• Duration of intervention: 8 weeks

2) Wait list (classified as WL, n = 33)

• Mean number of sessions: 0
• Duration of intervention: 8 weeks

Outcomes

Time points for assessment: baseline, post-treatment (week 9), 6 months follow-up

Measures: Sheehan Patient-Rated Anxiety Scale (SPRAS), Agoraphobia scale of the Fear Questionnaire
(FQ-Ag), Beck Depression Inventory (BDI), Anxiety Sensitivity Index (ASI), panic diary

The following outcomes were used for quantitative analyses:

ST-Remission: recovery* at post-treatment

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Anxiety Sensitivity Index (ASI)

LT-Remission/Response: not measured

Notes

Risk of bias

* "The two groups were compared on a composite index of recovery defined as the proportion of patients
attaining normal levels of functioning on all three major facets of the disorder (i.e. panic attacks, anxiety
and panic-related avoidance)." Recovery criterion for panic attack was set at 0, for anxiety it was SPRAS
score < 30, for avoidance it was FQ-Ag < 12.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Telch 1993  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Unclear risk

No information provided

Unclear risk

No information provided

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

High risk

The 3 measures used to assess the high end-state functioning status (panic fre-
quency, SPRAS score, FQ score) are all self reported

Incomplete outcome data
(attrition bias) 
Short-term

Selective reporting (re-
porting bias)

Low risk

No dropout in either group

Unclear risk

Study protocol unavailable

Researcher allegiance

High risk

"A 65-page treatment manual ( Telch 1990 ) describes the specific goals and
strategies for each session."

Therapist allegiance

High risk

Treatment fidelity

Low risk

"All sessions were conducted by one primary therapist (MJT, JL or NBS) and a
graduate student assistant." As noted above, MJ Telch and NB Schmidt may
have a vested interested in the success of their active treatment.

"To help protect the integrity of the treatment, therapists and their assistants fol-
lowed a procedural outline for each therapy session. In addition, all treatment
sessions were videotaped and randomly selected segments were rated for con-
sistency with the written treatment protocol."

Tyrer 1988 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM-III diagnosis of generalised anxiety disorder, panic disorder or dysthymic dis-
order; currently receiving no psychotropic drugs (and had not been taking benzodiazepines, neurolep-
tic drugs or antidepressants in regular dosage for at least 4 weeks before entry to the study); willing to
enter the study, in which they understood that they would receive either drug or psychological treat-
ments for up to 10 weeks

Exclusion criteria: major depressive episode or other psychiatric disorders that take diagnostic prece-
dence over the 3 diagnoses above in the DSM-III classification

Characteristic of the panic disorder sub-sample:

• Age: not specified (in the full sample median age was 35 years, range 17 to 76)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: 0%

Interventions

Participants (panic disorder sub-sample, n = 74) were randomly assigned to either:

1) Cognitive and behaviour therapy (classified as CT, n = 33)

• Therapy format: not specified
• Duration of each session: 60 minutes

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

180

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tyrer 1988  (Continued)

• Mean number of sessions: 5
• Duration of intervention: 6 weeks

2) Self help treatment package (classified as APP, n = 17)

Cochrane Database of Systematic Reviews

• Therapy format: not specified
• Duration of each session: 15 minutes
• Mean number of sessions: 5
• Duration of intervention: 6 weeks

3) Diazepam (not included, n = 7)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: not specified
• Duration of intervention: 6 weeks

4) Dothiepin (not included, n = 7)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: not specified
• Duration of intervention: 6 weeks

5) Placebo (not included, n = 10)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: not specified
• Duration of intervention: 6 weeks

Outcomes

Time points for assessment: baseline, mid-treatment (2, 4, 6 weeks), post-treatment (10 weeks), 16
weeks follow-up, 32 weeks follow-up, 1 year follow-up, 2 years follow-up, 5 years follow-up, 12 years
follow-up

Measures: Comprehensive Psychopathological Rating Scale (CPRS), Montgomery & Asberg Depression
Rating Scale (MADRS), Brief Anxiety Scale (BAS), Hospital Anxiety and Depression Scale (HADS), General
Neurotic Syndrome Scale (GNSS), Life Events Schedule, Personality Assessment Schedule (PAS)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured

ST- Response: not measured

ST-Dropouts: non-completers

Continuous scale: although measured, none of the available scales is considered for this review (see
Secondary outcomes)

Notes

Risk of bias

Bias

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

"The randomised treatments were indicated by opening a sealed envelope once
patients satisfied the inclusion criteria for the study."

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tyrer 1988  (Continued)

Allocation concealment
(selection bias)

Unclear risk

It is unclear whether envelopes were opaque and sequentially numbered

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

Considering only panic disorder patients allocated to either CBT (n = 33) or self
help treatment package (n = 17), 3 patients were lost at post-treatment assess-
ment (personal communication: 2 patients in the CBT arm, 1 patient in the self
help arm). Therefore, missing outcome data are low in number and balanced
across intervention groups.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Unclear risk

No information provided

Williams 1996 

Methods

Participants

Study design: randomised controlled trial

Inclusion criteria: DSM-III-R diagnosis of panic disorder with or without agoraphobia, at least 2 DSM-
III-R-defined panic attacks per week over a 2-week baseline period. Subjects were asked to refrain from
receiving any other psychological treatment for panic, phobia or depression during the study until af-
ter the 6-week follow-up. Subjects taking regularly prescribed medications were asked not to alter their
medication regimen during the programme, and all subjects were asked to refrain from taking discre-
tionary medication.

Exclusion criteria: none

Characteristic of the sample:

• Age: mean 38 years (range 17 to 76)
• Percentage of agoraphobic patients: 91.67%
• Percentage of patients on drug therapy: 62.5%
• Percentage of patients with major depression: 52.08%

Interventions

Participants (n = 48) were randomly assigned to either:

1) Cognitive treatment (classified as CT, n = 14)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks

2) Performance treatment (classified as BT, n = 12)

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks

3) Combined treatment (classified as CBT, n = 13)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Williams 1996  (Continued)

Cochrane Database of Systematic Reviews

• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks

4) Delayed treatment (classified as WL, n = 9)

• Mean number of sessions: 0
• Duration of intervention: 8 weeks

Outcomes

Time points for assessment: baseline, post-treatment, 6 weeks follow-up, 1 to 2 years follow-up

Measures: panic diary, Self-Efficacy Scales for Agoraphobia (SESA), Fear Questionnaire (FQ), panic cop-
ing self efficacy, Agoraphobic Cognitions Questionnaire (ACQ), Body Sensations Questionnaire (BSQ),
Beck Depression Inventory (BDI)

The following outcomes were used for quantitative analyses:

ST-Remission: panic-free at post-treatment

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)

LT-Remission/Response: panic-free at 1 to 2 years follow-up

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

High risk

Panic frequency is a self rated measure

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Incomplete outcome data
(attrition bias) 
Short-term

Low risk

Incomplete outcome data
(attrition bias) 
Long-term

Unclear risk

"All Ss completed the treatment program; there were no dropouts in any treat-
ment condition."

Among the 39 subjects allocated to the 3 active intervention arm, 34 were as-
sessed at 1 to 2-year follow-up. Dropouts (n = 5) were 2/14 in cognitive treat-
ment group, 2/12 in the performance treatment group and 1/13 in the com-
bined treatment group. Missing outcome data are balanced across interven-
tion groups. It is unclear whether the proportion of missing outcomes com-
pared with the observed event risk is enough to have a clinically relevant im-
pact on the intervention effect estimate.

Selective reporting (re-
porting bias)

Unclear risk

Study protocol unavailable

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Williams 1996  (Continued)

Researcher allegiance

High risk

Cochrane Database of Systematic Reviews

"The performance-based treatment was an office-based adaptation of guid-
ed mastery treatment ( Williams 1990 ; Williams, Dooseman & Kleifield 1984;
Williams & Zane 1989; Zane & Williams 1993), which emphasizes the importance
of performance successes in helping people gain a sense of mastery and self-effi-
cacy." Williams SL is among the study authors.

Therapist allegiance

Unclear risk

Insufficient information provided

Treatment fidelity

Low risk

"All treatment sessions were audiotaped, and for each treatment condition, one
tape from each therapist was chosen randomly, and all therapist statements on
it were transcribed and assembled into sets containing five consecutive state-
ments. Two assistants trained in the coding manual independently, coded the
sets of statements, while remaining unaware of Ss' assigned treatment condi-
tion and of the hypotheses under investigation. Based on the codes of one ran-
domly chosen coder, in the performance treatment sessions, 72% of the sets of
therapist statements contained performance interventions and 0% cognitive
interventions. Sets of therapist statements in the cognitive treatment sessions
contained 58% cognitive interventions and 0% performance interventions. Com-
bined treatment sessions contained 54% performance interventions and 29%
cognitive interventions."

Wollburg 2011 

Methods

Study design: randomised controlled trial

Participants

Inclusion criteria: DSM-IV diagnosis of panic disorder with or without agoraphobia, willing to accept
an 8-week treatment delay if assigned to the wait list

Exclusion criteria: history of schizophrenia, bipolar disorder, dementia, alcohol or drug abuse, cur-
rent use of medications with pronounced sympathetic, parasympathetic or respiratory effects, current
score on the BDI exceeding 30, current suicidality

Characteristic of the sample:

• Age (by group): mean 43.8 years (SD10.7); mean 43.7 years (SD 14.5); mean 38.3 years (SD 14.4)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified (8.1% imputed from BDI)

Interventions

Participants (n = 74) were randomly assigned to either:

1) Lower-CO2 breathing retraining (classified as PT, n = 19)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 5
• Duration of intervention: 5 weeks

2) Raise-CO2 breathing retraining (classified as PT, n = 28)

• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 5
• Duration of intervention: 5 weeks

3) Wait list (classified as WL, n = 27)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wollburg 2011  (Continued)

• Mean number of sessions: 0
• Duration of intervention: 8 weeks

Outcomes

Time points for assessment: baseline, 1-month follow-up (coincides with end of wait list), 6-month
follow-up

Measures: Panic Disorder Severity Scale (PDSS), Anxiety Sensitivity Index (ASI), Beck Depression Inven-
tory (BDI), Mobility Inventory for Agoraphobia (MI), Agoraphobic Cognitions Questionnaire (ACQ), Anxi-
ety Control Questionnaire, Beck Anxiety Inventory (BAI), Body Sensations Questionnaire (BSQ)

The following outcomes were used for quantitative analyses:

ST-Remission: not measured (imputed from continuous scale)

ST- Response: not measured (imputed from continuous scale)

ST-Dropouts: non-completers

Continuous scale: Anxiety Sensitivity Index (ASI). Note that reported SDs are uncommonly low, so we
considered them as being SEs.

LT-Remission/Response: not measured

None

Authors' judgement

Support for judgement

Unclear risk

No information provided

Unclear risk

No information provided

High risk

ASI is a self rated measure

Low risk

No dropouts at 1-month follow-up (see study flow chart)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of outcome as-
sessment (detection bias) 
ST-Remission

Incomplete outcome data
(attrition bias) 
Short-term

Selective reporting (re-
porting bias)

High risk

Study protocol available. PDSS scores at 1-month follow-up (primary out-
come) are not reported.

Researcher allegiance

Low risk

To our knowledge, the researchers involved do not have a vested interest for
or against the psychological therapy under study.

Therapist allegiance

Unclear risk

No information provided

Treatment fidelity

Low risk

"All sessions were audiotaped. Of the 50 treatment completers, the session for
20 were randomly selected and rated for therapist competence and adherence.
Overall competence ratings of all therapists ranged from 3 (good) to 5 (excel-
lent). The mean adherence rating as measured by application of respiratory be-
havioral techniques was 5.35 (SD 0.67), with rating of 6 being excellent."

3W: third-wave
AAAS: African American Acculturation Scale - Short Form
AAQ: Acceptance and Action Questionnaire

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

185

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ACQ: Agoraphobic Cognitions Questionnaire
ADIS–IV: Anxiety Disorders Interview Schedule–IV
API: Acute Panic Inventory
APP: attention/psychological placebo
APQ: Autonomic Perception Questionnaire
AR: applied relaxation
ART: applied relaxation training
ASI: Anxiety Sensitivity Index
ATQ: Attitude Toward Treatment Questionnaire/Automatic Thoughts Questionnaire
AWS: Anxiety and Willingness Scale
BAI: Beck Anxiety Inventory
BATs: Behavioral Avoidance Tests
BBSIQ: Brief Body Sensations Interpretation Questionnaire
BDI: Beck Depression Inventory
BSI: Brief Symptom Inventory
BSQ: Body Sensations Questionnaire
BT: behaviour therapy
CART: capnometry-assisted breathing training
CBT: cognitive behaviour therapy
CCLAS: Anxiety Scale of the Cognitions Checklist
CGI: Clinician Global Impression
CT: cognitive training
DPAR: Daily Panic Attack Records
DSI: Depressive Symptoms Inventory
DSM: Diagnostic and Statistical Manual of Mental Disorders
DSQ: Diagnostic Symptom Questionnaire
ECQ: Emotional Control Questionnaire
EMDR: eye movement desensitisation and reprocessing
FQ: Fear Questionnaire
FQ-Ag: Fear Questionnaire-Agoraphobia Subscale
FSS-IZZ: Fear Surrey Schedule-III
GNSS: General Neurotic Syndrome Scale
HAM-D: Hamilton Depression Scale
HARS: Hamilton Anxiety Rating Scale
HARS-R: Hamilton Anxiety Rating Scale - Revised
HEF: high end-state functioning
HR: heart rate
HRV: heart rate variability
IBT: Irrational Belief Test
ICD-10: International Classification of Diseases
IET: Interoceptive Exposure Test
ITT: intention-to-treat
IVExp: in vivo exposure
LEAS: Levels of Emotional Awareness Scale
LOCF: last observation carried forward
LT: long-term
MAO: monoamine oxidase
MCMI: Millon Clinical Multiaxial Inventory
MMPI: Minnesota Multiphasic Personality Inventory
NT: no treatment
OCD: obsessive compulsive disorder
OQ: Outcome Questionnaire
PACQ: Panic Cognitions Questionnaire
PAI: Panic Appraisal Inventory
PARS: Phobic Avoidance Rating Scale
PAS: Panic Agoraphobia Scale/Personality Assessment Schedule
PASQ: Panic Symptoms Questionnaire
PBQ: Panic Belief Questionnaire
PCT: panic control therapy
PD/A: Panic disorder with or without agoraphobia
PDS-MI: Panic Disorder Scale and Mobility Inventory
PDSS: Panic Disorder Severity Scale

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

186

 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

PE: psychoeducation
PFPP: panic focused psychodynamic therapy
PPGAS: Panic, Phobia and Generalized Anxiety Scale
PQ: Presence Questionnaire
PSEQ: Panic Self-Efficacy Questionnaire
PSWQ: Penn State Worry Questionnaire
PT: physiological therapies
PTSD: post-traumatic stress disorder
QOLI: Quality of Life Inventory
RR: respiration rate
SAS-SR: Social Adjustment Scale-Self-Report
SCL: Symptom Check List
SD: standard deviation
SE: standard error
SESA: Self-Efficacy Scales for Agoraphobia
SP: supportive psychotherapy
SPRAS: Sheehan Patient-Rated Anxiety Scale
SSQ: Simulation Sickness Questionnaire
ST: short-term
STAI: State–Trait Anxiety Inventory
SUD: Subjective Units of Discomfort
TAU: treatment as usual
VLQ: Valued Living Questionnaire
VRET: virtual reality exposure therapy
WBSI: White Bear Suppression Inventory
WL: wait list
WSA: Work and Social Adjustment scale

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Andersson 2011

Mixed sample. More than 20% of patients are under 18 (personal communication) [Ongoing study]

Barlow 2000a

Drug versus placebo versus CBT versus CBT + drug versus CBT + placebo. In the related study ex-
ploring EFT versus CBT, not all patients in the EFT arm were randomised.

Benecke 2014

All participants are required to have a comorbid personality disorder [Ongoing study]

Borden 1986

Assignment to WL was not randomised

Bélanger 2006

Quasi-randomised design (personal communication)

Elsesser 2002

Quasi-randomised design (personal communication)

Fava 1997

The study focuses on refractory patients

Gloster 2010a

The study focuses on refractory patients

Ito 2001

Since data for the intervention arms include data from re-randomised WL patients, data for WL arm
cannot be extracted (double-count): the 3 remaining arms would be BT(I) versus BT(E) versus BT(I
+E). Comparison not feasible. Randomisation probably not respected: "twenty patients left the tri-
al before week 4 and were replaced", "the final sample of 80 patients included 10 of the WL who were
re-randomised". Number of patients originally randomised to each arm unclear. Assessment of the
original arms (without the re-randomised and the substitutes) not reported.

Michelson 1996

Replacements are not evenly distributed and constitute more than 15% of the final sample

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Teusch 1996

Zane 1993

Reason for exclusion

Replacements constitute 24.5% of the final sample

The study explicitly focuses on agoraphobia, reporting that only 73% of participants had a comor-
bid panic disorder. We considered studies focusing on agoraphobia, rather than panic disorder,
when it could be safely assumed that at least 80% of the participants were suffering from panic dis-
order.

BT: behaviour therapy
CBT: cognitive behaviour therapy
EFT: emotion focused therapy
WL: wait list

Characteristics of studies awaiting assessment [ordered by study ID]

Bressi 2010a 

Methods

Randomised controlled trial

Participants

35 patients with a diagnosis of panic disorder (DSM IV-TR)

Interventions

CBT versus PD versus NT (usual care)

Outcomes

• Hamilton Rating Scale for Depression (HAM-D)
• Hamilton Rating Scale for Anxiety (HAM-A)
• Panic and Anticipatory Anxiety Scale (PAAAS)
• Toronto Alexithymia Scale–20 items (TAS-20)

Notes

Only abstract available. No reply after trying to contact the author at the available email addresses.

Foley 2006 

Methods

Participants

Randomised controlled trial

Mixed sample (diagnosis for depressive and/or anxiety related disorders according the Anxiety Dis-
orders Interview Schedule)

Interventions

CBT versus 3W (each administered in 8 weekly group therapy sessions)

Outcomes

• Hamilton Depression Rating Scale
• Depression and Anxiety Stress Scales
• Freiburg Mindfulness Inventory

Notes

Only abstract available. No reply after trying to contact the author at the available email addresses.

Franklin 1990 

Methods

Unclear

Participants

56 patients with chronic panic disorder

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Franklin 1990  (Continued)

Cochrane Database of Systematic Reviews

Interventions

BT + SMT (self mastery training) versus BT + APP (imaginal rehearsal)

Outcomes

• Anxiety
• Panic frequency
• Phobic avoidance
• Help seeking
• Drug usage
• Composite criterion of clinical improvement

Notes

Only abstract available. No reply after trying to contact the author at the available email addresses.

Irgens 2009 

Methods

Allocation: randomised
Endpoint classification: efficacy study
Intervention model: single group assignment
Masking: single-blind (outcomes assessor)
Primary purpose: treatment

Participants

72 patients, age 18 years or older, diagnosis of agoraphobia, score on Mobility Inventory "Alone" of
2.5 or more

Interventions

TFT (thought field therapy: not included) versus CBT versus WL

Outcomes

Change in agoraphobic situation scores in ADIS. Among secondary outcomes: MI, ACQ, BSQ, BDI,
BAI.

Notes

(Personal communication)

Margraf 1991 

Methods

Participants

Interventions

Outcomes

Notes

Milrod 2006b 

Methods

Unclear

Unclear

Unclear

Unclear

Full report not retrievable. No reply after trying to contact the author at the available email ad-
dresses.

Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: single-blind (outcomes assessor)
Primary purpose: treatment

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Milrod 2006b  (Continued)

Participants

Age 18 to 70 years, DSM-IV diagnosis criteria for primary PD with or without agoraphobia, history of
at least 1 spontaneous panic attack per week within the month prior to study entry

Interventions

CBT versus PD versus PT

Outcomes

Notes

Richards 1997 

Methods

Participants

Interventions

Outcomes

Notes

Roache 1998 

Methods

Panic Disorder Severity Scale (PDSS)

Only protocol available. Study completed but not yet published.

Unclear

Unclear

Unclear

Unclear

Full report not retrievable. No reply after trying to contact the author at the available email ad-
dresses.

Randomised controlled trial

Participants

30 patients with generalised anxiety or panic disorder

Interventions

CBT versus NT

Outcomes

• Self administration of capsules (alprazolam/placebo)
• Level of anxiety (scale used not specified)

Notes

Only abstract. No reply after trying to contact the author at the available email addresses.

Strauss 1997 

Methods

Unclear

Participants

58 patients with the DSM-III-R diagnosis of panic disorder with and without agoraphobia

Interventions

CBT versus PT versus CBT+Imipramine versus BT + imipramine

Outcomes

• Beck Anxiety Inventory
• Fear Questionnaire
• Fear Diary
• HAM-D
• HAM-A
• Global Improvement Scale

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Strauss 1997  (Continued)

• Behaviour test (DBTA)

Cochrane Database of Systematic Reviews

Notes

Only abstract. No reply after trying to contact the author at the available email addresses.

Vincelli 2003 

Methods

Participants

Randomised controlled trial

12 patients with a "DSM-IV diagnosis of anxiety disorders for a minimum of 6 months as determined
by independent clinicians on clinical interviews." 
Exclusion criteria are: psychotic or bipolar disorders, high suicidal risks, medical illness (i.e. cardiac
conduction disease, vestibular dysfunction), pregnant women

Interventions

Experiential-cognitive therapy (ECT) versus CBT versus WL

Outcomes

Notes

Vincelli 2004 

Methods

• Beck Depression Inventory (BDI)
• State-Trait Anxiety Inventory (STAI)
• Agoraphobic Cognitions Questionnaire (ACQ)
• Fear Questionnaire (FQ)

The diagnosis of participants is unclear. No reply after trying to contact the author at the available
email addresses.

Randomised controlled trial

Participants

36 patients (age 35 to 53) with a diagnosis of panic disorder with agoraphobia

Interventions

CBT (12 sessions) versus CBT plus virtual reality exposure (8 sessions) versus WL

Outcomes

Notes

• Panic frequency
• Level of depression (scale not specified)
• State and trait anxiety (scale not specified)

Only abstract. Maybe continuation of Vincelli 2003a. No reply after trying to contact the author at
the available email addresses.

3W: third-wave
ACQ: Agoraphobic Cognitions Questionnaire
ADIS: Anxiety Disorders Interview Schedule
APP: attention/psychological placebo
BAI: Beck Anxiety Inventory
BDI: Beck Depression Inventory
BSQ: Body Sensations Questionnaire
BT: behaviour therapy
CBT: cognitive behaviour therapy
DSM: Diagnostic and Statistical Manual of Mental Disorders
FQ: Fear Questionnaire
HAM-A: Hamilton Anxiety Rating Scale
HAM-D: Hamilton Depression Scale
PAAAS: Panic and Anticipatory Anxiety Scale
PD: psychodynamic therapies

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

PDSS: Panic Disorder Severity Scale
PT: physiological therapies
MI: Mobility Inventory
NT: no treatment
SMT: self mastery training
STAI: State-Trait Anxiety Inventory
WL: wait list

Characteristics of ongoing studies [ordered by study ID]

Barlow 2010 

Trial name or title

NCT01243606

Methods

Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment

Participants

Age 18 years or older, fluent in the English language, who have a principal DSM-IV diagnosis of SAD,
PD/A, GAD or OCD

Interventions

CBT (disorder specific) versus CBT (unified protocol) versus WL

Outcomes

• Anxiety Disorders Interview Schedule for DSM-IV-Lifetime Version (ADIS-IV)
• Clinical Global Impression Severity (CGI-S) and Improvement Scales (CGI-I)
• Structured Interview Guide for the Hamilton Anxiety and Depression Rating Scale (SIGH-A and

SIGH-D)

Starting date

December 2010

Contact information

David H Barlow: dhbarlow@bu.edu

Todd J Farchione: tfarchio@bu.edu

Notes

Completion expected by December 2014

Caspi 2012 

Trial name or title

NCT01677429

Methods

Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: double-blind (subject, caregiver, outcomes assessor)
Primary purpose: treatment

Participants

Age 18 to 45 years, clinical diagnosis of panic disorder, stable on the same drug and dosage for at
least 1 month

Interventions

BT (with VR balance challenge) versus BT (without VR balance challenge) versus CBT

Outcomes

• Hamilton Rating Scale for Anxiety (HAM-A)
• Panic Disorder Severity Scale (PDSS)
• Panic and Agoraphobia Scale (PAS)

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Caspi 2012  (Continued)

Starting date

September 2012

Contact information

Revital Amiaz: amiazr@gmail.com

Efrat Czerniak: efrat30.3@gmail.com

Notes

Completion expected by September 2013

Gensichen 2012 

Trial name or title

DRKS00004386

Methods

Study type: interventional
Allocation: randomised controlled trial
Blinding: open (masking not used)
Control: active control
Purpose: treatment
Assignment: parallel

Participants

Age 18 or older, clinical diagnosis of panic disorder with or without agoraphobia (ICD-10: F.41.0 or
F40.01), positive screening questionnaires, sufficient German language skills, private telephone

Interventions

CBT versus NT

Outcomes

Severity of anxiety, measured by the Beck Anxiety Inventory (BAI)

Starting date

October 2012

Contact information

Thomas Hiller: Thomas.Hiller@med.uni-jena.de

Notes

Completion expected by Spring 2015

Sandell 2012 

Trial name or title

NCT01606592

Methods

Participants

Allocation: randomised
Endpoint classification: efficacy study
Intervention model: factorial assignment
Masking: open-label
Primary purpose: treatment

Age between 18 and 60, DSM-V diagnosis of panic disorder (with or without agoraphobia), willing-
ness to stop other ongoing psychotherapy treatments and to refrain from non-study treatments
during follow-up

Interventions

Randomised CBT/PD versus chosen CBT/PD versus WL

Outcomes

• Panic Disorder Severity Scale (PDSS)
• Occupational status
• Absence from work due to sickness

Starting date

January 2010

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sandell 2012  (Continued)

Contact information

Not specified

Notes

Completion expected by 2017

Teismann 2012 

Trial name or title

NCT01680237

Methods

Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment

Participants

Age between 18 and 65 years, diagnosis of panic disorder with agoraphobia

Interventions

CBT versus BT

Outcomes

Change (from baseline) in the Mobility Inventory

Starting date

October 2011

Contact information

Tobias Teismann: tobias.teismann@rub.de

Juergen Margraf: juergen.margraf@rub.de

Notes

Completion expected by August 2015

ADIS: Anxiety Disorders Interview Schedule
BAI: Beck Anxiety Inventory
BT: behaviour therapy
CBT: cognitive behaviour therapy
CGI: Clinical Global Impression
DSM: Diagnostic and Statistical Manual of Mental Disorders
GAD: generalised anxiety disorder
HAM-A: Hamilton Rating Scale for Anxiety
ICD-10: International Classification of Diseases
NT: no treatment
OC: obsessive compulsive disorder
PAS: Panic and Agoraphobia Scale
PD: psychodynamic therapies
PD/A panic disorder with/without agoraphobia
PDSS: Panic Disorder Severity Scale
SAD: social anxiety disorder
SIGH-A/SIGH-D: Structured Interview Guide for the Hamilton Anxiety and Depression Rating Scale
VR: virtual reality
WL: wait list

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

 
 
 
 
 
 
A D D I T I O N A L   T A B L E S
Table 1.   Short-term remission: pairwise meta-analyses and NMA results 

Comparison

Pairwise meta-analyses

(X vs Y)

(common τ = 0.69)

Standard NMA

(τ = 0.64)

ΝΜΑ adjusted for SSE

(τ = 0.59)

# of stud-
ies

OR

CI (lower)

CI (upper)

OR

CI (lower)

CI (upper)

OR

CrI (lower)

CrI (upper)

PT vs SP

BT vs SP

BT vs PT

CT vs SP

CT vs PT

CT vs BT

CBT vs SP

CBT vs PT

CBT vs BT

CBT vs CT

WL vs SP

WL vs PT

WL vs BT

WL vs CT

WL vs CBT

NT vs SP

NT vs PT

-

-

2

-

1

1

3

4

10

1

-

4

3

2

18

-

1

-

-

-

-

-

-

1.11

0.21

6.00

-

1.22

0.95

0.68

1.56

2.09

1.69

-

0.21

0.12

0.12

0.13

-

-

0.20

0.12

0.24

0.62

1.10

0.21

-

0.06

0.04

0.02

0.07

-

-

7.48

7.47

1.91

3.94

3.97

13.47

-

0.70

0.43

0.61

0.22

-

0.70

0.11

4.33

0.36

0.37

1.03

0.47

1.33

1.29

0.68

1.90

1.84

1.43

0.08

0.23

0.23

0.18

0.12

0.26

0.73

0.11

0.12

0.42

0.11

0.44

0.41

0.25

0.98

1.06

0.48

0.03

0.12

0.12

0.06

0.07

0.04

0.14

1.18

1.15

2.28

2.07

4.05

4.07

1.83

3.69

3.22

4.23

0.26

0.48

0.45

0.52

0.21

1.82

3.68

0.35

0.38

1.10

0.44

1.27

1.15

0.67

1.95

1.77

1.53

0.22

0.64

0.58

0.50

0.33

0.24

0.70

0.10

0.12

0.51

0.10

0.41

0.37

0.25

1.02

1.02

0.52

0.06

0.27

0.25

0.15

0.16

0.03

0.14

1.11

1.19

2.50

1.90

3.91

3.61

1.82

3.97

3.11

4.68

0.78

1.65

1.36

1.77

0.69

1.67

3.48

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

1
9
5

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 1.   Short-term remission: pairwise meta-analyses and NMA results  (Continued)

NT vs BT

NT vs CT

NT vs CBT

NT vs WL

PD vs SP

PD vs PT

PD vs BT

PD vs CT

PD vs CBT

PD vs WL

PD vs NT

-

1

-

-

-

1

-

-

1

-

-

-

-

-

0.57

0.09

3.48

-

-

-

-

-

-

-

-

-

4.21

0.70

25.49

-

-

-

-

-

-

0.51

0.09

2.99

-

-

-

-

-

-

0.71

0.55

0.38

3.11

0.71

1.99

1.94

1.50

1.05

8.50

2.73

0.13

0.11

0.07

0.58

0.14

0.57

0.50

0.30

0.30

2.27

0.36

3.96

2.73

2.05

16.78

3.52

7.02

7.48

7.43

3.68

31.84

20.56

0.64

0.55

0.36

1.10

0.71

2.05

1.88

1.61

1.06

3.21

2.91

0.11

0.11

0.07

0.18

0.14

0.60

0.48

0.33

0.29

0.75

0.40

3.51

2.71

1.85

6.26

3.42

7.38

7.17

8.17

3.66

12.87

22.56

OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less than one favours treatment Y. Note that in the
main text, where necessary, we inverted the values presented in Table 4 for an easier presentation, in which an OR greater than 1 stands for a higher number of events (short-term
remissions) in the intervention group when compared to the control group. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CrI: credible interval
CT: cognitive training
NMA: network meta-analysis
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
SSE: small study effects
WL: wait list

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

1
9
6

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 2.   Short-term remission: I2 values and their 95% confidence intervals 

Comparison

CBT vs SP

WL vs CBT

CBT vs BT

WL vs BT

WL vs PT

CBT vs PT

I2(%)

0

58

5

34

56

0

95% CI

0 to 90

29 to 75

0 to 64

0 to 78

0 to 85

0 to 85

This values refer to standard meta-analyses, where each comparison has its own heterogeneity variance.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CT: cognitive training
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Table 3.   Short-term remission: ranking of treatments 

Treatment

SUCRA

88

76

73

50

41

35

25

13

SP

CBT

PD

CT

BT

PT

NT

WL

BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

 
 
 
 
 
 
Table 4.   Short-term response: pairwise meta-analyses and NMA results 

Comparison

Pairwise meta-analyses

(X vs Y)

(common τ = 0.55)

Standard NMA

(τ = 0.63)

NMA adjusted for SSE

(τ = 0.65)

# of stud-
ies

OR

CI (lower)

CI (upper)

OR

CI (lower)

CI (upper)

OR

CrI (lower)

CrI (upper)

PT vs SP

BT vs SP

BT vs PT

CT vs SP

CT vs PT

CT vs BT

CBT vs SP

CBT vs PT

CBT vs BT

CBT vs CT

WL vs SP

WL vs PT

WL vs BT

WL vs CT

WL vs CBT

NT vs SP

NT vs PT

NT vs BT

-

-

2

-

1

1

3

4

10

1

-

4

4

1

17

-

1

-

-

-

-

-

-

-

0.90

0.21

3.90

-

0.94

0.20

1.02

1.23

1.78

2.92

-

0.15

0.32

0.31

0.19

-

-

0.18

0.03

0.38

0.56

1.00

0.43

-

0.05

0.14

0.02

0.05

-

-

4.97

1.46

2.73

2.71

3.18

19.98

-

0.44

0.73

4.27

0.31

-

0.31

0.06

1.62

-

-

-

0.68

0.589

0.87

0.39

0.58

0.66

1.04

1.54

1.77

2.65

0.17

0.25

0.29

0.43

0.16

0.16

0.24

0.27

0.20

0.18

0.41

0.07

0.16

0.18

0.36

0.81

1.02

0.73

0.05

0.12

0.15

0.12

0.10

0.02

0.05

0.05

2.31

1.93

1.88

2.07

2.09

2.51

2.99

2.94

3.04

9.62

0.53

0.50

0.54

1.61

0.26

1.21

1.25

1.59

0.69

0.69

1.00

0.36

0.53

0.53

1.12

1.62

1.61

3.08

0.45

0.65

0.65

1.24

0.40

0.15

0.22

0.22

0.20

0.21

0.46

0.07

0.14

0.13

0.40

0.84

0.92

0.81

0.12

0.24

0.28

0.26

0.18

0.02

0.04

0.03

2.41

2.33

2.23

1.96

2.04

2.07

3.26

3.17

2.86

12.26

1.93

1.91

1.68

6.42

1.00

1.22

1.25

1.37

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

1
9
8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 4.   Short-term response: pairwise meta-analyses and NMA results  (Continued)

NT vs CT

NT vs CBT

NT vs WL

PD vs SP

PD vs PT

PD vs BT

PD vs CT

PD vs CBT

PD vs WL

PD vs NT

1

-

-

-

1

-

-

1

-

-

0.33

0.06

1.68

-

-

-

-

-

-

-

-

-

4.22

0.84

21.31

-

-

-

-

-

-

0.34

0.07

1.76

-

-

-

-

-

-

0.41

0.16

0.96

1.02

1.51

1.73

2.59

0.98

6.02

6.28

0.08

0.03

0.17

0.20

0.42

0.44

0.45

0.27

1.60

0.80

2.13

0.87

5.46

5.28

5.35

6.70

14.82

3.47

22.61

49.20

0.42

0.14

0.33

1.07

1.54

1.54

2.94

0.95

2.37

7.03

0.07

0.02

0.04

0.20

0.42

0.37

0.47

0.25

0.49

0.84

2.31

0.80

2.32

5.70

5.92

6.41

18.59

3.60

10.75

61.98

OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less than one favours treatment Y. Note that in the
main text, where necessary, we inverted the values presented in Table 4 for an easier presentation, in which an OR greater than 1 stands for a higher number of events (short-term
remissions) in the intervention group when compared to the control group. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CrI: credible interval
CT: cognitive training
NMA: network meta-analysis
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
SSE: small study effects
WL: wait list

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

1
9
9

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 5.   Short-term response: I2 values and their 95% confidence intervals 

Comparison

CBT vs SP

WL vs CBT

CBT vs BT

WL vs BT

WL vs PT

CBT vs PT

I2(%)

7

39

22

26

14

45

95% CI

0 to 90

0 to 66

0 to 62

0 to 72

0 to 87

0 to 82

This values refer to standard meta-analyses, where each comparison has its own heterogeneity variance.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CT: cognitive training
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Table 6.   Short-term response: ranking of treatments 

Treatment

SUCRA

84

74

72

53

52

31

27

7

CBT

PD

SP

BT

PT

WL

CT

NT

BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

200

 
 
 
 
 
 
Table 7.   Short-term dropouts: pairwise meta-analyses and NMA results 

Comparison

Pairwise meta-analysis

Network meta-analysis

(τ = 0.33)

# of studies

OR

CI (lower)

CI (upper)

OR

CI (lower)

CI (upper)

PT vs SP

BT vs SP

BT vs PT

CT vs SP

CT vs PT

CT vs BT

CBT vs SP

CBT vs PT

CBT vs BT

CBT vs CT

WL vs SP

WL vs PT

WL vs BT

WL vs CT

WL vs CBT

NT vs SP

NT vs PT

NT vs BT

-

-

2

-

1

-

3

3

10

-

-

5

4

-

14

-

1

-

-

-

2.19

-

5.59

-

0.63

0.56

0.89

-

-

0.74

0.34

-

0.70

-

0.29

-

-

-

0.46

-

0.59

-

0.21

0.24

0.52

-

-

0.30

0.16

-

0.42

-

0.01

-

-

-

10.38

-

52.73

-

1.89

1.28

1.51

-

-

1.83

0.69

-

1.16

-

7.51

-

0.76

0.92

1.20

1.06

1.38

1.15

0.64

0.83

0.69

0.60

0.48

0.63

0.52

0.46

0.76

0.10

0.13

0.11

0.28

0.35

0.60

0.20

0.33

0.26

0.28

0.46

0.42

0.14

0.19

0.35

0.30

0.11

0.48

0.00

0.01

0.00

2.08

2.28

2.40

5.62

5.86

5.20

1.43

1.50

1.15

2.60

1.22

1.15

0.93

1.97

1.20

2.18

3.10

2.69

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
0
1

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 7.   Short-term dropouts: pairwise meta-analyses and NMA results  (Continued)

NT vs CT

NT vs CBT

NT vs WL

PD vs SP

PD vs PT

PD vs BT

PD vs CT

PD vs CBT

PD vs WL

PD vs NT

APP vs SP

APP vs PT

APP vs BT

APP vs CT

APP vs CBT

APP vs WL

APP vs NT

APP vs PD

PE vs SP

PE vs PT

PE vs BT

1

-

-

-

1

-

-

1

-

-

-

-

-

1

-

-

-

-

-

-

-

0.07

0.00

1.37

-

-

-

-

-

-

-

-

-

0.16

0.03

0.84

-

-

-

-

-

-

1.21

0.27

5.35

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.97

0.08

11.51

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

0.16

0.21

0.33

0.44

0.36

0.32

0.52

0.69

3.31

0.84

1.10

0.92

0.80

1.32

1.75

8.37

2.53

0.84

1.10

0.92

0.00

0.01

0.09

0.08

0.12

0.10

0.05

0.15

0.19

0.11

0.07

0.10

0.08

0.09

0.12

0.16

0.21

0.17

0.01

0.01

0.01

1.93

3.80

5.01

1.46

1.52

1.35

2.04

1.80

2.50

97.03

10.61

12.30

10.49

7.21

14.61

19.51

333.81

36.70

97.42

119.64

100.89

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
0
2

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
0
3

Table 7.   Short-term dropouts: pairwise meta-analyses and NMA results  (Continued)

PE vs CT

PE vs CBT

PE vs WL

PE vs NT

PE vs PD

PE vs APP

3W vs SP

3W vs PT

3W vs BT

3W vs CT

3W vs CBT

3W vs WL

3W vs NT

3W vs PD

3W vs APP

3W vs PE

-

-

-

-

-

-

-

-

-

-

1

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.56

0.13

2.51

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.80

1.32

1.75

8.36

2.53

1.00

0.36

0.47

0.39

0.34

0.56

0.74

3.55

1.07

0.42

0.42

0.01

0.01

0.02

0.04

0.02

0.02

0.06

0.08

0.07

0.04

0.11

0.14

0.10

0.13

0.02

0.00

77.96

142.93

189.75

1954.05

316.00

55.66

2.12

2.65

2.15

3.03

2.88

4.04

126.65

8.31

7.74

60.45

OR (X vs Y) is defined as (Odds X)/(Odds Y). Of course, since this is dropout outcome, an OR smaller than one favours treatment X. Statistically significant results are written in bold.
3W: third-wave
APP: attention/psychological placebo
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CrI: credible interval
CT: cognitive training
NMA: network meta-analysis
NT: no treatment

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
PD: psychodynamic therapies
PE: psychoeducation
PT: physiological therapies
SP: supportive psychotherapy
SSE: small study effects
WL: wait list

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
0
4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 8.   Short-term dropouts: I2 values and their 95% confidence intervals 

Comparison

CBT vs SP

WL vs CBT

CBT vs BT

WL vs BT

WL vs PT

CBT vs PT

I2(%)

49

0

0

0

25

12

95% CI

0 to 85

0 to 55

0 to 62

0 to 85

0 to 70

0 to 91

This values refer to standard meta-analyses, where each comparison has its own heterogeneity variance.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CT: cognitive training
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Table 9.   Short-term dropouts: ranking of treatments 

Treatment

SUCRA

NT

PD

WL

3W

CBT

APP

PE

PT

CT

BT

SP

85

75

67

67

51

42

42

38

29

28

26

Note that higher ranking treatments correspond to lower dropout rate.
3W: third-wave
APP: attention/psychological placebo
BT: behaviour therapy
CBT: cognitive behaviour therapy

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

205

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PE: psychoeducation
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

206

 
 
 
Table 10.   Short-term improvement: pairwise meta-analyses and NMA results 

Comparison

(X vs Y)

Pairwise meta-analysis

Network meta-analysis

(τ = 0.34)

# of studies

SMD

CI (lower)

CI (upper)

SMD

CI (lower)

CI (upper)

PT vs SP

BT vs SP

BT vs PT

CT vs SP

CT vs PT

CT vs BT

CBT vs SP

CBT vs PT

CBT vs BT

CBT vs CT

WL vs SP

WL vs PT

WL vs BT

WL vs CT

WL vs CBT

NT vs SP

NT vs PT

NT vs BT

-

-

1

-

1

1

3

5

10

2

-

4

3

1

17

-

1

-

-

-

-0.26

-

-0.02

0.65

-0.08

-0.05

-0.24

0.03

-

0.87

0.92

0.60

1.14

-

0.36

-

-

-

-0.98

-

-0.67

-0.16

-0.40

-0.30

-0.45

-0.88

-

0.09

0.59

-0.27

0.87

-

-0.26

-

-

-

0.46

-

0.64

1.46

0.24

0.19

-0.03

0.94

-

1.65

1.26

1.47

1.41

-

0.98

-

0.24

0.16

-0.08

0.17

-0.08

0.00

-0.05

-0.29

-0.21

-0.21

1.05

0.80

0.89

0.88

1.09

0.78

-0.46

0.62

-0.35

-0.42

-0.47

-0.56

-0.63

-0.56

-0.56

-0.60

-0.48

-0.73

0.49

0.47

0.57

0.34

0.88

-0.06

-1.12

-0.09

0.84

0.74

0.31

0.90

0.48

0.57

0.47

0.02

0.07

0.31

1.60

1.13

1.20

1.42

1.31

1.63

0.21

1.33

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
0
7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
0
8

Table 10.   Short-term improvement: pairwise meta-analyses and NMA results  (Continued)

NT vs CT

NT vs CBT

NT vs WL

PD vs SP

PD vs PT

PD vs BT

PD vs CT

PD vs CBT

PD vs WL

PD vs NT

PE vs APP

3W vs SP

3W vs PT

3W vs BT

3W vs CT

3W vs CBT

3W vs WL

3W vs NT

3W vs PD

1

1

-

-

1

-

-

1

-

-

1

-

-

-

-

1

-

-

-

0.39

1.30

-

-

-0.25

0.46

-

-

1.03

2.14

-

-

-1.18

-1.79

-0.57

-

-

-

-

-

-

0.57

-0.07

1.2

-

-

-

-

-

-

-0.25

-0.87

0.38

-

-

-

-

-

-

-

-

-

-

-

-

0.26

-0.33

0.84

-

-

-

-

-

-

-

-

-

0.61

0.83

-0.27

-0.21

-0.46

-0.38

-0.38

-0.17

-1.26

-1.00

-

0.20

-0.04

0.04

0.04

0.25

-0.84

-0.58

0.42

-0.11

0.16

-0.96

-1.05

-1.12

-1.09

-1.21

-0.83

-1.95

-1.91

-

-0.82

-0.98

-0.89

-0.99

-0.64

-1.76

-1.69

-0.69

1.34

1.50

0.42

0.63

0.21

0.34

0.45

0.50

-0.57

-0.07

-

1.22

0.90

0.97

1.07

1.14

0.07

0.53

1.53

A positive SMD for Χ vs Y means treatment Y is better than X, the opposite for a negative SMD (this is because for the scales used a lower score corresponds to a better treatment).
Statistically significant results are written in bold.
3W: third-wave
APP: attention/psychological placebo

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PE: psychoeducation
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
0
9

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 11.   Short-term improvement: I2 values and their 95% confidence intervals 

Comparison

CBT vs SP

CBT vs PT

WL vs PT

CBT vs BT

WL vs BT

WL vs CBT

I2(%)

0

0

79

0

23

61

95% CI

0 to 90

0 to 79

45 to 92

0 to 62

0 to 92

34 to 77

This values refer to standard meta-analyses, where each comparison has its own heterogeneity variance.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CT: cognitive training
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Table 12.   Short-term improvement: ranking of treatments 

Treatment

SUCRA

83

79

69

54

53

52

43

14

4

PD

CBT

SP

CT

3W

BT

PT

NT

WL

3W: third-wave
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

210

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

211

 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
1
2

Table 13.   Long-term remission/response: pairwise meta-analyses and NMA results 

Comparison

Pairwise meta-analyses

Network meta-analysis

(X vs Y)

PT vs SP

BT vs SP

BT vs PT

CT vs SP

CT vs PT

CT vs BT

CBT vs SP

CBT vs PT

CBT vs BT

CBT vs CT

PD vs SP

PD vs PT

PD vs BT

PD vs CT

PD vs CBT

# of studies

OR

CI (lower)

CI (upper)

OR

CI (lower)

CI (upper)

-

-

1

-

1

1

1

2

5

1

-

-

-

-

1

-

-

1.17

-

0.83

0.38

2.09

1.33

1.66

1.56

-

-

-

-

-

-

0.28

-

0.25

0.08

0.80

0.47

0.80

0.34

-

-

-

-

-

-

4.87

-

2.80

1.86

5.47

3.76

3.44

7.11

-

-

-

-

0.80

0.26

9.86

1.31

1.27

0.97

0.96

0.74

0.76

2.09

1.60

1.64

2.16

1.67

1.28

1.31

1.73

0.80

0.33

0.38

0.37

0.21

0.26

0.28

0.73

0.64

0.90

0.73

0.33

0.28

0.34

0.34

0.24

5.25

4.27

2.57

4.36

2.06

2.31

5.98

3.95

2.97

6.37

8.33

5.81

5.07

8.79

2.69

OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less than one favours treatment Y. Note that in the
main text, where necessary, we inverted the values presented in Table 4 for an easier presentation, in which an OR greater than 1 stands for a higher number of events (short-
term remissions) in the intervention group when compared to the control group.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
PD: psychodynamic therapies
PT: physiological therapies

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
SP: supportive psychotherapy
WL: wait list

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
1
3

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 14.   Long-term remission/response: ranking of treatments 

Treatment

SUCRA

CBT

PD

PT

BT

SP

CT

BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

85

64

49

43

31

27

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

214

 
 
 
 
Table 15.   Sensitivity analyses: pairwise meta-analyses and NMA results for short-term remission excluding group therapy trials 

Comparison

Pairwise meta-analyses

Standard NMA

NMA adjusted for SSE

(common τ 0.05)

(τ 

 0)

≅

(τ 

 0.60)

≅

# of stud-
ies

OR

CI (lower)

CI (upper)

OR

CI (lower)

CI (upper)

OR

CrI (lower)

CrI (upper)

PT vs SP

BT vs SP

BT vs PT

CT vs SP

CT vs PT

CT vs BT

CBT vs SP

CBT vs PT

CBT vs BT

CBT vs CT

WL vs SP

WL vs PT

WL vs BT

WL vs CT

WL vs CBT

PD vs SP

PD vs PT

PD vs BT

-

-

2

-

-

1

3

3

9

1

-

4

3

2

11

-

1

-

-

-

-

-

-

-

0.98

0.26

3.74

-

-

0.95

0.67

2.02

1.90

1.69

-

0.22

0.17

0.12

0.10

-

-

-

0.19

0.33

0.85

1.15

0.33

-

0.09

0.08

0.03

0.05

-

-

-

4.84

1.35

4.76

3.16

8.76

-

0.53

0.36

0.46

0.19

-

4.22

1.17

15.15

-

-

-

0.27

0.35

1.29

0.43

1.60

1.24

0.67

2.46

1.90

1.54

0.07

0.25

0.19

0.16

0.10

0.61

2.25

1.74

0.11

0.16

0.69

0.13

0.51

0.44

0.34

1.39

1.26

0.55

0.03

0.14

0.12

0.06

0.07

0.21

0.93

0.68

0.64

0.75

2.42

1.47

4.96

3.51

1.27

4.33

2.88

4.32

0.15

0.45

0.31

0.43

0.16

1.80

5.42

4.47

0.34

0.38

1.10

0.44

1.27

1.15

0.67

1.94

1.76

1.53

0.22

0.64

0.58

0.51

0.33

0.24

0.70

0.64

0.10

0.12

0.51

0.10

0.41

0.37

0.24

1.02

1.02

0.52

0.06

0.27

0.26

0.15

0.16

0.03

0.14

0.11

1.08

1.16

2.52

1.87

3.90

3.68

1.77

3.97

3.13

4.66

0.76

1.66

1.36

1.82

0.70

1.64

3.66

3.60

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
1
5

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 15.   Sensitivity analyses: pairwise meta-analyses and NMA results for short-term remission excluding group therapy trials  (Continued)

PD vs CT

PD vs CBT

PD vs WL

-

1

-

-

-

-

0.51

0.15

1.76

-

-

-

1.41

0.91

8.97

0.37

0.38

3.50

5.34

2.19

22.95

0.55

0.36

1.09

0.11

0.07

0.18

2.74

1.87

6.45

OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less than one favours treatment Y. Note that in the
main text, where necessary, we inverted the values presented in Table 4 for an easier presentation, in which an OR greater than 1 stands for a higher number of events (short-term
remissions) in the intervention group when compared to the control group. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CrI: credible interval
CT: cognitive training
NMA: network meta-analysis
NT: no treatment
PD: psychodynamic therapies
PE: psychoeducation
PT: physiological therapies
SP: supportive psychotherapy
SSE: small study effects
WL: wait list

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
1
6

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 16.   Sensitivity analyses: I2 values and their 95% confidence intervals for short-term remission excluding
group therapy trials 

Comparison

WL vs PT

WL vs BT

WL vs CBT

CBT vs BT

CBT vs SP

CBT vs PT

I2(%)

56

34

21

6

0

0

95% CI

0 to 85

0 to 78

0 to 60

0 to 67

0 to 90

0 to 90

This values refer to standard meta-analyses, where each comparison has its own heterogeneity variance.
BT: behaviour therapy
CBT: cognitive behaviour therapy
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Table 17.   Sensitivity analyses: ranking of treatments for short-term remission excluding group therapy trials 

Treatment

SUCRA

89

76

73

50

40

35

26

13

SP

CBT

PD

CT

BT

PT

NT

WL

BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

217

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Table 18.   Sensitivity analyses: pairwise meta-analyses and I2 for short-term remission excluding trials in which a
concomitant pharmacotherapy is allowed 

Comparison (X vs Y)

Pairwise meta-analyses

WL vs CBT

CBT vs BT

CBT vs SP

WL vs BT

NT vs CT

CT vs PT

NT vs PT

# of studies

OR

CI (lower)

CI (upper)

3

2

2

1

1

1

1

0.07

2.21

0.51

0.22

0.57

1.22

0.70

0.01

0.96

0.22

0.11

0.17

0.36

0.27

0.30

5.10

1.23

0.44

1.91

4.12

1.10

I2

0.0%

0.7%

0.0%

-

-

-

-

OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less than one
favours treatment Y. Note that in the main text, where necessary, we inverted the values presented in Table 4 for an easier presentation,
in which an OR greater than 1 stands for a higher number of events (short-term remissions) in the intervention group when compared to
the control group. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

218

 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
1
9

Table 19.   Sensitivity analyses: pairwise meta-analyses with their I2 and NMA results for short-term remission excluding from the analyses trials in
which pharmacotherapy stabilisation was not required 

Comparison

(X vs Y)

BT vs PT

CBT vs PT

CBT vs BT

WL vs PT

WL vs BT

WL vs CBT

Pairwise meta-analyses

Network meta-analysis

(tau = 0.63)

# of studies

OR

CI (lower)

CI (upper)

-

3

2

3

1

6

-

1.56

4.04

0.22

0.02

0.06

-

0.69

0.73

0.01

0.00

0.03

-

3.55

22.52

4.04

0.32

0.014

I2

-

30

72

69

-

0

OR

0.56

1.80

3.16

0.11

0.19

0.06

CI (lower)

CI (upper)

0.12

0.69

0.93

0.03

0.04

0.02

2.67

4.67

10.71

0.36

0.87

0.16

OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less than one favours treatment Y. Note that in the
main text, where necessary, we inverted the values presented in Table 4 for an easier presentation, in which an OR greater than 1 stands for a higher number of events (short-term
remissions) in the intervention group when compared to the control group. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

Table 20.   Sensitivity analyses: pairwise meta-analyses for short-term remission using a fixed-effect rather than a random-effects model 

Comparison

(X vs Y)

BT vs PT

CT vs PT

CT vs BT

# of studies

Random-effects

Fixed-effect

pairwise meta-analyses

pairwise meta-analyses

OR

1.09

1.22

0.95

CI (lower)

CI (upper)

0.22

0.36

0.20

5.52

4.12

4.54

OR

0.96

1.22

0.95

CI (lower)

CI (upper)

0.27

0.36

0.20

3.46

4.12

4.54

2

1

1

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 20.   Sensitivity analyses: pairwise meta-analyses for short-term remission using a fixed-effect rather than a random-effects model  (Continued)

CBT vs SP

CBT vs PT

CBT vs BT

CBT vs CT

PT vs WL

BT vs WL

CT vs WL

CBT vs WL

PT vs NT

CT vs NT

PD vs PT

PD vs CBT

3

4

10

1

4

3

2

18

1

1

1

1

0.67

1.43

2.05

1.69

4.55

8.33

8.33

9.09

1.43

1.75

4.22

0.51

0.35

0.78

1.29

0.35

0.89

2.33

2.22

4.76

0.41

0.52

1.27

0.16

1.27

2.62

3.27

8.22

25.00

25.00

33.33

20.00

5.00

5.88

13.95

1.613

0.67

1.43

2.05

1.69

4.55

5.56

8.33

5.56

1.43

1.75

4.22

0.51

0.35

0.78

1.30

0.35

1.96

2.94

2.22

3.70

0.41

0.52

1.27

0.16

1.27

2.62

3.22

8.22

10.00

11.11

33.33

8.33

5.00

5.88

13.95

1.613

OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less than one favours treatment Y. Statistically significant
results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list

C
o
p
y
r
i
g
h
t

©
2
0
1
6
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

P
s
y
c
h
o
l
o
g
i
c
a
l

t
h
e
r
a
p
i
e
s
f
o
r
p
a
n
i
c
d
i
s
o
r
d
e
r
w

i
t
h
o
r
w

i
t
h
o
u
t
a
g
o
r
a
p
h
o
b
i
a
i

n
a
d
u
l
t
s
:
a
n
e
t
w
o
r
k
m
e
t
a
-
a
n
a
l
y
s
i
s
(
R
e
v
i
e
w

)

2
2
0

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

A P P E N D I C E S

Appendix 1. CCDANCTR-References Register search (psychotherapies for panic)

1. (therap* or psychotherap*) [ti,ab]

2. psychotherapy [kw]

3. (acceptance* or commitment* or “activity scheduling” or adlerian or art or aversion or brief or “client cent*” or cognitive* or color or
colour or compassion-focused or “compassion* focus*” or compassionate or conjoint or conversion or conversational or couples or dance
or dialectic* or diffusion or distraction or eclectic or (emotion and focus*) or emotion-focus* or existential or experiential or exposure
or expressive or family or focus-oriented or “focus oriented” or freudian or gestalt or “group” or humanistic or implosive or insight or
integrative or interpersonal or jungian or kleinian or logo or marital or metacognitive or meta-cognitive or milieu or morita or multimodal
or multi-modal or music or narrative or nondirective or non-directive or “non directive” or nonspecific or non-specific or “non specific”
or  “object  relations”  or  “personal  construct”  or  “person  cent*”  or  person-cent*  or  persuasion  or  play  or  ((pleasant  or  pleasing)  and
event*) or primal or problem-focused or “problem focused” or problem-solving or “problem solving” or process-experiential or “process
experiential” or psychodynamic or “rational emotive” or reality or “reciprocal inhibition” or relationship* or reminiscence or restructuring
or rogerian or schema* or self-control* or “self control*” or “short term” or short-term or sex or “social effectiveness” or “social skill*” or
socio-environment* or “socio environment*” or “solution focused” or solution-focused or “stress management” or supportive or time-
limited or “time limited” or “third wave” or transference or transtheoretical or validation)

4.  (abreaction  or  “acting  out”  or  “age  regression”  or  ((assertive*  or  attention  or  autogenic  or  mind  or  sensitivity)  and  train*)  or
autosuggestion or “balint group” or ((behavior* or behaviour*) and (activation or therap* or treatment or contracting or modification))
or  bibliotherap*  or  biofeedback  or  catharsis  or  *cognitive*  or  *CBT*  or  “mind  training”  or  counsel*  or  “contingency  management”  or
countertransference  or  “covert  sensitization”  or  “eye  movement  desensiti*”  or  EMDR  or  “crisis  intervention”  or  “dream  analysis”  or
“emotional freedom” or “free association” or “functional analys*” or griefwork or hypno* or imagery or meditation* or “mental healing”
or mindfulness* or “panic program” or psychoanaly* or psychodrama or psychoeducat* or (psycho* and support*) or psychotherap* or
relaxation or “role play*” or “self analysis” or “self esteem” or “self-help or “self help” or “sensitivity training” or “support group*” or
therapist or “therapeutic technique*” or “transactional analysis”)

5. ((1 or 2) and 3) or 4

6. panic

7. (5 and 6)

Appendix 2. PubMed search strategy

((("randomized  controlled  trial"[Publication  Type])  OR  ("controlled  clinical  trial"[Publication  Type])  OR  ("clinical  trials  as  topic"[MeSH
Terms]) OR ((randomized[Title/Abstract]) OR randomised[Title/Abstract]) OR (randomly[Title/Abstract]) OR (placebo[Title/Abstract]) OR
(trial[Title])) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])) AND (("psychotherapy"[MeSH Terms]) OR (psychotherap* OR
psychoanaly* OR psychodynamic OR psychodrama OR psychoeducat*[Title/Abstract])) AND (("agoraphobia"[MeSH Terms]) OR ("panic
disorder"[MeSH Terms]) OR ("panic"[MeSH]) OR (panic OR agoraphobi*[Title/Abstract]))

Appendix 3. Statistical software details

We used Stata for most analyses presented in this review. We employed the mvmeta command for the network meta-analyses (White 2011).
We performed network plots and inconsistency plots using the network_graphs package in Stata (Chaimani 2013).

We used OpenBUGS to fit the small study effects network meta-analyses. We assumed minimally informative prior distributions for the
logarithm of the treatment effects, and the heterogeneity standard deviation, τ˜U(0,5). The results presented pertain to a sample obtained
from two independent chains with 100,000 iterations each, after a 10,000 burn-in period. We confirmed convergence using the Brooks-
Gelman-Rubin criterion (Brooks 1998).

C O N T R I B U T I O N S   O F   A U T H O R S

TAF and AP conceived the study.

AP led the project under TAF supervision.

AP, TAF and GS worked on the protocol; HI, AT and OE provided suggestions and input.

GS and OE performed the statistical analyses.

AP and TAF worked on the review; HI, AT, OE and GS provided suggestions and input.

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

221

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

All authors reviewed and approved the final version of the review.

D E C L A R A T I O N S   O F   I N T E R E S T

AP has no competing interests.

TAF has received honoraria for speaking at CME meetings sponsored by Asahi Kasei, Eli Lilly, GlaxoSmithKline, Mochida, MSD, Otsuka,
Pfizer, Shionogi and Tanabe-Mitsubishi. He is a diplomate of the Academy of Cognitive Therapy. He has received royalties from Igaku-
Shoin, Seiwa-Shoten and Nihon Bunka Kagaku-sha. He is on the advisory board for Sekisui Chemicals and Takeda Science Foundation. The
Japanese Ministry of Education, Science, and Technology, the Japanese Ministry of Health, Labor and Welfare, and the Japan Foundation
for Neuroscience and Mental Health have funded his research projects.

HI has no competing interests.

AT has received honoraria for speaking at a meeting sponsored by Eli Lilly.

OE has no competing interests.

GS has no competing interests.

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

We first planned to use scale endpoint data, which typically cannot have negative values and are easier to interpret from a clinical point
of view. However, as a post hoc decision, we decided to use change data in an attempt to reduce the amount of heterogeneity due to the
baseline imbalance found across studies.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Agoraphobia  [psychology]  [*therapy];  Panic Disorder  [psychology]  [*therapy];  Psychotherapy  [*methods];  Randomized Controlled
Trials as Topic

MeSH check words

Adult; Humans

Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

222
